<SEC-DOCUMENT>0001829126-23-002504.txt : 20230331
<SEC-HEADER>0001829126-23-002504.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331163049
ACCESSION NUMBER:		0001829126-23-002504
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13341
		FILM NUMBER:		23788295

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>titanpharma_10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ttnp="http://titanpharm.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_ttnp_titanpharm.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000910267 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0000910267</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0124" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-01-012022-12-31_us-gaap_ProductMember" id="xdx2ixbrl0176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0190" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0235" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:AmortizationOfRestrictedStockShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0259" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0273" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0319" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:ShareBasedPaymentArrangementMilestonePayment" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:RetirementOfPropertyAndEquipment" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:AccumulatedDepreciationOnRetiredPropertyAndEquipment" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0667" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31" id="xdx2ixbrl0671" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0804" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0839" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0942" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0961" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ttnp:DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" id="xdx2ixbrl0996" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ttnp-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:RubinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:RubinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeeStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">ttnp:EmployeeStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmployeeStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">ttnp:EmployeeStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-20_custom_PaycheckProtectionProgramLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-31_custom_PaycheckProtectionProgramLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredFiveYearAndSixMonthWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012022-03-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:CommonStockToMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:CommonStockToMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:ServicesAgreementWithMaximMdmWorldwideSolutionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:ServicesAgreementWithMaximMdmWorldwideSolutionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_TwoThousandFifteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_January2021OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:January2021OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-31_custom_January2021OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:January2021OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-08-31_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-02-28_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2002-07-31_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2002-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-15_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-15_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-15_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-15_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-15_custom_Plan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SegmentDiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_JTPharmaAgreementMember_custom_JTPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ttnp:JTPharmaAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttnp:JTPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000841" toRefs="Footnote000852"></ix:relationship>
  <ix:relationship fromRefs="Fact000843" toRefs="Footnote000852"></ix:relationship>
  <ix:relationship fromRefs="Fact000845" toRefs="Footnote000853"></ix:relationship>
  <ix:relationship fromRefs="Fact000847" toRefs="Footnote000853"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington, D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20220101__20221231_zRIe3tIevu26"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentAnnualReport_c20220101__20221231_zU9ex5Pkqao3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span> <b>ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the fiscal&#160;year ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20220101__20221231_z4EOyoHsXZz2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_904_edei--CurrentFiscalYearEndDate_c20220101__20221231" title="Current Fiscal Year End Date"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--DocumentTransitionReport_c20220101__20221231_zKlSA3x12e38"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span> <b>TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission file number <span id="xdx_90C_edei--EntityFileNumber_c20220101__20221231_zqFbSCiLjn1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-13341</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20220101__20221231_zGTT89H1nvi5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">TITAN PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zCQwhLC3NxDa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; text-align: center; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20220101__20221231_zr6hRUxlkLy4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">94-3171940</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction&#160;of</b><br /> <b>incorporation or organization)</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer</b><br /> <b>Identification Number)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20220101__20221231_zWTjobGpwrF7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">400 Oyster Point Blvd.</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20220101__20221231_z8MgrK5rlTck"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite 505</ix:nonNumeric></span>,</b><br /> <b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20220101__20221231_zSl2yEjgZQFl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">South San Francisco</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20220101__20221231_zXZos1XoJn8h"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20220101__20221231_zjlUQPLek8ic"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">94080</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of principal executive offices)</b></span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip&#160;code)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s telephone number, including area code: <span id="xdx_90F_edei--CityAreaCode_c20220101__20221231_zcGSg0HhsKSl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(650)</ix:nonNumeric></span>&#160;<span id="xdx_905_edei--LocalPhoneNumber_c20220101__20221231_zCN33bY2yOTk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">244-4990</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20220101__20221231_zMKZx5j1A4F3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common Stock, par value $0.001</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20220101__20221231_zQ8PnmdZ9zMa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">TTNP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20220101__20221231_ztlMZ0rXlvd8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities registered pursuant to Section 12(g) of the Act: None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule&#160;405 of the Securities Act. Yes&#160;&#9744;&#160;&#160;&#160;<span id="xdx_906_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zf20n04NHhGf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act.&#160;Yes&#160;&#9744;&#160;&#160;&#160;<span id="xdx_90D_edei--EntityVoluntaryFilers_c20220101__20221231_zf4qp7b80Shl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Exchange Act during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to the filing requirements for the past 90&#160;days. <span id="xdx_90F_edei--EntityCurrentReportingStatus_c20220101__20221231_zl1l0aGGVvN8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted&#160;pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_907_edei--EntityInteractiveDataCurrent_c20220101__20221231_zRJmjKWXXCrl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;&#160;&#160;No</span>&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; width: 27%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20220101__20221231_zI3yT5KHO2ge"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    Reporting Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntitySmallBusiness_c20220101__20221231_zAaeqSdBjgOc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20220101__20221231_zSEEMGG7OTrl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;<span id="xdx_907_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zdCpheQB0Jc8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes &#9744;&#160;&#160;&#160;<span id="xdx_90F_edei--EntityShellCompany_c20220101__20221231_zmzWekYFobSa"><span title="Entity Small Business"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based on the closing price on June&#160;30, 2022 was approximately $<span id="xdx_903_edei--EntityPublicFloat_iI_pn3n3_dm_c20220630_zKcbfbePNbk4" title="Entity Public Float"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">8.1</ix:nonFraction></span>&#160;million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 24, 2023, <span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_pid_c20230324_zEmEgGRjIVJ9" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-24" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,016,295</ix:nonFraction></span> shares of common stock, $0.001 par value, of the registrant were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS INCORPORATED BY REFERENCE:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NONE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Titan Pharmaceuticals,&#160;Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual Report on Form&#160;10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Fiscal Year Ended December 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: justify; width: 9%">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify; width: 81%">&#160;</td>
    <td style="text-align: left; width: 1%; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page #</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART I</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Item 1.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Item 1A.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk Factors</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Item 1B.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Item 2.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Properties</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Item 3.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Legal Proceedings</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Item 4.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Mine Safety Disclosures</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">PART II</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Item 5.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Item 6.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">[Reserved]</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Item 7.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Item 7A.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Item 8.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Financial Statements and Supplementary Data</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Item 9.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Item 9A.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Controls and Procedures</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Item 9B.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Other Information</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Item 9C.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">PART III</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Item 10.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Item 11.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Executive Compensation</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Item 12.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Item 13.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Item 14.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Principal Accounting Fees and Services</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="2" style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">PART IV</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Item 15.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Exhibits, Financial Statement Schedules</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">40</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Item 16.</a></span></td>
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Form 10-K Summary</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">40</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">SIGNATURES</a></span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART&#160;I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Annual Report on Form&#160;10-K or in the documents incorporated by reference herein may contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933 (the &#8220;Securities Act&#8221;) and Section&#160;21E of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) that involve substantial risks and uncertainties. We have attempted to identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements included or incorporated by reference in this report or our other filings with the Securities and Exchange Commission, or the SEC, include, but are not necessarily limited to, those relating to uncertainties relating to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise capital when needed;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties or delays in the product development process, including the results of preclinical studies or clinical trials;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financing and strategic agreements and relationships;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties or delays in the regulatory approval process;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse side effects or inadequate therapeutic efficacy of our drug candidates that could slow or prevent product development or commercialization;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dependence on third party suppliers;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing, sales, marketing and distribution of any of our drug candidates that may be successfully developed and approved for commercialization;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protection for our patents and other intellectual property or trade secrets; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management&#8217;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties, including the risks outlined under &#8220;Risk Factors&#8221; or elsewhere in this report, that could cause actual performance or results to differ materially from what is expressed in or suggested by the forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to give undue weight to such projections, assumptions and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;Titan,&#8221; and &#8220;our company&#8221; refer to Titan Pharmaceuticals,&#160;Inc. unless the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Probuphine<sup>&#174;
</sup>and ProNeura<sup>&#174;</sup> are trademarks of our company. This Annual Report on Form&#160;10-K also includes trade names and
trademarks of companies other than Titan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item 1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura<sup>&#174;</sup>, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our first product based on our ProNeura technology was Probuphine&#174; (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo&#8482;) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020 to allow us to focus our limited resources on product development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In December 2021, we announced
our intention to work with our financial advisor to explore strategic alternatives to enhance stockholder value, potentially including
an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other transaction. In June 2022, we
implemented a plan to reduce expenses and conserve capital that included a company-wide reduction in salaries and a scale back of certain
operating expenses to enable us to maintain sufficient resources as we pursued potential strategic alternatives. In July 2022, David Lazar
and Activist Investing LLC (collectively, &#8220;Activist&#8221;) acquired an approximately 25% ownership interest in Titan, filed a proxy
statement and nominated six additional directors, each of whom was elected to our board of directors (the &#8220;Board&#8221;) at a special
meeting of stockholders held on August 15, 2022 (the &#8220;Special Meeting&#8221;). The exploration and evaluation of possible strategic
alternatives by the Board has continued following the Special Meeting. Following the election of the new directors at the Special Meeting,
Dr. Marc Rubin was replaced as our Executive Chairman, and David Lazar assumed the role of Chief Executive Officer. In connection with
the termination of his employment as Executive Chairman, Dr. Rubin will receive aggregate severance payments of approximately $0.4 million,
of which, approximately $165,000 have been paid as of December 31, 2022. In December 2022, we implemented additional cost reduction measures
including a reduction in our workforce.</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProNeura Continuous Drug Delivery Platform</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our ProNeura continuous drug
delivery system consists of a small, solid rod-shaped implant made from a mixture of EVA and a given drug substance. The resulting product
is a solid matrix that is placed subdermally, normally in the inside part of the upper arm in a brief procedure using a local anaesthetic
and is removed in a similar manner at the end of the treatment period. The drug substance is released continuously through the process
of dissolution-controlled diffusion. This results in a continuous, steady rate of release generally similar to intravenous administration.
We believe that such long-term, near linear release characteristics are desirable as they avoid the fluctuating peak and trough drug levels
seen with oral dosing that often poses treatment problems in a range of diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ProNeura platform was developed to address the need for a simple, practical method to achieve continuous long-term drug delivery, and, depending on the characteristics of the compound to be delivered, can potentially provide treatment on an outpatient basis over extended periods of up to 12 months. We believe that the benefits of this technology have been demonstrated by the clinical results seen to date with Probuphine, and, in addition, that the development and regulatory process have been affirmed by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, and Health Canada approvals of this product. We have further demonstrated the feasibility of the ProNeura platform with small molecules, hormones, and bio-active peptides. The delivery system works with both hydrophobic and hydrophilic molecules. We have also shown the flexibility of the platform by experimenting with the release characteristics of the EVA implants, layering the implants with varying concentrations of drug, and generating implants of different sizes and porosity to achieve a desired delivery profile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development Programs</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have the following development programs for which development activities have been substantially curtailed while we are exploring several financing and strategic alternatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TP-2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several years ago, we began limited non-clinical laboratory experiments in collaboration with JT Pharmaceuticals, Inc., or JT Pharma, to assess the feasibility of delivering JT Pharma&#8217;s kappa opioid agonist peptide, or TP-2021, utilizing our ProNeura system. Following our acquisition of TP-2021 in October 2020, we successfully manufactured a prototype implant containing TP-2021 (TP-2021 - ProNeura) to be used in appropriate small animal models. While our initial work focused on TP-2021&#8217;s ability to activate peripheral kappa opioid receptors, potentially providing a non-addictive treatment for certain types of pain, in January 2021, our research pivoted to explore the feasibility of using TP-2021 in the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks. According to a 2015 review by Mollanazar, N., et al., an estimated 23 &#8211; 44 million Americans suffer from chronic pruritus of both cutaneous and systemic etiologies. Current treatments include antihistamines, corticosteroids, and over-the-counter lotions, all of which are relatively ineffective and/or have undesirable side-effect profiles. The antipruritic effect of kappa opioid agonists is thought to be related to their binding to kappa opioid receptors on keratinocytes, immune cells, and peripheral itch neurons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2021, we announced that early non-clinical studies of TP-2021 showed very high affinity and specificity for the human kappa opioid receptor and demonstrated potent antipruritic activity when injected subcutaneously in a mouse model for moderate to severe pruritus. TP-2021 - ProNeura implants were then formulated and tested in this model. In November 2021, data presented at the annual meeting of the Society for Neuroscience demonstrated that significant reduction in scratching behavior in this proven animal model for pruritus was maintained in mice who received the TP-2021 - ProNeura implant through Day 56 post-implantation, when compared with control untreated mice, with no safety issues observed for the implanted animals over the three-month duration of treatment. Subsequently, efficacy in this pruritus model has been extended through Day 84 post-implantation. In addition, the TP-2021 - ProNeura implant provided sustained supra-therapeutic plasma levels of the peptide through Day 84 post-implantation in a separate pharmacokinetic study in mice. We believe that subdermal implantation of TP-2021 - ProNeura could potentially deliver therapeutic concentrations of TP-2021 in human subjects for up to six months or longer following a single in-office procedure. Investigational New Drug, or IND, enabling non-clinical safety and pharmacology studies will need to be conducted in preparation for regulatory approval to enter human clinical studies. Additional funding from external sources for progression of the non-clinical program is required but will be dependent on finding a suitable partner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nalmefene Development Program</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A subdermal ProNeura implant containing nalmefene for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The FDA cleared the IND for this program in July 2022. To date, this program has been partially supported by a September 2019 grant from the National Institute for Drug Addiction, or NIDA, which provided approximately $8.7 million of Federal money for the completion of implant formulation development, cGMP manufacturing and non-clinical studies required for filing an IND. Following the clearance of the IND, we may be eligible for additional grant funding of approximately $6.3 million from NIDA. However, this funding availability is dependent on a progress review at NIDA. Additional funding from external sources for progression of the clinical program will be separately sought but will be dependent on finding a suitable partner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In early 2020, following a meeting with the FDA to review our non-clinical development plans and obtain guidance regarding filing an IND, the FDA provided clear guidance on the type of development plan that we should follow. Specifically, the FDA advised that this product development should follow the more expansive 505(b)(1) regulatory pathway rather than the shorter, more streamlined 505(b)(2) regulatory pathway we had been pursuing. In September 2021, the FDA advised that it was reconsidering the regulatory pathway for the nalmefene implant and could ultimately determine that the 505(b)(2) process is potentially appropriate. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gates Foundation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, we received an approximately $500,000 grant from the Bill and Melinda Gates Foundation to demonstrate the ability to deliver a combination HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls in low- and middle-income countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JT Pharmaceuticals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In October 2020, we entered
into an Asset Purchase Agreement, or the JT Agreement, with JT Pharmaceuticals, Inc., or JT Pharma, to acquire JT Pharma&#8217;s kappa
opioid agonist peptide, TP-2021, for use in combination with our ProNeura long-term, continuous drug delivery technology for the treatment
of chronic pruritus and other potential medical applications. Under the terms of the JT Agreement, JT Pharma received a $15,000 closing
payment and is entitled to receive future milestone payments, payable in cash or in stock, based on the achievement of regulatory milestones,
and single-digit percentage earn-out payments on net sales of the product if successfully developed and approved for commercialization.
In January 2022, in connection with our entry into a clarification agreement with JT Pharma, we made the first milestone payment under
the JT Agreement of $100,000 and issued 51,021 shares of our common stock related to the successful completion of a proof-of-concept study
in an animal model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Knight</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to an agreement (as amended, the Knight Agreement), we granted Knight Therapeutics&#160;Inc., or Knight, an exclusive license to commercialize Probuphine in Canada as well as a right of first negotiation in the event we intend to license commercialization rights to any other products in Canada. We are entitled to receive royalty payments from Knight on net sales of Probuphine in Canada ranging in&#160;percentage from the low-teens to the mid-thirties. In addition, we agreed to be the exclusive supplier of Probuphine to Knight subject to a supply agreement between us and Knight. During the term of the Knight Agreement, we may not commercialize any product in Canada containing buprenorphine that is intended for a treatment duration of six&#160;months or more.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless earlier terminated, the initial term of the Knight Agreement will expire on the 15th anniversary of the date of the first commercial sale of Probuphine for opioid addiction in Canada, which occurred during the fourth quarter of 2018. If Probuphine is approved for another indication in Canada after the fifth anniversary of the first commercial sale of Probuphine for opioid addiction in Canada, we must negotiate in good faith whether to extend the initial term. After the initial term, the Knight Agreement will automatically renew for two-year periods until either party provides the other party with written notice of its intent not to renew at least 180&#160;days prior to the expiration of the initial term or then-current term. We or Knight may terminate the Knight Agreement in the event that (i)&#160;either party determines in good faith that it is not advisable for Knight to continue to commercialize Probuphine in Canada as a result of a bona fide safety issue, (ii)&#160;the other party has filed for bankruptcy, reorganization, liquidation or receivership proceedings, or (iii)&#160;the other party materially breached the agreement and has not cured such breach within a specified time period. In addition, subject to certain exceptions and requirements, we may terminate the Knight Agreement (i)&#160;if Knight discontinues the commercial sale of Probuphine for a period of at least three&#160;months and fails to resume sales within the specified cure period, or (ii)&#160;in the event that Knight commences any legal proceedings seeking to challenge the validity or ownership of any of our patents related to Probuphine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of termination, among other things, Knight shall (i)&#160;cease commercialization of Probuphine in Canada, (ii)&#160;transfer title to all current and pending regulatory submissions and regulatory approvals for Probuphine to us and (iii)&#160;pay any royalty payments generated by Knight&#8217;s sales of Probuphine in Canada due to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual Property</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our goal is to obtain, maintain and enforce patent protection for our product candidates, formulations, processes, methods and any other proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidates and any future product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the United States and abroad. However, patent protection may not afford us with complete protection against competitors who seek to circumvent our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also depend upon the skills, knowledge, experience and know-how of our management and research and development personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how, which may not be patentable, and for inventions for which patents may be difficult to enforce, we currently rely and will in the future rely on trade secret protection and confidentiality agreements to protect our interests. To this end, we require all of our employees, consultants, advisors and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2010, the United States Patent and Trademark Office, or USPTO, issued a patent covering methods of using Probuphine for the treatment of opiate addiction. Titan is the owner of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphine and EVA, a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent will expire in April 2024. We have filed a Patent Cooperation Treaty patent application to the use of a kappa-opioid receptor agonist implant for the treatment of pruritus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also have pending patent applications in the U.S., Australia, Canada, China, Europe, Hong Kong, India, Japan and Mexico for implants for release of lipophilic or amphiphilic pharmaceutical substances, and for loadable porous structures for use as implants. We also have pending patent applications in the U.S., Australia, Canada, China, Europe, Hong Kong, India, Japan, South Korea, Mexico, Singapore, and South Africa for implants with reduced initial burst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have additional patents for a heterogeneous implant designed with some unique properties that may provide benefits to the structural integrity of the implants and potentially enhance drug delivery. Patents for this heterogeneous implant have been granted in the U.S., Australia, Canada, Europe, Hong Kong, India, Japan, South Korea, Mexico, Singapore, and South Africa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future court decisions or changes in patent law might materially affect the patents or patent applications, including, but not limited to, their expiration dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">The pharmaceutical and biotechnology industries are characterized by rapidly evolving technology and intense competition. Our product development programs are currently in non-clinical stages of development and once these commence clinical development we can assess and provide details on specific competitive environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing formulation development is conducted at a dedicated facility established at Southwest Research Institute, or SwRI<sup>&#174;</sup>, in San Antonio, Texas that includes cGMP manufacturing and testing capabilities. We also receive support services from the vast array of SwRI groups with expertise in manufacturing and material sciences. The facilities are compliant with both FDA and Drug Enforcement Agency, or DEA, requirements enabling us to work with controlled substances, and the manufacturing scale is ideal for product development during non-clinical and clinical testing stages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing of Probuphine was primarily conducted at DPT Laboratories, Inc., or DPT, pursuant to a commercial manufacturing agreement with DPT that governed the terms of the production and supply of Probuphine for the U.S., Canada and EU. In October 2020, we entered into Debt Settlement and Release Agreement, or DSRA, which transferred the manufacturing facility at DPT to L. Molteni &amp; C. Dei Frattelli Alitti Societa Di Esercizio S.P.A., or Molteni. Under the agreement, we retain access to the facility, through Molteni, for the manufacture and supply of Probuphine to Knight for Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government Regulation</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Government authorities in the
United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labelling, packaging, storage, record-keeping, promotion, advertising, distribution,
post-approval monitoring and reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed,
considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory
authority, submitted for review and approved by the regulatory authority.</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the United States, the FDA regulates drugs and devices under the Food, Drug and Cosmetics Act, or FDCA. Drugs and devices are also subject to other federal, state and local statutes and regulations. Products composed of both a drug product and device product are deemed combination products. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction over its regulation based on a determination of the combination product&#8217;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of some of our product candidates, we expect the primary mode of action to be attributable to the drug component of the product, which means that the FDA&#8217;s Center for Drug Evaluation and Research would have primary jurisdiction over the premarket development, review and approval. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and includes the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates must be approved by the FDA through the New Drug Application, or NDA, process before they may be legally marketed in the United States. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of extensive nonclinical laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed drug for each proposed indication;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of an NDA for a new drug;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A determination by the FDA within 60&#160;days of its receipt of an NDA to file the NDA for review;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential FDA audit of the nonclinical study and/or clinical trial sites that generated the data in support of the NDA; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The nonclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The data required to support an NDA is generated in two distinct development stages: nonclinical and clinical. For new chemical entities, the nonclinical development stage generally involves synthesizing the active component, developing the formulation and determining the manufacturing process, as well as carrying out non-human toxicology, pharmacology and drug metabolism studies in the laboratory, which support subsequent clinical testing. These nonclinical tests include laboratory evaluation of product chemistry, formulation, stability and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal regulations, including GLPs. The sponsor must submit the results of the nonclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. Some nonclinical testing may continue even after the IND is submitted, but an IND must become effective before human clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s)&#160;for human trials. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials, including concerns that human research subjects will be exposed to unreasonable health risks, and places the IND on clinical hold within that 30&#45;day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The clinical stage of development involves the administration of the drug candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completion. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Additionally, a manufacturer may need to recall a product from the market. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 24, 2023, we had four full-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We were incorporated under the laws of the State of Delaware in February 1992. Our principal executive offices are located at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080. Our telephone number is (650) 244-4990. We make our SEC filings available on the Investor Relations page of our website, http://titanpharm.com. Information contained on our website is not part of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.75in; text-align: left"><span id="a_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item</b></span> 1A.</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Risk Factors</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to Our Financial Condition and Need for Additional Capital</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We have incurred net losses in almost every&#160;year since our inception, which losses will continue for the foreseeable future and raise substantial doubt about our ability to continue as a going concern</i></b><span style="font-style: normal; font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">We have incurred net losses in almost every year since our inception. Our financial statements have been prepared assuming that we will continue as a going concern. For the years ended December 31, 2022 and 2021, we had net losses of approximately $10.2 million and $8.8 million, respectively, and had net cash used in operating activities of approximately $8.2 million and $7.9 million, respectively. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital, which have declined in the past year. At December 31, 2022, we had working capital of approximately $1.0 million compared to working capital of approximately $4.6 million at December 31, 2021. At December 31, 2022, we had cash and cash equivalents of approximately $2.9 million. We expect to continue to incur net losses and negative operating cash flow for the foreseeable future as we focus on development of ProNeura based products. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to obtain government or third-party funding for our development programs. Our history of losses raises substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We will require additional proceeds to fund our product development programs and working capital requirements</i></b><span style="font-style: normal; font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently estimate that our available cash and cash equivalents will be sufficient to fund our working capital needs and product development efforts into the second quarter of 2023. We will require substantial additional funds to advance our kappa opioid agonist program beyond the proof-of-concept stage, and to fund any of our ProNeura development programs, including nalmefene, into the clinic and to complete the regulatory approval process necessary to commercialize any products we might develop. Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. While we are currently evaluating the alternatives available to us, including the possible sale of our Probuphine assets, government grants, third-party collaborations for one or more of our ProNeura programs and potential merger opportunities, our efforts to address our liquidity requirements may not be successful. Furthermore, there can be no assurance that any source of capital will be available to us on acceptable terms or will not involve substantial dilution to our stockholders. Our failure to obtain substantial funds in the next several months would likely result in the cessation of one or more of our development programs or the wind-down of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our net operating losses and research and development tax credits may not be available to reduce future federal and state income tax payments.</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, we had federal net operating loss and tax credit carryforwards of approximately $237.4 million and approximately $6.8 million, respectively, and state net operating loss and tax credit carryforwards of approximately $115.2 million and approximately $9.2 million, respectively, available to offset future taxable income, if any. Current federal and state tax laws include substantial restrictions on the utilization of net operating loss and tax credits in the event of an ownership change and we cannot assure you that our net operating loss and tax carryforwards will continue to be available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to Our Business and Industry</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our ProNeura development programs are at very early stages and will require substantial additional resources that may not be available to us.</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, other than our work on Probuphine in OUD and our work on nalmefene, we have conducted only limited research and development activities assessing our ProNeura delivery system&#8217;s applicability in other potential indications. While the nalmefene program has been funded in large part by NIDA, there is no assurance that NIDA will continue to provide the necessary funding to complete the regulatory approval process for this product candidate. We will also require substantial additional funds to advance our kappa opioid agonist program beyond the proof-of-concept stage and to support further research and development activities, including the anticipated costs of nonclinical studies and clinical trials, regulatory approvals, and eventual commercialization of any therapeutic based on our ProNeura platform technology. If we are unable to obtain substantial government grants or enter into third party collaborations to fund our ProNeura programs, we will need to seek additional sources of financing, which may not be available on favorable terms, if at all. If we are unsuccessful in obtaining the requisite funding for our ProNeura programs, we could be forced to discontinue product development. Furthermore, funding arrangements with collaborative partners or others may require us to relinquish rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves or license rights to technologies, product candidates or products on terms that are less favorable to us than might otherwise be available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Our ability to successfully develop any future product candidates based on our ProNeura drug delivery technology is subject to the risks of failure and delay inherent in the development of new pharmaceutical products, including: delays in product development, clinical testing, or manufacturing; unplanned expenditures in product development, clinical testing, or manufacturing; failure to receive regulatory approvals; emergence of superior or equivalent products; inability to manufacture on our own, or through any others, product candidates on a commercial scale; and failure to achieve market acceptance. Because of these risks, our research and development efforts may not result in any commercially viable products and our business, financial condition, and results of operations could be materially harmed.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical trials required for new product candidates are expensive and time-consuming, and their outcome is uncertain</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting clinical trials is a lengthy, time-consuming, and expensive process. The length of time may vary substantially according to the type, complexity, novelty, and intended use of the product candidate, and often can be several&#160;years or more per trial. Delays associated with products for which we are directly conducting clinical trials may cause us to incur additional operating expenses. The commencement and rate of completion of clinical trials may be delayed by many factors, including, for example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to manufacture sufficient quantities of qualified materials under cGMP for use in clinical trials;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower than expected rates of patient recruitment;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to recruit a sufficient number of patients; modification of clinical trial protocols;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory requirements for clinical trials;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of effectiveness during clinical trials;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the emergence of unforeseen safety issues;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays, suspension, or termination of the clinical trials due to the institutional review board responsible for overseeing the study at a particular study site; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of the trials.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results from early clinical trials are not necessarily predictive of results obtained in later clinical trials. Accordingly, even if we obtain positive results from early clinical trials, we may not achieve the same success in future clinical trials. Clinical trials may not demonstrate statistically significant safety and effectiveness to obtain the requisite regulatory approvals for product candidates. The failure of clinical trials to demonstrate safety and effectiveness for the desired indications could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical trials could materially harm our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We face risks associated with third parties conducting preclinical studies and clinical trials of our products</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend on third-party laboratories and medical institutions to conduct preclinical studies and clinical trials for our products and other third-party organizations to perform data collection and analysis, all of which must maintain both good laboratory and good clinical practices. We also depend upon third party manufacturers for the production of any products we may successfully develop to comply with cGMP of the FDA, which are similarly outside our direct control. If third party laboratories and medical institutions conducting studies of our products fail to maintain both good laboratory and clinical practices, the studies could be delayed or have to be repeated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We face risks associated with product liability lawsuits that could be brought against us</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing, manufacturing, marketing and sale of human therapeutic products entail an inherent risk of product liability claims. We currently have a limited amount of product liability insurance, which may not be sufficient to cover claims that may be made against us in the event that the use or misuse of our product candidates causes, or merely appears to have caused, personal injury or death. In the event we are forced to expend significant funds on defending product liability actions, and in the event those funds come from operating capital, we will be required to reduce our business activities, which could lead to significant losses. Adequate insurance coverage may not be available in the future on acceptable terms, if at all. If available, we may not be able to maintain any such insurance at sufficient levels of coverage and any such insurance may not provide adequate protection against potential liabilities. Whether or not a product liability insurance policy is obtained or maintained in the future, any claims against us, regardless of their merit, could severely harm our financial condition, strain our management and other resources or destroy the prospects for commercialization of the product which is the subject of any such claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We may be unable to protect our patents and proprietary rights</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future success will depend to a significant extent on our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and keep patent protection for our products, methods and technologies on a domestic and international basis;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforce our patents to prevent others from using our inventions;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain and prevent others from using our trade secrets; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate and commercialize products without infringing on the patents or proprietary rights of others.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We cannot assure you that our patent rights will afford any competitive advantages, and these rights may be challenged or circumvented by third parties. Further, patents may not be issued on any of our pending patent applications in the U.S. or abroad. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before a potential product can be commercialized, any related patent may expire or remain in existence for only a short period following commercialization, reducing or eliminating any advantage of the patent. If we sue others for infringing our patents, a court may determine that such patents are invalid or unenforceable. Even if the validity of our patent rights is upheld by a court, a court may not prevent the alleged infringement of our patent rights on the grounds that such activity is not covered by our patent claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, third parties may sue us for infringing their patents. In the event of a successful claim of infringement against us, we may be required to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay substantial damages;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stop using our technologies and methods;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stop certain research and development efforts;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop non-infringing products or methods; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain one or more licenses from third parties.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If required, we cannot assure you that we will be able to obtain such licenses on acceptable terms, or at all. If we are sued for infringement, we could encounter substantial delays in development, manufacture and commercialization of our product candidates. Any litigation, whether to enforce our patent rights or to defend against allegations that we infringe third party rights, will be costly, time consuming, and may distract management from other important tasks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also rely in our business on trade secrets, know-how and other proprietary information. We seek to protect this information, in part, through the use of confidentiality agreements with employees, consultants, advisors and others. Nonetheless, we cannot assure you that those agreements will provide adequate protection for our trade secrets, know-how or other proprietary information and prevent their unauthorized use or disclosure. To the extent that consultants, key employees or other third parties apply technological information independently developed by them or by others to our proposed products, disputes may arise as to the proprietary rights to such information, which may not be resolved in our favor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We must comply with extensive government regulations</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The research, development, manufacture,
labelling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of pharmaceutical products are
subject to an extensive regulatory approval process by the FDA in the U.S. and comparable health authorities in foreign markets. The process
of obtaining required regulatory approvals for drugs is lengthy, expensive and uncertain. Approval policies or regulations may change,
and the FDA and foreign authorities have substantial discretion in the pharmaceutical approval process, including the ability to delay,
limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product
candidates, regulatory approval is never guaranteed. Regulatory approval may entail limitations on the indicated usage of a drug, which
may reduce the drug&#8217;s market potential. Even if regulatory clearance is obtained, post-market evaluation of the products, if required,
could result in restrictions on a product&#8217;s marketing or withdrawal of the product from the market, as well as possible civil and
criminal sanctions. Of the large number of drugs in development, only a small&#160;percentage successfully complete the regulatory approval
process and are commercialized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We face intense competition</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">With respect to our product development
programs, we face competition from numerous companies that currently market, or are developing, products for the treatment of the diseases
and disorders we have targeted, many of which have significantly greater research and development capabilities, experience in obtaining
regulatory approvals and manufacturing, marketing, financial and managerial resources than we have. We also compete with universities
and other research institutions in the development of products, technologies and processes, as well as the recruitment of highly qualified
personnel. Our competitors may succeed in developing technologies or products that are more effective than the ones we have under development
or that render our proposed products or technologies non-competitive or obsolete. In addition, our competitors may achieve product commercialization
or patent protection earlier than we will.</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We depend on a small number of employees and consultants</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on the services of a limited number of personnel and the loss of one or more of such individuals could substantially impair our ongoing commercialization efforts. We compete in our hiring efforts with other pharmaceutical and biotechnology companies, and it may be difficult and could take an extended period of time because of the limited number of individuals in our industry with the range of skills and experience required and because of our limited resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, we retain scientific and clinical advisors and consultants to assist us in all aspects of our business. Competition to hire and retain consultants from a limited pool is intense. Further, because these advisors are not our employees, they may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us, and typically they will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us or our collaborators, from research institutions and our collaborators, and directly from individuals</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of personal information. In addition, most health care providers, including research institutions from which we or our collaborators obtain patient health information, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act. Although we are not directly subject to HIPAA, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rising inflation and interest rates could negatively impact our revenues, profitability and borrowing costs. In addition, if our costs increase and we are not able to correspondingly adjust our commercial relationships to account for this increase, our net income would be adversely affected, and the adverse impact may be material.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation rates, particularly in the U.S., have increased recently to levels not seen in years. Increased inflation may result in decreased demand for our products, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation. Increases in interest rates have had, and could continue to have, a material impact on our borrowing costs. In an inflationary environment, we may be unable to raise the sales prices of our products at or above the rate at which our costs increase, which could reduce our profit margins and have a material adverse effect on our financial results and net income. We also may experience lower than expected sales if there is a decrease in spending on products in our industry in general or a negative reaction to our pricing. A reduction in our revenue would be detrimental to our profitability and financial condition and could also have an adverse impact on our future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We face risks related to health epidemics, such as the COVID&#45;19 global pandemic, that could adversely affect our operations or financial results</i></b><span style="font-weight: normal">.</span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">The ongoing COVID-19 pandemic has had and may continue to have a material adverse effect on our business. While the duration of the pandemic and its potential economic impact are difficult to predict, it already has caused significant disruption in the healthcare industry and is likely to have continuing impacts as it continues. Although we expect that the primary impacts of the COVID-19 pandemic are behind us, as we have seen with the spread of the Delta and Omicron variants, the extent to which COVID-19 continues to impact our business, healthcare systems in general or the global economy as a whole will depend on future developments that are highly uncertain and cannot be predicted and may result in a sustained economic downturn that could affect our ability to access capital on reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We are increasingly dependent on information technology systems, infrastructure and data. Cybersecurity breaches could expose us to liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are increasingly dependent upon information technology systems, infrastructure and data. Our computer systems may be vulnerable to service interruption or destruction, malicious intrusion and random attack. Security breaches pose a risk that sensitive data, including intellectual property, trade secrets or personal information may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, denial-of service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our key business partners face similar risks, and a security breach of their systems could adversely affect our security posture. While we continue to invest in data protection and information technology, there can be no assurance that our efforts will prevent service interruptions, or identify breaches in our systems, that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to our Common Stock</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our share price may be volatile, which could prevent you from being able to sell your shares at or above your purchase price.</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of shares of our common stock has been and may continue to be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results of our product development efforts;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions with respect to our products under development or our competitors&#8217; products;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated fluctuations in our financial condition and operating results;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated fluctuations in our competitors&#8217; operating results or growth rate;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us, our potential future collaborators or our competitors of significant acquisitions, strategic collaborations, joint ventures, or capital commitments;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of new or updated research or reports by securities analysts;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inconsistent trading volume levels of our shares;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement or expectation of additional financing efforts;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock by us, our insiders or our other stockholders;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market conditions for biopharmaceutical stocks in general; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic and market conditions.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of shares of our common stock and could subject us to securities class action litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions provide that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the authorized number of directors can be changed only by resolution of our board of directors;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our bylaws may be amended or repealed by our board of directors or our stockholders;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stockholders may not call special meetings of the stockholders or fill vacancies on the board of directors;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our board of directors is authorized to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate as a &#8220;poison pill&#8221; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stockholders do not have cumulative voting rights, and therefore our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stockholders must comply with advance notice provisions to bring business before or nominate directors for election at a stockholder meeting.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If we cannot continue to satisfy the Nasdaq Capital Market continued listing standards and other Nasdaq rules, our common stock could be delisted, which would harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock is currently listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;). The listing standards of Nasdaq require that a company maintain stockholders&#8217; equity of at least $2.5 million and a minimum bid price subject to specific requirements of $1.00 per share. There is no assurance that we will be able to maintain compliance with the minimum closing price requirement or the minimum stockholders&#8217; equity requirement. Should we fail to comply with the minimum listing standards applicable to issuers listed on Nasdaq, our common stock may be delisted from Nasdaq. If our common stock is delisted, it could reduce the price of our common stock and the levels of liquidity available to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our common stock were to be delisted from Nasdaq and was not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our failure to meet the continued listing requirements of Nasdaq could result in a de-listing of our common stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, our stockholders&#8217; equity was below the $2,500,000 minimum stockholders&#8217; equity requirement for continued listing. We have previously received notices of noncompliance due to our failure to maintain the $2,500,000 minimum stockholders&#8217; equity requirement for continued listing. In the past, were able to regain compliance with that requirement through capital raises and our discontinuation of the expenses associated with Probuphine commercial operations. There can be no assurance that we will continue to meet all of the criteria necessary for Nasdaq to allow us to remain listed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2023, we received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, or Nasdaq, notifying us that we were no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed companies to maintain a minimum bid price of $1.00 per share. The letter noted that the bid price of our common stock was below $1.00 for the 30-day period ending March 15, 2023. The notification letter had no immediate effect on our listing on the Nasdaq Capital Market. Nasdaq has provided us with 180 days, or until September 12, 2023, to regain compliance with the minimum bid price requirement by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, we received a notice from Nasdaq, regarding the fact that we had not yet held an annual meeting of shareholders within twelve months of the end of our fiscal year ended December 31, 2021 and we no longer comply with Listing Rules for continued listing. In February 2023, we provided Nasdaq with a plan to regain compliance. If the plan is accepted by Nasdaq, we will have until June 29, 2023 to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, we received a notice from Nasdaq regarding the fact that the market price of our common stock was below the $1.00 minimum bid price requirement for continued listing. In July 2022, we were able to regain compliance with the minimum bid requirement and remain listed on Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our common stock is delisted from Nasdaq, our common stock would likely then trade only in the over-the- counter market. If our common stock were to trade on the over-the-counter market, selling our common stock could be more difficult because smaller quantities of shares would likely be bought and sold, transactions could be delayed, and we could face significant material adverse consequences, including: a limited availability of market quotations for our securities; reduced liquidity with respect to our securities; a determination that our shares are a &#8220;penny stock,&#8221; which will require brokers trading in our securities to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our securities; a reduced amount of news and analyst coverage for our company; and a decreased ability to issue additional securities or obtain additional financing in the future. These factors could result in lower prices and larger spreads in the bid and ask prices for our common stock and would substantially impair our ability to raise additional funds and could result in a loss of institutional investor interest and fewer development opportunities for us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the foregoing, if our common stock is delisted from Nasdaq and it trades on the over-the- counter market, the application of the &#8220;penny stock&#8221; rules could adversely affect the market price of our common stock and increase the transaction costs to sell those shares. The Securities and Exchange Commission, or SEC, has adopted regulations which generally define a &#8220;penny stock&#8221; as an equity security that has a market price of less than $5.00 per share, subject to specific exemptions. If our common stock is delisted from Nasdaq and it trades on the over-the- counter market at a price of less than $5.00 per share, our common stock would be considered a penny stock. The SEC&#8217;s penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and the salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&#8217;s account. In addition, the penny stock rules generally require that before a transaction in a penny stock occurs, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s agreement to the transaction. If applicable in the future, these rules may restrict the ability of brokers-dealers to sell our common stock and may affect the ability of investors to sell their shares, until our common stock no longer is considered a penny stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales by our stockholders of a substantial number of shares of our common stock in the public market could occur in the future. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will seek to raise additional funds and may finance acquisitions or develop strategic relationships by issuing securities that would dilute your ownership. Depending on the terms available to us, if these activities result in significant dilution, it may negatively impact the trading price of our shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have financed our operations, and we expect to continue seeking to finance our operations, acquisitions, if any, and the development of strategic relationships by issuing equity and/or convertible securities, which could significantly reduce the percentage ownership of our existing stockholders. Further, any additional financing that we secure, including any debt financing, may require the granting of rights, preferences or privileges senior to, or pari passu with, those of our common stock. Any issuances by us of equity securities may be at or below the prevailing market price of our common stock and in any event may have a dilutive impact on your ownership interest, which could cause the market price of our common stock to decline. We may also raise additional funds through the incurrence of debt or the issuance or sale of other securities or instruments senior to our shares of common stock. The holders of any securities or instruments we may issue may have rights superior to the rights of our common stockholders. If we experience dilution from the issuance of additional securities and we grant superior rights to new securities over common stockholders, it may negatively impact the trading price of our shares of common stock and you may lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>One of our stockholders, David E. Lazar, has significant voting power over our common stock and may vote his shares in a manner that is not in the best interest of other stockholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One of our stockholders, David E. Lazar, controls approximately 24.96% of the voting power represented by our outstanding shares of common stock. He may be able to exert significant control over our management and affairs requiring stockholder approval, including approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of all of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We have never paid any cash dividends and have no plans to pay any cash dividends in the future.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of shares of our common stock are entitled to receive such dividends as may be declared by our board of directors. To date, we have paid no cash dividends on our shares of our preferred or common stock and we do not expect to pay cash dividends in the foreseeable future. In addition, the declaration and payment of cash dividends is restricted under the terms of our existing Loan Agreement. We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any return investors in our preferred or common stock may have will be in the form of appreciation, if any, in the market value of their shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item 1B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unresolved Staff Comments.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item 2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our executive offices are located in approximately 3,295 square feet of office space in South San Francisco, California that we occupy under a three-year operating lease expiring in June 2024. It is our intention to continue to be based in South San Francisco.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item 3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal Proceedings</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A legal proceeding has been initiated by a former employee alleging wrongful termination, retaliation, infliction of emotional distress, negligent supervision, hiring and retention and slander. An independent investigation into this individual&#8217;s allegations of whistleblower retaliation, while still an employee, was conducted utilizing an outside investigator and concluded that such allegations were not substantiated. We intend to vigorously defend the lawsuit (which we have compelled into arbitration); however, in light of our cash position, there can be no assurance that the defense and/or settlement of this matter will not have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item 4.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mine Safety Disclosures.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>PART&#160;II</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span id="a_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 5.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;TTNP&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate Number of Equity Security Holders</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 24, 2023, there were 15,016,295 shares of our common stock outstanding held by 94 holders of record. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never declared or paid any cash dividends on our common stock, and we do not anticipate paying any cash dividends to stockholders in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board and will be dependent upon our financial condition, results of operations, capital requirements, and such other factors as the Board deems relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity Compensation Plan Information</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth aggregate information regarding our equity compensation plans in effect as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; vertical-align: bottom">Plan category</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities to<br /> be issued upon exercise<br /> of outstanding options,<br /> warrant and rights<br /> (a)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average<br /> exercise price of<br /> outstanding<br /> options,<br /> warrants and rights<br /> (b)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities<br /> remaining available for<br /> future issuance under<br /> equity compensation<br /> plans<br /> (c)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Equity compensation plans approved by security holders(1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">925,738</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">7.29</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">74,262</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Equity compensation plans not approved by security holders(2)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,189</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">541.80</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">926,927</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">7.97</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">74,262</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January&#160;2021, our stockholders approved an amendment to the 2015 Omnibus Equity Incentive plan to increase the number of authorized shares to 1,000,000 shares.</span></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 1,189 non-qualified stock options and restricted share awards granted to employees, directors and consultants under our 2014 Incentive Plan. For a description of the 2014 Plan, see Note&#160;8 to the financial statements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item 6.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span id="a_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura<sup>&#174;</sup>, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our first product based on our ProNeura technology was Probuphine&#174; (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo&#8482;) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020 to allow us to focus our limited resources on product development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, we announced our intention to work with our financial advisor to explore strategic alternatives to enhance stockholder value, potentially including an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other transaction. In June 2022, we implemented a plan to reduce expenses and conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses to enable us to maintain sufficient resources as we pursued potential strategic alternatives. In July 2022, David Lazar and Activist Investing LLC (collectively, &#8220;Activist&#8221;) acquired an approximately 25% ownership interest in Titan, filed a proxy statement and nominated six additional directors, each of whom was elected to our board of directors (the &#8220;Board&#8221;) at a special meeting of stockholders held on August 15, 2022 (the &#8220;Special Meeting&#8221;). The exploration and evaluation of possible strategic alternatives by the Board has continued following the Special Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical Accounting Policies and the Use of Estimates</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. Actual results could differ materially from those estimates. We believe the following accounting policies for the&#160;years ended December 31, 2022 and 2021 to be applicable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue Recognition</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have contracts with NIDA,
the Bill &amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities
that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue
from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized
when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net Product Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transferred, generally upon shipment or delivery, to our customers, including distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Returns&#160;&#8211; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement. During the&#160;year ended December&#160;31, 2019, we entered into agreements with large national specialty pharmacies with a distribution channel different from that of our existing customers and, therefore, the related reserves had unique considerations. We continued to evaluate the activities with these specialty pharmacies and updated the related reserves accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebates&#160;&#8211; Our provision for rebates was estimated based on our customers&#8217; contracted rebate programs and our historical experience of rebates paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounts&#160;&#8211;
The provision was estimated based upon invoice billings, utilizing historical customer payment experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance Obligations</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Price</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocation of Consideration</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Timing of Recognition</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inventories</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are recorded at the lower of cost or net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantities on hand and write down to its net realizable value any inventory that we believe to be impaired. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share-Based Payments</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize compensation expense for all share-based awards made to employees, directors and consultants. The fair value of share-based awards is estimated at the grant date based on the fair value of the award and is recognized as expense, net of estimated pre-vesting forfeitures, ratably over the vesting period of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the Black-Scholes option pricing model to estimate the fair value method of our awards. Calculating stock-based compensation expense requires the input of highly subjective assumptions, including the expected term of the share-based awards, stock price volatility, and pre-vesting forfeitures. We estimate the expected term of stock options granted for the&#160;years ended December 31, 2022 and 2021 based on the historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and the expectations of future employee behavior. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock. The assumptions used in calculating the fair value of stock-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future. In addition, we are required to estimate the expected pre-vesting forfeiture rate and only recognize expense for those shares expected to vest. We estimate the pre-vesting forfeiture rate based on historical experience. If our actual forfeiture rate is materially different from our estimate, our stock-based compensation expense could be significantly different from what we have recorded in the current period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income Taxes</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the process of preparing our financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves us estimating our current tax exposure under the most recent tax laws and assessing temporary differences resulting from differing treatment of items for tax and accounting purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We assess the likelihood that we will be able to recover our deferred tax assets. We consider all available evidence, both positive and negative, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. If it is not more likely than not that we will recover our deferred tax assets, we will increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical Trial Accruals</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. The actual clinical trial costs for studies conducted in the past two&#160;years have not differed materially from the estimated projection of expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants Issued in Connection with Equity Financing</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle warrants in cash. For warrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrants as a liability at each reporting period and record changes in the estimated fair value as a non-cash gain or loss in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have funded our operations since inception primarily through the sale of our securities and the issuance of debt, as well as with proceeds from warrant and option exercises, corporate licensing and collaborative agreements, the sale of royalty rights, sales of Probuphine and government-sponsored research grants. At December 31, 2022, we had working capital of approximately $1.0 million compared to working capital of approximately $4.6 million at December&#160;31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">As of December 31:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Cash and cash equivalents</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">2,937</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">6,037</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Working capital</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">973</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">4,560</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Current ratio</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37:1</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7:1</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">For the Years Ended December 31:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Cash used in operating activities</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(8,183</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(7,899</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Cash used in investing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(23</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Cash provided by financing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">4,984</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">8,841</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating activities for the year ended December 31, 2022 consisted primarily of the net loss for the period of approximately $10.2 million. This was partially offset by an approximately $0.9 million of non-cash stock-based compensation, $0.5 million of stock based payments, approximately $0.2 million of depreciation and amortization expense and approximately $0.4 million related to net changes in other operating assets and liabilities. Uses of cash in operating activities were primarily to fund our product development programs and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No net cash was used or provided by in investing activities during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by financing activities for the year ended December 31, 2022 consisted primarily of approximately $5.0 million in proceeds from our equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, we completed a registered direct offering with an accredited investor pursuant to which we issued an aggregate of 1,100,000 shares of our common stock and 2,274,242 pre-funded warrants to purchase shares of our common stock, with an exercise price of $0.001 per share. In a concurrent private placement, we sold unregistered pre-funded warrants to purchase an aggregate of 1,289,796 shares of common stock with an exercise price of $0.001 per share and issued unregistered five year and six month warrants to purchase an aggregate of 4,664,038 shares of common stock with an exercise price of $1.14. The net cash proceeds from these offerings were approximately $5.0 million after deduction of underwriting fees and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January&#160;2021, we completed a registered direct offering pursuant to which we issued 2,725,000 shares of our common stock at an offering price of $3.55 per share and private placement warrants to purchase 2,725,000 shares of our common stock with an exercise price of $3.55 per share. We received net cash proceeds of approximately $8.8 million after the deduction of underwriting fees and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, we had cash and cash equivalents of approximately $2.9 million, which we believe is sufficient to fund our planned operations into the second quarter of 2023. There is substantial doubt about our ability to continue as a going concern. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Year Ended December 31, 2022 Compared to&#160;Year Ended December&#160;31, 2021</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years ended December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in thousands)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Revenue:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">License revenue</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">60</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">13</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">47</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Product revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">236</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(236</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Grant revenue</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">497</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,277</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(780</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in; vertical-align: top">Total revenue</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">557</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,526</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(969</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License revenues for the years ended December 31, 2022 consists of an upfront license payment of approximately $50,000 related to the use of our ProNeura technology for ophthalmic use and royalties received on sales of Probuphine by Knight in Canada. License revenues for the years ended December 31, 2021 reflect royalties received on sales of Probuphine by Knight in Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product revenues for the year ended December 31, 2021 consisted of sales of our Probuphine product materials to Molteni and Knight for the EU and Canada, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decrease in grant revenue was primarily due to decreased activities related to the NIDA grant for the development of a nalmefene implant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years&#160;ended&#160;December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in thousands)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Operating expenses:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Cost of goods sold</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">199</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(199</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Research and development</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,758</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5,692</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(934</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">General and administrative</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">6,034</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">4,989</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,045</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in; text-indent: -0.125in; vertical-align: top">Total operating expenses</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">10,792</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">10,880</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(88</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of goods sold reflects costs and expenses associated with sales of Probuphine product materials to Molteni and Knight for the EU and Canada, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decrease in research and development costs was primarily associated with reduced activities related to non-clinical studies required for the IND submission as part of our NIDA grant for the development of a nalmefene implant, decreases in expenses related to initial non-clinical proof of concept studies related to our TP-2021 implant program and decreases in research and development personnel-related costs and other expenses. Other research and development expenses include internal operating costs such as research and development personnel-related expenses, non-clinical and clinical product development related travel expenses, and allocation of facility and corporate costs. As a result of the risks and uncertainties inherently associated with pharmaceutical research and development activities described elsewhere in this document, we are unable to estimate the specific timing and future costs of our clinical development programs or the timing of material cash inflows, if any, from our product candidates. However, we anticipate that our research and development expenses will increase as we continue our current or any future ProNeura development programs to the extent these costs are not supported through grants or partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The increase in general and administrative expenses was primarily related to increases in non-cash stock-based compensation, employee related expenses and legal and other professional fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other Expenses, Net</i></b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years&#160;ended&#160;December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in thousands)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Other income (expense):</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Interest income, net</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">53</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">52</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Other expense, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(24</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(84</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">60</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Non-cash gain on debt extinguishment</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">661</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(661</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.375in; text-indent: -0.125in; vertical-align: top">Other income, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">29</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">578</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(549</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decrease in other income, net was primarily due to a gain on debt extinguishment resulting from the May 2021 forgiveness of our outstanding PPP Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net Loss and Net Loss per Share</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our net loss applicable to common stockholders for the year ended December 31, 2022 was approximately $10.2 million, or approximately $0.76 per share, compared to our net loss continuing operations applicable to common stockholders of approximately $8.8 million, or approximately $0.90 per share, for the comparable period in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance Sheet Arrangements</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never entered into any off-balance sheet financing arrangements and we have never established any special purpose entities. We have not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item 7A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative and Qualitative Disclosures About Market Risk</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>Item 8.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Supplementary Data.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The response to this item is included in a separate section of this Report. See &#8220;Index to Financial Statements&#8221; on Page&#160;F&#45;1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>Item 9.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes and Disagreements with Accountants on Accounting and Financial Disclosure.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>Item 9A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controls and Procedures.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <i>Evaluation of Disclosure Controls and Procedures</i>: Our principal executive and financial officers reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule&#160;13a&#45;15(e)) as of the end of the period covered by this Annual Report on Form&#160;10&#45;K. Based on that evaluation, our principal executive and financial officers concluded that our disclosure controls and procedures are effective in timely providing them with material information relating to Titan, as required to be disclosed in the reports we file under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"> <span style="font: 10pt Times New Roman, Times, Serif">(b)</span> <span style="font: 10pt Times New Roman, Times, Serif"><i>Management&#8217;s Annual Report on Internal Control Over Financial Reporting</i>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal control over financial reporting refers to the process designed by, or under the supervision of, our principal executive officer and principal financial officer, and effected by our Board, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our management and directors; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of our assets that could have a material effect on the financial statements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management overrides. Due to such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining adequate internal control over financial reporting for Titan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has used the framework set forth in the report entitled <i>Internal Control&#8212;Integrated Framework</i> published by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), known as COSO, to evaluate the effectiveness of Titan&#8217;s internal control over financial reporting. Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <i>Changes in Internal Control Over Financial Reporting</i>: There were no changes in our internal control over financial reporting (as defined in Rules&#160;13(a)&#45;15(f)&#160;and 15(d)&#45;15(f)&#160;under the Securities Act) during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>Item 9B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Information.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>Item 9C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>PART&#160;III</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>Item&#160;10.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors, Executive Officers and Corporate Governance</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set forth below are the name, age and position and a brief account of the business experience of each of our executive officers and directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Office</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
    Since</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David E. Lazar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Chairman of the Board</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Katherine Beebe DeVarney, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Operating Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph A. Akers (1)(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    2014</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avraham Ben-Tzvi, Adv. (1)(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter L. Chasey, Esq. (2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Greenberg (2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. David MacFarlane, Ph.D. (1)(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2002</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew C. McMurdo, Esq. (1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James R. McNab, Jr. (1)(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    2014</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Natan (1)(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc Rubin, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    2007</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the audit committee</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the compensation committee</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the nominating and governance committee</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>David E. Lazar</i></b> has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018. Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018. In his role as Chief Executive Officer of Custodian Ventures LLC, Mr. Lazar has successfully served as a custodian to numerous public companies across a wide range of industries, including without limitation, C2E Energy, Inc. (OTCMKTS: OOGI), China Botanic Pharmaceutical Inc. (OTCMKTS: CBPI), One 4 Art Ltd., Romulus Corp., Moveix, Inc., Arax Holdings Corp. (OTCMKTS: ARAT), ESP Resources, Inc. (OTCMKTS: ESPIQ), Adorbs, Inc., Exobox Technologies Corp. (OTCMKTS: EXBX), Petrone Worldwide, Inc. (OTCMKTS: PFWIQ), Superbox, Inc. (OTCMKTS: SBOX), Sino Green Land Corp. (OTCMKTS: SGLA), SIPP International Industries, Inc. (OTCMKTS: SIPN), Cereplast, Inc. (OTCMKTS: CERPQ), Energy 1 Corp. (OTCMKTS: EGOC), ForU Holdings, Inc. (OTCMKTS: FORU), China Yanyuan Yuhui National Education Group, Inc. (OTCMKTS: YYYH), Pan Global Corp. (OTCMKTS: PGLO), Shengtang International, Inc. (OTCMKTS: SHNL), Alternaturals, Inc. (OTCMKTS: ANAS), USA Recycling Industries, Inc. (OTCMKTS: USRI), Tele Group Corp., Xenoics Holdings, Inc. (OTCMKTS: XNNHQ), Richland Resources International Group, Inc. (OTCMKTS: RIGG), AI Technology Group, Inc., Reliance Global Group, Inc. (NASDAQ: RELI), Melt, Inc., Ketdarina Corp., 3D MarkerJet, Inc. (OTCMKTS: MRJT), Lvpai Group Ltd., Gushen, Inc., FHT Future Technology Ltd., Inspired Builders, Inc., Houmu Holdings Ltd. (OTCMKTS: HOMU), Born, Inc. (OTCMKTS: BRRN), Changsheng International Group Ltd., Sollensys Corp. (OTCMKTS: SOLS), Guozi Zhongyu Capital Holdings Co. (OTCMKTS: GZCC) and Cang Bao Tian Xia International Art Trade Center, Inc. Mr. Lazar currently serves as an Advisor to PROMAX Investments LLC, a position he has held since July 2022, and as an Ambassador at Large for the Arab African Council for Integration and Development, since March 2022. Based on Mr. Lazar&#8217;s diverse knowledge of financial, legal and operations management, public company management, accounting, audit preparation, due diligence reviews and SEC regulations, our Board believes that Mr. Lazar has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Katherine Beebe DeVarney, Ph.D.</i></b> joined Titan in February&#160;2007 and currently serves as our President and Chief Operating Officer.&#160;She has been a member of the Board since December&#160;2019. During her 15&#160;years with us, she has served in various scientific and medical research and development capacities, with primary responsibility for oversight of our product research and development, Regulatory Affairs, and Medical Affairs. Dr.&#160;Beebe DeVarney has 26&#160;years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics. Prior to her pharmaceutical career, Dr.&#160;Beebe DeVarney was a hospital-based clinician and worked in academic medicine for 10&#160;years. She received her Ph.D. in Clinical Neuropsychology from George Mason University and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania. Based on Dr.&#160;Beebe DeVarney&#8217;s extensive knowledge of the medical, research, and regulatory requirements of product development programs, our Board believes that Dr.&#160;Beebe DeVarney has the appropriate set of skills to serve as member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Joseph A. Akers</i></b> was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July&#160;2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July&#160;2002. Mr.&#160;Akers received a B.S. in marketing and an M.B.A. in finance from the University of California at Berkeley. Based on Mr.&#160;Akers&#8217; extensive management experience in the pharmaceutical industry, particularly in the areas of administration and finance, our Board believes that Mr.&#160;Akers has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Avraham Ben-Tzvi, Adv.</i></b> is the Founder of ABZ Law Office, a boutique Israeli law firm specializing in outsourced general counsel services for publicly traded as well as private companies and corporations, Investments &amp; Securities Laws, Commercial Law &amp; Contracts and various civil law matters, which he established in January 2017. Mr. Ben-Tzvi served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, from November 2015 until April 2020. Prior to that, Mr. Ben-Tzvi served as General Counsel and Company Secretary at Medigus Ltd. (NASDAQ/TASE: MDGS), a minimally invasive endosurgical tools medical device and miniaturized imaging equipment company, from April 2014 until November 2015. Mr. Ben-Tzvi is a member of the Israel Bar Association, and is also licensed as a Notary by the Israeli Ministry of Justice. Prior to that he served as an attorney at one of Israel&#8217;s leading international law firms where, amongst other corporate and commercial work, he advised companies and underwriters on various offerings by Israeli companies listing in the U.S. and on various SEC related filings. Prior to becoming a lawyer, Mr. Ben-Tzvi worked in a number of business development, corporate finance and banking roles at companies in the financial services, lithium battery manufacturing and software development industries. Mr. Ben-Tzvi holds a B.A., <i>magna cum laude</i>, in Economics from Yeshiva University in New York and an LL.B., <i>magna cum laude </i>with Honors from Sha&#8217;arei Mishpat College of Law in Hod HaSharon, Israel. Based on Mr. Ben-Tzvi&#8217;s extensive legal experience and knowledge in the fields of civil-commercial law and corporate and securities law, and his previous public company and commercial business experience, our Board believes that Mr. Ben-Tzvi has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Peter L. Chasey, Esq.</i></b> currently serves as the Owner of Chasey Law Offices, a law practice specializing in personal litigation, business litigation and commercial law, since founding the practice in 2005. Earlier in his career, Mr. Chasey served as staff counsel for one of the largest insurance companies in the world defending general claims against insured businesses and also served as a land surveyor. Mr. Chasey holds a B.S. in Political Science and Government from the University of San Diego and a J.D. from the University of San Diego School of Law. Based on Mr. Chasey&#8217;s commercial law expertise, coupled with his experience leading his own law firm, our Board believes that Mr. Chasey has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eric Greenberg</i></b> has over 40 years of capital markets experience. As a trader and portfolio manager at hedge funds, his areas of expertise included the development of trading strategies, portfolio management and deal structuring. Mr. Greenberg was Co-Founder of Blink Charging Co. (NASDAQ: BLNK), a leader in the EV charging infrastructure industry. In addition, Mr. Greenberg provides investor relation and digital marketing services for companies across a variety of industries, such as life sciences, fintech, internet platforms and others. Mr. Greenberg holds a B.B.A in Finance from Baruch College and an M.B.A. in Finance from Baruch College Zicklin School of Business. Based on Mr. Greenberg&#8217;s more than 40 years&#8217; experience in trading, developing strategies, and portfolio management and public markets experience in the microcap sector, our Board believes that Mr. Greenberg has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>M. David MacFarlane, Ph.D.</i></b> served as Vice President and Responsible Head of Regulatory Affairs of Genentech,&#160;Inc. from 1989 until his retirement in August&#160;1999. Prior to joining Genentech,&#160;Inc., he served in various positions with Glaxo&#160;Inc., last as Vice President of Regulatory Affairs. Based on Dr.&#160;MacFarlane&#8217;s management experience in the pharmaceutical industry, particularly in the area of clinical and regulatory affairs, our Board believes that Dr.&#160;MacFarlane has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Matthew C. McMurdo, Esq.</i></b> currently serves as Managing Member of McMurdo Law Group, LLC, a corporate and securities law practice, since 2010. Previously, Mr. McMurdo was a Partner at Nannarone &amp; McMurdo, LLP, a boutique law firm, from 2008 to 2010. In addition, Mr. McMurdo served as General Counsel of Berkley Asset Management LLC, the general partner of a real estate fund focused on opportunistic and distressed real estate assets, from 2011 to 2013. Mr. McMurdo holds a B.S. in Finance from Lehigh University and a J.D.,&#160;<i>cum laude,&#160;</i>from Benjamin N. Cardozo School of Law. Based on Mr. McMurdo&#8217;s extensive experience in corporate and securities law and advising many public companies on federal securities law, our Board believes that Mr. McMurdo has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>James R. McNab,&#160;Jr.</i></b> has served since June&#160;2014 as chief executive officer of JT Pharmaceuticals,&#160;Inc., a privately-held drug discovery company he founded. Mr.&#160;McNab served as executive chairman of FirstString Research,&#160;Inc., a privately-held biopharmaceutical company from 2009 to 2019. Mr.&#160;McNab has co-founded several privately-held companies, including Sontra Medical Corporation, a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products. He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. Based on Mr.&#160;McNab&#8217;s extensive management experience in the pharmaceutical industry, our Board believes that Mr.&#160;McNab has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>David Natan</i></b> currently serves as President and Chief Executive Officer of Natan &amp; Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, since 2007. From February 2010 to May 2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on the solar industry and LED lighting products. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of PharmaNet Development Group, Inc., a drug development services company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to that, Mr. Natan served in various roles of increasing responsibility with Deloitte &amp; Touche LLP, a global consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Global Diversified Marketing Group, Inc. (OTCMKTS: GDMK), a manufacturer, marketer and distributor of food and snack products, since February 2021 and serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (NASDAQ: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Additionally in December 2022, Mr. Natan was appointed to the board of Directors and Audit Committee Chair of Vivakor Inc. (NASDAQ: VIVK). Previously, Mr. Natan served as Chairman of the Board of Directors of ForceField Energy, Inc., from April 2015 to May 2020, and as a member of the Board of Directors of Global Technovations, Inc., from December 1999 to December 2001. Mr. Natan holds a B.A. in Economics from Boston University. Based on Mr. Natan&#8217;s extensive experience, our Board believes that Mr. Natan has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marc Rubin, M.D.</i></b> served as our President and Chief Executive from October&#160;2007 until December&#160;2008 and was re-engaged as our Executive Chairman from May&#160;2009 until August 2022. Until February&#160;2007, Dr.&#160;Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June&#160;2006, Dr.&#160;Rubin was a member of the Executive Board of Schering AG since joining us in October&#160;2003, as well as Chairman of Schering Berlin&#160;Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August&#160;2003, Dr.&#160;Rubin was employed by GlaxoSmithKline where he held positions of increasing responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, he was Senior Vice President of Global Clinical Pharmacology&#160;&amp; Discovery Medicine. Dr.&#160;Rubin holds an M.D. from Cornell University Medical College. Dr.&#160;Rubin currently serves on the board of directors of Curis&#160;Inc. and Galectin Therapeutics. Based on Dr.&#160;Rubin&#8217;s previous position as our Executive Chairman, his extensive senior management experience and service on boards of directors in the biotechnology and pharmaceutical industries and his medical background, our Board believed that Dr.&#160;Rubin had the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As indicated above, each of our directors has extensive management and operational experience in one or more facets of the pharmaceutical industry, including research, product development, clinical and regulatory affairs, manufacturing and sales and marketing, providing our company with the leadership needed by a biotechnology company in all stages of its development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors serve until the next annual meeting or until their successors are elected and qualified. Officers serve at the discretion of the Board, subject to rights, if any, under contracts of employment. See &#8220;Item&#160;11. Executive Compensation&#8212;Employment Agreements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Leadership Structure</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, our principal executive officer and chairman of the Board positions are held by David E. Lazar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code of Ethics</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We adopted a Code of Business Conduct and Ethics (the &#8220;Code&#8221;) in February&#160;2013 that applies to all directors, officers and employees. The Code is filed as an exhibit to this Annual Report on Form&#160;10&#45;K and is available on our website at <i>www.titanpharm.com. </i>A copy of our code of ethics will also be provided to any person without charge, upon written request sent to us at our offices located at 400 Oyster Point Blvd, Suite&#160;505, South San Francisco, California 94080.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes in Director Nomination Process for Stockholders</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p> <!-- Field: Split-Segment; Name: 01 -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span>Item&#160;11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive Compensation</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY COMPENSATION TABLE</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides information regarding the compensation paid during the&#160;years ended December 31, 2022 and 2021 to each of the executive officers named below, who are collectively referred to as &#8220;named executive officers&#8221; elsewhere in this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; vertical-align: bottom">Name and Principal Position</td>
    <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options<br /> Awards<br /> ($)<sup>(1)</sup></b></span></p></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br /> Awards<br /> ($)<sup>(1)</sup></b></span></p></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br /> Compensation<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc Rubin, MD<sup>(2)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">2022</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">204,083</td>
    <td style="width: 1%; text-align: left"><sup>(3)</sup>&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">57,582</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">164,583</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">426,248</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Executive Chairman</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">390,244</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">490,003</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">884,247</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">David Lazar</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">152,250</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">152,250</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Katherine Beebe DeVarney, Ph.D.</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">308,000</td>
    <td style="text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">54,340</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">362,340</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">President and Chief Operating Officer</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">383,641</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">490,003</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">877,644</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Amounts shown represent the grant date fair value computed in accordance with FASB ASC 718. The assumptions used by us with respect to the valuation of option grants and stock awards are set forth in Note&#160;8 to the financial statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Dr. Rubin&#8217;s employment was terminated in August 2022. He was due to receive severance payments through July 2023. However, the Board has agreed to suspend the severance payments until such time as we are able to pay all officer and director compensation.</span> <span style="font-size: 10pt">He received approximately $165,000 related to severance payments during 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On June 15, 2022, we implemented a plan to reduce expenses and conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses. The cost-savings measures are being undertaken to enable us to maintain sufficient resources as we work with our advisors on potential strategic alternatives for maximizing shareholder value. As part of the aforementioned plan, Dr. Rubin and Dr. Beebe DeVarney each agreed to waive 40% of their base salaries for six months.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt">(4)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On December 14, 2022, we entered into an employment agreement with Mr. Lazar pursuant to which Mr. Lazar was hired to serve as our Chief Executive Officer, effective August 16, 2022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee Benefits Plans</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal purpose of our stock incentive plans is to attract, motivate, reward and retain selected employees, consultants and directors through the granting of stock-based compensation awards. The stock option plans provide for a variety of awards, including non-qualified stock options, incentive stock options (within the meaning of Section&#160;422 of the Code), stock appreciation rights, restricted stock awards, performance-based awards and other stock-based awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2002 Stock Incentive Plan</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July&#160;2002, we adopted the 2002 Stock Incentive Plan, or the 2002 Plan. Under the 2002 Plan, as amended, a total of approximately 7,234 shares of our common stock were authorized for issuance to employees, officers, directors, consultants, and advisers. The 2002 Plan expired by its terms in July&#160;2012. On December&#160;31, 2022, no options to purchase shares of our common stock were outstanding under the 2002 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2014 Incentive Plan</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February&#160;2014, our Board adopted the 2014 Incentive Plan, or the 2014 Plan, pursuant to which 2,526 shares of our common stock were authorized for issuance to employees, directors, officers, consultants and advisors. On December 31, 2022, options to purchase 1,189 shares of our common stock were outstanding under the 2014 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2015 Omnibus Equity Incentive Plan</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August&#160;2015, our stockholders approved the 2015 Omnibus Equity Incentive Plan, or the 2015 Plan. The 2015 Plan, as amended, authorized a total of 1,000,000 shares of our common stock for issuance to employees, directors, officers, consultants and advisors. On December 31, 2022, options to purchase 925,738 shares of our common stock were outstanding under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding Equity Awards at Fiscal&#160;Year-End</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the number of securities underlying outstanding plan awards for each named executive officer as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="8" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></p></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></p></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities Underlying Unexercised Awards (#) Exercisable</b></span></p></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities Underlying Unexercised Awards (#) Unexercisable</b></span></p></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price ($)</b></span></p></td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration Date</b></span></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Marc Rubin, M.D.</td>
    <td>&#160;</td>
    <td style="text-align: center">203</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">594.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">3/16/2025</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">506</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">918.00</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">12/14/2025</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">440</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">918.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">02/02/2026</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">390</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">702.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">02/13/2027</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">946</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">174.60</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">03/07/2028</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2,779</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">52.50</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">4/2/2029</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">150,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.02</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2/10/2031</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">65,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.18</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">01/05/2032</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Katherine Beebe DeVarney, Ph.D.</td>
    <td>&#160;</td>
    <td style="text-align: center">142</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">594.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">3/16/2025</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">223</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">46.58</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">12/14/2025</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">223</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">46.58</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2/13/2027</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">945</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">174.60</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">3/7/2028</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">150,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.02</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2/10/2031</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">55,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.18</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">01/05/2032</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, Dr. Rubin and Dr. Beebe DeVarney were granted options to purchase 65,000 and 55,000 shares of common stock, respectively. The options were to vest over 24 months with 50% of the awarded options vesting on the six-month anniversary of the grant date with the remaining balance vesting over the remaining eighteen months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, a Special Meeting of Stockholders was held at the request of Activist Investing, LLC, or Activist, to increase the size of our Board from five members to eleven members and to elect Activist&#8217;s slate of six nominees to serve as directors in addition to the existing five Board members. As a result of the change of control, all unvested options granted under the 2015 Plan prior to August 15, 2022, immediately became vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2022, the Board granted Dr. Beebe DeVarney, subject to the receipt of stockholder approval, options to purchase 100,000 shares of common stock at an exercise price of $1.31 per share, such price being the closing price of our common stock and the fair market value as defined under the 2015 Plan on the September 15, 2022 grant date. The options vest in twelve equal monthly allotments through the first anniversary of the grant date. In the event of a change of control (as defined under the 2015 Plan), any outstanding unvested options will automatically vest and become exercisable on the date of such change of control in accordance with the terms of the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no options exercised by our named executive officers during 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pension Benefits</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not sponsor any qualified or non-qualified defined benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonqualified Deferred Compensation</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not maintain any non-qualified defined contribution or deferred compensation plans. The Compensation Committee, which is comprised solely of &#8220;outside directors&#8221; as defined for purposes of Section 162(m) of the Code, may elect to provide our officers and other employees with non-qualified defined contribution or deferred compensation benefits if the Compensation Committee determines that doing so is in our best interests. We sponsor a tax qualified defined contribution 401(k) plan in which Dr. Rubin, Dr. Beebe DeVarney and Mr. Bhonsle participated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment Agreements</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In April&#160;2019, we entered
into an employment agreement with Dr.&#160;Rubin providing for base annual salaries of $325,000. The employment agreements contain the
following terms:</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonuses. The executive may, at the sole discretion of the board of directors or the compensation committee, be considered for an annual bonus of up to 50% of his then base salary, payable in cash or awards under our equity incentive plan.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term; Termination. The Employment Agreements have a 24-month term expiring on April&#160;1, 2021 but may be terminated by us for any reason at any time. In the event of termination by us without cause or by the executive for good reason not in connection with a change of control, as those terms are defined in such agreements, the executive is entitled to (i)&#160;severance for the greater of 12&#160;months or the balance of the term, (ii)&#160;a pro rata portion of any annual bonus, (iii)&#160;12&#160;months of COBRA payments, and (iv)&#160;the immediate accelerated vesting of any unvested restricted shares and stock options. In the event such a termination is within 30&#160;days prior to or six&#160;months following a change of control, the executive is entitled to an additional six&#160;months of COBRA payments.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictive Covenants. The Employment Agreements contain one-year post-termination noncompetition and non-solicitation provisions.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback. The Employment Agreements contain a two-year post-termination clawback of benefits provision in the event of a restatement of financial results upon which such benefits were based.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November&#160;2018, we entered into an employment agreement with Dr.&#160;Beebe DeVarney providing for a base annual salary of $365,000. The employment agreement contains the following terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonuses. The executive may, at the sole discretion of the board of directors or the compensation committee, be considered for an annual bonus of up to 50% of her then base salary, payable in cash or awards under our equity incentive plan.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term; Termination. The Employment Agreement may be terminated by us for any reason at any time. In the event of termination by us without cause or by the executive for good reason or in connection with a change of control, as those terms are defined in such agreements, the executive is entitled to (i)&#160;severance for 12&#160;months following the termination date, (ii)&#160;a pro rata portion of any annual bonus, (iii)&#160;12&#160;months of COBRA payments, and (iv)&#160;the immediate accelerated vesting of any unvested restricted shares and stock options.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictive Covenants. The Employment Agreement contains six-month post-termination noncompetition and non-solicitation provisions.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2021, Dr. Rubin&#8217;s and Dr. Beebe DeVarney&#8217;s employment agreements were amended to provide for annual salaries of $395,000 and $385,000, respectively, and the term of Dr. Rubin&#8217;s agreement was extended to September 30, 2021. In October 2021, Dr. Rubin&#8217;s agreement was further extended to December 31, 2022. Dr. Rubin&#8217;s employment was terminated in August 2022. All other agreement terms remain substantially the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">On August 2, 2022, the compensation
committee of the Board implemented a retention plan (the &#8220;Retention Plan&#8221;) in recognition of the change in the composition
of the Board following the special meeting of  our stockholders (the &#8220;Special Meeting&#8221;) on August 15, 2022. The purpose
of the Retention Plan is to help ensure a smooth transition, including the continuation of service by our current employees and directors
following the Special Meeting, while the newly reconstituted Board explores and evaluates strategic alternatives to maximize the value
of our assets and enhance stockholder value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">As part of the Retention
Plan, the employment agreements with Dr. Rubin and Dr. Beebe DeVarney were amended to (i) accelerate the vesting of their options following
the reconstitution of the Board; and (ii) remove from the definition of &#8220;Good Reason&#8221; the current proviso that a change in
the executive&#8217;s title would not necessarily constitute Good Reason. The agreement with Dr. Rubin was also amended to state that
the term of his employment shall continue until it is terminated in accordance with the existing provisions of such agreement. All other
agreement terms remained substantially the same. Following the Special Meeting, Mr. Lazar replaced Dr. Rubin as our Chief Executive Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 14, 2022, we entered into an employment agreement with Mr. Lazar providing for a base annual salary of $406,000. The employment agreement contains the following terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Bonuses. Mr. Lazar will be eligible to receive an annual bonus, with a target of fifty percent (50%) of his base salary. In addition, Mr. Lazar will be eligible for three performance bonuses on an annual basis, payable in (i) cash and/or (ii) restricted stock under the Plan, each equal to fifty percent (50%) of his base salary, which shall be dependent on our achievement of certain milestones. Furthermore, in the event of a Change of Control (as defined in the Mr. Lazar&#8217;s employment agreement), we shall pay Mr. Lazar a bonus equal to three percent (3%) of the increased valuation of the surviving corporation resulting from such Change of Control.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Term; Termination. The
    employment agreement has a three-year term but may be terminated by us for any reason at any time. In the event of termination by us
    without Cause or his resignation for Good Reason, not in connection with a Change of Control (as those terms are defined in such
    agreements), the executive is entitled to (i) severance in the form of continuation of his base salary for the greater of a period
    of 12 months or the remaining term, (ii) payment of executive&#8217;s annual medical and dental reimbursement for a period of 12
    months, (iii) a pro rata portion of any annual or performance bonus, and (iv) the immediate accelerated vesting of any unvested
    restricted shares and stock options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictive Covenants. The employment agreement contains 12-month post-termination noncompetition and non-solicitation provisions.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTOR COMPENSATION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary of Director Compensation</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table summarizes
compensation that our non-employee directors earned during the&#160;years ended December 31, 2022 and 2021 for services as members of
our Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or<br /> Paid in Cash<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Awards<br /> ($)<sup>(1)</sup>&#160;</b></span></p></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br /> ($)</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left">Joseph A. Akers (2)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">2022</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">62,500</td>
    <td style="width: 1%; text-align: left"><sup>(3)</sup>&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 7%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">8,859</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 7%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 7%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 7%; text-align: right">-</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">71,359</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">62,500</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">82,334</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">144,834</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Avraham Ben-Tzvi</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">24,375</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">24,375</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Peter L. Chasey</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">20,625</td>
    <td style="text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">20,625</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Eric Greenberg</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,500</td>
    <td style="text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,500</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">M. David MacFarlane (4)</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">61,250</td>
    <td style="text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,859</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">70,109</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">62,500</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">82,334</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">144,832</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Matthew C. McMurdo</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">18,750</td>
    <td style="text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">18,750</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">James R. McNab, Jr. (5)</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">62,500</td>
    <td style="text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,859</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">71,359</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">62,500</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">82,334</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">144,832</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">David Natan</td>
    <td>&#160;</td>
    <td style="text-align: center">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,438</td>
    <td style="text-align: left"><sup>(3)</sup>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,438</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts shown represent the grant date fair value computed in accordance with FASB ASC 718. The assumptions used by us with respect to the valuation of option grants and stock awards are set forth in Note&#160;8 to the financial statements.</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate number of option awards held at December 31, 2022 was 35,207.</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts reported in the &#8220;Fees Earned or Paid in Cash&#8221; column includes directors fees earned for 2022 that have been deferred to 2023 at the director&#8217;s election.</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate number of option awards held at December 31, 2022 was 35,220.</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate number of option awards held at December 31, 2022 was 35,207.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The above table does not include options granted to certain directors on August 15, 2022 and September 15, 2022, as these options are conditioned on the approval by our stockholders of an increase in the authorized number of shares available for issuance under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no options exercised by members of our Board during 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0%"></td>
    <td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_021"></span>Item 12.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth as of March 24, 2023, the number of shares of our common stock beneficially owned by (i) each person who is known by us to be the beneficial owner of more than five percent of our common stock; (ii) each director and director nominee; (iii) each of the named executive officers in the Summary Compensation Table; and (iv) all directors and executive officers as a group. As of March 24, 2023, we had 15,016,295 shares of common stock issued and outstanding. Beneficial ownership is determined in accordance with the rules&#160;of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and generally includes voting or investment power with respect to securities. Unless otherwise indicated, the stockholders listed in the table have sole voting and investment power with respect to the shares indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Address of Beneficial Owner<sup>(1)</sup></b></span></p></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares Beneficially<br /> Owned<sup>(2)</sup></b></span></p></td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent of Shares Beneficially Owned</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph A. Akers<sup>(3)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">37,504</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Avraham Ben-Tzvi</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Peter L. Chasey</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kate Beebe DeVarney, Ph.D.<sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">206,613</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.4</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Eric Greenberg</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David E. Lazar<sup>(5)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,747,968</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">24.96</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. David MacFarlane, Ph.D.<sup>(6)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">36,237</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James R. McNab, Jr.<sup>(7)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">89,009</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Matthew C. McMurdo</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">David Natan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc Rubin, M.D.<sup>(8)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">225,590</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.5</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All executive officers and directors as a group (11) persons<sup>(9)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,342,921</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">27.9</td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than 1%.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, the address of such individual is c/o Titan Pharmaceuticals,&#160;Inc., 400 Oyster Point Boulevard, Suite&#160;505, South San Francisco, California 94080.</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In computing the number of shares beneficially owned by a person and the&#160;percentage ownership of a person, shares of our common stock subject to options held by that person that are currently exercisable or exercisable within 60&#160;days of March 24, 2024 are deemed outstanding. Such shares, however, are not deemed outstanding for purposes of computing the&#160;percentage ownership of each other person. Except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock.</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 35,207 shares issuable upon exercise of outstanding options and (ii) 1,112 shares issuable upon exercise of outstanding warrants.</span></td> </tr>
  <tr style="vertical-align: top; text-align: justify">
    <td></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 206,533 shares issuable upon exercise of outstanding options.</span></td> </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 359,066 shares of Common Stock directly beneficially owned by Activist Investing, LLC. By virtue of his position as the sole member and Chief Executive Officer of Activist Investing, LLC, Mr. Lazar may be deemed to be the beneficial owner of these shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 35,220 shares issuable upon exercise of outstanding options and (ii) 445 shares issuable upon exercise of outstanding warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 35,207 shares issuable upon exercise of outstanding options, (ii) 1,112 shares issuable upon exercise of outstanding warrants and (iii) 51,021 shares owned by JT Pharma. Mr. McNab is a principal of JT Pharma and has voting and dispositive power with respect to these shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 220,264 shares issuable upon exercise of outstanding options and (ii) 2,223 shares issuable upon exercise of outstanding warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 532,431 shares issuable upon exercise of outstanding options and (ii) 4,892 shares issuable upon exercise of outstanding warrants held by our executive officers and directors listed above.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_022"></span>Item&#160;13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain Relationships and Related Transactions, and Director Independence</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain Relationships and Related Transactions.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In January 2022, we entered
into an agreement with JT Pharma, a company for which James R. McNab, Jr., a member of our Board, serves as chief executive officer, to
clarify certain provisions of the JT Agreement, pursuant to which we agreed that the proof-of-concept milestone provided for in the JT
Agreement was achieved, made a payment of $100,000 and issued 51,021 shares of our common stock to JT Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">During
the year ended December 31, 2022, we made payments related to legal fees of approximately $75,000 to a law firm operated by one of our
Board members.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Independence of Directors</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following members of our Board meet the independence requirements and standards currently established by the Nasdaq: Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Matthew C. McMurdo, and James R. McNab,&#160;Jr. and David Natan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Committees</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board has established the following three standing committees: audit committee; compensation committee; and nominating and governance committee, or governance committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The audit committee was formed in compliance with Section&#160;3(a)(58)(A)&#160;of the Exchange Act and consists of Joseph A. Akers, Avraham Ben-Tzvi, M. David MacFarlane, Matthew C. McMurdo, James R. McNab,&#160;Jr. and David Natan (chair), each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. In addition, the Board has determined that Mr. Akers and Mr. Natan are &#8220;audit committee financial expert&#8221; and &#8220;independent&#8221; as defined under the relevant rules&#160;of the SEC and Nasdaq. The audit committee assists the Board by overseeing the performance of the independent auditors and the quality and integrity of Titan&#8217;s internal accounting, auditing and financial reporting practices. The audit committee is responsible for retaining (subject to stockholder ratification) and, as necessary, terminating, the independent auditors, annually reviews the qualifications, performance and independence of the independent auditors and the audit plan, fees and audit results, and pre-approves audit and non-audit services to be performed by the auditors and related fees. The audit committee met four times during the fiscal year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The compensation committee makes recommendations to the Board concerning salaries and incentive compensation for our officers, including our Principal Executive Officer, and employees and administers our stock option plans. The compensation committee consists of Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Ph.D., James R. McNab, Jr. and David Natan (chair), each of whom meets the independence requirements and standards currently established by Nasdaq. The compensation committee met four times during the fiscal year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purpose of the nominating and governance committee is to assist the Board in identifying qualified individuals to become Board members, in determining the composition of the Board and in monitoring the process to assess Board effectiveness. The nominating and governance committee first considers a candidate&#8217;s management experience and then considers issues of judgment, background, stature, conflicts of interest, integrity, ethics, and commitment to the goal of maximizing stockholder value when considering director candidates. The nominating and governance committee also focuses on issues of diversity, such as diversity of gender, race and national origin, education, professional experience, and differences in viewpoints and skills. The nominating and governance committee does not have a formal policy with respect to diversity; however, our Board and the nominating and governance committee believe that it is essential that the directors represent diverse viewpoints. In considering candidates for our Board, the nominating and governance committee considers the entirety of each candidate&#8217;s credentials in the context of these standards The nominating and governance committee consists of Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Ph.D., and James R. McNab, Jr. (chair), each of whom meets the independence requirements and standards currently established by Nasdaq. The nominating and governance committee did not meet during the fiscal year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The charters for the audit, compensation and nominating and governance committees, which have been adopted by our Board, contain detailed descriptions of the committees&#8217; duties and responsibilities and are available in the &#8220;About Titan&#8221; section of our website at <i>www.titanpharm.com.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Role of the Board in Risk Oversight</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our audit committee is primarily responsible for overseeing our risk management processes on behalf of the full Board. The audit committee receives reports from management at least quarterly regarding our assessment of risks. In addition, the audit committee reports regularly to the full Board, which also considers our risk profile. The audit committee and the full Board focus on the most significant risks we face and our general risk management strategies. While the Board oversees our risk management, our management team is responsible for day-to-day risk management processes. Our Board expects management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the audit committee and the Board. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our Board leadership structure, which also emphasizes the independence of the Board in its oversight of its business and affairs, supports this approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Meetings</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Our business affairs are managed under the direction of our Board, which is currently comprised of eleven (11) members. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to our management. During the fiscal year ended December 31, 2022, the Board met 32 times and took action by written consent one time. With the exception of Dr. Rubin, who is not standing for re-election at our upcoming annual stockholder meeting, no director attended fewer than 75% of the meetings of the Board and Board committees of which the director was a member. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_023"></span>Item&#160;14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Accounting Fees and Services.</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate fees billed by WithumSmith+Brown, formerly OUM &amp; Co. LLP, or Withum, an independent registered public accounting firm, during the fiscal years ended December 31, 2022 and 2021 were as follows:</span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Audit Fees</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">301,079</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">297,850</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Audit-Related Fees</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Tax Fees</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">45,720</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">48,850</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">346,799</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">346,700</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit Fees</b>&#160;&#8212; This category includes aggregate fees billed by our independent auditors for the audit of our annual financial statements, audit of management&#8217;s assessment and effectiveness of internal controls over financial reporting, review of financial statements included in our quarterly reports on Form&#160;10&#45;Q and services that are normally provided by the auditor in connection with statutory and regulatory filings for those fiscal&#160;years, including consents and comfort letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit-Related Fees</b>&#160;&#8212; This category consists of services by our independent auditors that, including accounting consultations on transaction related matters, are reasonably related to the performance of the audit or review of our financial statements and are not reported above under Audit Fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax Fees</b>&#160;&#8212; This category consists of professional services rendered for tax compliance and preparation of our corporate tax returns and other tax advice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other Fees</b>&#160;&#8212; During the&#160;years ended December 31, 2022 and 2021, Withum did not incur any fees for other professional services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The audit committee reviewed and approved all audit and non-audit services provided by Withum and concluded that these services were compatible with maintaining its independence. The audit committee approved the provision of all non-audit services by Withum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-Approval Policies and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the SEC&#8217;s auditor independence rules, the audit committee has established the following policies and procedures by which it approves in advance any audit or permissible non-audit services to be provided to us by our independent auditor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the engagement of the independent auditors for any fiscal&#160;year&#8217;s audit, management submits to the audit committee for approval lists of recurring audits, audit-related, tax and other services expected to be provided by the independent auditors during that fiscal&#160;year. The audit committee adopts pre-approval schedules describing the recurring services that it has pre-approved, and is informed on a timely basis, and in any event by the next scheduled meeting, of any such services rendered by the independent auditor and the related fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fees for any services listed in a pre-approval schedule are budgeted, and the audit committee requires the independent auditor and management to report actual fees versus the budget periodically throughout the&#160;year. The audit committee will require additional pre-approval if circumstances arise where it becomes necessary to engage the independent auditor for additional services above the amount of fees originally pre-approved. Any audit or non-audit service not listed in a pre-approval schedule must be separately pre-approved by the audit committee on a case-by-case basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every request to adopt or amend a pre-approval schedule or to provide services that are not listed in a pre-approval schedule must include a statement by the independent auditors as to whether, in their view, the request is consistent with the SEC&#8217;s rules&#160;on auditor independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The audit committee will not grant approval for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any services prohibited by applicable law or by any rule&#160;or regulation of the SEC or other regulatory body applicable to us;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provision by the independent auditors to us of strategic consulting services of the type typically provided by management consulting firms; or</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the retention of the independent auditors in connection with a transaction initially recommended by the independent auditors, the tax treatment of which may not be clear under the Internal Revenue Code and related regulations and which it is reasonable to conclude will be subject to audit procedures during an audit of our financial statements.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax services proposed to be provided by the auditor to any director, officer or employee of Titan who is in an accounting role or financial reporting oversight role must be approved by the audit committee on a case-by-case basis where such services are to be paid for by us, and the audit committee will be informed of any services to be provided to such individuals that are not to be paid for by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining whether to grant pre-approval of any non-audit services in the &#8220;all other&#8221; category, the audit committee will consider all relevant facts and circumstances, including the following four basic guidelines:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the service creates a mutual or conflicting interest between the auditor and us;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the service places the auditor in the position of auditing his or her own work;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the service results in the auditor acting as management or an employee of our company; and</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the service places the auditor in a position of being an advocate for our company.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_024"></span>PART&#160;IV</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_025"></span>Item&#160;15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits and Financial Statements Schedules.</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><b>(a)</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An index to Financial Statements appears on page&#160;F&#45;1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Schedules</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All financial statement schedules are omitted because they are not applicable, not required under the instructions or all the information required is set forth in the financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_026"></span>Item&#160;16.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form&#160;10&#45;K Summary</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TITAN PHARMACEUTICALS,&#160;INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_001">Report of Independent Registered Public Accounting Firm (<i>PCAOB ID <span id="xdx_902_edei--AuditorFirmId_c20220101__20221231_zvGbWR2NXRm4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">100</ix:nonNumeric></span></i>)</a> </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_002">Balance Sheets as of December 31, 2022 and 2021</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_003">Statements of Operations  for the years ended December 31, 2022 and 2021</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_004">Statements of Stockholders&#8217; Equity for the years ended December 31, 2022 and 2021</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_005">Statements of Cash Flows for the years ended December 31, 2022 and 2021</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_006">Notes to Financial Statements</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="b_001"></span>Report of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the Stockholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Titan Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion on the Financial Statements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We have audited the accompanying balance sheets
of Titan Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the related statements of operations,
stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes to the
financial statements (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations
and its cash flows for each of the two years in the period ended December&#160;31, 2022, in conformity with accounting principles generally
accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern Uncertainty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has had recurring losses from operations, an accumulated deficit at December 31, 2022, and insufficient cash at December 31, 2022 to fund operations for twelve months from the date of issuance. All of these matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis for Opinion </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Critical audit matters are matters arising from
the current period audit of the financial statements that were communicated or required to be communicated to the Audit Committee and
that: (1) relate to accounts or disclosures that are material to the financial statements; and (2) involved our especially challenging,
subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial
statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical
audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounting for Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Description of the Matter </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As discussed in Note 1 and Note 7 to the financial
statements, the Company completed a registered directed offering and issued pre-funded warrants to purchase shares of common stock. In
a concurrent private placement, the Company sold pre-funded warrants to purchase an aggregate share of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Auditing the accounting conclusions for the issuance
of the warrants was challenging because of the complex provisions affecting classification and required extensive audit effort. The accounting
for the issuance of the warrants involved an assessment of the particular features of the warrant, and the impact of those features on
the accounting and classification of the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>How We Addressed the Matter in Our Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">To test the accounting and determine proper classification
of the warrants, our audit procedures included, among others, inspecting the agreements and evaluating the completeness and accuracy of
the Company&#8217;s technical accounting analyses and application of the relevant accounting guidance. Our audit procedures also included
the involvement of subject matter resources to assist in evaluating management&#8217;s conclusion on the interpretation and application
of the relevant accounting literature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ <span id="xdx_907_edei--AuditorName_c20220101__20221231_zwoMzGsmStU"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">WithumSmith+Brown, PC</ix:nonNumeric></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; width: 50%"><span style="font-size: 10pt">We have served as the Company&#8217;s auditor since 2004.</span></td>
    <td style="text-align: left; width: 50%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt"><span id="xdx_904_edei--AuditorLocation_c20220101__20221231_z92zx6RasV88"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">San Francisco, California</ix:nonNumeric></span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">March <span style="color: black">31</span>, 2023</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-size: 10pt">PCAOB ID Number 100</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_002"></span>TITAN PHARMACEUTICALS,&#160;INC.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BALANCE SHEETS</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_pn3n3_zlRpL0hhDIN" summary="xdx: Statement - BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_492_20221231_zGpEaGXDOi7c" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_499_20211231_zoXdg07DpXHb" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(In thousands, except share and per share data)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z0YUp03c6GK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_zYy4whCM1Mri" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current assets:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzMAk_zpQUMWlI3hW4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,937</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,037</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RestrictedCash_i02I_maCzMAk_zQq3JVV01Eg8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Restricted cash</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzMAk_zu5Y4RhNk996" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryNet_i02I_maCzMAk_zGx0iJWPoLW2" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Inventory</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzMAk_zD6BAlvHp5jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzMAk_zUf8WbD1Ttj7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Discontinued operations - current assets</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_mtCzMAk_maCz07i_zirZVsiV2nB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total current assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,603</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,229</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCz07i_ztQzlwk3ITp4" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherAssetsNoncurrent_i01I_pn3n3_maCz07i_zU60JmvUDzKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_maCz07i_zxm27OSFel2a" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Operating lease right-of-use asset</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">183</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">297</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCz07i_zEqkilCCWXj4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,058</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,994</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center">Liabilities and Stockholders&#8217; Equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zipYPqtahVy1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_maCztYU_zSjvhEwAKUa" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">795</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedClinicalTrialsExpensesCurrent_i02I_maCztYU_zmsFfwPpdxB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued clinical trials expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:AccruedClinicalTrialsExpensesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:AccruedClinicalTrialsExpensesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_maCztYU_z6Q0CkEOM3Ia" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other accrued liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,483</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCztYU_zFNgVIJyeER3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating lease liability, current</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredGrantRevenue_i02I_maCztYU_zQcnOJLzGDyj" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred grant revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:DeferredGrantRevenue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:DeferredGrantRevenue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_pn3n3_maCztYU_zv0uX5GOzOni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Discontinued operations - current liabilities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,144</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_mtCztYU_maCzNjT_zJHJzM24PlHd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,630</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,669</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzNjT_zUNhWiobJ8ij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Operating lease liability, non-current</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtCzNjT_maCziSJ_zWrwEgu82Dre" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Total liabilities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,695</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,856</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingenciesDisclosureAbstract_i01B_zXbYGRlJKgSg" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commitments and contingencies (Note 5)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stockholders&#8217; equity:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_maCzEZr_zogpjCC8PIrg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred stock, $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zrm77tvDe1Zh" title="Preferred shares, par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zwAl02Qwjcfd" title="Preferred shares, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zOYAt1HJ2vx1" title="Preferred shares, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_zAzUmEeFJeH9" title="Preferred shares, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20221231_z0PPV3UuG2ec" title="Preferred shares, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20221231_zwq0AQQNEhrj" title="Preferred shares, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20211231_zF5eJnK9gNRc" title="Preferred shares, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20211231_zgs4ijN47eQb" title="Preferred shares, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued or outstanding at December 31, 2022 and 2021.</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0124">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0125">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockValue_i02I_maCzEZr_z3MnEJbISOOb" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock, at amounts paid-in, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_z4p4n0NbTTpl" title="Common stock, par or stated value per share"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_znjclBwjhpN" title="Common stock, par or stated value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_z17s1ex1xXxj" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_zYjxl0Ve5VW3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zf3q2r4tp87f" title="Common stock shares, issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zAdOFyuqobZ6" title="Common stock shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,016,295</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zYUV5O1mxe02" title="Common stock shares, issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zW3aCbxoRam5" title="Common stock shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,914,158</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2022 and 2021, respectively.</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapital_i02I_maCzEZr_z8HZZvdGlqgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,609</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">381,183</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzEZr_zfwSd2HPCWdl" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Accumulated deficit</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">386,261</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">376,055</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_mtCzEZr_maCziSJ_zOJiU4VdKEHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,363</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,138</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCziSJ_zhXtut94CKY9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,058</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,994</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_003"></span>TITAN PHARMACEUTICALS,&#160;INC.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_pn3n3_zdTHhxXLve0k" summary="xdx: Statement - STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49F_20220101__20221231_zk5jtthu9tP9" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_490_20210101__20211231_zgPYsgMGVSZ6" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br /> Years ended<br /> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(In thousands, except per share data)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Revenue:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">License revenue</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_pn3n3" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-01-012022-12-31_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_pn3n3" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2021-01-012021-12-31_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Product revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3n3" title="Total revenue" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0176">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3n3" title="Total revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2021-01-012021-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">236</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Grant revenue</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" title="Total revenue" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-01-012022-12-31_us-gaap_GrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">497</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--GrantMember_pn3n3" title="Total revenue" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2021-01-012021-12-31_us-gaap_GrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,277</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_maCzTWP_zAbs4jl1CGQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">557</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,526</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpensesAbstract_iB_zcOB7fACKBkk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating expenses:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfGoodsAndServicesSold_i01_maCzglP_zenLNsQUhjyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Cost of goods sold</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0190">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">199</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzglP_z82nY20DhQSi" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,758</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,692</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzglP_zTUhpXEVodl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">General and administrative</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,034</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,989</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpenses_i01T_mtCzglP_msCzTWP_zuUHHhpC6L1e" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total operating expenses</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,792</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,880</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01T_mtCzTWP_maCzDPS_znOhsV6Vjpb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Loss from operations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,235</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,354</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z9KcLW2udzPg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expense):</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestIncomeExpenseNonoperatingNet_i01_maCzyho_zkI8HnX5O0P2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest income, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingExpense_i01N_di_msCzyho_zOvyNX2A01Oj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other expense, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maCzyho_zMhe2lTFYk99" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Non-cash gain on debt extinguishment</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">661</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzyho_maCzDPS_zvxD9xTBOrD7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Other income, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">578</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtCzDPS_z861eRHHHF62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,206</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,776</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--BasicAndDilutedNetLossPerCommonShare_pid_z4O9jy6fFQRl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share </td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="ttnp:BasicAndDilutedNetLossPerCommonShare" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.76</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="ttnp:BasicAndDilutedNetLossPerCommonShare" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.90</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare_pid_zZye1aB3FsM1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Weighted average shares used in computing basic and diluted net loss per common share</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ttnp:WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,434</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ttnp:WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,730</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_004"></span>TITAN PHARMACEUTICALS, INC.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_114_pn3n3_zstbR3qef0Cc" summary="xdx: Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zKgWpWmo953" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zg718SHpcnpe" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zvGnxHtzSqPi" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zMB1nyWMdgk3" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_4B0_zF5DS7lvXLyl" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-In</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_438_c20210101__20211231_eus-gaap--StockholdersEquity_iS_z5Rqpdgdqce6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 30%; text-align: left">Balances at
    December 31, 2020</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOWCNFOadwHb" title="Beginning Balance, shares" style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ6q3SrrV7vf" title="Beginning Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,139</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">370,804</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">367,279</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,532</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0240">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,776</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,776</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of common stock, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJnwbJHsmoq9" title="Issuance of common stock, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,775</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,838</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,841</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_z6Libmv0phxc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Amortization of restricted stock</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_ecustom--AmortizationOfRestrictedStockShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbBn9S1V53c7" title="Amortization of restricted stock, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Stock-based compensation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z4D4SVY1Ehrh" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Balances at December
    31, 2021</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLogM8XnMcr2" title="Beginning Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjRUZalu3Myj" title="Beginning Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,914</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">381,183</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">376,055</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,138</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_zQkoBkLJprCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,206</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,206</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkilCjjyjve7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of common stock, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9Ex7I0FwwH6" title="Issuance of common stock, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,151</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,029</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,030</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueOther_iP3us-gaap--StockIssuedDuringPeriodSharesNewIssues_zvCZ3LlLPW8d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of common stock upon exercise of warrants</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesOther_iP3us-gaap--StockIssuedDuringPeriodValueOther_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsylWnLhzY4" title="Issuance of common stock upon exercises of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,564</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_zVdVfnyITbI" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Amortization of restricted stock</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--AmortizationOfRestrictedStockShares_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm50C2qjneJl" title="Amortization of restricted stock, shares" style="text-align: right"><ix:nonFraction name="ttnp:AmortizationOfRestrictedStockShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">387</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">450</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">450</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zJEhaNc6A1U3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Stock-based compensation</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">947</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">947</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20220101__20221231_eus-gaap--StockholdersEquity_iE_z4PSBK2mT1Df" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balances at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgHTDuGxvlH1" title="Ending Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXztnbF9gVO6" title="Ending Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,016</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,609</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">386,261</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,363</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_005"></span>TITAN PHARMACEUTICALS,&#160;INC.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_112_pn3n3_zq9M6UI5HV7a" summary="xdx: Statement - STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_499_20220101__20221231_z1vC78o96Tyf" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49B_20210101__20211231_zLyc2obw3abk" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br /> Years Ended<br /> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(In thousands)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zLEaBuM8pCii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01_maCzZw5_zhH4DBhxHY1l" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,206</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,776</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zvILLyXFi5cg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzZw5_zjqGf9cmWAN5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherNoncashExpense_i02_maCzZw5_zQBslnNXaQMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash interest expense</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzZw5_z9dc29bOe4m5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash gain on debt extinguishment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">661</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--ShareBasedPaymentArrangementMilestonePayment_i02_maCzZw5_zE2xmfJtbbHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock-based milestone payment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:ShareBasedPaymentArrangementMilestonePayment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_i02_maCzZw5_zwxiUYRLGlMk" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock-based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">947</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AmortizationOfRestrictedStock_i02_maCzZw5_z2bhz1V9xve8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of restricted stock</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:AmortizationOfRestrictedStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">450</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:AmortizationOfRestrictedStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherOperatingIncomeExpenseNet_i02N_di_msCzZw5_zDVRzZNzaww4" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zvAJ7XTtBi95" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msCzZw5_zxQaMN18kZPb" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">76</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">772</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msCzZw5_zDurys0h5yX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Inventory</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">187</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzZw5_z2eWPYYLAWl4" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepaid expenses and other assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">164</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">163</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maCzZw5_zFQsKKmJFISe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">751</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,191</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maCzZw5_zZRAQqkZs588" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other accrued liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">801</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInDeferredRevenue_i03_maCzZw5_zW3rYo3yRzRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Deferred revenue</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">99</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzZw5_maCzLSE_zSYks3hFO908" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,183</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,899</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z2i9hPkXfMX6" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from investing activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pn3n3_di_msCzZNJ_zRddWif8c0eb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Purchases of furniture and equipment</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzZNJ_maCzLSE_z6JK56qeOgsa" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z7hTlqj65Fmj" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from financing activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromEquityOfferings_i01_maCz8Fv_z4CnVrDdZz1g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from equity offerings</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:ProceedsFromEquityOfferings" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,980</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:ProceedsFromEquityOfferings" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,841</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromWarrantExercises_i01_maCz8Fv_zovHsz5UgZT5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Proceeds from the exercise of warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCz8Fv_maCzLSE_zBArJIx9IcGd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,984</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,841</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzLSE_zFIYpiJedJ89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net change in cash, cash equivalents and restricted cash</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,199</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">919</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zU4pqXpaKVvd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash at beginning of year</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,332</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,413</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zPMxXKXC1ui9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash at end of year</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,133</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,332</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zZEMQxUY7WOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplemental disclosure of cash flow information</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization_i01_zuMCDP1cA9K7" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Right of use asset obtained in exchange for lease liability, net of amortization</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RetirementOfPropertyAndEquipment_i01_zQJA9hXWqeVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Retirement of property and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:RetirementOfPropertyAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,372</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AccumulatedDepreciationOnRetiredPropertyAndEquipment_i01_zZ2Kx6XlK1f1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accumulated depreciation on retired property and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="ttnp:AccumulatedDepreciationOnRetiredPropertyAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,372</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; padding-left: 0in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zVNDC9e3YKah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 0in; width: 76%; text-align: left">Cash and cash equivalents</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,937</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,037</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RestrictedCash_iE_zZ0eU90fyVoc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; padding-left: 0in; text-align: left; padding-bottom: 1pt">Restricted cash</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CashAndCashEquivalentsAndRestrictedCashEquivalents_iE_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 0in; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted
    cash as shown in the statements of cash flows</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,133</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,332</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_006"></span>TITAN PHARMACEUTICALS,&#160;INC.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES&#160;TO FINANCIAL STATEMENTS</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zZNWBbxitBej" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zgg5wPALvye9">Organization and Summary of Significant Accounting Policies</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ttnp:CompanyPolicyPolicyTextBlock"><p id="xdx_844_ecustom--CompanyPolicyPolicyTextBlock_zA3vYvJ9BHpf" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zyV5j9abquta">The Company</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura<sup>&#174;</sup>, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician&#8217;s assistants in a HCP&#8217;s office or other clinical setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our first product based on our ProNeura technology was Probuphine<sup>&#174;</sup> (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo&#8482;) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our commercial operations has allowed us to focus our limited resources on important product development programs and transition back to a product development company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, we announced our intention to work with our financial
advisor to explore strategic alternatives to enhance stockholder value, potentially including an acquisition, merger, reverse merger,
other business combination, sales of assets, licensing or other transaction. In June 2022, we implemented a plan to reduce expenses and
conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses to enable us to maintain
sufficient resources as we pursued potential strategic alternatives. In July 2022, David Lazar and Activist Investing LLC, or, collectively,
Activist acquired an approximately 25% ownership interest in Titan, filed a proxy statement and nominated six additional directors, each
of whom was elected to our board of directors or the Board, at a special meeting of stockholders held on August 15, 2022, or Special Meeting.
The exploration and evaluation of possible strategic alternatives by the Board has continued following the Special Meeting. Following
the election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced as our Executive Chairman, and David Lazar assumed
the role of Chief Executive Officer. In connection with the termination of his employment as Executive Chairman, Dr. Rubin will receive
aggregate severance payments of approximately $<span id="xdx_907_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220101__20221231__srt--CounterpartyNameAxis__custom--RubinMember_zcMNACqel82a" title="Aggregate severance payments"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2022-01-012022-12-31_custom_RubinMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million, of which, approximately $165,000 had been paid to Dr. Rubin as of December
31, 2022. In December 2022, we implemented additional cost reduction measures including a reduction in our workforce. As a result of the
salary reductions, replacement of Dr. Rubin and the workforce reduction we have accrued approximately $<span id="xdx_90E_ecustom--AccruedSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zouBYEU4EPN2" title="Accrued severance"><ix:nonFraction name="ttnp:AccruedSeverance" contextRef="AsOf2022-12-31_custom_RubinMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million and approximately $<span id="xdx_90E_ecustom--DeferredCompensationAndEmployeeSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zPEcATZqIfL" title="Deferred compensation and employee severance"><ix:nonFraction name="ttnp:DeferredCompensationAndEmployeeSeverance" contextRef="AsOf2022-12-31_custom_RubinMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million related to deferred compensation and employee severance, respectively, as of December 31, 2022</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming we will continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, we had cash and cash equivalents of approximately $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231_zcp1qz4aXPTk" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million, which we believe is sufficient to fund our planned operations into the second quarter of 2023. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful. There is substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DiscontinuedOperationsPolicyTextBlock"><p id="xdx_846_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zZxEa46wNTd2" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJy10FlShte5">Discontinued Operations</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind down our commercialization activities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization activities as discontinued operations (see Note 10). The accompanying financial statements are generally presented in conformity with our historical format. We believe this format provides comparability with the previously filed financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_zdh4gOojcxKa" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zTDBcthOPDrf">Use of Estimates</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zFnDMMuwezW4" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ttnp:SubstantialDoubtAboutGoingConcernPolicyTextBlock"><p id="xdx_84F_ecustom--SubstantialDoubtAboutGoingConcernPolicyTextBlock_z11IfNBdjWuh" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zDAugIUAEpm9">Going concern assessment</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one&#160;year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by Accounting Standard Update ASU No.&#160;2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No.&#160;2014-15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Annual Report on Form&#160;10-K for the&#160;year ended December 31, 2022, we did not have sufficient cash to fund our operations for the next 12&#160;months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12&#160;months after the date the financial statements were issued. Additionally, we have suffered recurring losses from operations and have an accumulated deficit that raises substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zg4dbgUlF9C7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zXYtwxiugYXa">Inventories</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are recorded at the lower of cost or net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantities on hand and write down to its net realizable value any inventory that we believe to be impaired. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. The components of inventories are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zFw8I2RCUKCb" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8BD_zwQgDXxd7ph2" style="display: none">Schedule of components of inventories</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20221231_zopClSbFJpig" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20211231_zNRl7QSozVuk" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pn3n3_maINzzRz_zqTD0rCQOSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Raw materials and supplies</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINzzRz_zRvj2dGzynQ" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Finished goods</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzzRz_zisJ2WMp8qd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;Total inventories</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zf5WdfiqAL72" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The approximately $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_c20221231_pn3n3" title="Finished goods inventory"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_pn3n3_c20211231_zGijA3qiRnx9" title="Finished goods inventory"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66,000</ix:nonFraction></span> of finished goods inventory at December 31, 2022 and 2021, respectively, included materials held for potential sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2Q40KMCUtfc" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zuJgaBuOSELi">Stock-Based Compensation</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize compensation expense using a fair-value based method, for all stock-based payments including stock options and restricted stock awards and stock issued under an employee stock purchase plan. These standards require companies to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. See Note&#160;8 &#8220;Stock Plans,&#8221; for a discussion of our stock-based compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ttnp:WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock"><p id="xdx_846_ecustom--WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock_zA6tHAxrO7C7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zqvhPwBSTsbd">Warrants Issued in Connection with Equity Financing</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle the warrants in cash. For warrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrants as a liability at each reporting period and record changes in the estimated fair value as a non-cash gain or loss in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_z4aIGzSmdWAg" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLPT0H3eQSmk" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zXe98InXtkq8">Cash and Cash Equivalents</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our investment policy emphasizes liquidity and preservation of principal over other portfolio considerations. We select investments that maximize interest income to the extent possible given these two constraints. We satisfy liquidity requirements by investing excess cash in securities with different maturities to match projected cash needs and limit concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers and limit the amount of credit exposure to any one issuer. The estimated fair values have been determined using available market information. We do not use derivative financial instruments in our investment portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All investments with original maturities of three&#160;months or less are considered to be cash equivalents. We had money market funds of approximately $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC6PDamtx5g7" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million and $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zB7daW2mtYrb" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million as of December 31, 2022 and 2021, respectively, included in our cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20221231_zaI6b590ufC5" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250,000</ix:nonFraction></span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on our financial condition, results of operations, and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zGLIxeAchWRi" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><i><span id="xdx_86C_zp5ppOHjV962">Restricted Cash</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In accordance with ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash, we explain the change during the period in the total of cash, cash equivalents and
restricted cash, and include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period
total amounts shown on the statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table provides
a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet dates that comprise the total of the
same such amounts shown in the statements of cash flows for the years presented herein (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zQzdvtfknjY7" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule of restricted cash</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_z67EUQUyzh1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,037</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_zSrOlLFABlA9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">295</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_z3E6GZdShyOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,133</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrnYI4RuKmW" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zBnqgHuuFLy8">Property and Equipment</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets
ranging from three <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zAImnZ9dZ4wk" title="property, plant and equipment, estimated useful lives" style="display: none"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to five <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKKN5BZgih38" title="property, plant and equipment, estimated useful lives" style="display: none"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years. Leasehold improvements are amortized over the shorter of the lease term or the estimated
useful life of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zv9A4l1Csre7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zL7NyY6UmKZ4">Revenue Recognition</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department of Health and Human Services, or HHS, the Bill &amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net Product Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_z2jX4ojXOZ3b" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Returns &#8211; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebates &#8211; Our provision for rebates was estimated based on our customers&#8217; contracted rebate programs and our historical experience of rebates paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounts
&#8211; The provision was estimated based upon invoice billings, utilizing historical customer payment experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance Obligations</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Price</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognize revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocation of Consideration</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_ztsRc5clZ3Ee" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Timing of Recognition</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Assets and liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the activity related to our accounts receivable for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span id="xdx_8B6_zlxRgL6XG39b" style="display: none">Schedule of activity related to our accounts receivable</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><i>(In thousands)</i></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Balance at January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" title="Beginning Balance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">884</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Additions" id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right"><ix:nonFraction name="ttnp:ContractWithCustomerAssetAdditions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,526</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td title="Deductions" id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ttnp:ContractWithCustomerAssetDeductions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,298</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Balance at December 31, 2021</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td title="Beginning Balance" id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" title="Additions" style="text-align: right"><ix:nonFraction name="ttnp:ContractWithCustomerAssetAdditions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">557</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" title="Deductions" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ttnp:ContractWithCustomerAssetDeductions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">633</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric></ix:nonNumeric><p id="xdx_8A4_zozZ1SMAQem5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvYi38FlWXy7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zupjTsqyUHTh">Research and Development Costs and Related Accrual</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (&#8220;CRO&#8221;) activities, sponsored research studies, product registration, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfDqOmscuOD4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zgESb6Qe4M6">Net Loss Per Share</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share excludes the effect of dilution and is computed by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method. Basic and diluted net loss per share was the same for each of the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of shares of common stock outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the&#160;years ended (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z7qmzFS4y2a8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zSErRwgCzgI" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B6_zjVqoyveczlk" style="display: none">Schedule of anti-dilutive effect</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted-average anti-dilutive common shares resulting from stock awards</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_zFPiHclvpiCc" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_EmployeeStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">964</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_z53MATNY3cG8" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_custom_EmployeeStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">617</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Weighted-average anti-dilutive common shares resulting from warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zIrI6wAmeRxi" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,661</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zbWBbapW6Blb" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,374</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdC0Xwmolla4" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,625</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zPx2K45tzhpi" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,991</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z1Yyx7WKv6C6" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zefpL2dPPYc9" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zkDFHNQZ39I1">Leases</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the minimum lease payments of our operating lease as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zgROnTpnXa71" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B6_zpn4eCwuDock" style="display: none">Schedule of minimum operating lease payments</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20221231_zTvF1iEavTxd" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2023</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2024</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total minimum lease payments (base rent)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">196</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zfKHFgWnsUQ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Less: imputed interest</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total operating lease liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zu2nSUyCQer5" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z4kb8wfQKuG4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zBFHIrbW1K9i">Subsequent Events</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have evaluated events that have occurred subsequent to December 31, 2022 and through the date that the financial statements are issued. See Note 12 Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbefMA3aXZTd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zWsUoEVgA2y2">Fair Value Measurements</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8211; quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8211; inputs that are unobservable (for example cash flow modelling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. The approximately $<span id="xdx_90B_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20221231_zZsgdzlXokR4" title="Money Market Funds, at Carrying Value"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million and $<span id="xdx_904_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20211231_zAZRblcItV26" title="Money Market Funds, at Carrying Value"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.7</ix:nonFraction></span> million fair values of money market funds as of December 31, 2022 and 2021, included in our cash and cash equivalents are classified as Level 1 and were derived from quoted market prices as active markets for these instruments exists. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zRBFJRU9GNEj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zdP35IW7RjDd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUz5PGUW6GWj">Recent Accounting Pronouncements</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently Adopted Accounting Pronouncements</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the FASB issued FASB issued ASU 2021-10, <i>Disclosures by Business Entities about Government Assistance</i>. The ASU codifies new requirements to disclose information about the nature of certain government assistance received, the accounting policy used to account for the transactions, the location in the financial statements where such transactions were recorded and significant terms and conditions associated with such transactions. The guidance is effective for annual periods beginning after December 15, 2021. The adoption of ASU No. 2021-10 did not have a material impact to our financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounting Standards Not Yet Adopted</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses</i>, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January 1, 2023. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the FASB issued ASU 2020-04, <i>Reference Rate Reform</i>, which provides companies with optional guidance, including expedients and exceptions for applying GAAP to contracts and other transactions affected by reference rate reform, such as the London Interbank Offered Rate, or LIBOR. This new standard was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are evaluating the effects that the adoption of this guidance will have on our financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU No. 2020-06, <i>Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective beginning after December 15, 2023 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. We are currently evaluating the impact this guidance will have on our financial statements and related disclosures.</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zuEQIH6vXgJk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_z48fzNOdWvU1">Property and Equipment</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_ztT9QvDQYfej" summary="xdx: Disclosure - Property and Equipment (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BA_z2LPCDycrEk6" style="display: none">Schedule of property and equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Furniture and office equipment</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" title="Property, Plant and Equipment, Gross" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" title="Property, Plant and Equipment, Gross" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Laboratory equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" title="Property, Plant and Equipment, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_PropertyPlantAndEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,108</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" title="Property, Plant and Equipment, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_PropertyPlantAndEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,108</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Computer equipment</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" title="Property, Plant and Equipment, Gross" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">577</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" title="Property, Plant and Equipment, Gross" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">577</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pn3n3" title="Property, Plant and Equipment, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,817</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" title="Property, Plant and Equipment, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,817</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Less accumulated depreciation and amortization</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zJPDPRrj4IVd" title="Less accumulated depreciation and amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,593</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zqykeNhDEr91" title="Less accumulated depreciation and amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,397</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Property and equipment, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20221231_znkThjA8sIt3" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zmJ1vNClmGbd" title="Property and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ttnp:JTPharmaceuticalsAssetPurchaseAgreementTextBlock"><p id="xdx_80E_ecustom--JTPharmaceuticalsAssetPurchaseAgreementTextBlock_zDPARa0EmA2k" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zlDHRtmIFfHj">JT Pharmaceuticals Asset Purchase Agreement</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, we entered into an Asset Purchase Agreement, or JT Agreement, with JT Pharmaceuticals, Inc., or JT Pharma, to acquire JT Pharma&#8217;s kappa opioid agonist peptide, TP-2021 (formerly JT-09) for use in combination with our ProNeura long-term, continuous drug delivery technology, for the treatment of chronic pruritus and other medical conditions. Under the terms of the JT Agreement, JT Pharma received a $<span id="xdx_90C_ecustom--FutureMilestonePayments_c20201001__20201031__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pn3n3" title="Closing payment"><ix:nonFraction name="ttnp:FutureMilestonePayments" contextRef="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></span> closing payment and is entitled to receive future milestone payments, payable in cash or in stock, based on the achievement of certain developmental and regulatory milestones, and single-digit percentage earn-out payments on net sales of the product if successfully developed and approved for commercialization. In January 2022, we entered into an agreement with JT Pharma to clarify certain provisions of the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved and made a payment of $<span id="xdx_905_ecustom--MilestonePayments_pn3n3_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zDja14sdsAfh" title="Milestone Payments"><ix:nonFraction name="ttnp:MilestonePayments" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,000</ix:nonFraction></span> and issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zW2vbvcwMIT8" title="Issuance of common stock, net (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,021</ix:nonFraction></span> shares of our common stock to JT Pharma. The related expense was included in research and development expenses in our statements of operations.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ttnp:AssetPurchaseAgreementTextBlock"><p id="xdx_807_ecustom--AssetPurchaseAgreementTextBlock_zXrYPCrHjQFh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zu0Ogfm3Fsnh">Ocular Therapeutix License Agreement</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, we entered into a license agreement, or Ocular Agreement, with Ocular Therapeutix, Inc., or Ocular to license the exclusive rights to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the United States, or Licensed Patents. The grant of the Ocular license by us to Ocular is for an exclusive (even as to us), perpetual, fully paid-up license to use the Licensed Patents. The license comes with the right to sublicense. The Ocular paid a one-time fee of $<span id="xdx_90E_ecustom--ReimbursementFees_pn3n3_c20220101__20221231_zi536lXPCWc8" title="Reimbursement fees"><ix:nonFraction name="ttnp:ReimbursementFees" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,000</ix:nonFraction></span> and will reimburse our attorneys&#8217; fees incurred by it in connection with the preparation and negotiation of the Ocular Agreement. Ocular shall make additional payments upon the achievement of certain milestone events as set forth in the License Agreement.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zNDhKU9LeMV1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_z5gjm9uNSEN7">Commitments and Contingencies</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease Commitments</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We lease our office facility under operating lease that expires in June&#160;2024. Rent expense associated with this lease was approximately $<span id="xdx_90A_ecustom--OperatingLeasesRentExpenses_pn3n3_dm_c20221001__20221231_zOOLAqWsA099" title="Rent expense"><ix:nonFraction name="ttnp:OperatingLeasesRentExpenses" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and $<span id="xdx_907_ecustom--OperatingLeasesRentExpenses_pn3n3_dm_c20220101__20221231_zRSgsurwZ8Rl" title="Rent expense"><ix:nonFraction name="ttnp:OperatingLeasesRentExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million for&#160;years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Guarantees and Indemnifications</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As permitted under Delaware law and in accordance with our Bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving at our request in such capacity. The term of the indemnification period is for the officer&#8217;s or director&#8217;s lifetime. The maximum amount of potential future indemnification is unlimited; however, we have a director and officer insurance policy that limits our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements is minimal. Accordingly, we have not recorded any liabilities for these agreements as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, we have commitments to make certain milestone payments to various clinical research organizations in connection with our clinical trial activities. Payments are contingent upon the achievement of specific milestones or events as defined in the agreements, and we have made appropriate accruals in our financial statements for those milestones that were achieved as of December 31, 2022. We also provide indemnifications of varying scope to our CROs and investigators against claims made by third parties arising from the use of our products and processes in clinical trials. Historically, costs related to these indemnification provisions were immaterial. We also maintain various liability insurance policies that limit our exposure. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Proceedings</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A legal proceeding has been initiated by a former employee alleging wrongful termination, retaliation, infliction of emotional distress, negligent supervision, hiring and retention and slander. An independent investigation into this individual&#8217;s allegations of whistleblower retaliation, while still an employee, was conducted utilizing an outside investigator and concluded that such allegations were not substantiated. We intend to vigorously defend the lawsuit (which we have compelled into arbitration); however, in light of our cash position, there can be no assurance that the defense and/or settlement of this matter will not have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zcmt9geVxk8b" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zocpVBJgfIpc">Debt Agreements</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paycheck Protection Program Loan</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 20, 2020, we received an approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_pn3n3_c20200401__20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zIAv1QhZHGh2" title="Loan proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2020-04-012020-04-20_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">654,000</ix:nonFraction></span> loan, or PPP Loan, pursuant to the Paycheck Protection Program of the CARES Act that bore interest at the annual rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20200401__20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_z3RxkSHNxWp4" title="Loan annual interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-04-012020-04-20_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% and matured in April 2022. The proceeds of the PPP Loan were to be used to retain workers and maintain payroll and make mortgage interest, lease and utility payments and were subject to forgiveness in accordance with requirements of the Small Business Administration. The PPP Loan originally had a six-month deferral of payments period which was extended to sixteen months during the third quarter of 2020. In May 2021, the entire balance of the PPP loan along with accrued interest was forgiven and the approximately $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_dm_c20210501__20210531__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zolHoTTrAaDd" title="Non-cash gain (loss) on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-05-012021-05-31_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million gain on extinguishment of the debt was included in other income (expense) in our statements of operations.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrvV2W0rGyjk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zNlcEU1qPsc6">Stockholders&#8217; Equity</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock outstanding as of December 31, 2022 and December 31, 2021 was <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_z5wD4L0KYZyc" title="Common stock shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,016,295</ix:nonFraction></span> shares and <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zJhoBYyybtm1" title="Common stock shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,914,158</ix:nonFraction></span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment to Bylaws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, the Board amended our Bylaws to effect certain enhancements to the ability of stockholders to call for a special meeting of stockholders and make changes to the composition of the Board. This included (i) reducing the holdings required for stockholders to call a special meeting of stockholders from a majority to twenty-five percent (25%); (ii) enabling increases in the size of the Board to be effectuated by stockholders or directors at any annual or special meeting or by stockholder action by written consent in lieu of a meeting; (iii) provide that Board vacancies and newly created directorships resulting from action taken by the stockholders at a meeting or by written consent in lieu thereof shall be filled initially by the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Activist Investing, LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, we received a letter from Activist requesting that our Board call the Special Meeting in accordance with Article II, Section 5 of our Bylaws, as amended.in order for stockholders to consider and vote upon the following two proposals:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in the size of the Board by six (6) members from five (5) members to eleven (11) members in total; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The election of Activist&#8217;s six nominees to serve as directors to fill the vacancies left by the foregoing increase.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Activist&#8217;s request, the Board set the record date for the Special Meeting as July 22, 2022, and the Special Meeting was held on August 15, 2022, resulting in the approval of the increase in the size of the Board and the election of the six nominees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>February 2022 Offerings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, we completed a registered direct offering with an accredited investor pursuant to which we issued an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zmpiwYWf79N" title="Issuance of common stock, net, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></span> shares of our common stock and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zYqZSqlEJHb" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,274,242</ix:nonFraction></span> pre-funded warrants to purchase shares of our common stock, with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z5Qcc39g51ak" title="Exercise price of warrants (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. In a concurrent private placement, we sold unregistered pre-funded warrants to purchase an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z5qx8xJaXZ6e" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,289,796</ix:nonFraction></span> shares of common stock with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zzrYpPfpoZNh" title="Exercise price of warrants (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share and issued unregistered five year and six month warrants to purchase an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z7UqE9qDdLI5" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,664,038</ix:nonFraction></span> shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zwQrpnmMpqH8" title="Exercise price of warrants (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span>. The unregistered warrants were registered in April 2022. The warrants were classified as equity.  The net cash proceeds from these offerings were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_dm_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zmolLXFHG3e" title="Proceeds from sale of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million after deduction of underwriting fees and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Exercises</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, we received approximately $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20220301__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-03-012022-03-31_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span> from the exercise of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zvAy6XpwVD49" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-03-31_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">974,242</ix:nonFraction></span> pre-funded warrants issued in the February 2022 registered direct offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zWagnvPUNLt8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2022, we received approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20220401__20220430__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-04-012022-04-30_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,300</ix:nonFraction></span> from the exercise of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220430__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zzQow3noLc94" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-30_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,300,000</ix:nonFraction></span> pre-funded warrants issued in the February 2022 registered direct offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, we received approximately $<span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_c20220501__20220531__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-05-012022-05-31_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,290</ix:nonFraction></span> from the exercise of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zhb1LkiMrlEc" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-05-31_custom_PreFundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,289,796</ix:nonFraction></span> pre-funded warrants issued in the February 2022 private placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>JT Pharma Milestone</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, we entered into an agreement with JT Pharma to clarify certain provisions of the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved and made a payment of $<span id="xdx_902_ecustom--MilestonePayment_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pn3n3" title="Milestone payment"><ix:nonFraction name="ttnp:MilestonePayment" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,000</ix:nonFraction></span> and issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pdd" title="Issuance of common stock, net, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,021</ix:nonFraction></span> shares of our common stock to JT Pharma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Restricted Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2022, we agreed to issue <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockToMaximGroupLlcMember_zpY5xeZY4yrd" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-11-30_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">337,078</ix:nonFraction></span> shares of our common stock to Maxim Group, LLC in connection with the entry into an amendment to our existing advisory agreement. The shares vested immediately. We recorded approximately $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockToMaximGroupLlcMember_zJSI2mmuoiK3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million of stock-based compensation expense during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, we agreed to issue <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementWithMaximMdmWorldwideSolutionsMember_znnJP41tTw2d" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of our common stock pursuant to an advisory services agreement with Maxim MDM Worldwide Solutions, Inc. The shares vested immediately. We recorded approximately $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementWithMaximMdmWorldwideSolutionsMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79,000</ix:nonFraction></span> of stock-based compensation expense during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2021, we agreed to issue <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zZqqZkC0NlBa" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of our common stock pursuant to a restricted stock agreement with Maxim Partners, LLC in connection with the entry into an amendment to our existing advisory agreement. The shares vested monthly over <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_z7xWei8ts4Ah" title="Vesting period"><ix:nonNumeric contextRef="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span> months. We recorded approximately $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">71,000</ix:nonFraction></span> of stock-based compensation expense during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restricted stock activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_pn3n3_z9moU5jNuzZf" summary="xdx: Disclosure - Stockholders&apos; Equity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span id="xdx_8B4_zjh42pIkomY2" style="display: none">Summary of restricted stock activity</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"></td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; vertical-align: top">Outstanding at December 31, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231_zFW1l7qB0tPk" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Issued</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231_zuZnIkngtQaf" title="Issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">387,078</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Forfeited or expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220101__20221231_z9KSdmYjmAh3" title="Forfeited or expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top">Released</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_pid_c20220101__20221231_z4QGZMT50lpg" title="Released" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ttnp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">437,078</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Outstanding at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220101__20221231_zinqwJKWrsD" title="Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zBnBm0qYfqk9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual Meeting of Stockholders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, our stockholders approved an amendment to the 2015 Omnibus Equity Incentive plan to increase the number of authorized shares to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwoThousandFifteenPlanMember_zoMDksnCUs9h" title="Number of additional shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-01-012021-01-31_custom_TwoThousandFifteenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January 2021 Offering</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, we completed an offering with several accredited institutional investors pursuant to which we issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zy3bQkVjas3k" title="Issuance of common stock, net, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-01-31_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,725,000</ix:nonFraction></span> shares of our common stock in a registered direct offering and warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z1dMW6oDY7ed" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-01-31_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,725,000</ix:nonFraction></span> shares of our common stock with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_ziUjcjmse6s6" title="Exercise price of warrants, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-01-31_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.55</ix:nonFraction></span> per share in a concurrent private placement. The warrants were classified as equity, were exercisable immediately and will expire in July 2026. The net cash proceeds from this offering were approximately $8.8 million after deduction of underwriting fees and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zUZKOeqsynA7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the following warrants to purchase shares of our common stock were outstanding (in thousands, except per share price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_pn3n3_zVVf7z7xIT6i" summary="xdx: Disclosure - Stockholders&apos; Equity (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_8BA_zbRxWQFJpH85" style="display: none">Schedule of warrants to purchase</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date Issued</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration&#160;Date</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise&#160;Price</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">07/27/2017</ix:nonNumeric></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 23%; text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">07/27/2024</ix:nonNumeric></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 22%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_z6sUk06JPpOf" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.00</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 22%; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_zF2WqR6vmWZf" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">03/21/2018</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">03/21/2025</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zMx4xgeR7sIa" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">216.00</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zphKQvGQXgye" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">03/21/2018</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">03/21/2025</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zojOlollJpSl" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">216.00</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zjEhHIdgPgn7" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">09/25/2018</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">09/25/2023</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zGW8AgAcCbW4" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.00</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zy7G5aAqAGKa" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">09/25/2018</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">09/25/2023</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_z4lGSm1yvi9k" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50.40</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_zxutXXMAyUy3" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">08/09/2019</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">02/09/2025</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_zuxtVyhmz747" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.10</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_ztdRyIub9sXj" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">10/18/2019</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">10/18/2024</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_z2J8SrtCHIUl" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_zmfl9eJ2sL27" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">01/09/2020</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">07/09/2025</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_z20QogSQuYji" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_zWfaS2xKM2P7" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">10/30/2020</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">12/01/2025</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zo2cTgTkbN7l" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zwSWDbIeN906" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,644</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">01/20/2021</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">07/26/2026</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zngUN6Ov2Emb" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.55</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zphRdumVeLqg" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,725</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_z3J7cL5Aswqd" title="Date Issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsIssueDate">02/04/2022</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zeCb7jssfk4i" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember" format="ixt:datemonthdayyear" name="ttnp:ClassOfWarrantsOrRightsExpirationDate">08/04/2027</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zbVprxbLBT6k" title="Exercise Price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zrriKhX0HiUi" title="Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,664</ix:nonFraction></span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zWyiDrxSuvj9" title="Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,826</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z97tWCJR8f2d" style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares Reserved for Future Issuance</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, shares of common stock reserved by us for future issuance consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ttnp:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_zPsdhuFo4Fz" summary="xdx: Disclosure - Stockholders&apos; Equity (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B5_zxwXu46gpOdg" style="display: none">Schedule of shares of common stock reserved for future issuance</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Stock options outstanding</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSnOPPSWHEcg" title="Common stock, capital shares reserved for future issuance" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">927</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Shares issuable upon the exercise of warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zxipqE8V8488" title="Common stock, capital shares reserved for future issuance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,826</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220930_zy3yxUBNEiVg" title="Common stock, capital shares reserved for future issuance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,753</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z9XRyZui6vek" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zT5KZC21LHe6">Stock Plans</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August&#160;2015, our stockholders approved the 2015 Omnibus Equity Incentive Plan (the &#8220;2015 Plan&#8221;). The 2015 Plan, as subsequently amended, authorized a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_zbKufc88w3F8" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2015-08-31_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of our common stock for issuance to employees, directors, officers, consultants and advisors. As of December 31, 2022, options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_zQ0abPWqQY9e" title="Shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2015-08-31_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,262</ix:nonFraction></span> shares of our common stock were available for grant and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_z5yMe3m8x1Bj" title="Common stock outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2015-08-31_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">925,738</ix:nonFraction></span> shares of our common stock outstanding under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February&#160;2014, our Board adopted the 2014 Incentive Plan (the &#8220;2014 Plan&#8221;), pursuant to which <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20140228__us-gaap--PlanNameAxis__custom--Plan2015Member_zI2gSYfXDqZb" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2014-02-28_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,526</ix:nonFraction></span> shares of our common stock were authorized for issuance to employees, directors, officers, consultants and advisors. The 2014 Plan was terminated upon the approval of the 2015 Plan. As of December 31, 2022, options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20140228__us-gaap--PlanNameAxis__custom--Plan2015Member_zCWnHRcRk8R3" title="Common stock outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2014-02-28_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189</ix:nonFraction></span> shares of our common stock were outstanding under the 2014 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July&#160;2002, we adopted the 2002 Stock Incentive Plan (the &#8220;2002 Plan&#8221;). The 2002 Plan, as amended in 2005, authorized a total of approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20020731__us-gaap--PlanNameAxis__custom--Plan2015Member_zBzhUZnmJzG2" title="Number of shares agreed to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2002-07-31_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,234</ix:nonFraction></span> shares of our common stock for issuance to employees, officers, directors, consultants, and advisers. The exercise prices of options granted under the 2002 Plan were 100% of the fair market value of our common stock on the date of grant. The 2002 Plan expired by its terms in July&#160;2012. As of December 31, 2022, no options to purchase shares of our common stock were outstanding under the 2002 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z4NqZTrKZXc5" summary="xdx: Disclosure - Stock Plans (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BA_zRTCYfMaY5pf" style="display: none">Schedule of our option activity</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares<br /> (in thousands)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br /> Exercise Price<br />
per Share</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br /> Remaining
    Contractual<br /> Term (years)</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate<br /> Intrinsic Value<br /> (in
    thousands)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td> </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zeoMgsXWZ6Wh" title="Outstanding at Beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">682</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zvp5FJQKfEAe" title="Weighted Average Exercise Price, Outstanding at Beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.53</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zhImmUb5p52h" title="Weighted Average Remaining Contractual Term, Outstanding (Years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.98</ix:nonNumeric></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20221231_zmc3srTqtBCj" title="Aggregate Intrinsic Value, Outstanding at beginning" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zMwkGictmsCh" title="Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">310</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zK4zzYJcwOR1" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.18</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/expired</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_z29ZI741Es42" title="Shares, Cancelled/expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zcoYLHtlQG5d" title="Weighted Average Exercise Price, Cancelled/expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.40</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zwEwtYAOrEw1" title="Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">927</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zF0pmW48IIy4" title="Weighted Average Exercise Price, Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.97</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zw7hKCJ6DXng" title="Weighted Average Remaining Contractual Term, Outstanding (Years)"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.34</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20221231_zvcUa3QjkpS1" title="Aggregate Intrinsic Value, Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zE7h3trfQ5Wf" title="Shares, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">927</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zHJIgUzBq6M9" title="Weighted Average Exercise Price Per Share, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.97</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zDH1q3Jdd1Ub" title="Weighted Average Remaining Contractual Term, Exercisable"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.34</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20221231_pn3n3" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zs4kvnoEU1fb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zMyjZlJWHXhi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zqsYXrZbwc42" summary="xdx: Disclosure - Stock Plans (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BE_zPgA46M4ggo1" style="display: none">Schedule of assumptions to estimate the fair value of options</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br /> Years Ended<br /> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Weighted-average risk-free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zimxS1yvFL7d" title="Weighted-average risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.9</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231_zIwhvJPbZuab" title="Weighted-average risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Expected dividend payments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220101__20221231_pn3n3" title="Expected dividend payments" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231_pn3n3" title="Expected dividend payments" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Expected holding period (years)(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_fKDEp_zXc30gJDtOE" title="Expected holding period (years)"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" id="Fact000841" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.26</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_fKDEp_zSWaTKOeVK1h" title="Expected holding period (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" id="Fact000843" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.45</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Weighted-average volatility factor(2)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_fKDIp_zL35OYstqh33" title="Weighted-average volatility factor"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-01to2022-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.16</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20210101__20211231_fKDIp_zxaLCerXnlF6" title="Weighted-average volatility factor"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2021-01-012021-12-31" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.14</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Estimated forfeiture rates for options granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20221231_zY92hkuGfTb4" title="Estimated forfeiture rates for options granted"><ix:nonFraction name="ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20210101__20211231_zNytV6xmn0Eb" title="Estimated forfeiture rates for options granted"><ix:nonFraction name="ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0C_zUnIg0WPiaN8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zwaiP8AJBf74" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000852" xml:lang="en-US">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F02_zudaHfL6q9m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zibsMcMXUBKb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000853" xml:lang="en-US">Weighted average volatility is based on the historical volatility of our common stock.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F05_zyhzoOTkCcwj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zhVrqttXD5j1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000854" xml:lang="en-US">Estimated forfeiture rates are based on historical data.</ix:footnote></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zConnyx0AKug" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based upon the above methodology, the weighted-average fair value of options and awards granted during the&#160;years ended December 31, 2022 and 2021 was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_ziRFRxoXK9kg" title="Weighted-average fair value of options and awards granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction> </span>and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z9RfQCsbqQwd" title="Weighted-average fair value of options and awards granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.29</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the stock-based compensation expense (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_znRWAMNGLuE2" summary="xdx: Disclosure - Stock Plans (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BD_zus3gRP7DoR7" style="display: none">Schedule of the stock-based compensation expense</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br /> Years Ended<br /> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Research and development</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Total stock-based compensation" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">553</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Total stock-based compensation" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">749</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">General and administrative</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">394</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total stock-based compensation expenses</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">947</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_pn3n3" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zXzkhGsPpWO2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, there was approximately $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_dm_c20221231_zjHxAVykCw1l" title="Total unrecognized compensation expense related to non-vested stock option"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million of total unrecognized compensation expense related to non-vested stock options subject to shareholder approval. This expense is expected to be recognized over a weighted-average period of approximately <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_zmzJqiVOZNFg" title="Weighted-average period for recognizing non-vested stock option"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.7</ix:nonNumeric></span>&#160;year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 2, 2022, our Board of Directors, or Board, modified the outstanding options to purchase common stock under our 2015 Omnibus Equity Incentive Plan, or 2015 Plan, to allow for the acceleration of vesting of all unvested 2015 Plan options in the event of a change in control through the election of a majority of new members to our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Special Meeting was held at the request of Activist, to increase the size of our Board from five members to eleven members and elect Activist&#8217;s slate of six nominees to serve as directors in addition to the existing five Board members. As a result of the change of control, all unvested options granted under the 2015 Plan prior to August 15, 2022, immediately became vested. We recognized approximately $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20220801__20220815__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYMEqZXNiOee" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-08-012022-08-15_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million of stock-based compensation related to the acceleration of vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, our Board granted <span id="xdx_908_ecustom--PurchaseCommonStock_pid_c20220801__20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_zQ3UQiD8n7ee" title="Purchase common stock"><ix:nonFraction name="ttnp:PurchaseCommonStock" contextRef="From2022-08-012022-08-15_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span> options to purchase common stock at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_z6kVfYFRoyj4" title="Purchase price, per value"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-08-15_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.52</ix:nonFraction></span> per share which are subject to shareholder approval of an amendment to increase the number of shares reserved for issuance under our 2015 Plan. The options vest monthly over a 12-month period from the grant dates. As the shares underlying these options have not been approved by our stockholders, they have been excluded from the table above as of December 31, 2022. We have recognized approximately $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220801__20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-08-012022-08-15_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,000</ix:nonFraction></span> of stock-based compensation related to these grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zVS2cC2R6Hml" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2022, our Board granted <span id="xdx_90D_ecustom--PurchaseCommonStock_pid_c20220901__20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_z2QbgzO6dpyi" title="Purchase common stock"><ix:nonFraction name="ttnp:PurchaseCommonStock" contextRef="From2022-09-012022-09-15_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,000</ix:nonFraction></span> options to purchase common stock at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_zOO879p58Nv5" title="Purchase price, per value"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-15_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction> </span>per share which are subject to shareholder approval of an amendment to increase the number of shares reserved for issuance under our 2015 Plan. The options vest monthly over a 12-month period from the grant dates. As the shares underlying these options have not been approved by our stockholders, they have been excluded from the table above as of December 31, 2022. We have recognized approximately $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn3n3_c20220901__20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_zVel9wJ41u1e" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-09-012022-09-15_custom_Plan2015Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250,000</ix:nonFraction></span> of stock-based compensation related to these grants.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zWOgoeSkwngh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zD5nHuahUuZ">Income Taxes</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, we had federal net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zFOqvOabhB66" title="Operating Loss Carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">183.0</ix:nonFraction></span> million that expire at various dates through <span id="xdx_900_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember" title="Operating Loss Carry Forwards Expiration Year"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember" name="ttnp:OperatingLossCarryForwardsExpirationYear">2037</ix:nonNumeric></span> and approximately $<span id="xdx_90A_ecustom--OperatingLossCarryForwardsNotSubjectToExpiration_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znEVJNcVYQkj" title="Operating Loss Carry forwards Not Subject To Expiration"><ix:nonFraction name="ttnp:OperatingLossCarryForwardsNotSubjectToExpiration" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">54.3</ix:nonFraction></span> million which do not expire but are subject to <span id="xdx_90C_ecustom--OperatingLossCarryforwardsLimitationsOnUsePercentage_pid_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zucri4uBBe2l" title="Operating Loss Carryforwards, Limitations on Use Percentage"><ix:nonFraction name="ttnp:OperatingLossCarryforwardsLimitationsOnUsePercentage" contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% taxable income limitations. As of December 31, 2022, we had federal research and development tax credits of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zepekVoVY6J9" title="Operating Loss Carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">6.8</ix:nonFraction></span> million that expire at various dates through <span id="xdx_902_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember" title="Operating Loss Carry Forwards Expiration Year"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember" name="ttnp:OperatingLossCarryForwardsExpirationYear">2042</ix:nonNumeric></span>. We also had net operating loss carryforwards for California income tax purposes of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zs3nAlM2TuM6" title="Operating Loss Carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">115.2</ix:nonFraction></span> million that expire at various dates through <span id="xdx_902_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember" title="Operating Loss Carry Forwards Expiration Year"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember" name="ttnp:OperatingLossCarryForwardsExpirationYear">2042</ix:nonNumeric></span> and state research and development tax credits of approximately $<span id="xdx_902_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zG3ZzKBM3QJj" title="Tax Credit Carryforward, Amount"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">9.2</ix:nonFraction></span> million which do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current federal and California tax laws include substantial restrictions on the utilization of net operating losses and tax credits in the event of an ownership change of a corporation under Internal Revenue Code Section&#160;382 and 383.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and operating loss and credit carryforwards. Significant components of our deferred tax assets are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zsJNgv0oAJja" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BD_zRakmePcaTng" style="display: none">Schedule of deferred tax assets</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20221231_zzbQ8yFBDFh" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20211231_zyqaklV3x5wg" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Deferred tax assets:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGzHnT_zFloHNuGRon6" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Net operating loss carryforwards</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,895</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62,097</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3n3_maDTAGzHnT_zw5i3kmAgoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Research credit carryforwards</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,521</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,738</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGzHnT_z6KwMd6nSwWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Other, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,968</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,113</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzHnT_maDTALNzIFN_z7td1LOyCXhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total deferred tax assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,384</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,948</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Deferred tax liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDITLzija_z1MxwDEHj1t6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Other, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pn3n3_di_mtDITLzija_msDTALNzIFN_z5QaVimw2M1i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total deferred tax liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTALNzIFN_zfGjl7uejAH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,338</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,883</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNzIFN_zVgZrRQCX1M6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Net deferred tax assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zL0uaKTGQoC" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, our management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by approximately $<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_dm_c20220101__20221231_z00Xw7qIg175" title="Changes in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.5</ix:nonFraction></span> million during 2022 and decreased by approximately $<span id="xdx_90A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_dm_c20210101__20211231_zr7U6BQmwUD5" title="Changes in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million during 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for income taxes consists of state minimum taxes due. The effective tax rate of our provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zc2Gg4gSXEO6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zHv9ijIk1wUf" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B5_zyw4XYXvdES4" style="display: none">Schedule of effective tax rate</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20220101__20221231_zQLiD52LDRD6" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49B_20210101__20211231_z1RgChIYsCH5" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br /> Years&#160;Ended<br /> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zViet8yeubch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Computed at 21%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,144</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,842</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zPhvjNAlsNZd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">State taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">488</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">67</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zLjEnK9bPSwd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,545</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,939</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zegCp17Q5T6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Other</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ziC4fAHAm2g8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Stock based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">627</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_zIeDUTepL5Bf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Research and development credits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,489</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--TaxAttributesExpirations_iN_pn3n3_di_zGXoRsMlqR5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Tax attributes expirations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:TaxAttributesExpirations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,216</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="ttnp:TaxAttributesExpirations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,767</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxReconciliationImpactOfInternalRevenueCode_zCTKlJufGY7b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Impact of IRC 162m</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ttnp:IncomeTaxReconciliationImpactOfInternalRevenueCode" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">159</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ttnp:IncomeTaxReconciliationImpactOfInternalRevenueCode" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zfhlnh9RtI05" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A2_zh2Hk9fzpFm5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20221231_zq4AlMX0YeHc" title="Changes in valuation allowance"><span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20211231_zpm2bmCy8Nl7" title="Unrecognized Tax Benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> unrecognized tax benefits or any amounts accrued for interest and penalties for the three&#160;years ended December 31, 2022. Our policy is to recognize interest and penalties related to income taxes as a component of income tax expense. We do not expect the amount of unrecognized tax benefits will materially change in the next twelve&#160;months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We file tax returns in the U.S. federal jurisdiction and various state jurisdictions. We are subject to the U.S. federal and state income tax examination by tax authorities for such&#160;years 2003 through 2022, due to net operating losses that are being carried forward for tax purposes.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p id="xdx_800_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zli9EvY5et31" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zJuNTmfcGRL7">Discontinued Operations</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information related to assets and liabilities reported as discontinued operations in our balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zNJs6Da8N5Ua" summary="xdx: Disclosure - Discontinued Operations (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span id="xdx_8B4_zQhLzqUB8xze" style="display: none">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zfUoIBsVycG3" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49F_20211231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zodZD3RsaaG8" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(In thousands)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzCWn_zUKunQHZMdfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt; vertical-align: top">Prepaid expenses and other current assets</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzCWn_z8nbOICulzsh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Discontinued operations &#8211; current assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIz3aE_zVaRSiYLgd76" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">782</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_iI_pn3n3_maLODGIz3aE_zGoMJz5pUsQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top">Other accrued liabilities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ttnp:DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">362</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIz3aE_zK8QBODzFzok" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Discontinued operations &#8211; current liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,144</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, we recognized non-cash stock-based compensation expenses of approximately $<span id="xdx_905_ecustom--NoncashStockbasedCompensationExpenses_pn3n3_dm_c20220101__20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zENLmcOZxrcc" title="Non-cash stock-based compensation expenses"><ix:nonFraction name="ttnp:NoncashStockbasedCompensationExpenses" contextRef="From2022-01-012022-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million which is included in discontinued operations.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHEsoDDzUQw2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>11.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_823_z8mgodIatQ9g">Related Party Transactions</span></b></span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In January 2022, we entered into an agreement
with JT Pharma, a company for which James R. McNab, Jr., a member of our Board, serves as chief executive officer, to clarify certain
provisions of the JT Agreement, pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved,
made a payment of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--TransactionTypeAxis__custom--JTPharmaAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JTPharmaMember_zDet9oliVWMl" title="Value of stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_JTPharmaAgreementMember_custom_JTPharmaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> and issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--TransactionTypeAxis__custom--JTPharmaAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JTPharmaMember_z2YXVDq3L6M6" title="Stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_JTPharmaAgreementMember_custom_JTPharmaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,021</ix:nonFraction></span> shares of our common stock to JT Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">During the year ended December 31, 2022, we made
payments related to legal fees of approximately $<span id="xdx_901_eus-gaap--LegalFees_pn3p0_c20220101__20221231_z2iiS2rgq4b5" title="Payment of legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">75,000</ix:nonFraction></span> to a law firm operated by one of our Board members.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zUuLOH3YVMYk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zX38P1zSQWzc">Subsequent Events</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 10, 2023, the Federal Deposit Insurance Corporation, or FDIC, announced that it had closed and taken control of Silicon Valley Bank, or SVB.  On March 13, 2023, pursuant to a joint statement released by the U.S. Department of the Treasury and the FDIC, the U.S. government reassured that all depositors will be fully protected. We held deposits with this bank. As a result of the above actions, our insured and uninsured deposits have been restored. </span></p>

</ix:nonNumeric><p id="xdx_81C_zbRLMoF2qsbb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b) Exhibits</b></span></p>

<p style="margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="vertical-align: top; text-align: justify; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as amended<sup>(2)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420415056647/v421014_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation dated September 24, 2015<sup>(4)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation dated January 23, 2019<sup>(10)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920131098/tm2037359d1_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation dated November 30, 2020<sup>(20)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420417054170/tv477697_ex3-3.htm">By-laws of the Registrant<sup>(1)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465921154063/tm2136487d2_ex3-1.htm">Amendment to the By-laws of the Registrant dated December 29, 2021<sup>(23)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922077431/tm2220416d1_ex3-1.htm">Amendment to the By-laws of the Registrant dated July 5, 2022<sup>(25)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420417038785/v471646_ex4-4.htm">Form of Lender Warrant<sup>(6)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420418016884/tv489507_ex10-3.htm">Form of Rights Agreement Warrant<sup>(7)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420418050743/tv503422_ex4-1.htm">Warrant Agency Agreement between Titan Pharmaceuticals, Inc. and Continental Stock Transfer &amp; Trust Company and Form of Offering Warrant<sup>(9)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420418050743/tv503422_ex4-2.htm">Representative&#8217;s Purchase Warrant<sup>(9)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420419038636/tv527052_ex4-2.htm">Form of August 2019 Private Placement Warrant<sup>(11)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465919054978/tm1920490d1_ex4-1.htm">Class B Warrant Agency Agreement dated October 16, 2019 between Titan Pharmaceuticals, Inc. and Maxim Group LLC Form of January 2020 Private Placement Warrant<sup>(12)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920002040/tm201430-1_ex41.htm">Form of January 2020 Private Placement Warrant<sup>(13)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex412.htm">Form of March 3, 2020 Warrant Amendment Agreement<sup>(16)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920040354/tm205305-1_ex413.htm">Description of the Registrant&#8217;s Common Stock<sup>(15)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920118552/tm2033419d5_ex4-10.htm">Warrant Agency Agreement between Titan Pharmaceuticals, Inc. and Continental Stock Transfer &amp; Trust Company and Form of Warrant<sup>(18)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex4-1.htm">Form of January 2021 Private Placement Warrant<sup>(21)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922011419/tm225246d1_ex4-1.htm">Form of February 2022 Registered Pre-Funded Warrant<sup>(24)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922011419/tm225246d1_ex4-2.htm">Form of February 2022 Private Pre-Funded Warrant<sup>(24)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922011419/tm225246d1_ex4-3.htm">Form of February 2022 Placement Warrant<sup>(24)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex10-1.htm">Titan Pharmaceuticals, Inc. Third Amended and Restated 2015 Omnibus Equity Incentive Plan<sup>(10)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420419018020/tv517982_ex10-2.htm">Employment Agreement between the Registrant and Marc Rubin<sup>(5)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3 &#177;</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420418044671/tv499850_ex10-22.htm">Distribution and Sublicense Agreement dated February 1, 2016 as amended by agreement dated August 2, 2018 between Titan Pharmaceuticals, Inc. and Knight Therapeutics Inc.<sup>(8)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420418044671/tv499850_ex10-23.htm">Amendment to lease for Registrant&#8217;s facility dated March 21, 2016<sup>(8)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420419017459/tv516475_ex10-27.htm">Employment Agreement between the Registrant and Katherine Beebe DeVarney<sup>(14)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920117956/tm2033419d3_ex10-1.htm">Debt Settlement and Release Agreement by and between Titan Pharmaceuticals, Inc., Horizon Technology Finance Corporation and L. Molteni &amp; C. Dei Frattelli Alitti Societ&#224; Di Esercizio S.P.A.<sup>(17)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#177;&#177;</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920125466/tm2029565d1_ex10-28.htm">Asset Purchase Agreement dated October 27, 2020 between Titan Pharmaceuticals, Inc. and JT Pharmaceuticals, Inc.<sup>(19)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465921004940/tm213361d1_ex10-2.htm">Placement Agency Agreement dated January 15, 2021, by and between Titan Pharmaceuticals, Inc. and Maxim Group LLC<sup>(21)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465921130586/tm2131195d1_ex10-1.htm">Amendment to Employment Agreement between the Registrant and Marc Rubin<sup>(22)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922011419/tm225246d1_ex10-1.htm">Form of February 2022 Securities Purchase Agreement<sup>(24)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922011419/tm225246d1_ex10-2.htm">Placement Agency Agreement dated February 2, 2022, by and between Titan Pharmaceuticals, Inc. and Maxim Group LLC<sup>(24)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922086697/tm2222653d1_ex10-1.htm">Form of Amendment to Employment Agreement with Marc Rubin<sup>(26)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922086697/tm2222653d1_ex10-2.htm">Form of Amendment to Employment Agreement with Kate DeVarney<sup>(26)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912622017040/titanpharma_ex10-1.htm">Form of Stock Option Agreement<sup>(27)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/910267/000182912622019258/titanpharma_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan (subject to stockholder approval)<sup>(28)</sup></span></a></td></tr>
  </table>

<p style="margin: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 41 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="vertical-align: top; text-align: justify; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912622020168/titanpharma_ex10-1.htm">License Agreement between Titan Pharmaceuticals, Inc. and Ocular Therapeutix, Inc., dated as of December 6, 2022<sup>(29)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912622020321/titanpharma_ex10-1.htm">Employment Agreement, dated December 14, 2022, between Titan Pharmaceuticals, Inc. and David E. Lazar<sup>(30)</sup></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/910267/000119312513111045/d444155dex141.htm">Code of Business Conduct and Ethics<sup>(3)</sup></a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="titanpharma_ex23-1.htm">Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="titanpharma_ex31-1.htm">Certification of the Principal Executive and Financial Officer pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934</a></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="titanpharma_ex32-1.htm">Certification of the Principal Executive and Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#177;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential treatment has been granted as to certain portions of this exhibit.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#177;&#177;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain information has been omitted from this exhibit in reliance upon Item 601(b)(10) of Regulation S-K.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Registration Statement on Form S-3 (File No. 333-221126).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Registration Statement on Form 10 filed on January 14, 2010.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K filed on September 28, 2015.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K filed on April 3, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K filed on July 27, 2017.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K filed on March 26, 2018.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2018.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated September 25, 2018.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated January 25, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated August 8, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated October 18, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated January 7, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Annual Report on Form 10-K dated April 1, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Annual Report on Form 10-K dated March 30, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated October 26, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Registration Statement on Form S-1/A dated October 27, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated December&#160;1, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form 8-K dated January 19, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated October&#160;28, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated December&#160;29, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated February&#160;3, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated July 5, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated August 5, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated September 21, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated December 12, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the Registrant&#8217;s Current Report on Form&#160;8-K dated December 15, 2022.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 66; Value: 41 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_027"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TITAN PHARMACEUTICALS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David E. Lazar</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David E. Lazar</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal Executive and Principal Financial Officer)</i></span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David E. Lazar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David E. Lazar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(principal executive officer and principal financial officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Katherine Beebe DeVarney, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Operating Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Katherine Beebe DeVarney, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph A. Akers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph A. Akers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Avraham Ben-Tzvi, Adv.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avraham Ben-Tzvi, Adv.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Peter L. Chasey, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter L. Chasey, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eric Greenberg</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Greenberg</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ M. David MacFarlane, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. David MacFarlane, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew C. McMurdo, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew C. McMurdo, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James R. McNab, Jr.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James R. McNab, Jr.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Natan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Natan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brian E. Crowley</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Finance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;31, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian E. Crowley</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(principal accounting officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 67; Value: 41 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>titanpharma_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File Nos. 333- 226841, 333-233722,
333-249550, 333-251187, 333-252482 and 333-262614), Form S-3 (File Nos. 333-230742 and 333-221126) and Form S-8 (File Nos. 333-171181
and 333-207950) of Titan Pharmaceuticals, Inc. of our report dated March&nbsp;31, 2023, <FONT STYLE="background-color: white">which
includes an explanatory paragraph relating to the Company&rsquo;s ability to continue as a going concern,&nbsp;</FONT>relating
to the financial statements of Titan Pharmaceuticals, Inc., which appears in this Form 10-K.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    WithumSmith+Brown, PC</FONT></TD>
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Francisco, California</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&nbsp;31, 2023</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>titanpharma_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David E. Lazar, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form&nbsp;10-K of Titan Pharmaceuticals,&nbsp;Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)&nbsp;for
the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under my supervision, to ensure that material information relating to the
                                            registrant, including its subsidiaries, is made known to me by others within those entities,
                                            particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under my supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March&nbsp;31, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David E. Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    E. Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer and Principal Financial Officer)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>titanpharma_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION&nbsp;1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION&nbsp;906</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Annual Report on Form&nbsp;10-K of Titan Pharmaceuticals,&nbsp;Inc. (the &ldquo;Company&rdquo;) for the year ended
December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned
officer of the Company hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002, that to the best of his knowledge:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March&nbsp;31, 2023</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David E. Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    E. Lazar</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer and Principal Financial Officer)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->















</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ttnp-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Qpo7xRiXgOn8uPaXcsSaeE+bP9xpJ7SZkhtGl6fQmaTyUoTSGDySw+gCYWsbQE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ttnp="http://titanpharm.com/20221231" elementFormDefault="qualified" targetNamespace="http://titanpharm.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://titanpharm.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000008 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" id="JtPharmaceuticalsAssetPurchaseAgreement">
	  <link:definition>00000009 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreement" id="OcularTherapeutixLicenseAgreement">
	  <link:definition>00000010 - Disclosure - Ocular Therapeutix License Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/DebtAgreements" id="DebtAgreements">
	  <link:definition>00000012 - Disclosure - Debt Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000013 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockPlans" id="StockPlans">
	  <link:definition>00000014 - Disclosure - Stock Plans</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000015 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
	  <link:definition>00000016 - Disclosure - Discontinued Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000017 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000018 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000021 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000022 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockPlansTables" id="StockPlansTables">
	  <link:definition>00000023 - Disclosure - Stock Plans (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000024 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" id="DiscontinuedOperationsTables">
	  <link:definition>00000025 - Disclosure - Discontinued Operations (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1">
	  <link:definition>00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
	  <link:definition>00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3">
	  <link:definition>00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4">
	  <link:definition>00000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
	  <link:definition>00000032 - Disclosure - Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" id="JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative">
	  <link:definition>00000033 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative" id="OcularTherapeutixLicenseAgreementDetailsNarrative">
	  <link:definition>00000034 - Disclosure - Ocular Therapeutix License Agreement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/DebtAgreementsDetailsNarrative" id="DebtAgreementsDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Debt Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000037 - Disclosure - Stockholders' Equity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000038 - Disclosure - Stockholders' Equity (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
	  <link:definition>00000039 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockPlansDetails" id="StockPlansDetails">
	  <link:definition>00000041 - Disclosure - Stock Plans (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockPlansDetails1" id="StockPlansDetails1">
	  <link:definition>00000042 - Disclosure - Stock Plans (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockPlansDetails2" id="StockPlansDetails2">
	  <link:definition>00000043 - Disclosure - Stock Plans (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" id="StockPlansDetailsNarrative">
	  <link:definition>00000044 - Disclosure - Stock Plans (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000045 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000046 - Disclosure - Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000047 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" id="DiscontinuedOperationsDetails">
	  <link:definition>00000048 - Disclosure - Discontinued Operations (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative" id="DiscontinuedOperationsDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Discontinued Operations (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000050 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="ttnp_RubinMember" name="RubinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_EmployeeStockAwardsMember" name="EmployeeStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_JtPharmaceuticalsMember" name="JtPharmaceuticalsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_February2022OfferingsMember" name="February2022OfferingsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PreFundedWarrantsMember" name="PreFundedWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_UnregisteredPrefundedWarrantsMember" name="UnregisteredPrefundedWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" name="UnregisteredFiveYearAndSixMonthWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CommonStockToMaximGroupLlcMember" name="CommonStockToMaximGroupLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" name="ServicesAgreementWithMaximMdmWorldwideSolutionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" name="RestrictedStockAgreementWithMaximGroupLlcMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_TwoThousandFifteenPlanMember" name="TwoThousandFifteenPlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_January2021OfferingMember" name="January2021OfferingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateOneMember" name="ClassOfWarrantOrRightIssuedDateOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateTwoMember" name="ClassOfWarrantOrRightIssuedDateTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateThreeMember" name="ClassOfWarrantOrRightIssuedDateThreeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateFourMember" name="ClassOfWarrantOrRightIssuedDateFourMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateFiveMember" name="ClassOfWarrantOrRightIssuedDateFiveMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateSixMember" name="ClassOfWarrantOrRightIssuedDateSixMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember" name="ClassOfWarrantOrRightIssuedDateSevenMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateEightMember" name="ClassOfWarrantOrRightIssuedDateEightMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateNineMember" name="ClassOfWarrantOrRightIssuedDateNineMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateTenMember" name="ClassOfWarrantOrRightIssuedDateTenMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantOrRightIssuedDateElevenMember" name="ClassOfWarrantOrRightIssuedDateElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_Plan2015Member" name="Plan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_U.s.CommercializationActivitiesMember" name="U.s.CommercializationActivitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_JTPharmaAgreementMember" name="JTPharmaAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_JTPharmaMember" name="JTPharmaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AccruedClinicalTrialsExpensesCurrent" name="AccruedClinicalTrialsExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DeferredGrantRevenue" name="DeferredGrantRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_BasicAndDilutedNetLossPerCommonShare" name="BasicAndDilutedNetLossPerCommonShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" name="WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AmortizationOfRestrictedStockShares" name="AmortizationOfRestrictedStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ShareBasedPaymentArrangementMilestonePayment" name="ShareBasedPaymentArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AmortizationOfRestrictedStock" name="AmortizationOfRestrictedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ProceedsFromEquityOfferings" name="ProceedsFromEquityOfferings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" name="RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_RetirementOfPropertyAndEquipment" name="RetirementOfPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment" name="AccumulatedDepreciationOnRetiredPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" name="CashAndCashEquivalentsAndRestrictedCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" name="DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock" name="JTPharmaceuticalsAssetPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract" name="DisclosureOcularTherapeutixLicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AssetPurchaseAgreementTextBlock" name="AssetPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_CompanyPolicyPolicyTextBlock" name="CompanyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock" name="SubstantialDoubtAboutGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" name="WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ContractWithCustomerAssetAdditions" name="ContractWithCustomerAssetAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ContractWithCustomerAssetDeductions" name="ContractWithCustomerAssetDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_AccruedSeverance" name="AccruedSeverance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DeferredCompensationAndEmployeeSeverance" name="DeferredCompensationAndEmployeeSeverance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_FutureMilestonePayments" name="FutureMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_MilestonePayments" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ReimbursementFees" name="ReimbursementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_OperatingLeasesRentExpenses" name="OperatingLeasesRentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantsOrRightsIssueDate" name="ClassOfWarrantsOrRightsIssueDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_ClassOfWarrantsOrRightsExpirationDate" name="ClassOfWarrantsOrRightsExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" name="EstimatedForfeitureRatesForOptionsGrantedToManagement" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PurchaseCommonStock" name="PurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_TaxAttributesExpirations" name="TaxAttributesExpirations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode" name="IncomeTaxReconciliationImpactOfInternalRevenueCode" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration" name="OperatingLossCarryForwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage" name="OperatingLossCarryforwardsLimitationsOnUsePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" name="DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_NoncashStockbasedCompensationExpenses" name="NoncashStockbasedCompensationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ttnp-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/BalanceSheets" xlink:href="ttnp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/BalanceSheetsParenthetical" xlink:href="ttnp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfOperations" xlink:href="ttnp-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfStockholdersEquity" xlink:href="ttnp-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfCashFlows" xlink:href="ttnp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipment" xlink:href="ttnp-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:href="ttnp-20221231.xsd#JtPharmaceuticalsAssetPurchaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreement" xlink:href="ttnp-20221231.xsd#OcularTherapeutixLicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:href="ttnp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DebtAgreements" xlink:href="ttnp-20221231.xsd#DebtAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquity" xlink:href="ttnp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlans" xlink:href="ttnp-20221231.xsd#StockPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxes" xlink:href="ttnp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperations" xlink:href="ttnp-20221231.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactions" xlink:href="ttnp-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEvents" xlink:href="ttnp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipmentTables" xlink:href="ttnp-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityTables" xlink:href="ttnp-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansTables" xlink:href="ttnp-20221231.xsd#StockPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesTables" xlink:href="ttnp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipmentDetails" xlink:href="ttnp-20221231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:href="ttnp-20221231.xsd#JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:href="ttnp-20221231.xsd#OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ttnp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DebtAgreementsDetailsNarrative" xlink:href="ttnp-20221231.xsd#DebtAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails1" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails2" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails" xlink:href="ttnp-20221231.xsd#StockPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails1" xlink:href="ttnp-20221231.xsd#StockPlansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails2" xlink:href="ttnp-20221231.xsd#StockPlansDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:href="ttnp-20221231.xsd#StockPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetails" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetails1" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetailsNarrative" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ttnp-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccruedClinicalTrialsExpensesCurrent" xlink:label="loc_ttnpAccruedClinicalTrialsExpensesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ttnpAccruedClinicalTrialsExpensesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DeferredGrantRevenue" xlink:label="loc_ttnpDeferredGrantRevenue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ttnpDeferredGrantRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:label="loc_ttnpShareBasedPaymentArrangementMilestonePayment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ttnpShareBasedPaymentArrangementMilestonePayment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AmortizationOfRestrictedStock" xlink:label="loc_ttnpAmortizationOfRestrictedStock" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ttnpAmortizationOfRestrictedStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ProceedsFromEquityOfferings" xlink:label="loc_ttnpProceedsFromEquityOfferings" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ttnpProceedsFromEquityOfferings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:title="00000009 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OcularTherapeutixLicenseAgreement" xlink:title="00000010 - Disclosure - Ocular Therapeutix License Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DebtAgreements" xlink:title="00000012 - Disclosure - Debt Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlans" xlink:title="00000014 - Disclosure - Stock Plans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperations" xlink:title="00000016 - Disclosure - Discontinued Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipmentTables" xlink:title="00000021 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansTables" xlink:title="00000023 - Disclosure - Stock Plans (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:title="00000025 - Disclosure - Discontinued Operations (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsAndSuppliesNetOfReserves" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:title="00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:title="00000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Property and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:title="00000033 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:title="00000034 - Disclosure - Ocular Therapeutix License Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000035 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DebtAgreementsDetailsNarrative" xlink:title="00000036 - Disclosure - Debt Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails" xlink:title="00000037 - Disclosure - Stockholders&apos; Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails1" xlink:title="00000038 - Disclosure - Stockholders&apos; Equity (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails2" xlink:title="00000039 - Disclosure - Stockholders&apos; Equity (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails" xlink:title="00000041 - Disclosure - Stock Plans (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails1" xlink:title="00000042 - Disclosure - Stock Plans (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails2" xlink:title="00000043 - Disclosure - Stock Plans (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:title="00000044 - Disclosure - Stock Plans (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetails" xlink:title="00000045 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetails1" xlink:title="00000046 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:title="00000048 - Disclosure - Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:label="loc_ttnpDisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_ttnpDisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative" xlink:title="00000049 - Disclosure - Discontinued Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000050 - Disclosure - Related Party Transactions (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ttnp-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/BalanceSheets" xlink:href="ttnp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/BalanceSheetsParenthetical" xlink:href="ttnp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfOperations" xlink:href="ttnp-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfStockholdersEquity" xlink:href="ttnp-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfCashFlows" xlink:href="ttnp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipment" xlink:href="ttnp-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:href="ttnp-20221231.xsd#JtPharmaceuticalsAssetPurchaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreement" xlink:href="ttnp-20221231.xsd#OcularTherapeutixLicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:href="ttnp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DebtAgreements" xlink:href="ttnp-20221231.xsd#DebtAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquity" xlink:href="ttnp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlans" xlink:href="ttnp-20221231.xsd#StockPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxes" xlink:href="ttnp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperations" xlink:href="ttnp-20221231.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactions" xlink:href="ttnp-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEvents" xlink:href="ttnp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipmentTables" xlink:href="ttnp-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityTables" xlink:href="ttnp-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansTables" xlink:href="ttnp-20221231.xsd#StockPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesTables" xlink:href="ttnp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipmentDetails" xlink:href="ttnp-20221231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:href="ttnp-20221231.xsd#JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:href="ttnp-20221231.xsd#OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ttnp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DebtAgreementsDetailsNarrative" xlink:href="ttnp-20221231.xsd#DebtAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails1" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails2" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails" xlink:href="ttnp-20221231.xsd#StockPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails1" xlink:href="ttnp-20221231.xsd#StockPlansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails2" xlink:href="ttnp-20221231.xsd#StockPlansDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:href="ttnp-20221231.xsd#StockPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetails" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetails1" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetailsNarrative" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ttnp-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaapGrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapGrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapOperatingExpenses_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapOperatingIncomeLoss_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapOtherNonoperatingExpense_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapNonoperatingIncomeExpense_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_BasicAndDilutedNetLossPerCommonShare" xlink:label="loc_ttnpBasicAndDilutedNetLossPerCommonShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpBasicAndDilutedNetLossPerCommonShare_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" xlink:label="loc_ttnpWeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpWeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare_90" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AmortizationOfRestrictedStockShares" xlink:label="loc_ttnpAmortizationOfRestrictedStockShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpAmortizationOfRestrictedStockShares_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:title="00000009 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OcularTherapeutixLicenseAgreement" xlink:title="00000010 - Disclosure - Ocular Therapeutix License Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DebtAgreements" xlink:title="00000012 - Disclosure - Debt Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlans" xlink:title="00000014 - Disclosure - Stock Plans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperations" xlink:title="00000016 - Disclosure - Discontinued Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipmentTables" xlink:title="00000021 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansTables" xlink:title="00000023 - Disclosure - Stock Plans (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:title="00000025 - Disclosure - Discontinued Operations (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:title="00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_EmployeeStockAwardsMember" xlink:label="loc_ttnpEmployeeStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_ttnpEmployeeStockAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:title="00000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RubinMember" xlink:label="loc_ttnpRubinMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpRubinMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSeveranceCosts1_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccruedSeverance" xlink:label="loc_ttnpAccruedSeverance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ttnpAccruedSeverance_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DeferredCompensationAndEmployeeSeverance" xlink:label="loc_ttnpDeferredCompensationAndEmployeeSeverance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ttnpDeferredCompensationAndEmployeeSeverance_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryFinishedGoods_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:title="00000033 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_FutureMilestonePayments" xlink:label="loc_ttnpFutureMilestonePayments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpFutureMilestonePayments_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MilestonePayments" xlink:label="loc_ttnpMilestonePayments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpMilestonePayments_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:title="00000034 - Disclosure - Ocular Therapeutix License Agreement (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000035 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DebtAgreementsDetailsNarrative" xlink:title="00000036 - Disclosure - Debt Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PaycheckProtectionProgramLoanMember" xlink:label="loc_ttnpPaycheckProtectionProgramLoanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ttnpPaycheckProtectionProgramLoanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails" xlink:title="00000037 - Disclosure - Stockholders&apos; Equity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails1" xlink:title="00000038 - Disclosure - Stockholders&apos; Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateOneMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateTwoMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateThreeMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateFourMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateFiveMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateSixMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateSevenMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateEightMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateNineMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateTenMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateElevenMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateElevenMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantsOrRightsIssueDate" xlink:label="loc_ttnpClassOfWarrantsOrRightsIssueDate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ttnpClassOfWarrantsOrRightsIssueDate_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_ttnpClassOfWarrantsOrRightsExpirationDate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ttnpClassOfWarrantsOrRightsExpirationDate_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_240" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails2" xlink:title="00000039 - Disclosure - Stockholders&apos; Equity (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_February2022OfferingsMember" xlink:label="loc_ttnpFebruary2022OfferingsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ttnpFebruary2022OfferingsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_January2021OfferingMember" xlink:label="loc_ttnpJanuary2021OfferingMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ttnpJanuary2021OfferingMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PreFundedWarrantsMember" xlink:label="loc_ttnpPreFundedWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpPreFundedWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_UnregisteredPrefundedWarrantsMember" xlink:label="loc_ttnpUnregisteredPrefundedWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredPrefundedWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:label="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_CommonStockToMaximGroupLlcMember" xlink:label="loc_ttnpCommonStockToMaximGroupLlcMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpCommonStockToMaximGroupLlcMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" xlink:label="loc_ttnpServicesAgreementWithMaximMdmWorldwideSolutionsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpServicesAgreementWithMaximMdmWorldwideSolutionsMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:label="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_TwoThousandFifteenPlanMember" xlink:label="loc_ttnpTwoThousandFifteenPlanMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpTwoThousandFifteenPlanMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MilestonePayment" xlink:label="loc_ttnpMilestonePayment_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ttnpMilestonePayment_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_240" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails" xlink:title="00000041 - Disclosure - Stock Plans (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails1" xlink:title="00000042 - Disclosure - Stock Plans (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails2" xlink:title="00000043 - Disclosure - Stock Plans (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:title="00000044 - Disclosure - Stock Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_Plan2015Member" xlink:label="loc_ttnpPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PurchaseCommonStock" xlink:label="loc_ttnpPurchaseCommonStock_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpPurchaseCommonStock_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_120" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetails" xlink:title="00000045 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetails1" xlink:title="00000046 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_ttnpOperatingLossCarryForwardsExpirationYear_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ttnpOperatingLossCarryForwardsExpirationYear_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="loc_ttnpOperatingLossCarryForwardsNotSubjectToExpiration_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ttnpOperatingLossCarryForwardsNotSubjectToExpiration_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage" xlink:label="loc_ttnpOperatingLossCarryforwardsLimitationsOnUsePercentage_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ttnpOperatingLossCarryforwardsLimitationsOnUsePercentage_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:title="00000048 - Disclosure - Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_U.s.CommercializationActivitiesMember" xlink:label="loc_ttnpU.s.CommercializationActivitiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="loc_ttnpU.s.CommercializationActivitiesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:label="loc_ttnpDisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_ttnpDisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative" xlink:title="00000049 - Disclosure - Discontinued Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_NoncashStockbasedCompensationExpenses" xlink:label="loc_ttnpNoncashStockbasedCompensationExpenses_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_ttnpNoncashStockbasedCompensationExpenses_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000050 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaAgreementMember" xlink:label="loc_ttnpJTPharmaAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ttnpJTPharmaAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaMember" xlink:label="loc_ttnpJTPharmaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ttnpJTPharmaMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLegalFees_30" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ttnp-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RubinMember" xlink:label="ttnp_RubinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RubinMember" xlink:to="ttnp_RubinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_RubinMember_lbl" xml:lang="en-US">Rubin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_EmployeeStockAwardsMember" xlink:label="ttnp_EmployeeStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_EmployeeStockAwardsMember" xlink:to="ttnp_EmployeeStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_EmployeeStockAwardsMember_lbl" xml:lang="en-US">Stock Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="ttnp_JtPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_JtPharmaceuticalsMember" xlink:to="ttnp_JtPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_JtPharmaceuticalsMember_lbl" xml:lang="en-US">JT Pharmaceuticals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PaycheckProtectionProgramLoanMember" xlink:label="ttnp_PaycheckProtectionProgramLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PaycheckProtectionProgramLoanMember" xlink:to="ttnp_PaycheckProtectionProgramLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">PPP loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_February2022OfferingsMember" xlink:label="ttnp_February2022OfferingsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_February2022OfferingsMember" xlink:to="ttnp_February2022OfferingsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_February2022OfferingsMember_lbl" xml:lang="en-US">February 2022 Offerings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PreFundedWarrantsMember" xlink:label="ttnp_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PreFundedWarrantsMember" xlink:to="ttnp_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_UnregisteredPrefundedWarrantsMember" xlink:label="ttnp_UnregisteredPrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredPrefundedWarrantsMember" xlink:to="ttnp_UnregisteredPrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_UnregisteredPrefundedWarrantsMember_lbl" xml:lang="en-US">Unregistered prefunded warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:label="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:to="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_lbl" xml:lang="en-US">Unregistered five year and six month warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_CommonStockToMaximGroupLlcMember" xlink:label="ttnp_CommonStockToMaximGroupLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CommonStockToMaximGroupLlcMember" xlink:to="ttnp_CommonStockToMaximGroupLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CommonStockToMaximGroupLlcMember_lbl" xml:lang="en-US">Common Stock To Maxim Group Llc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" xlink:label="ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" xlink:to="ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember_lbl" xml:lang="en-US">Services Agreement With Maxim Mdm Worldwide Solutions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:label="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:to="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_lbl" xml:lang="en-US">Restricted stock agreement with Maxim Group, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_TwoThousandFifteenPlanMember" xlink:label="ttnp_TwoThousandFifteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_TwoThousandFifteenPlanMember" xlink:to="ttnp_TwoThousandFifteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_TwoThousandFifteenPlanMember_lbl" xml:lang="en-US">2015 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_January2021OfferingMember" xlink:label="ttnp_January2021OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_January2021OfferingMember" xlink:to="ttnp_January2021OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_January2021OfferingMember_lbl" xml:lang="en-US">January 2021 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateOneMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateOneMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateOneMember_lbl" xml:lang="en-US">Class of Warrant or Right Issued Date One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateTwoMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateTwoMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateTwoMember_lbl" xml:lang="en-US">Class of Warrant or Right Issued Date Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateThreeMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateThreeMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateThreeMember_lbl" xml:lang="en-US">Class of Warrant or Right Issued Date Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateFourMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateFourMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateFourMember_lbl" xml:lang="en-US">Class Of Warrant or Right Issued Date Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateFiveMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateFiveMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateFiveMember_lbl" xml:lang="en-US">Class Of Warrant or Right Issued Date Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateSixMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateSixMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateSixMember_lbl" xml:lang="en-US">Class Of Warrant or Right Issued Date Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateSevenMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember_lbl" xml:lang="en-US">Class Of Warrant or Right Issued Date Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateEightMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateEightMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateEightMember_lbl" xml:lang="en-US">Class Of Warrant or Right Issued Date Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateNineMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateNineMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateNineMember_lbl" xml:lang="en-US">Class Of Warrant Or Right Issued Date Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateTenMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateTenMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateTenMember_lbl" xml:lang="en-US">Class Of Warrant Or Right Issued Date Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateElevenMember" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateElevenMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateElevenMember_lbl" xml:lang="en-US">Class Of Warrant Or Right Issued Date Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_Plan2015Member" xlink:label="ttnp_Plan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_Plan2015Member" xlink:to="ttnp_Plan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_Plan2015Member_lbl" xml:lang="en-US">Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_U.s.CommercializationActivitiesMember" xlink:label="ttnp_U.s.CommercializationActivitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_U.s.CommercializationActivitiesMember" xlink:to="ttnp_U.s.CommercializationActivitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_U.s.CommercializationActivitiesMember_lbl" xml:lang="en-US">U.s. Commercialization Activities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaAgreementMember" xlink:label="ttnp_JTPharmaAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_JTPharmaAgreementMember" xlink:to="ttnp_JTPharmaAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_JTPharmaAgreementMember_lbl" xml:lang="en-US">J T Pharma Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaMember" xlink:label="ttnp_JTPharmaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_JTPharmaMember" xlink:to="ttnp_JTPharmaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_JTPharmaMember_lbl" xml:lang="en-US">J T Pharma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Discontinued operations - current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccruedClinicalTrialsExpensesCurrent" xlink:label="ttnp_AccruedClinicalTrialsExpensesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AccruedClinicalTrialsExpensesCurrent" xlink:to="ttnp_AccruedClinicalTrialsExpensesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AccruedClinicalTrialsExpensesCurrent_lbl" xml:lang="en-US">Accrued clinical trials expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DeferredGrantRevenue" xlink:label="ttnp_DeferredGrantRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DeferredGrantRevenue" xlink:to="ttnp_DeferredGrantRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DeferredGrantRevenue_lbl" xml:lang="en-US">Deferred grant revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Discontinued operations - current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued or outstanding at December 31, 2022 and 2021.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 15,016,295 and 9,914,158 shares issued and outstanding at December 31, 2022 and 2021, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred shares, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred shares, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred shares, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Non-cash gain on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_BasicAndDilutedNetLossPerCommonShare" xlink:label="ttnp_BasicAndDilutedNetLossPerCommonShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_BasicAndDilutedNetLossPerCommonShare" xlink:to="ttnp_BasicAndDilutedNetLossPerCommonShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_BasicAndDilutedNetLossPerCommonShare_lbl" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" xlink:label="ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" xlink:to="ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare_lbl" xml:lang="en-US">Weighted average shares used in computing basic and diluted net loss per common share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock upon exercises of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Amortization of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AmortizationOfRestrictedStockShares" xlink:label="ttnp_AmortizationOfRestrictedStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AmortizationOfRestrictedStockShares" xlink:to="ttnp_AmortizationOfRestrictedStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AmortizationOfRestrictedStockShares_lbl" xml:lang="en-US">Amortization of restricted stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Non-cash gain on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:label="ttnp_ShareBasedPaymentArrangementMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:to="ttnp_ShareBasedPaymentArrangementMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ShareBasedPaymentArrangementMilestonePayment_lbl" xml:lang="en-US">Stock-based milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AmortizationOfRestrictedStock" xlink:label="ttnp_AmortizationOfRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AmortizationOfRestrictedStock" xlink:to="ttnp_AmortizationOfRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ttnp_AmortizationOfRestrictedStock_lbl" xml:lang="en-US">Amortization of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ProceedsFromEquityOfferings" xlink:label="ttnp_ProceedsFromEquityOfferings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ProceedsFromEquityOfferings" xlink:to="ttnp_ProceedsFromEquityOfferings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ProceedsFromEquityOfferings_lbl" xml:lang="en-US">Proceeds from equity offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" xlink:label="ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" xlink:to="ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization_lbl" xml:lang="en-US">Right of use asset obtained in exchange for lease liability, net of amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RetirementOfPropertyAndEquipment" xlink:label="ttnp_RetirementOfPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RetirementOfPropertyAndEquipment" xlink:to="ttnp_RetirementOfPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_RetirementOfPropertyAndEquipment_lbl" xml:lang="en-US">Retirement of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment" xlink:label="ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment" xlink:to="ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation on retired property and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:label="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:to="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:label="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:to="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract_lbl" xml:lang="en-US">Jt Pharmaceuticals Asset Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock" xlink:label="ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock" xlink:to="ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock_lbl" xml:lang="en-US">JT Pharmaceuticals Asset Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract" xlink:label="ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract" xlink:to="ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract_lbl" xml:lang="en-US">Ocular Therapeutix License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AssetPurchaseAgreementTextBlock" xlink:label="ttnp_AssetPurchaseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetPurchaseAgreementTextBlock" xlink:to="ttnp_AssetPurchaseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ttnp_AssetPurchaseAgreementTextBlock_lbl" xml:lang="en-US">Ocular Therapeutix License Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_CompanyPolicyPolicyTextBlock" xlink:label="ttnp_CompanyPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CompanyPolicyPolicyTextBlock" xlink:to="ttnp_CompanyPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CompanyPolicyPolicyTextBlock_lbl" xml:lang="en-US">The Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US">Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:label="ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:to="ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going concern assessment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" xlink:label="ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" xlink:to="ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock_lbl" xml:lang="en-US">Warrants Issued in Connection with Equity Financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs and Related Accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of components of inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of activity related to our accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of activity related to our accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of restricted stock activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:label="ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:to="ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Schedule of shares of common stock reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of our option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions to estimate the fair value of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of the stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_lbl" xml:lang="en-US">Raw materials and supplies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">&#160;Total inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="us-gaap_ContractWithCustomerAssetGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetGross" xlink:to="us-gaap_ContractWithCustomerAssetGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerAssetGross_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ContractWithCustomerAssetAdditions" xlink:label="ttnp_ContractWithCustomerAssetAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetAdditions" xlink:to="ttnp_ContractWithCustomerAssetAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ContractWithCustomerAssetDeductions" xlink:label="ttnp_ContractWithCustomerAssetDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetDeductions" xlink:to="ttnp_ContractWithCustomerAssetDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ContractWithCustomerAssetDeductions_lbl" xml:lang="en-US">Deductions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetGross" xlink:to="us-gaap_ContractWithCustomerAssetGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerAssetGross_2_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments (base rent)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Aggregate severance payments</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccruedSeverance" xlink:label="ttnp_AccruedSeverance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AccruedSeverance" xlink:to="ttnp_AccruedSeverance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AccruedSeverance_lbl" xml:lang="en-US">Accrued severance</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DeferredCompensationAndEmployeeSeverance" xlink:label="ttnp_DeferredCompensationAndEmployeeSeverance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DeferredCompensationAndEmployeeSeverance" xlink:to="ttnp_DeferredCompensationAndEmployeeSeverance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DeferredCompensationAndEmployeeSeverance_lbl" xml:lang="en-US">Deferred compensation and employee severance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">property, plant and equipment, estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_FutureMilestonePayments" xlink:label="ttnp_FutureMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_FutureMilestonePayments" xlink:to="ttnp_FutureMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_FutureMilestonePayments_lbl" xml:lang="en-US">Closing payment</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MilestonePayments" xlink:label="ttnp_MilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayments" xlink:to="ttnp_MilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_MilestonePayments_lbl" xml:lang="en-US">Milestone Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ReimbursementFees" xlink:label="ttnp_ReimbursementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ReimbursementFees" xlink:to="ttnp_ReimbursementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ReimbursementFees_lbl" xml:lang="en-US">Reimbursement fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLeasesRentExpenses" xlink:label="ttnp_OperatingLeasesRentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLeasesRentExpenses" xlink:to="ttnp_OperatingLeasesRentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_OperatingLeasesRentExpenses_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Loan proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Loan annual interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Non-cash gain (loss) on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xml:lang="en-US">Released</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantsOrRightsIssueDate" xlink:label="ttnp_ClassOfWarrantsOrRightsIssueDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantsOrRightsIssueDate" xlink:to="ttnp_ClassOfWarrantsOrRightsIssueDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantsOrRightsIssueDate_lbl" xml:lang="en-US">Date Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantsOrRightsExpirationDate" xlink:label="ttnp_ClassOfWarrantsOrRightsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantsOrRightsExpirationDate" xlink:to="ttnp_ClassOfWarrantsOrRightsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_ClassOfWarrantsOrRightsExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock, capital shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MilestonePayment" xlink:label="ttnp_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayment" xlink:to="ttnp_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares agreed to issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Number of additional shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Shares, Cancelled/expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Weighted-average risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividend payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected holding period (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Weighted-average volatility factor</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:label="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:to="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_lbl" xml:lang="en-US">Estimated forfeiture rates for options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average fair value of options and awards granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation expense related to non-vested stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average period for recognizing non-vested stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PurchaseCommonStock" xlink:label="ttnp_PurchaseCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PurchaseCommonStock" xlink:to="ttnp_PurchaseCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PurchaseCommonStock_lbl" xml:lang="en-US">Purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price, per value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed at 21%</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_TaxAttributesExpirations" xlink:label="ttnp_TaxAttributesExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_TaxAttributesExpirations" xlink:to="ttnp_TaxAttributesExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ttnp_TaxAttributesExpirations_lbl" xml:lang="en-US">Tax attributes expirations</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode" xlink:label="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode" xlink:to="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode_lbl" xml:lang="en-US">Impact of IRC 162m</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryForwardsExpirationYear" xlink:label="ttnp_OperatingLossCarryForwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLossCarryForwardsExpirationYear" xlink:to="ttnp_OperatingLossCarryForwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_OperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US">Operating Loss Carry Forwards Expiration Year</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:to="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Operating Loss Carry forwards Not Subject To Expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage" xlink:label="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage" xlink:to="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage_lbl" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Changes in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xml:lang="en-US">Discontinued operations &#8211; current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:label="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:to="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xml:lang="en-US">Discontinued operations &#8211; current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_NoncashStockbasedCompensationExpenses" xlink:label="ttnp_NoncashStockbasedCompensationExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_NoncashStockbasedCompensationExpenses" xlink:to="ttnp_NoncashStockbasedCompensationExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_NoncashStockbasedCompensationExpenses_lbl" xml:lang="en-US">Non-cash stock-based compensation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Value of stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Payment of legal fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetAdditions" xlink:to="ttnp_ContractWithCustomerAssetAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ContractWithCustomerAssetAdditions_doc" xml:lang="en-US">The amount of increase in contract assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ContractWithCustomerAssetDeductions" xlink:to="ttnp_ContractWithCustomerAssetDeductions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ContractWithCustomerAssetDeductions_doc" xml:lang="en-US">The amount of decrease in contract assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_EmployeeStockAwardsMember" xlink:to="ttnp_EmployeeStockAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_EmployeeStockAwardsMember_doc" xml:lang="en-US">Represents the information pertaining to employee stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_FutureMilestonePayments" xlink:to="ttnp_FutureMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_FutureMilestonePayments_doc" xml:lang="en-US">This information is pertaining to the amount received a closing payment and is entitled to receive future milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_JtPharmaceuticalsMember" xlink:to="ttnp_JtPharmaceuticalsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_JtPharmaceuticalsMember_doc" xml:lang="en-US">This member stands for JT Pharmaceuticals.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayments" xlink:to="ttnp_MilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_MilestonePayments_doc" xml:lang="en-US">This information is pertaining to the amount received a closing payment and is entitled to receive milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLeasesRentExpenses" xlink:to="ttnp_OperatingLeasesRentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_OperatingLeasesRentExpenses_doc" xml:lang="en-US">Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PaycheckProtectionProgramLoanMember" xlink:to="ttnp_PaycheckProtectionProgramLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_PaycheckProtectionProgramLoanMember_doc" xml:lang="en-US">Represents the information pertaining to loans from Paycheck Protection Program of the CARES Act administered by the U.S. Small Business Administration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_February2022OfferingsMember" xlink:to="ttnp_February2022OfferingsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_February2022OfferingsMember_doc" xml:lang="en-US">Represents the information pertaining to February 2022 Offerings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PreFundedWarrantsMember" xlink:to="ttnp_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_PreFundedWarrantsMember_doc" xml:lang="en-US">N/A.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredPrefundedWarrantsMember" xlink:to="ttnp_UnregisteredPrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_UnregisteredPrefundedWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to unregistered prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:to="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to unregistered five year and six month warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MilestonePayment" xlink:to="ttnp_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_MilestonePayment_doc" xml:lang="en-US">Amount of milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:to="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_RestrictedStockAgreementWithMaximGroupLlcMember_doc" xml:lang="en-US">Represents the information pertaining to restricted stock agreement with Maxim Group, LLC.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_January2021OfferingMember" xlink:to="ttnp_January2021OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_January2021OfferingMember_doc" xml:lang="en-US">Represents the information pertaining to January 2021 offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantsOrRightsIssueDate" xlink:to="ttnp_ClassOfWarrantsOrRightsIssueDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ClassOfWarrantsOrRightsIssueDate_doc" xml:lang="en-US">Class of warrants or rights issue date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateSevenMember_doc" xml:lang="en-US">Represents the information pertaining to warrant or right issued date seven.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateEightMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateEightMember_doc" xml:lang="en-US">Represents the information pertaining to warrant or right issued date eight.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateNineMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateNineMember_doc" xml:lang="en-US">Represents the information pertaining to warrant or right issued date nine.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantOrRightIssuedDateTenMember" xlink:to="ttnp_ClassOfWarrantOrRightIssuedDateTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ClassOfWarrantOrRightIssuedDateTenMember_doc" xml:lang="en-US">Represents the information pertaining to warrant or right issued date ten.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_ClassOfWarrantsOrRightsExpirationDate" xlink:to="ttnp_ClassOfWarrantsOrRightsExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_ClassOfWarrantsOrRightsExpirationDate_doc" xml:lang="en-US">Class of warrants or rights expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:to="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement_doc" xml:lang="en-US">Estimated forfeiture rates for options granted to management.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:to="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_OperatingLossCarryForwardsNotSubjectToExpiration_doc" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage" xlink:to="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage_doc" xml:lang="en-US">Represents the information pertaining to operating loss carry forward percentage of limitation on use.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_OperatingLossCarryForwardsExpirationYear" xlink:to="ttnp_OperatingLossCarryForwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_OperatingLossCarryForwardsExpirationYear_doc" xml:lang="en-US">Operating loss carry forwards expiration year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_TaxAttributesExpirations" xlink:to="ttnp_TaxAttributesExpirations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_TaxAttributesExpirations_doc" xml:lang="en-US">Tax attributes expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode" xlink:to="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode_doc" xml:lang="en-US">Represents income tax reconciliation impact of internal revenue code.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:to="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_doc" xml:lang="en-US">Amount classified as other accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AmortizationOfRestrictedStock" xlink:to="ttnp_AmortizationOfRestrictedStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AmortizationOfRestrictedStock_2_lbl" xml:lang="en-US">AmortizationOfRestrictedStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_2_lbl" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:to="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CashAndCashEquivalentsAndRestrictedCashEquivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_AssetPurchaseAgreementTextBlock" xlink:to="ttnp_AssetPurchaseAgreementTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_AssetPurchaseAgreementTextBlock_2_lbl" xml:lang="en-US">AssetPurchaseAgreementTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_2_lbl" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_2_lbl" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetGross" xlink:to="us-gaap_ContractWithCustomerAssetGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetGross_3_lbl" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_TaxAttributesExpirations" xlink:to="ttnp_TaxAttributesExpirations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_TaxAttributesExpirations_3_lbl" xml:lang="en-US">Tax Attributes Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:to="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_3_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Accrued Liabilities, Current</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ttnp-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/BalanceSheets" xlink:href="ttnp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/BalanceSheetsParenthetical" xlink:href="ttnp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfOperations" xlink:href="ttnp-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfStockholdersEquity" xlink:href="ttnp-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StatementsOfCashFlows" xlink:href="ttnp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipment" xlink:href="ttnp-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:href="ttnp-20221231.xsd#JtPharmaceuticalsAssetPurchaseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreement" xlink:href="ttnp-20221231.xsd#OcularTherapeutixLicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:href="ttnp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DebtAgreements" xlink:href="ttnp-20221231.xsd#DebtAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquity" xlink:href="ttnp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlans" xlink:href="ttnp-20221231.xsd#StockPlans" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxes" xlink:href="ttnp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperations" xlink:href="ttnp-20221231.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactions" xlink:href="ttnp-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/SubsequentEvents" xlink:href="ttnp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipmentTables" xlink:href="ttnp-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityTables" xlink:href="ttnp-20221231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansTables" xlink:href="ttnp-20221231.xsd#StockPlansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesTables" xlink:href="ttnp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ttnp-20221231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/PropertyAndEquipmentDetails" xlink:href="ttnp-20221231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:href="ttnp-20221231.xsd#JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:href="ttnp-20221231.xsd#OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ttnp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DebtAgreementsDetailsNarrative" xlink:href="ttnp-20221231.xsd#DebtAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails1" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetails2" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:href="ttnp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails" xlink:href="ttnp-20221231.xsd#StockPlansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails1" xlink:href="ttnp-20221231.xsd#StockPlansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetails2" xlink:href="ttnp-20221231.xsd#StockPlansDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:href="ttnp-20221231.xsd#StockPlansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetails" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetails1" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/IncomeTaxesDetailsNarrative" xlink:href="ttnp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative" xlink:href="ttnp-20221231.xsd#DiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ttnp-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccruedClinicalTrialsExpensesCurrent" xlink:label="loc_ttnpAccruedClinicalTrialsExpensesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ttnpAccruedClinicalTrialsExpensesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DeferredGrantRevenue" xlink:label="loc_ttnpDeferredGrantRevenue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ttnpDeferredGrantRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaapGrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_BasicAndDilutedNetLossPerCommonShare" xlink:label="loc_ttnpBasicAndDilutedNetLossPerCommonShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpBasicAndDilutedNetLossPerCommonShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" xlink:label="loc_ttnpWeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpWeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AmortizationOfRestrictedStockShares" xlink:label="loc_ttnpAmortizationOfRestrictedStockShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ttnpAmortizationOfRestrictedStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ShareBasedPaymentArrangementMilestonePayment" xlink:label="loc_ttnpShareBasedPaymentArrangementMilestonePayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ttnpShareBasedPaymentArrangementMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AmortizationOfRestrictedStock" xlink:label="loc_ttnpAmortizationOfRestrictedStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ttnpAmortizationOfRestrictedStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ProceedsFromEquityOfferings" xlink:label="loc_ttnpProceedsFromEquityOfferings" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ttnpProceedsFromEquityOfferings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" xlink:label="loc_ttnpRightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpRightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RetirementOfPropertyAndEquipment" xlink:label="loc_ttnpRetirementOfPropertyAndEquipment" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpRetirementOfPropertyAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment" xlink:label="loc_ttnpAccumulatedDepreciationOnRetiredPropertyAndEquipment" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ttnpAccumulatedDepreciationOnRetiredPropertyAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:label="loc_ttnpCashAndCashEquivalentsAndRestrictedCashEquivalents" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_ttnpCashAndCashEquivalentsAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipment" xlink:title="00000008 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement" xlink:title="00000009 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement">
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:label="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock" xlink:label="loc_ttnpJTPharmaceuticalsAssetPurchaseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:to="loc_ttnpJTPharmaceuticalsAssetPurchaseAgreementTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OcularTherapeutixLicenseAgreement" xlink:title="00000010 - Disclosure - Ocular Therapeutix License Agreement">
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract" xlink:label="loc_ttnpDisclosureOcularTherapeutixLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AssetPurchaseAgreementTextBlock" xlink:label="loc_ttnpAssetPurchaseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureOcularTherapeutixLicenseAgreementAbstract" xlink:to="loc_ttnpAssetPurchaseAgreementTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DebtAgreements" xlink:title="00000012 - Disclosure - Debt Agreements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlans" xlink:title="00000014 - Disclosure - Stock Plans">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperations" xlink:title="00000016 - Disclosure - Discontinued Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_CompanyPolicyPolicyTextBlock" xlink:label="loc_ttnpCompanyPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpCompanyPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:label="loc_ttnpSubstantialDoubtAboutGoingConcernPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpSubstantialDoubtAboutGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" xlink:label="loc_ttnpWarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpWarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipmentTables" xlink:title="00000021 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:label="loc_ttnpScheduleOfSharesReservedForFutureIssuanceTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ttnpScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansTables" xlink:title="00000023 - Disclosure - Stock Plans (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsTables" xlink:title="00000025 - Disclosure - Discontinued Operations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsAndSuppliesNetOfReserves" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaapContractWithCustomerAssetGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ContractWithCustomerAssetAdditions" xlink:label="loc_ttnpContractWithCustomerAssetAdditions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpContractWithCustomerAssetAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ContractWithCustomerAssetDeductions" xlink:label="loc_ttnpContractWithCustomerAssetDeductions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ttnpContractWithCustomerAssetDeductions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaapContractWithCustomerAssetGross_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:title="00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_EmployeeStockAwardsMember" xlink:label="loc_ttnpEmployeeStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_ttnpEmployeeStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:title="00000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RubinMember" xlink:label="loc_ttnpRubinMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_ttnpRubinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_AccruedSeverance" xlink:label="loc_ttnpAccruedSeverance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ttnpAccruedSeverance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DeferredCompensationAndEmployeeSeverance" xlink:label="loc_ttnpDeferredCompensationAndEmployeeSeverance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ttnpDeferredCompensationAndEmployeeSeverance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/PropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative" xlink:title="00000033 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:label="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract" xlink:to="loc_us-gaapAssetAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_FutureMilestonePayments" xlink:label="loc_ttnpFutureMilestonePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpFutureMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MilestonePayments" xlink:label="loc_ttnpMilestonePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_ttnpMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative" xlink:title="00000034 - Disclosure - Ocular Therapeutix License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract" xlink:label="loc_ttnpDisclosureOcularTherapeutixLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ReimbursementFees" xlink:label="loc_ttnpReimbursementFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ttnpDisclosureOcularTherapeutixLicenseAgreementAbstract" xlink:to="loc_ttnpReimbursementFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000035 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLeasesRentExpenses" xlink:label="loc_ttnpOperatingLeasesRentExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_ttnpOperatingLeasesRentExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DebtAgreementsDetailsNarrative" xlink:title="00000036 - Disclosure - Debt Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PaycheckProtectionProgramLoanMember" xlink:label="loc_ttnpPaycheckProtectionProgramLoanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ttnpPaycheckProtectionProgramLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails" xlink:title="00000037 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="loc_ttnpShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ttnpShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails1" xlink:title="00000038 - Disclosure - Stockholders&apos; Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateOneMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateTwoMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateThreeMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateFourMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateFiveMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateSixMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateSevenMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateEightMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateNineMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateTenMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantOrRightIssuedDateElevenMember" xlink:label="loc_ttnpClassOfWarrantOrRightIssuedDateElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpClassOfWarrantOrRightIssuedDateElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantsOrRightsIssueDate" xlink:label="loc_ttnpClassOfWarrantsOrRightsIssueDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ttnpClassOfWarrantsOrRightsIssueDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_ttnpClassOfWarrantsOrRightsExpirationDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ttnpClassOfWarrantsOrRightsExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetails2" xlink:title="00000039 - Disclosure - Stockholders&apos; Equity (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_February2022OfferingsMember" xlink:label="loc_ttnpFebruary2022OfferingsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ttnpFebruary2022OfferingsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_January2021OfferingMember" xlink:label="loc_ttnpJanuary2021OfferingMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ttnpJanuary2021OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PreFundedWarrantsMember" xlink:label="loc_ttnpPreFundedWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_UnregisteredPrefundedWarrantsMember" xlink:label="loc_ttnpUnregisteredPrefundedWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember" xlink:label="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ttnpUnregisteredFiveYearAndSixMonthWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JtPharmaceuticalsMember" xlink:label="loc_ttnpJtPharmaceuticalsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_ttnpJtPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_CommonStockToMaximGroupLlcMember" xlink:label="loc_ttnpCommonStockToMaximGroupLlcMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpCommonStockToMaximGroupLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember" xlink:label="loc_ttnpServicesAgreementWithMaximMdmWorldwideSolutionsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpServicesAgreementWithMaximMdmWorldwideSolutionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_RestrictedStockAgreementWithMaximGroupLlcMember" xlink:label="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ttnpRestrictedStockAgreementWithMaximGroupLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_TwoThousandFifteenPlanMember" xlink:label="loc_ttnpTwoThousandFifteenPlanMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpTwoThousandFifteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MilestonePayment" xlink:label="loc_ttnpMilestonePayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ttnpMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails" xlink:title="00000041 - Disclosure - Stock Plans (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails1" xlink:title="00000042 - Disclosure - Stock Plans (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:label="loc_ttnpEstimatedForfeitureRatesForOptionsGrantedToManagement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_ttnpEstimatedForfeitureRatesForOptionsGrantedToManagement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetails2" xlink:title="00000043 - Disclosure - Stock Plans (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/StockPlansDetailsNarrative" xlink:title="00000044 - Disclosure - Stock Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_Plan2015Member" xlink:label="loc_ttnpPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ttnpPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PurchaseCommonStock" xlink:label="loc_ttnpPurchaseCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ttnpPurchaseCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetails" xlink:title="00000045 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetails1" xlink:title="00000046 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_TaxAttributesExpirations" xlink:label="loc_ttnpTaxAttributesExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ttnpTaxAttributesExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode" xlink:label="loc_ttnpIncomeTaxReconciliationImpactOfInternalRevenueCode" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ttnpIncomeTaxReconciliationImpactOfInternalRevenueCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_ttnpOperatingLossCarryForwardsExpirationYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ttnpOperatingLossCarryForwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryForwardsNotSubjectToExpiration" xlink:label="loc_ttnpOperatingLossCarryForwardsNotSubjectToExpiration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ttnpOperatingLossCarryForwardsNotSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage" xlink:label="loc_ttnpOperatingLossCarryforwardsLimitationsOnUsePercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ttnpOperatingLossCarryforwardsLimitationsOnUsePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetails" xlink:title="00000048 - Disclosure - Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_U.s.CommercializationActivitiesMember" xlink:label="loc_ttnpU.s.CommercializationActivitiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="loc_ttnpU.s.CommercializationActivitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:label="loc_ttnpDisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_ttnpDisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative" xlink:title="00000049 - Disclosure - Discontinued Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_NoncashStockbasedCompensationExpenses" xlink:label="loc_ttnpNoncashStockbasedCompensationExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_ttnpNoncashStockbasedCompensationExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000050 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaAgreementMember" xlink:label="loc_ttnpJTPharmaAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_ttnpJTPharmaAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_JTPharmaMember" xlink:label="loc_ttnpJTPharmaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ttnpJTPharmaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287441200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-13341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TITAN PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000910267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3171940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Oyster Point Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">244-4990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TTNP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,016,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287204544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 6,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations - current assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,603<span></span>
</td>
<td class="nump">7,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">7,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AccruedClinicalTrialsExpensesCurrent', window );">Accrued clinical trials expenses</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DeferredGrantRevenue', window );">Deferred grant revenue</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations - current liabilities</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">2,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">2,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued or outstanding at December 31, 2022 and 2021.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 15,016,295 and 9,914,158 shares issued and outstanding at December 31, 2022 and 2021, respectively.</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">387,609<span></span>
</td>
<td class="nump">381,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(386,261)<span></span>
</td>
<td class="num">(376,055)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">5,138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 4,058<span></span>
</td>
<td class="nump">$ 7,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AccruedClinicalTrialsExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AccruedClinicalTrialsExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DeferredGrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DeferredGrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919289684208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares, issued</a></td>
<td class="nump">15,016,295<span></span>
</td>
<td class="nump">9,914,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares, outstanding</a></td>
<td class="nump">15,016,295<span></span>
</td>
<td class="nump">9,914,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919289376832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 1,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,758<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="nump">4,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,792<span></span>
</td>
<td class="nump">10,880<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,235)<span></span>
</td>
<td class="num">(9,354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Non-cash gain on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,206)<span></span>
</td>
<td class="num">$ (8,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_BasicAndDilutedNetLossPerCommonShare', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare', window );">Weighted average shares used in computing basic and diluted net loss per common share</a></td>
<td class="nump">13,434<span></span>
</td>
<td class="nump">9,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 1,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_BasicAndDilutedNetLossPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_BasicAndDilutedNetLossPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287097440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 370,804<span></span>
</td>
<td class="num">$ (367,279)<span></span>
</td>
<td class="nump">$ 3,532<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,776)<span></span>
</td>
<td class="num">(8,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">8,838<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Amortization of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AmortizationOfRestrictedStockShares', window );">Amortization of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">381,183<span></span>
</td>
<td class="num">(376,055)<span></span>
</td>
<td class="nump">5,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,206)<span></span>
</td>
<td class="num">(10,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,029<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon exercises of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Amortization of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AmortizationOfRestrictedStockShares', window );">Amortization of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 387,609<span></span>
</td>
<td class="num">$ (386,261)<span></span>
</td>
<td class="nump">$ 1,363<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AmortizationOfRestrictedStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AmortizationOfRestrictedStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919289309920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (10,206)<span></span>
</td>
<td class="num">$ (8,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Non-cash gain on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ShareBasedPaymentArrangementMilestonePayment', window );">Stock-based milestone payment</a></td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AmortizationOfRestrictedStock', window );">Amortization of restricted stock</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable</a></td>
<td class="num">(751)<span></span>
</td>
<td class="num">(1,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">801<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(99)<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,183)<span></span>
</td>
<td class="num">(7,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of furniture and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ProceedsFromEquityOfferings', window );">Proceeds from equity offerings</a></td>
<td class="nump">4,980<span></span>
</td>
<td class="nump">8,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="nump">8,841<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(3,199)<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">6,332<span></span>
</td>
<td class="nump">5,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">3,133<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization', window );">Right of use asset obtained in exchange for lease liability, net of amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_RetirementOfPropertyAndEquipment', window );">Retirement of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment', window );">Accumulated depreciation on retired property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,937<span></span>
</td>
<td class="nump">6,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</a></td>
<td class="nump">$ 3,133<span></span>
</td>
<td class="nump">$ 6,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AmortizationOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AmortizationOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ProceedsFromEquityOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ProceedsFromEquityOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_RetirementOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_RetirementOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ShareBasedPaymentArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ShareBasedPaymentArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287308272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_806_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zZNWBbxitBej" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zgg5wPALvye9">Organization and Summary of Significant Accounting Policies</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--CompanyPolicyPolicyTextBlock_zA3vYvJ9BHpf" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zyV5j9abquta">The Company</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura<sup>&#174;</sup>, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician&#8217;s assistants in a HCP&#8217;s office or other clinical setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our first product based on our ProNeura technology was Probuphine<sup>&#174;</sup> (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo&#8482;) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our commercial operations has allowed us to focus our limited resources on important product development programs and transition back to a product development company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, we announced our intention to work with our financial
advisor to explore strategic alternatives to enhance stockholder value, potentially including an acquisition, merger, reverse merger,
other business combination, sales of assets, licensing or other transaction. In June 2022, we implemented a plan to reduce expenses and
conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses to enable us to maintain
sufficient resources as we pursued potential strategic alternatives. In July 2022, David Lazar and Activist Investing LLC, or, collectively,
Activist acquired an approximately 25% ownership interest in Titan, filed a proxy statement and nominated six additional directors, each
of whom was elected to our board of directors or the Board, at a special meeting of stockholders held on August 15, 2022, or Special Meeting.
The exploration and evaluation of possible strategic alternatives by the Board has continued following the Special Meeting. Following
the election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced as our Executive Chairman, and David Lazar assumed
the role of Chief Executive Officer. In connection with the termination of his employment as Executive Chairman, Dr. Rubin will receive
aggregate severance payments of approximately $<span id="xdx_907_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220101__20221231__srt--CounterpartyNameAxis__custom--RubinMember_zcMNACqel82a" title="Aggregate severance payments">0.4</span> million, of which, approximately $165,000 had been paid to Dr. Rubin as of December
31, 2022. In December 2022, we implemented additional cost reduction measures including a reduction in our workforce. As a result of the
salary reductions, replacement of Dr. Rubin and the workforce reduction we have accrued approximately $<span id="xdx_90E_ecustom--AccruedSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zouBYEU4EPN2" title="Accrued severance">0.3</span> million and approximately $<span id="xdx_90E_ecustom--DeferredCompensationAndEmployeeSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zPEcATZqIfL" title="Deferred compensation and employee severance">0.6</span>
million related to deferred compensation and employee severance, respectively, as of December 31, 2022</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming we will continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, we had cash and cash equivalents of approximately $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231_zcp1qz4aXPTk" title="Cash and cash equivalents">2.9</span> million, which we believe is sufficient to fund our planned operations into the second quarter of 2023. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful. There is substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zZxEa46wNTd2" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJy10FlShte5">Discontinued Operations</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind down our commercialization activities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization activities as discontinued operations (see Note 10). The accompanying financial statements are generally presented in conformity with our historical format. We believe this format provides comparability with the previously filed financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--UseOfEstimates_zdh4gOojcxKa" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zTDBcthOPDrf">Use of Estimates</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p id="xdx_84F_ecustom--SubstantialDoubtAboutGoingConcernPolicyTextBlock_z11IfNBdjWuh" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zDAugIUAEpm9">Going concern assessment</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one&#160;year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by Accounting Standard Update ASU No.&#160;2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No.&#160;2014-15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Annual Report on Form&#160;10-K for the&#160;year ended December 31, 2022, we did not have sufficient cash to fund our operations for the next 12&#160;months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12&#160;months after the date the financial statements were issued. Additionally, we have suffered recurring losses from operations and have an accumulated deficit that raises substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zg4dbgUlF9C7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zXYtwxiugYXa">Inventories</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are recorded at the lower of cost or net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantities on hand and write down to its net realizable value any inventory that we believe to be impaired. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. The components of inventories are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zFw8I2RCUKCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8BD_zwQgDXxd7ph2" style="display: none">Schedule of components of inventories</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20221231_zopClSbFJpig" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20211231_zNRl7QSozVuk" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pn3n3_maINzzRz_zqTD0rCQOSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Raw materials and supplies</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">60</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">227</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINzzRz_zRvj2dGzynQ" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Finished goods</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">46</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">66</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzzRz_zisJ2WMp8qd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;Total inventories</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">106</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">293</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zf5WdfiqAL72" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The approximately $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_c20221231_pn3n3" title="Finished goods inventory">46,000</span> and $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_pn3n3_c20211231_zGijA3qiRnx9" title="Finished goods inventory">66,000</span> of finished goods inventory at December 31, 2022 and 2021, respectively, included materials held for potential sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2Q40KMCUtfc" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zuJgaBuOSELi">Stock-Based Compensation</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize compensation expense using a fair-value based method, for all stock-based payments including stock options and restricted stock awards and stock issued under an employee stock purchase plan. These standards require companies to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. See Note&#160;8 &#8220;Stock Plans,&#8221; for a discussion of our stock-based compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock_zA6tHAxrO7C7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zqvhPwBSTsbd">Warrants Issued in Connection with Equity Financing</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle the warrants in cash. For warrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrants as a liability at each reporting period and record changes in the estimated fair value as a non-cash gain or loss in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLPT0H3eQSmk" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zXe98InXtkq8">Cash and Cash Equivalents</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our investment policy emphasizes liquidity and preservation of principal over other portfolio considerations. We select investments that maximize interest income to the extent possible given these two constraints. We satisfy liquidity requirements by investing excess cash in securities with different maturities to match projected cash needs and limit concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers and limit the amount of credit exposure to any one issuer. The estimated fair values have been determined using available market information. We do not use derivative financial instruments in our investment portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All investments with original maturities of three&#160;months or less are considered to be cash equivalents. We had money market funds of approximately $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC6PDamtx5g7" title="Cash and cash equivalents">2.6</span> million and $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zB7daW2mtYrb" title="Cash and cash equivalents">5.7</span> million as of December 31, 2022 and 2021, respectively, included in our cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20221231_zaI6b590ufC5" title="Cash, FDIC insured amount">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on our financial condition, results of operations, and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zGLIxeAchWRi" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><i><span id="xdx_86C_zp5ppOHjV962">Restricted Cash</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In accordance with ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash, we explain the change during the period in the total of cash, cash equivalents and
restricted cash, and include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period
total amounts shown on the statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table provides
a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet dates that comprise the total of the
same such amounts shown in the statements of cash flows for the years presented herein (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zQzdvtfknjY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule of restricted cash</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_z67EUQUyzh1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,037</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_zSrOlLFABlA9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">295</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_z3E6GZdShyOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,133</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>


<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrnYI4RuKmW" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zBnqgHuuFLy8">Property and Equipment</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets
ranging from three <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zAImnZ9dZ4wk" style="display: none" title="property, plant and equipment, estimated useful lives">3</span> to five <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKKN5BZgih38" style="display: none" title="property, plant and equipment, estimated useful lives">5</span> years. Leasehold improvements are amortized over the shorter of the lease term or the estimated
useful life of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zv9A4l1Csre7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zL7NyY6UmKZ4">Revenue Recognition</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department of Health and Human Services, or HHS, the Bill &amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net Product Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Returns &#8211; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebates &#8211; Our provision for rebates was estimated based on our customers&#8217; contracted rebate programs and our historical experience of rebates paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounts
&#8211; The provision was estimated based upon invoice billings, utilizing historical customer payment experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance Obligations</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Price</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognize revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocation of Consideration</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Timing of Recognition</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Assets and liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the activity related to our accounts receivable for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span id="xdx_8B6_zlxRgL6XG39b" style="display: none">Schedule of activity related to our accounts receivable</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><i>(In thousands)</i></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Balance at January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance">884</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions">1,526</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(2,298</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Balance at December 31, 2021</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance">112</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions">557</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(633</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">36</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zozZ1SMAQem5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/>&#160;</p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvYi38FlWXy7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zupjTsqyUHTh">Research and Development Costs and Related Accrual</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (&#8220;CRO&#8221;) activities, sponsored research studies, product registration, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfDqOmscuOD4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zgESb6Qe4M6">Net Loss Per Share</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share excludes the effect of dilution and is computed by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method. Basic and diluted net loss per share was the same for each of the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of shares of common stock outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the&#160;years ended (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zSErRwgCzgI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B6_zjVqoyveczlk" style="display: none">Schedule of anti-dilutive effect</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted-average anti-dilutive common shares resulting from stock awards</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_zFPiHclvpiCc" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">964</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_z53MATNY3cG8" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">617</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Weighted-average anti-dilutive common shares resulting from warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zIrI6wAmeRxi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">5,661</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zbWBbapW6Blb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,374</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdC0Xwmolla4" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,625</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zPx2K45tzhpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,991</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z1Yyx7WKv6C6" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zefpL2dPPYc9" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zkDFHNQZ39I1">Leases</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the minimum lease payments of our operating lease as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zgROnTpnXa71" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B6_zpn4eCwuDock" style="display: none">Schedule of minimum operating lease payments</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20221231_zTvF1iEavTxd" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2023</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">130</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2024</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">66</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total minimum lease payments (base rent)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">196</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zfKHFgWnsUQ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Less: imputed interest</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(9</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total operating lease liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">187</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zu2nSUyCQer5" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_84F_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z4kb8wfQKuG4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zBFHIrbW1K9i">Subsequent Events</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have evaluated events that have occurred subsequent to December 31, 2022 and through the date that the financial statements are issued. See Note 12 Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbefMA3aXZTd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zWsUoEVgA2y2">Fair Value Measurements</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8211; quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8211; inputs that are unobservable (for example cash flow modelling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. The approximately $<span id="xdx_90B_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20221231_zZsgdzlXokR4" title="Money Market Funds, at Carrying Value">2.6</span> million and $<span id="xdx_904_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20211231_zAZRblcItV26" title="Money Market Funds, at Carrying Value">5.7</span> million fair values of money market funds as of December 31, 2022 and 2021, included in our cash and cash equivalents are classified as Level 1 and were derived from quoted market prices as active markets for these instruments exists. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zdP35IW7RjDd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUz5PGUW6GWj">Recent Accounting Pronouncements</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently Adopted Accounting Pronouncements</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the FASB issued FASB issued ASU 2021-10, <i>Disclosures by Business Entities about Government Assistance</i>. The ASU codifies new requirements to disclose information about the nature of certain government assistance received, the accounting policy used to account for the transactions, the location in the financial statements where such transactions were recorded and significant terms and conditions associated with such transactions. The guidance is effective for annual periods beginning after December 15, 2021. The adoption of ASU No. 2021-10 did not have a material impact to our financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounting Standards Not Yet Adopted</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses</i>, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January 1, 2023. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the FASB issued ASU 2020-04, <i>Reference Rate Reform</i>, which provides companies with optional guidance, including expedients and exceptions for applying GAAP to contracts and other transactions affected by reference rate reform, such as the London Interbank Offered Rate, or LIBOR. This new standard was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are evaluating the effects that the adoption of this guidance will have on our financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU No. 2020-06, <i>Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective beginning after December 15, 2023 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. We are currently evaluating the impact this guidance will have on our financial statements and related disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919291073392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zuEQIH6vXgJk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_z48fzNOdWvU1">Property and Equipment</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_ztT9QvDQYfej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BA_z2LPCDycrEk6" style="display: none">Schedule of property and equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Furniture and office equipment</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross">132</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross">132</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Laboratory equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,108</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,108</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Computer equipment</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross">577</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross">577</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,817</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,817</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Less accumulated depreciation and amortization</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zJPDPRrj4IVd" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization">(1,593</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zqykeNhDEr91" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization">(1,397</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Property and equipment, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20221231_znkThjA8sIt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">224</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zmJ1vNClmGbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">420</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919291009120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JT Pharmaceuticals Asset Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract', window );"><strong>Jt Pharmaceuticals Asset Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock', window );">JT Pharmaceuticals Asset Purchase Agreement</a></td>
<td class="text"><p id="xdx_80E_ecustom--JTPharmaceuticalsAssetPurchaseAgreementTextBlock_zDPARa0EmA2k" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zlDHRtmIFfHj">JT Pharmaceuticals Asset Purchase Agreement</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, we entered into an Asset Purchase Agreement, or JT Agreement, with JT Pharmaceuticals, Inc., or JT Pharma, to acquire JT Pharma&#8217;s kappa opioid agonist peptide, TP-2021 (formerly JT-09) for use in combination with our ProNeura long-term, continuous drug delivery technology, for the treatment of chronic pruritus and other medical conditions. Under the terms of the JT Agreement, JT Pharma received a $<span id="xdx_90C_ecustom--FutureMilestonePayments_c20201001__20201031__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pn3n3" title="Closing payment">15,000</span> closing payment and is entitled to receive future milestone payments, payable in cash or in stock, based on the achievement of certain developmental and regulatory milestones, and single-digit percentage earn-out payments on net sales of the product if successfully developed and approved for commercialization. In January 2022, we entered into an agreement with JT Pharma to clarify certain provisions of the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved and made a payment of $<span id="xdx_905_ecustom--MilestonePayments_pn3n3_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zDja14sdsAfh" title="Milestone Payments">100,000</span> and issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zW2vbvcwMIT8" title="Issuance of common stock, net (in shares)">51,021</span> shares of our common stock to JT Pharma. The related expense was included in research and development expenses in our statements of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919290346448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ocular Therapeutix License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract', window );"><strong>Ocular Therapeutix License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AssetPurchaseAgreementTextBlock', window );">Ocular Therapeutix License Agreement</a></td>
<td class="text"><p id="xdx_807_ecustom--AssetPurchaseAgreementTextBlock_zXrYPCrHjQFh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zu0Ogfm3Fsnh">Ocular Therapeutix License Agreement</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, we entered into a license agreement, or Ocular Agreement, with Ocular Therapeutix, Inc., or Ocular to license the exclusive rights to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the United States, or Licensed Patents. The grant of the Ocular license by us to Ocular is for an exclusive (even as to us), perpetual, fully paid-up license to use the Licensed Patents. The license comes with the right to sublicense. The Ocular paid a one-time fee of $<span id="xdx_90E_ecustom--ReimbursementFees_pn3n3_c20220101__20221231_zi536lXPCWc8" title="Reimbursement fees">50,000</span> and will reimburse our attorneys&#8217; fees incurred by it in connection with the preparation and negotiation of the Ocular Agreement. Ocular shall make additional payments upon the achievement of certain milestone events as set forth in the License Agreement.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AssetPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AssetPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919291001824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies (Note 5)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zNDhKU9LeMV1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_z5gjm9uNSEN7">Commitments and Contingencies</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease Commitments</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We lease our office facility under operating lease that expires in June&#160;2024. Rent expense associated with this lease was approximately $<span id="xdx_90A_ecustom--OperatingLeasesRentExpenses_pn3n3_dm_c20221001__20221231_zOOLAqWsA099" title="Rent expense">0.1</span> million and $<span id="xdx_907_ecustom--OperatingLeasesRentExpenses_pn3n3_dm_c20220101__20221231_zRSgsurwZ8Rl" title="Rent expense">0.2</span> million for&#160;years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Guarantees and Indemnifications</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As permitted under Delaware law and in accordance with our Bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving at our request in such capacity. The term of the indemnification period is for the officer&#8217;s or director&#8217;s lifetime. The maximum amount of potential future indemnification is unlimited; however, we have a director and officer insurance policy that limits our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements is minimal. Accordingly, we have not recorded any liabilities for these agreements as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, we have commitments to make certain milestone payments to various clinical research organizations in connection with our clinical trial activities. Payments are contingent upon the achievement of specific milestones or events as defined in the agreements, and we have made appropriate accruals in our financial statements for those milestones that were achieved as of December 31, 2022. We also provide indemnifications of varying scope to our CROs and investigators against claims made by third parties arising from the use of our products and processes in clinical trials. Historically, costs related to these indemnification provisions were immaterial. We also maintain various liability insurance policies that limit our exposure. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Proceedings</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A legal proceeding has been initiated by a former employee alleging wrongful termination, retaliation, infliction of emotional distress, negligent supervision, hiring and retention and slander. An independent investigation into this individual&#8217;s allegations of whistleblower retaliation, while still an employee, was conducted utilizing an outside investigator and concluded that such allegations were not substantiated. We intend to vigorously defend the lawsuit (which we have compelled into arbitration); however, in light of our cash position, there can be no assurance that the defense and/or settlement of this matter will not have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919290355856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Agreements</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zcmt9geVxk8b" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zocpVBJgfIpc">Debt Agreements</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paycheck Protection Program Loan</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 20, 2020, we received an approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_pn3n3_c20200401__20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zIAv1QhZHGh2" title="Loan proceeds">654,000</span> loan, or PPP Loan, pursuant to the Paycheck Protection Program of the CARES Act that bore interest at the annual rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20200401__20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_z3RxkSHNxWp4" title="Loan annual interest rate">1.0</span>% and matured in April 2022. The proceeds of the PPP Loan were to be used to retain workers and maintain payroll and make mortgage interest, lease and utility payments and were subject to forgiveness in accordance with requirements of the Small Business Administration. The PPP Loan originally had a six-month deferral of payments period which was extended to sixteen months during the third quarter of 2020. In May 2021, the entire balance of the PPP loan along with accrued interest was forgiven and the approximately $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_dm_c20210501__20210531__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zolHoTTrAaDd" title="Non-cash gain (loss) on debt extinguishment">0.7</span> million gain on extinguishment of the debt was included in other income (expense) in our statements of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919291066080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrvV2W0rGyjk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zNlcEU1qPsc6">Stockholders&#8217; Equity</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock outstanding as of December 31, 2022 and December 31, 2021 was <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_z5wD4L0KYZyc" title="Common stock shares, outstanding">15,016,295</span> shares and <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zJhoBYyybtm1" title="Common stock shares, outstanding">9,914,158</span> shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment to Bylaws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, the Board amended our Bylaws to effect certain enhancements to the ability of stockholders to call for a special meeting of stockholders and make changes to the composition of the Board. This included (i) reducing the holdings required for stockholders to call a special meeting of stockholders from a majority to twenty-five percent (25%); (ii) enabling increases in the size of the Board to be effectuated by stockholders or directors at any annual or special meeting or by stockholder action by written consent in lieu of a meeting; (iii) provide that Board vacancies and newly created directorships resulting from action taken by the stockholders at a meeting or by written consent in lieu thereof shall be filled initially by the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Activist Investing, LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, we received a letter from Activist requesting that our Board call the Special Meeting in accordance with Article II, Section 5 of our Bylaws, as amended.in order for stockholders to consider and vote upon the following two proposals:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in the size of the Board by six (6) members from five (5) members to eleven (11) members in total; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The election of Activist&#8217;s six nominees to serve as directors to fill the vacancies left by the foregoing increase.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Activist&#8217;s request, the Board set the record date for the Special Meeting as July 22, 2022, and the Special Meeting was held on August 15, 2022, resulting in the approval of the increase in the size of the Board and the election of the six nominees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>February 2022 Offerings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, we completed a registered direct offering with an accredited investor pursuant to which we issued an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zmpiwYWf79N" title="Issuance of common stock, net, shares">1,100,000</span> shares of our common stock and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zYqZSqlEJHb" title="Number of warrants issued">2,274,242</span> pre-funded warrants to purchase shares of our common stock, with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z5Qcc39g51ak" title="Exercise price of warrants (in dollars per share)">0.001</span> per share. In a concurrent private placement, we sold unregistered pre-funded warrants to purchase an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z5qx8xJaXZ6e" title="Number of warrants issued">1,289,796</span> shares of common stock with an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zzrYpPfpoZNh" title="Exercise price of warrants (in dollars per share)">0.001</span> per share and issued unregistered five year and six month warrants to purchase an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z7UqE9qDdLI5" title="Number of warrants issued">4,664,038</span> shares of common stock with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zwQrpnmMpqH8" title="Exercise price of warrants (in dollars per share)">1.14</span>. The unregistered warrants were registered in April 2022. The warrants were classified as equity.  The net cash proceeds from these offerings were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_dm_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zmolLXFHG3e" title="Proceeds from sale of common stock">5.0</span> million after deduction of underwriting fees and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Exercises</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, we received approximately $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20220301__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises">1,000</span> from the exercise of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zvAy6XpwVD49" title="Number of warrants issued">974,242</span> pre-funded warrants issued in the February 2022 registered direct offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2022, we received approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20220401__20220430__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises">1,300</span> from the exercise of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220430__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zzQow3noLc94" title="Number of warrants issued">1,300,000</span> pre-funded warrants issued in the February 2022 registered direct offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, we received approximately $<span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_c20220501__20220531__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises">1,290</span> from the exercise of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zhb1LkiMrlEc" title="Number of warrants issued">1,289,796</span> pre-funded warrants issued in the February 2022 private placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>JT Pharma Milestone</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, we entered into an agreement with JT Pharma to clarify certain provisions of the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved and made a payment of $<span id="xdx_902_ecustom--MilestonePayment_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pn3n3" title="Milestone payment">100,000</span> and issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pdd" title="Issuance of common stock, net, shares">51,021</span> shares of our common stock to JT Pharma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Restricted Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2022, we agreed to issue <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockToMaximGroupLlcMember_zpY5xeZY4yrd" title="Number of shares agreed to issue">337,078</span> shares of our common stock to Maxim Group, LLC in connection with the entry into an amendment to our existing advisory agreement. The shares vested immediately. We recorded approximately $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockToMaximGroupLlcMember_zJSI2mmuoiK3" title="Stock-based compensation">0.3</span> million of stock-based compensation expense during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, we agreed to issue <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementWithMaximMdmWorldwideSolutionsMember_znnJP41tTw2d" title="Number of shares agreed to issue">50,000</span> shares of our common stock pursuant to an advisory services agreement with Maxim MDM Worldwide Solutions, Inc. The shares vested immediately. We recorded approximately $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementWithMaximMdmWorldwideSolutionsMember_pn3n3" title="Stock-based compensation">79,000</span> of stock-based compensation expense during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2021, we agreed to issue <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zZqqZkC0NlBa" title="Number of shares agreed to issue">50,000</span> shares of our common stock pursuant to a restricted stock agreement with Maxim Partners, LLC in connection with the entry into an amendment to our existing advisory agreement. The shares vested monthly over <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_z7xWei8ts4Ah" title="Vesting period">12</span> months. We recorded approximately $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_pn3n3" title="Stock-based compensation">71,000</span> of stock-based compensation expense during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restricted stock activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_pn3n3_z9moU5jNuzZf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span id="xdx_8B4_zjh42pIkomY2" style="display: none">Summary of restricted stock activity</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"/>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"/>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; vertical-align: top">Outstanding at December 31, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231_zFW1l7qB0tPk" style="width: 9%; text-align: right" title="Outstanding at beginning">50,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Issued</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231_zuZnIkngtQaf" style="text-align: right" title="Issued">387,078</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Forfeited or expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220101__20221231_z9KSdmYjmAh3" style="text-align: right" title="Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top">Released</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_pid_c20220101__20221231_z4QGZMT50lpg" style="border-bottom: Black 1pt solid; text-align: right" title="Released">(437,078</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Outstanding at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220101__20221231_zinqwJKWrsD" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zBnBm0qYfqk9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual Meeting of Stockholders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, our stockholders approved an amendment to the 2015 Omnibus Equity Incentive plan to increase the number of authorized shares to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwoThousandFifteenPlanMember_zoMDksnCUs9h" title="Number of additional shares authorized">1,000,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January 2021 Offering</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, we completed an offering with several accredited institutional investors pursuant to which we issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zy3bQkVjas3k" title="Issuance of common stock, net, shares">2,725,000</span> shares of our common stock in a registered direct offering and warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z1dMW6oDY7ed" title="Number of warrants issued">2,725,000</span> shares of our common stock with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_ziUjcjmse6s6" title="Exercise price of warrants, shares">3.55</span> per share in a concurrent private placement. The warrants were classified as equity, were exercisable immediately and will expire in July 2026. The net cash proceeds from this offering were approximately $8.8 million after deduction of underwriting fees and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the following warrants to purchase shares of our common stock were outstanding (in thousands, except per share price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_pn3n3_zVVf7z7xIT6i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_8BA_zbRxWQFJpH85" style="display: none">Schedule of warrants to purchase</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date Issued</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration&#160;Date</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise&#160;Price</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Date Issued">07/27/2017</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 23%; text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Expiration Date">07/27/2024</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 22%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_z6sUk06JPpOf" title="Exercise Price (in dollars per share)">45.00</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 22%; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_zF2WqR6vmWZf" title="Outstanding">12</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Date Issued">03/21/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Expiration Date">03/21/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zMx4xgeR7sIa" title="Exercise Price (in dollars per share)">216.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zphKQvGQXgye" title="Outstanding">1</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Date Issued">03/21/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Expiration Date">03/21/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zojOlollJpSl" title="Exercise Price (in dollars per share)">216.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zjEhHIdgPgn7" title="Outstanding">3</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Date Issued">09/25/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Expiration Date">09/25/2023</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zGW8AgAcCbW4" title="Exercise Price (in dollars per share)">18.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zy7G5aAqAGKa" title="Outstanding">154</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Date Issued">09/25/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Expiration Date">09/25/2023</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_z4lGSm1yvi9k" title="Exercise Price (in dollars per share)">50.40</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_zxutXXMAyUy3" title="Outstanding">8</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Date Issued">08/09/2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Expiration Date">02/09/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_zuxtVyhmz747" title="Exercise Price (in dollars per share)">32.10</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_ztdRyIub9sXj" title="Outstanding">95</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Date Issued">10/18/2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Expiration Date">10/18/2024</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_z2J8SrtCHIUl" title="Exercise Price (in dollars per share)">1.14</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_zmfl9eJ2sL27" title="Outstanding">230</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Date Issued">01/09/2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Expiration Date">07/09/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_z20QogSQuYji" title="Exercise Price (in dollars per share)">7.50</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_zWfaS2xKM2P7" title="Outstanding">290</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Date Issued">10/30/2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Expiration Date">12/01/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zo2cTgTkbN7l" title="Exercise Price (in dollars per share)">3.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zwSWDbIeN906" title="Outstanding">1,644</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Date Issued">01/20/2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Expiration Date">07/26/2026</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zngUN6Ov2Emb" title="Exercise Price (in dollars per share)">3.55</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zphRdumVeLqg" title="Outstanding">2,725</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_z3J7cL5Aswqd" title="Date Issued">02/04/2022</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zeCb7jssfk4i" title="Expiration Date">08/04/2027</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zbVprxbLBT6k" title="Exercise Price (in dollars per share)">1.14</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zrriKhX0HiUi" title="Outstanding">4,664</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zWyiDrxSuvj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding">9,826</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z97tWCJR8f2d" style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares Reserved for Future Issuance</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, shares of common stock reserved by us for future issuance consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_zPsdhuFo4Fz" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B5_zxwXu46gpOdg" style="display: none">Schedule of shares of common stock reserved for future issuance</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Stock options outstanding</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSnOPPSWHEcg" style="width: 9%; text-align: right" title="Common stock, capital shares reserved for future issuance">927</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Shares issuable upon the exercise of warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zxipqE8V8488" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock, capital shares reserved for future issuance">9,826</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220930_zy3yxUBNEiVg" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock, capital shares reserved for future issuance">10,753</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919290373408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plans</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z9XRyZui6vek" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zT5KZC21LHe6">Stock Plans</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August&#160;2015, our stockholders approved the 2015 Omnibus Equity Incentive Plan (the &#8220;2015 Plan&#8221;). The 2015 Plan, as subsequently amended, authorized a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_zbKufc88w3F8" title="Number of shares agreed to issue">1,000,000</span> shares of our common stock for issuance to employees, directors, officers, consultants and advisors. As of December 31, 2022, options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_zQ0abPWqQY9e" title="Shares available for grant">74,262</span> shares of our common stock were available for grant and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_z5yMe3m8x1Bj" title="Common stock outstanding">925,738</span> shares of our common stock outstanding under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February&#160;2014, our Board adopted the 2014 Incentive Plan (the &#8220;2014 Plan&#8221;), pursuant to which <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20140228__us-gaap--PlanNameAxis__custom--Plan2015Member_zI2gSYfXDqZb" title="Number of shares agreed to issue">2,526</span> shares of our common stock were authorized for issuance to employees, directors, officers, consultants and advisors. The 2014 Plan was terminated upon the approval of the 2015 Plan. As of December 31, 2022, options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20140228__us-gaap--PlanNameAxis__custom--Plan2015Member_zCWnHRcRk8R3" title="Common stock outstanding">1,189</span> shares of our common stock were outstanding under the 2014 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July&#160;2002, we adopted the 2002 Stock Incentive Plan (the &#8220;2002 Plan&#8221;). The 2002 Plan, as amended in 2005, authorized a total of approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20020731__us-gaap--PlanNameAxis__custom--Plan2015Member_zBzhUZnmJzG2" title="Number of shares agreed to issue">7,234</span> shares of our common stock for issuance to employees, officers, directors, consultants, and advisers. The exercise prices of options granted under the 2002 Plan were 100% of the fair market value of our common stock on the date of grant. The 2002 Plan expired by its terms in July&#160;2012. As of December 31, 2022, no options to purchase shares of our common stock were outstanding under the 2002 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z4NqZTrKZXc5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BA_zRTCYfMaY5pf" style="display: none">Schedule of our option activity</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares<br/> (in thousands)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Exercise Price<br/>
per Share</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Remaining
    Contractual<br/> Term (years)</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate<br/> Intrinsic Value<br/> (in
    thousands)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td> </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zeoMgsXWZ6Wh" style="width: 9%; text-align: right" title="Outstanding at Beginning">682</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zvp5FJQKfEAe" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at Beginning">12.53</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zhImmUb5p52h" title="Weighted Average Remaining Contractual Term, Outstanding (Years)">8.98</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20221231_zmc3srTqtBCj" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zMwkGictmsCh" style="text-align: right" title="Shares, Granted">310</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zK4zzYJcwOR1" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.18</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/expired</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_z29ZI741Es42" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Cancelled/expired">(65</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zcoYLHtlQG5d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/expired">23.40</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zwEwtYAOrEw1" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at Ending">927</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zF0pmW48IIy4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">7.97</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zw7hKCJ6DXng" title="Weighted Average Remaining Contractual Term, Outstanding (Years)">8.34</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20221231_zvcUa3QjkpS1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zE7h3trfQ5Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Exercisable">927</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zHJIgUzBq6M9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable">7.97</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zDH1q3Jdd1Ub" title="Weighted Average Remaining Contractual Term, Exercisable">8.34</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zs4kvnoEU1fb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zqsYXrZbwc42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BE_zPgA46M4ggo1" style="display: none">Schedule of assumptions to estimate the fair value of options</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/> Years Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Weighted-average risk-free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zimxS1yvFL7d" title="Weighted-average risk-free interest rate">1.9</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231_zIwhvJPbZuab" title="Weighted-average risk-free interest rate">0.5</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Expected dividend payments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220101__20221231_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Expected holding period (years)(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_fKDEp_zXc30gJDtOE" title="Expected holding period (years)">5.26</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_fKDEp_zSWaTKOeVK1h" title="Expected holding period (years)">5.45</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Weighted-average volatility factor(2)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_fKDIp_zL35OYstqh33" title="Weighted-average volatility factor">1.16</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20210101__20211231_fKDIp_zxaLCerXnlF6" title="Weighted-average volatility factor">1.14</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Estimated forfeiture rates for options granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20221231_zY92hkuGfTb4" title="Estimated forfeiture rates for options granted">6</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20210101__20211231_zNytV6xmn0Eb" title="Estimated forfeiture rates for options granted">30</span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0C_zUnIg0WPiaN8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zwaiP8AJBf74" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F02_zudaHfL6q9m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zibsMcMXUBKb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average volatility is based on the historical volatility of our common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F05_zyhzoOTkCcwj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zhVrqttXD5j1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated forfeiture rates are based on historical data.</span></td></tr>
  </table>

<p id="xdx_8A4_zConnyx0AKug" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based upon the above methodology, the weighted-average fair value of options and awards granted during the&#160;years ended December 31, 2022 and 2021 was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_ziRFRxoXK9kg" title="Weighted-average fair value of options and awards granted">0.95 </span>and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z9RfQCsbqQwd" title="Weighted-average fair value of options and awards granted">3.29</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the stock-based compensation expense (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_znRWAMNGLuE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BD_zus3gRP7DoR7" style="display: none">Schedule of the stock-based compensation expense</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> Years Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Research and development</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">553</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">749</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">General and administrative</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">394</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">756</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total stock-based compensation expenses</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">947</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">1,505</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zXzkhGsPpWO2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, there was approximately $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_dm_c20221231_zjHxAVykCw1l" title="Total unrecognized compensation expense related to non-vested stock option">0.8</span> million of total unrecognized compensation expense related to non-vested stock options subject to shareholder approval. This expense is expected to be recognized over a weighted-average period of approximately <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_zmzJqiVOZNFg" title="Weighted-average period for recognizing non-vested stock option">0.7</span>&#160;year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 2, 2022, our Board of Directors, or Board, modified the outstanding options to purchase common stock under our 2015 Omnibus Equity Incentive Plan, or 2015 Plan, to allow for the acceleration of vesting of all unvested 2015 Plan options in the event of a change in control through the election of a majority of new members to our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, the Special Meeting was held at the request of Activist, to increase the size of our Board from five members to eleven members and elect Activist&#8217;s slate of six nominees to serve as directors in addition to the existing five Board members. As a result of the change of control, all unvested options granted under the 2015 Plan prior to August 15, 2022, immediately became vested. We recognized approximately $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20220801__20220815__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYMEqZXNiOee" title="Stock-based compensation">0.5</span> million of stock-based compensation related to the acceleration of vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2022, our Board granted <span id="xdx_908_ecustom--PurchaseCommonStock_pid_c20220801__20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_zQ3UQiD8n7ee" title="Purchase common stock">125,000</span> options to purchase common stock at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_z6kVfYFRoyj4" title="Purchase price, per value">1.52</span> per share which are subject to shareholder approval of an amendment to increase the number of shares reserved for issuance under our 2015 Plan. The options vest monthly over a 12-month period from the grant dates. As the shares underlying these options have not been approved by our stockholders, they have been excluded from the table above as of December 31, 2022. We have recognized approximately $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220801__20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_pn3n3" title="Stock-based compensation">60,000</span> of stock-based compensation related to these grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2022, our Board granted <span id="xdx_90D_ecustom--PurchaseCommonStock_pid_c20220901__20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_z2QbgzO6dpyi" title="Purchase common stock">900,000</span> options to purchase common stock at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_zOO879p58Nv5" title="Purchase price, per value">1.31 </span>per share which are subject to shareholder approval of an amendment to increase the number of shares reserved for issuance under our 2015 Plan. The options vest monthly over a 12-month period from the grant dates. As the shares underlying these options have not been approved by our stockholders, they have been excluded from the table above as of December 31, 2022. We have recognized approximately $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn3n3_c20220901__20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_zVel9wJ41u1e" title="Stock-based compensation">250,000</span> of stock-based compensation related to these grants.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919291119120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zWOgoeSkwngh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zD5nHuahUuZ">Income Taxes</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, we had federal net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zFOqvOabhB66" title="Operating Loss Carryforwards">183.0</span> million that expire at various dates through <span id="xdx_900_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember" title="Operating Loss Carry Forwards Expiration Year">2037</span> and approximately $<span id="xdx_90A_ecustom--OperatingLossCarryForwardsNotSubjectToExpiration_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znEVJNcVYQkj" title="Operating Loss Carry forwards Not Subject To Expiration">54.3</span> million which do not expire but are subject to <span id="xdx_90C_ecustom--OperatingLossCarryforwardsLimitationsOnUsePercentage_pid_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zucri4uBBe2l" title="Operating Loss Carryforwards, Limitations on Use Percentage">80</span>% taxable income limitations. As of December 31, 2022, we had federal research and development tax credits of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zepekVoVY6J9" title="Operating Loss Carryforwards">6.8</span> million that expire at various dates through <span id="xdx_902_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember" title="Operating Loss Carry Forwards Expiration Year">2042</span>. We also had net operating loss carryforwards for California income tax purposes of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zs3nAlM2TuM6" title="Operating Loss Carryforwards">115.2</span> million that expire at various dates through <span id="xdx_902_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember" title="Operating Loss Carry Forwards Expiration Year">2042</span> and state research and development tax credits of approximately $<span id="xdx_902_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zG3ZzKBM3QJj" title="Tax Credit Carryforward, Amount">9.2</span> million which do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current federal and California tax laws include substantial restrictions on the utilization of net operating losses and tax credits in the event of an ownership change of a corporation under Internal Revenue Code Section&#160;382 and 383.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and operating loss and credit carryforwards. Significant components of our deferred tax assets are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zsJNgv0oAJja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BD_zRakmePcaTng" style="display: none">Schedule of deferred tax assets</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20221231_zzbQ8yFBDFh" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20211231_zyqaklV3x5wg" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Deferred tax assets:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGzHnT_zFloHNuGRon6" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Net operating loss carryforwards</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">57,895</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">62,097</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3n3_maDTAGzHnT_zw5i3kmAgoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Research credit carryforwards</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">10,521</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,738</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGzHnT_z6KwMd6nSwWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Other, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,968</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,113</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzHnT_maDTALNzIFN_z7td1LOyCXhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total deferred tax assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">70,384</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">77,948</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Deferred tax liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDITLzija_z1MxwDEHj1t6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Other, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(46</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(65</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pn3n3_di_mtDITLzija_msDTALNzIFN_z5QaVimw2M1i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total deferred tax liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(46</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(65</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTALNzIFN_zfGjl7uejAH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(70,338</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(77,883</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNzIFN_zVgZrRQCX1M6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Net deferred tax assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zL0uaKTGQoC" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, our management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by approximately $<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_dm_c20220101__20221231_z00Xw7qIg175" title="Changes in valuation allowance">7.5</span> million during 2022 and decreased by approximately $<span id="xdx_90A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_dm_c20210101__20211231_zr7U6BQmwUD5" title="Changes in valuation allowance">2.4</span> million during 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for income taxes consists of state minimum taxes due. The effective tax rate of our provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zHv9ijIk1wUf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B5_zyw4XYXvdES4" style="display: none">Schedule of effective tax rate</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20220101__20221231_zQLiD52LDRD6" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49B_20210101__20211231_z1RgChIYsCH5" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> Years&#160;Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zViet8yeubch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Computed at 21%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(2,144</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(1,842</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zPhvjNAlsNZd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">State taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(488</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(67</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zLjEnK9bPSwd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(7,545</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,939</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zegCp17Q5T6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Other</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ziC4fAHAm2g8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Stock based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">627</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_zIeDUTepL5Bf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Research and development credits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,489</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(9</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--TaxAttributesExpirations_iN_pn3n3_di_zGXoRsMlqR5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Tax attributes expirations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,216</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,767</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxReconciliationImpactOfInternalRevenueCode_zCTKlJufGY7b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Impact of IRC 162m</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(159</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">87</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zfhlnh9RtI05" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(4</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zh2Hk9fzpFm5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20221231_zq4AlMX0YeHc" title="Changes in valuation allowance"><span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20211231_zpm2bmCy8Nl7" title="Unrecognized Tax Benefits">no</span></span> unrecognized tax benefits or any amounts accrued for interest and penalties for the three&#160;years ended December 31, 2022. Our policy is to recognize interest and penalties related to income taxes as a component of income tax expense. We do not expect the amount of unrecognized tax benefits will materially change in the next twelve&#160;months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We file tax returns in the U.S. federal jurisdiction and various state jurisdictions. We are subject to the U.S. federal and state income tax examination by tax authorities for such&#160;years 2003 through 2022, due to net operating losses that are being carried forward for tax purposes.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919290991232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zli9EvY5et31" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zJuNTmfcGRL7">Discontinued Operations</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information related to assets and liabilities reported as discontinued operations in our balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zNJs6Da8N5Ua" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span id="xdx_8B4_zQhLzqUB8xze" style="display: none">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zfUoIBsVycG3" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49F_20211231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zodZD3RsaaG8" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(In thousands)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzCWn_zUKunQHZMdfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt; vertical-align: top">Prepaid expenses and other current assets</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">14</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">12</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzCWn_z8nbOICulzsh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Discontinued operations &#8211; current assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">14</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">12</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIz3aE_zVaRSiYLgd76" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">129</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">782</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_iI_pn3n3_maLODGIz3aE_zGoMJz5pUsQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top">Other accrued liabilities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">362</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIz3aE_zK8QBODzFzok" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Discontinued operations &#8211; current liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">129</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,144</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, we recognized non-cash stock-based compensation expenses of approximately $<span id="xdx_905_ecustom--NoncashStockbasedCompensationExpenses_pn3n3_dm_c20220101__20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zENLmcOZxrcc" title="Non-cash stock-based compensation expenses">0.1</span> million which is included in discontinued operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919290279184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHEsoDDzUQw2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>11.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_823_z8mgodIatQ9g">Related Party Transactions</span></b></span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In January 2022, we entered into an agreement
with JT Pharma, a company for which James R. McNab, Jr., a member of our Board, serves as chief executive officer, to clarify certain
provisions of the JT Agreement, pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved,
made a payment of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--TransactionTypeAxis__custom--JTPharmaAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JTPharmaMember_zDet9oliVWMl" title="Value of stock issued">100,000</span> and issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--TransactionTypeAxis__custom--JTPharmaAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JTPharmaMember_z2YXVDq3L6M6" title="Stock issued">51,021</span> shares of our common stock to JT Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">During the year ended December 31, 2022, we made
payments related to legal fees of approximately $<span id="xdx_901_eus-gaap--LegalFees_pn3p0_c20220101__20221231_z2iiS2rgq4b5" title="Payment of legal fees">75,000</span> to a law firm operated by one of our Board members.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919290320816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zUuLOH3YVMYk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zX38P1zSQWzc">Subsequent Events</span></b></span></td> </tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 10, 2023, the Federal Deposit Insurance Corporation, or FDIC, announced that it had closed and taken control of Silicon Valley Bank, or SVB.  On March 13, 2023, pursuant to a joint statement released by the U.S. Department of the Treasury and the FDIC, the U.S. government reassured that all depositors will be fully protected. We held deposits with this bank. As a result of the above actions, our insured and uninsured deposits have been restored. </span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919283847168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_CompanyPolicyPolicyTextBlock', window );">The Company</a></td>
<td class="text"><p id="xdx_844_ecustom--CompanyPolicyPolicyTextBlock_zA3vYvJ9BHpf" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zyV5j9abquta">The Company</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura<sup>&#174;</sup>, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician&#8217;s assistants in a HCP&#8217;s office or other clinical setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our first product based on our ProNeura technology was Probuphine<sup>&#174;</sup> (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo&#8482;) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our commercial operations has allowed us to focus our limited resources on important product development programs and transition back to a product development company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, we announced our intention to work with our financial
advisor to explore strategic alternatives to enhance stockholder value, potentially including an acquisition, merger, reverse merger,
other business combination, sales of assets, licensing or other transaction. In June 2022, we implemented a plan to reduce expenses and
conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses to enable us to maintain
sufficient resources as we pursued potential strategic alternatives. In July 2022, David Lazar and Activist Investing LLC, or, collectively,
Activist acquired an approximately 25% ownership interest in Titan, filed a proxy statement and nominated six additional directors, each
of whom was elected to our board of directors or the Board, at a special meeting of stockholders held on August 15, 2022, or Special Meeting.
The exploration and evaluation of possible strategic alternatives by the Board has continued following the Special Meeting. Following
the election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced as our Executive Chairman, and David Lazar assumed
the role of Chief Executive Officer. In connection with the termination of his employment as Executive Chairman, Dr. Rubin will receive
aggregate severance payments of approximately $<span id="xdx_907_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220101__20221231__srt--CounterpartyNameAxis__custom--RubinMember_zcMNACqel82a" title="Aggregate severance payments">0.4</span> million, of which, approximately $165,000 had been paid to Dr. Rubin as of December
31, 2022. In December 2022, we implemented additional cost reduction measures including a reduction in our workforce. As a result of the
salary reductions, replacement of Dr. Rubin and the workforce reduction we have accrued approximately $<span id="xdx_90E_ecustom--AccruedSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zouBYEU4EPN2" title="Accrued severance">0.3</span> million and approximately $<span id="xdx_90E_ecustom--DeferredCompensationAndEmployeeSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zPEcATZqIfL" title="Deferred compensation and employee severance">0.6</span>
million related to deferred compensation and employee severance, respectively, as of December 31, 2022</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming we will continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, we had cash and cash equivalents of approximately $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231_zcp1qz4aXPTk" title="Cash and cash equivalents">2.9</span> million, which we believe is sufficient to fund our planned operations into the second quarter of 2023. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful. There is substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p id="xdx_846_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zZxEa46wNTd2" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJy10FlShte5">Discontinued Operations</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind down our commercialization activities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization activities as discontinued operations (see Note 10). The accompanying financial statements are generally presented in conformity with our historical format. We believe this format provides comparability with the previously filed financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_zdh4gOojcxKa" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zTDBcthOPDrf">Use of Estimates</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock', window );">Going concern assessment</a></td>
<td class="text"><p id="xdx_84F_ecustom--SubstantialDoubtAboutGoingConcernPolicyTextBlock_z11IfNBdjWuh" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zDAugIUAEpm9">Going concern assessment</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one&#160;year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by Accounting Standard Update ASU No.&#160;2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No.&#160;2014-15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Annual Report on Form&#160;10-K for the&#160;year ended December 31, 2022, we did not have sufficient cash to fund our operations for the next 12&#160;months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12&#160;months after the date the financial statements were issued. Additionally, we have suffered recurring losses from operations and have an accumulated deficit that raises substantial doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zg4dbgUlF9C7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zXYtwxiugYXa">Inventories</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are recorded at the lower of cost or net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantities on hand and write down to its net realizable value any inventory that we believe to be impaired. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. The components of inventories are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zFw8I2RCUKCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8BD_zwQgDXxd7ph2" style="display: none">Schedule of components of inventories</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20221231_zopClSbFJpig" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20211231_zNRl7QSozVuk" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pn3n3_maINzzRz_zqTD0rCQOSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Raw materials and supplies</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">60</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">227</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINzzRz_zRvj2dGzynQ" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Finished goods</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">46</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">66</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzzRz_zisJ2WMp8qd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;Total inventories</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">106</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">293</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zf5WdfiqAL72" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The approximately $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_c20221231_pn3n3" title="Finished goods inventory">46,000</span> and $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_pn3n3_c20211231_zGijA3qiRnx9" title="Finished goods inventory">66,000</span> of finished goods inventory at December 31, 2022 and 2021, respectively, included materials held for potential sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2Q40KMCUtfc" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zuJgaBuOSELi">Stock-Based Compensation</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize compensation expense using a fair-value based method, for all stock-based payments including stock options and restricted stock awards and stock issued under an employee stock purchase plan. These standards require companies to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. See Note&#160;8 &#8220;Stock Plans,&#8221; for a discussion of our stock-based compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock', window );">Warrants Issued in Connection with Equity Financing</a></td>
<td class="text"><p id="xdx_846_ecustom--WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock_zA6tHAxrO7C7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zqvhPwBSTsbd">Warrants Issued in Connection with Equity Financing</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle the warrants in cash. For warrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrants as a liability at each reporting period and record changes in the estimated fair value as a non-cash gain or loss in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLPT0H3eQSmk" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zXe98InXtkq8">Cash and Cash Equivalents</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our investment policy emphasizes liquidity and preservation of principal over other portfolio considerations. We select investments that maximize interest income to the extent possible given these two constraints. We satisfy liquidity requirements by investing excess cash in securities with different maturities to match projected cash needs and limit concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers and limit the amount of credit exposure to any one issuer. The estimated fair values have been determined using available market information. We do not use derivative financial instruments in our investment portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All investments with original maturities of three&#160;months or less are considered to be cash equivalents. We had money market funds of approximately $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC6PDamtx5g7" title="Cash and cash equivalents">2.6</span> million and $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zB7daW2mtYrb" title="Cash and cash equivalents">5.7</span> million as of December 31, 2022 and 2021, respectively, included in our cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20221231_zaI6b590ufC5" title="Cash, FDIC insured amount">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on our financial condition, results of operations, and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zGLIxeAchWRi" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><i><span id="xdx_86C_zp5ppOHjV962">Restricted Cash</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In accordance with ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash, we explain the change during the period in the total of cash, cash equivalents and
restricted cash, and include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period
total amounts shown on the statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table provides
a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet dates that comprise the total of the
same such amounts shown in the statements of cash flows for the years presented herein (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zQzdvtfknjY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule of restricted cash</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_z67EUQUyzh1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,037</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_zSrOlLFABlA9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">295</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_z3E6GZdShyOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,133</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>


<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrnYI4RuKmW" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zBnqgHuuFLy8">Property and Equipment</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets
ranging from three <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zAImnZ9dZ4wk" style="display: none" title="property, plant and equipment, estimated useful lives">3</span> to five <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKKN5BZgih38" style="display: none" title="property, plant and equipment, estimated useful lives">5</span> years. Leasehold improvements are amortized over the shorter of the lease term or the estimated
useful life of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zv9A4l1Csre7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zL7NyY6UmKZ4">Revenue Recognition</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department of Health and Human Services, or HHS, the Bill &amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net Product Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Returns &#8211; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebates &#8211; Our provision for rebates was estimated based on our customers&#8217; contracted rebate programs and our historical experience of rebates paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounts
&#8211; The provision was estimated based upon invoice billings, utilizing historical customer payment experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance Obligations</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Price</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognize revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocation of Consideration</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Timing of Recognition</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Assets and liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the activity related to our accounts receivable for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span id="xdx_8B6_zlxRgL6XG39b" style="display: none">Schedule of activity related to our accounts receivable</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><i>(In thousands)</i></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Balance at January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance">884</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions">1,526</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(2,298</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Balance at December 31, 2021</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance">112</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions">557</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(633</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">36</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zozZ1SMAQem5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/>&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrnYI4RuKmW" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zBnqgHuuFLy8">Property and Equipment</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets
ranging from three <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zAImnZ9dZ4wk" style="display: none" title="property, plant and equipment, estimated useful lives">3</span> to five <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKKN5BZgih38" style="display: none" title="property, plant and equipment, estimated useful lives">5</span> years. Leasehold improvements are amortized over the shorter of the lease term or the estimated
useful life of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zv9A4l1Csre7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zL7NyY6UmKZ4">Revenue Recognition</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department of Health and Human Services, or HHS, the Bill &amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net Product Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Returns &#8211; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebates &#8211; Our provision for rebates was estimated based on our customers&#8217; contracted rebate programs and our historical experience of rebates paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discounts
&#8211; The provision was estimated based upon invoice billings, utilizing historical customer payment experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance Obligations</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Price</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognize revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocation of Consideration</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Timing of Recognition</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contract Assets and liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the activity related to our accounts receivable for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span id="xdx_8B6_zlxRgL6XG39b" style="display: none">Schedule of activity related to our accounts receivable</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><i>(In thousands)</i></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Balance at January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance">884</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions">1,526</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(2,298</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Balance at December 31, 2021</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance">112</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions">557</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(633</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">36</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs and Related Accrual</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvYi38FlWXy7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zupjTsqyUHTh">Research and Development Costs and Related Accrual</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (&#8220;CRO&#8221;) activities, sponsored research studies, product registration, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfDqOmscuOD4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zgESb6Qe4M6">Net Loss Per Share</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share excludes the effect of dilution and is computed by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method. Basic and diluted net loss per share was the same for each of the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of shares of common stock outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the&#160;years ended (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zSErRwgCzgI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B6_zjVqoyveczlk" style="display: none">Schedule of anti-dilutive effect</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted-average anti-dilutive common shares resulting from stock awards</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_zFPiHclvpiCc" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">964</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_z53MATNY3cG8" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">617</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Weighted-average anti-dilutive common shares resulting from warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zIrI6wAmeRxi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">5,661</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zbWBbapW6Blb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,374</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdC0Xwmolla4" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,625</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zPx2K45tzhpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,991</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z1Yyx7WKv6C6" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zefpL2dPPYc9" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zkDFHNQZ39I1">Leases</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the minimum lease payments of our operating lease as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zgROnTpnXa71" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B6_zpn4eCwuDock" style="display: none">Schedule of minimum operating lease payments</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20221231_zTvF1iEavTxd" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2023</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">130</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2024</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">66</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total minimum lease payments (base rent)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">196</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zfKHFgWnsUQ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Less: imputed interest</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(9</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total operating lease liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">187</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zu2nSUyCQer5" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z4kb8wfQKuG4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zBFHIrbW1K9i">Subsequent Events</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have evaluated events that have occurred subsequent to December 31, 2022 and through the date that the financial statements are issued. See Note 12 Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbefMA3aXZTd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zWsUoEVgA2y2">Fair Value Measurements</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#160;&#8211; quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#160;&#8211; quoted prices for similar assets and liabilities in active markets or inputs that are observable;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#160;&#8211; inputs that are unobservable (for example cash flow modelling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. The approximately $<span id="xdx_90B_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20221231_zZsgdzlXokR4" title="Money Market Funds, at Carrying Value">2.6</span> million and $<span id="xdx_904_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20211231_zAZRblcItV26" title="Money Market Funds, at Carrying Value">5.7</span> million fair values of money market funds as of December 31, 2022 and 2021, included in our cash and cash equivalents are classified as Level 1 and were derived from quoted market prices as active markets for these instruments exists. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zdP35IW7RjDd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUz5PGUW6GWj">Recent Accounting Pronouncements</span></i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently Adopted Accounting Pronouncements</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the FASB issued FASB issued ASU 2021-10, <i>Disclosures by Business Entities about Government Assistance</i>. The ASU codifies new requirements to disclose information about the nature of certain government assistance received, the accounting policy used to account for the transactions, the location in the financial statements where such transactions were recorded and significant terms and conditions associated with such transactions. The guidance is effective for annual periods beginning after December 15, 2021. The adoption of ASU No. 2021-10 did not have a material impact to our financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounting Standards Not Yet Adopted</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses</i>, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January 1, 2023. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the FASB issued ASU 2020-04, <i>Reference Rate Reform</i>, which provides companies with optional guidance, including expedients and exceptions for applying GAAP to contracts and other transactions affected by reference rate reform, such as the London Interbank Offered Rate, or LIBOR. This new standard was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are evaluating the effects that the adoption of this guidance will have on our financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU No. 2020-06, <i>Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the if converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective beginning after December 15, 2023 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. We are currently evaluating the impact this guidance will have on our financial statements and related disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_CompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_CompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287303104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of components of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zFw8I2RCUKCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8BD_zwQgDXxd7ph2" style="display: none">Schedule of components of inventories</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20221231_zopClSbFJpig" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20211231_zNRl7QSozVuk" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pn3n3_maINzzRz_zqTD0rCQOSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Raw materials and supplies</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">60</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">227</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINzzRz_zRvj2dGzynQ" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Finished goods</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">46</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">66</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzzRz_zisJ2WMp8qd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;Total inventories</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">106</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">293</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of activity related to our accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zQzdvtfknjY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Schedule of restricted cash</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_z67EUQUyzh1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,037</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_iI_zSrOlLFABlA9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">196</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">295</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_z3E6GZdShyOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,133</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,332</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of activity related to our accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><span id="xdx_8B6_zlxRgL6XG39b" style="display: none">Schedule of activity related to our accounts receivable</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><i>(In thousands)</i></td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top">Balance at January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance">884</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions">1,526</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(2,298</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Balance at December 31, 2021</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance">112</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Additions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions">557</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top">Deductions</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions">(633</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">36</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive effect</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zSErRwgCzgI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B6_zjVqoyveczlk" style="display: none">Schedule of anti-dilutive effect</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted-average anti-dilutive common shares resulting from stock awards</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_zFPiHclvpiCc" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">964</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_z53MATNY3cG8" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">617</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Weighted-average anti-dilutive common shares resulting from warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zIrI6wAmeRxi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">5,661</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zbWBbapW6Blb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,374</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdC0Xwmolla4" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,625</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zPx2K45tzhpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,991</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum operating lease payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zgROnTpnXa71" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B6_zpn4eCwuDock" style="display: none">Schedule of minimum operating lease payments</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20221231_zTvF1iEavTxd" style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2023</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">130</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">2024</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">66</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total minimum lease payments (base rent)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">196</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zfKHFgWnsUQ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Less: imputed interest</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(9</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Total operating lease liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">187</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287315712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_ztT9QvDQYfej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BA_z2LPCDycrEk6" style="display: none">Schedule of property and equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Furniture and office equipment</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross">132</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross">132</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Laboratory equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,108</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,108</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Computer equipment</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross">577</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross">577</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,817</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross">1,817</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Less accumulated depreciation and amortization</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zJPDPRrj4IVd" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization">(1,593</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zqykeNhDEr91" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization">(1,397</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Property and equipment, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20221231_znkThjA8sIt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">224</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zmJ1vNClmGbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">420</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287388672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of restricted stock activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_pn3n3_z9moU5jNuzZf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span id="xdx_8B4_zjh42pIkomY2" style="display: none">Summary of restricted stock activity</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"/>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"/>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; vertical-align: top">Outstanding at December 31, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231_zFW1l7qB0tPk" style="width: 9%; text-align: right" title="Outstanding at beginning">50,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Issued</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231_zuZnIkngtQaf" style="text-align: right" title="Issued">387,078</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Forfeited or expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220101__20221231_z9KSdmYjmAh3" style="text-align: right" title="Forfeited or expired"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top">Released</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_pid_c20220101__20221231_z4QGZMT50lpg" style="border-bottom: Black 1pt solid; text-align: right" title="Released">(437,078</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Outstanding at December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220101__20221231_zinqwJKWrsD" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants to purchase</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_pn3n3_zVVf7z7xIT6i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_8BA_zbRxWQFJpH85" style="display: none">Schedule of warrants to purchase</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date Issued</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration&#160;Date</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise&#160;Price</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Date Issued">07/27/2017</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 23%; text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Expiration Date">07/27/2024</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 22%; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_z6sUk06JPpOf" title="Exercise Price (in dollars per share)">45.00</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 22%; text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_zF2WqR6vmWZf" title="Outstanding">12</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Date Issued">03/21/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Expiration Date">03/21/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zMx4xgeR7sIa" title="Exercise Price (in dollars per share)">216.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zphKQvGQXgye" title="Outstanding">1</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_904_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Date Issued">03/21/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Expiration Date">03/21/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zojOlollJpSl" title="Exercise Price (in dollars per share)">216.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zjEhHIdgPgn7" title="Outstanding">3</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_906_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Date Issued">09/25/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Expiration Date">09/25/2023</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zGW8AgAcCbW4" title="Exercise Price (in dollars per share)">18.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zy7G5aAqAGKa" title="Outstanding">154</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Date Issued">09/25/2018</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Expiration Date">09/25/2023</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_z4lGSm1yvi9k" title="Exercise Price (in dollars per share)">50.40</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_zxutXXMAyUy3" title="Outstanding">8</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Date Issued">08/09/2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Expiration Date">02/09/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_zuxtVyhmz747" title="Exercise Price (in dollars per share)">32.10</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_ztdRyIub9sXj" title="Outstanding">95</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Date Issued">10/18/2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Expiration Date">10/18/2024</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_z2J8SrtCHIUl" title="Exercise Price (in dollars per share)">1.14</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_zmfl9eJ2sL27" title="Outstanding">230</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Date Issued">01/09/2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Expiration Date">07/09/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_z20QogSQuYji" title="Exercise Price (in dollars per share)">7.50</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_zWfaS2xKM2P7" title="Outstanding">290</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Date Issued">10/30/2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Expiration Date">12/01/2025</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zo2cTgTkbN7l" title="Exercise Price (in dollars per share)">3.00</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zwSWDbIeN906" title="Outstanding">1,644</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Date Issued">01/20/2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Expiration Date">07/26/2026</span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zngUN6Ov2Emb" title="Exercise Price (in dollars per share)">3.55</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zphRdumVeLqg" title="Outstanding">2,725</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_z3J7cL5Aswqd" title="Date Issued">02/04/2022</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zeCb7jssfk4i" title="Expiration Date">08/04/2027</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td>
    <td style="padding-bottom: 1pt; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zbVprxbLBT6k" title="Exercise Price (in dollars per share)">1.14</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zrriKhX0HiUi" title="Outstanding">4,664</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zWyiDrxSuvj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding">9,826</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of shares of common stock reserved for future issuance</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_zPsdhuFo4Fz" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B5_zxwXu46gpOdg" style="display: none">Schedule of shares of common stock reserved for future issuance</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Stock options outstanding</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSnOPPSWHEcg" style="width: 9%; text-align: right" title="Common stock, capital shares reserved for future issuance">927</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Shares issuable upon the exercise of warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zxipqE8V8488" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock, capital shares reserved for future issuance">9,826</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220930_zy3yxUBNEiVg" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock, capital shares reserved for future issuance">10,753</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919289375744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of our option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z4NqZTrKZXc5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BA_zRTCYfMaY5pf" style="display: none">Schedule of our option activity</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares<br/> (in thousands)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Exercise Price<br/>
per Share</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted Average<br/> Remaining
    Contractual<br/> Term (years)</b></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate<br/> Intrinsic Value<br/> (in
    thousands)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td> </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zeoMgsXWZ6Wh" style="width: 9%; text-align: right" title="Outstanding at Beginning">682</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zvp5FJQKfEAe" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at Beginning">12.53</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zhImmUb5p52h" title="Weighted Average Remaining Contractual Term, Outstanding (Years)">8.98</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20221231_zmc3srTqtBCj" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zMwkGictmsCh" style="text-align: right" title="Shares, Granted">310</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zK4zzYJcwOR1" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.18</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/expired</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_z29ZI741Es42" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Cancelled/expired">(65</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zcoYLHtlQG5d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/expired">23.40</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zwEwtYAOrEw1" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at Ending">927</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zF0pmW48IIy4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">7.97</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zw7hKCJ6DXng" title="Weighted Average Remaining Contractual Term, Outstanding (Years)">8.34</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20221231_zvcUa3QjkpS1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zE7h3trfQ5Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Exercisable">927</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zHJIgUzBq6M9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable">7.97</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zDH1q3Jdd1Ub" title="Weighted Average Remaining Contractual Term, Exercisable">8.34</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of assumptions to estimate the fair value of options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zqsYXrZbwc42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BE_zPgA46M4ggo1" style="display: none">Schedule of assumptions to estimate the fair value of options</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <br/> Years Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Weighted-average risk-free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zimxS1yvFL7d" title="Weighted-average risk-free interest rate">1.9</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231_zIwhvJPbZuab" title="Weighted-average risk-free interest rate">0.5</span></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Expected dividend payments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220101__20221231_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231_pn3n3" style="text-align: right" title="Expected dividend payments"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Expected holding period (years)(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_fKDEp_zXc30gJDtOE" title="Expected holding period (years)">5.26</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_fKDEp_zSWaTKOeVK1h" title="Expected holding period (years)">5.45</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Weighted-average volatility factor(2)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_fKDIp_zL35OYstqh33" title="Weighted-average volatility factor">1.16</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20210101__20211231_fKDIp_zxaLCerXnlF6" title="Weighted-average volatility factor">1.14</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Estimated forfeiture rates for options granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20221231_zY92hkuGfTb4" title="Estimated forfeiture rates for options granted">6</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20210101__20211231_zNytV6xmn0Eb" title="Estimated forfeiture rates for options granted">30</span></td>
    <td style="text-align: left">%</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0C_zUnIg0WPiaN8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zwaiP8AJBf74" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F02_zudaHfL6q9m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zibsMcMXUBKb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average volatility is based on the historical volatility of our common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F05_zyhzoOTkCcwj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zhVrqttXD5j1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated forfeiture rates are based on historical data.</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of the stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_znRWAMNGLuE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BD_zus3gRP7DoR7" style="display: none">Schedule of the stock-based compensation expense</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> Years Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Research and development</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">553</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation">749</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">General and administrative</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">394</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">756</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total stock-based compensation expenses</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">947</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">1,505</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287368112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zsJNgv0oAJja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8BD_zRakmePcaTng" style="display: none">Schedule of deferred tax assets</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20221231_zzbQ8yFBDFh" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_498_20211231_zyqaklV3x5wg" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Deferred tax assets:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGzHnT_zFloHNuGRon6" style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Net operating loss carryforwards</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">57,895</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">62,097</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3n3_maDTAGzHnT_zw5i3kmAgoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Research credit carryforwards</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">10,521</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,738</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGzHnT_z6KwMd6nSwWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Other, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,968</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">1,113</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzHnT_maDTALNzIFN_z7td1LOyCXhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total deferred tax assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">70,384</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">77,948</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Deferred tax liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDITLzija_z1MxwDEHj1t6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top">Other, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(46</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(65</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pn3n3_di_mtDITLzija_msDTALNzIFN_z5QaVimw2M1i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total deferred tax liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(46</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(65</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTALNzIFN_zfGjl7uejAH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Valuation allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(70,338</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(77,883</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNzIFN_zVgZrRQCX1M6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Net deferred tax assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zHv9ijIk1wUf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span id="xdx_8B5_zyw4XYXvdES4" style="display: none">Schedule of effective tax rate</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_497_20220101__20221231_zQLiD52LDRD6" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49B_20210101__20211231_z1RgChIYsCH5" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<br/> Years&#160;Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zViet8yeubch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Computed at 21%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(2,144</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(1,842</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zPhvjNAlsNZd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">State taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(488</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(67</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zLjEnK9bPSwd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(7,545</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,939</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zegCp17Q5T6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Other</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ziC4fAHAm2g8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Stock based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">627</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_zIeDUTepL5Bf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Research and development credits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,489</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(9</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--TaxAttributesExpirations_iN_pn3n3_di_zGXoRsMlqR5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Tax attributes expirations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,216</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,767</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxReconciliationImpactOfInternalRevenueCode_zCTKlJufGY7b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Impact of IRC 162m</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(159</td>
    <td style="padding-bottom: 1pt; text-align: left">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">87</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zfhlnh9RtI05" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(4</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919291131072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zNJs6Da8N5Ua" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><span id="xdx_8B4_zQhLzqUB8xze" style="display: none">Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_495_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zfUoIBsVycG3" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49F_20211231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zodZD3RsaaG8" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(In thousands)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzCWn_zUKunQHZMdfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt; vertical-align: top">Prepaid expenses and other current assets</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">14</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; width: 9%; text-align: right">12</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzCWn_z8nbOICulzsh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Discontinued operations &#8211; current assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">14</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">12</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIz3aE_zVaRSiYLgd76" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">129</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">782</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_iI_pn3n3_maLODGIz3aE_zGoMJz5pUsQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top">Other accrued liabilities</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">362</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIz3aE_zK8QBODzFzok" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top">Discontinued operations &#8211; current liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">129</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,144</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919284848752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">&#160;Total inventories</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919283861200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="nump">$ 6,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as shown in the statements of cash flows</a></td>
<td class="nump">$ 3,133<span></span>
</td>
<td class="nump">$ 6,332<span></span>
</td>
<td class="nump">$ 5,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919284003376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Beginning Balance</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ContractWithCustomerAssetAdditions', window );">Additions</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ContractWithCustomerAssetDeductions', window );">Deductions</a></td>
<td class="num">(633)<span></span>
</td>
<td class="num">(2,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Ending Balance</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ContractWithCustomerAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ContractWithCustomerAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ContractWithCustomerAssetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ContractWithCustomerAssetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919284031856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,625<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=ttnp_EmployeeStockAwardsMember', window );">Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">5,661<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=ttnp_EmployeeStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=ttnp_EmployeeStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287157632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 4)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments (base rent)</a></td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919288954800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods inventory</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,937<span></span>
</td>
<td class="nump">6,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money Market Funds, at Carrying Value</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">property, plant and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">property, plant and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ttnp_RubinMember', window );">Rubin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Aggregate severance payments</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_AccruedSeverance', window );">Accrued severance</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DeferredCompensationAndEmployeeSeverance', window );">Deferred compensation and employee severance</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_AccruedSeverance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_AccruedSeverance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DeferredCompensationAndEmployeeSeverance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DeferredCompensationAndEmployeeSeverance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ttnp_RubinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ttnp_RubinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919283908064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 1,817<span></span>
</td>
<td class="nump">$ 1,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(1,397)<span></span>
</td>
<td class="num">(1,593)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 577<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287284816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JT Pharmaceuticals Asset Purchase Agreement (Details Narrative) - JT Pharmaceuticals [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_FutureMilestonePayments', window );">Closing payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_MilestonePayments', window );">Milestone Payments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="nump">51,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_FutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This information is pertaining to the amount received a closing payment and is entitled to receive future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_FutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This information is pertaining to the amount received a closing payment and is entitled to receive milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919292124160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ocular Therapeutix License Agreement (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract', window );"><strong>Ocular Therapeutix License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ReimbursementFees', window );">Reimbursement fees</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919286822912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies (Note 5)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OperatingLeasesRentExpenses', window );">Rent expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_OperatingLeasesRentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_OperatingLeasesRentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919288945600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Agreements (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Non-cash gain (loss) on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ttnp_PaycheckProtectionProgramLoanMember', window );">PPP loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Loan proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Loan annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Non-cash gain (loss) on debt extinguishment</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttnp_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttnp_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287102608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued</a></td>
<td class="nump">387,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">Released</a></td>
<td class="num">(437,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919286910352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">9,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateOneMember', window );">Class of Warrant or Right Issued Date One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Jul. 27,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Jul. 27,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 45.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateTwoMember', window );">Class of Warrant or Right Issued Date Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Mar. 21,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Mar. 21,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 216.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateThreeMember', window );">Class of Warrant or Right Issued Date Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Mar. 21,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Mar. 21,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 216.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateFourMember', window );">Class Of Warrant or Right Issued Date Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Sep. 25,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Sep. 25,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateFiveMember', window );">Class Of Warrant or Right Issued Date Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Sep. 25,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Sep. 25,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 50.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateSixMember', window );">Class Of Warrant or Right Issued Date Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Aug.  09,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Feb.  09,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 32.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateSevenMember', window );">Class Of Warrant or Right Issued Date Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Oct. 18,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Oct. 18,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateEightMember', window );">Class Of Warrant or Right Issued Date Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Jan.  09,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Jul.  09,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateNineMember', window );">Class Of Warrant Or Right Issued Date Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Oct. 30,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec.  01,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateTenMember', window );">Class Of Warrant Or Right Issued Date Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Jan. 20,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Jul. 26,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">2,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateElevenMember', window );">Class Of Warrant Or Right Issued Date Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsIssueDate', window );">Date Issued</a></td>
<td class="text">Feb.  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Aug.  04,  2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding</a></td>
<td class="nump">4,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ClassOfWarrantsOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ClassOfWarrantsOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_ClassOfWarrantsOrRightsIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights issue date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_ClassOfWarrantsOrRightsIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_ClassOfWarrantOrRightIssuedDateElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919284861120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details 2) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">9,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919282569184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,016,295<span></span>
</td>
<td class="nump">9,914,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttnp_TwoThousandFifteenPlanMember', window );">2015 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">2,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Common Stock To Maxim Group Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Services Agreement With Maxim Mdm Worldwide Solutions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Restricted stock agreement with Maxim Group, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember', window );">JT Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="nump">1,289,796<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">974,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="nump">$ 1,290<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,274,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member] | Unregistered prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember', window );">February 2022 Offerings [Member] | Unregistered five year and six month warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,664,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_January2021OfferingMember', window );">January 2021 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttnp_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttnp_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttnp_CommonStockToMaximGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttnp_CommonStockToMaximGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttnp_RestrictedStockAgreementWithMaximGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttnp_RestrictedStockAgreementWithMaximGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ttnp_JtPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttnp_February2022OfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttnp_January2021OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttnp_January2021OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919288892000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at Beginning</a></td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Beginning</a></td>
<td class="nump">$ 12.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding (Years)</a></td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
<td class="text">8 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Shares, Cancelled/expired</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/expired</a></td>
<td class="nump">$ 23.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at Ending</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending</a></td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="nump">$ 12.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable</a></td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919284003808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected holding period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">5 years 3 months 3 days<span></span>
</td>
<td class="text">5 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility factor</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1.16%<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement', window );">Estimated forfeiture rates for options granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Weighted average volatility is based on the historical volatility of our common stock.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated forfeiture rates for options granted to management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919289274544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919284900832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th"><div>Jul. 31, 2002</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options and awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense related to non-vested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognizing non-vested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttnp_Plan2015Member', window );">Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">7,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,738<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_PurchaseCommonStock', window );">Purchase common stock</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per value</a></td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_PurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_PurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttnp_Plan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttnp_Plan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919289384976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 57,895<span></span>
</td>
<td class="nump">$ 62,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">10,521<span></span>
</td>
<td class="nump">14,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">70,384<span></span>
</td>
<td class="nump">77,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other, net</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(70,338)<span></span>
</td>
<td class="num">(77,883)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287485344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed at 21%</a></td>
<td class="num">$ (2,144)<span></span>
</td>
<td class="num">$ (1,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(488)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(7,545)<span></span>
</td>
<td class="num">(1,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock based compensation</a></td>
<td class="nump">627<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_TaxAttributesExpirations', window );">Tax attributes expirations</a></td>
<td class="nump">6,216<span></span>
</td>
<td class="nump">3,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode', window );">Impact of IRC 162m</a></td>
<td class="num">(159)<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents income tax reconciliation impact of internal revenue code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_TaxAttributesExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax attributes expirations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_TaxAttributesExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919286816064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Changes in valuation allowance</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 115,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OperatingLossCarryForwardsExpirationYear', window );">Operating Loss Carry Forwards Expiration Year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OperatingLossCarryForwardsExpirationYear', window );">Operating Loss Carry Forwards Expiration Year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OperatingLossCarryForwardsNotSubjectToExpiration', window );">Operating Loss Carry forwards Not Subject To Expiration</a></td>
<td class="nump">$ 54,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage', window );">Operating Loss Carryforwards, Limitations on Use Percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_OperatingLossCarryForwardsExpirationYear', window );">Operating Loss Carry Forwards Expiration Year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_OperatingLossCarryForwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_OperatingLossCarryForwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to operating loss carry forward percentage of limitation on use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919289384944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current assets</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current liabilities</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member] | U.s. Commercialization Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Discontinued operations &#8211; current liabilities</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 1,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ttnp_U.s.CommercializationActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ttnp_U.s.CommercializationActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287480816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttnp_NoncashStockbasedCompensationExpenses', window );">Non-cash stock-based compensation expenses</a></td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttnp_NoncashStockbasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttnp_NoncashStockbasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttnp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139919287466064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of stock issued</a></td>
<td class="nump">$ 5,030,000<span></span>
</td>
<td class="nump">$ 8,841,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Payment of legal fees</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=ttnp_JTPharmaAgreementMember', window );">J T Pharma Agreement [Member] | J T Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of stock issued</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="nump">51,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ttnp_JTPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ttnp_JTPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ttnp_JTPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ttnp_JTPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>titanpharma_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:ttnp="http://titanpharm.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ttnp-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RubinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:RubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RubinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttnp:RubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeeStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">ttnp:EmployeeStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EmployeeStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">ttnp:EmployeeStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ttnp:JtPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-04-20_custom_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-05-31_custom_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttnp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredPrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:UnregisteredFiveYearAndSixMonthWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:February2022OfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="From2022-03-012022-03-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-30_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="From2022-05-012022-05-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-30_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:CommonStockToMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:CommonStockToMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:ServicesAgreementWithMaximMdmWorldwideSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:ServicesAgreementWithMaximMdmWorldwideSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttnp:RestrictedStockAgreementWithMaximGroupLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_TwoThousandFifteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-31_custom_January2021OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:January2021OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-31_custom_January2021OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttnp:January2021OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttnp:ClassOfWarrantOrRightIssuedDateElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2015-08-31_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="AsOf2014-02-28_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="AsOf2002-07-31_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2002-07-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-15_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-15_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-15_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-15_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-15_custom_Plan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttnp:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ttnp:U.s.CommercializationActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SegmentDiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_JTPharmaAgreementMember_custom_JTPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttnp:JTPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ttnp:JTPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0000910267</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-01-012022-12-31_us-gaap_ProductMember"
      id="xdx2ixbrl0176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0235"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:AmortizationOfRestrictedStockShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0259"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0273"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0319"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:ShareBasedPaymentArrangementMilestonePayment
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:RetirementOfPropertyAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:AccumulatedDepreciationOnRetiredPropertyAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0667"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0671"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0942"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0961"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0977"
      unitRef="USD"
      xsi:nil="true"/>
    <ttnp:DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      id="xdx2ixbrl0996"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-13341</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">TITAN PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">94-3171940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">400 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite 505</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">244-4990</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">TTNP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="-3" unitRef="USD">8100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-24" decimals="INF" unitRef="Shares">15016295</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">100</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2937000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">196000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">295000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">36000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">112000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">106000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">293000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">314000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">480000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">14000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">12000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3603000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7229000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">420000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">48000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">48000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">183000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">297000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4058000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7994000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">695000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">795000</us-gaap:AccountsPayableCurrent>
    <ttnp:AccruedClinicalTrialsExpensesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5000</ttnp:AccruedClinicalTrialsExpensesCurrent>
    <ttnp:AccruedClinicalTrialsExpensesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">9000</ttnp:AccruedClinicalTrialsExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1483000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">314000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">122000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">112000</us-gaap:OperatingLeaseLiabilityCurrent>
    <ttnp:DeferredGrantRevenue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">196000</ttnp:DeferredGrantRevenue>
    <ttnp:DeferredGrantRevenue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">295000</ttnp:DeferredGrantRevenue>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">129000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1144000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2630000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2669000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">65000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">187000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2695000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">2856000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9914158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9914158</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">387609000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">381183000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-386261000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-376055000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5138000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4058000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7994000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-01-012022-12-31_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      unitRef="USD">60000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2021-01-012021-12-31_us-gaap_LicenseAndServiceMember"
      decimals="-3"
      unitRef="USD">13000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2021-01-012021-12-31_us-gaap_ProductMember"
      decimals="-3"
      unitRef="USD">236000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-01-012022-12-31_us-gaap_GrantMember"
      decimals="-3"
      unitRef="USD">497000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2021-01-012021-12-31_us-gaap_GrantMember"
      decimals="-3"
      unitRef="USD">1277000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">557000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1526000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">199000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4758000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">5692000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6034000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">4989000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">10792000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">10880000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10235000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-9354000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">53000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">24000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">84000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">661000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">29000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">578000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10206000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-8776000</us-gaap:NetIncomeLoss>
    <ttnp:BasicAndDilutedNetLossPerCommonShare
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.76</ttnp:BasicAndDilutedNetLossPerCommonShare>
    <ttnp:BasicAndDilutedNetLossPerCommonShare
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.90</ttnp:BasicAndDilutedNetLossPerCommonShare>
    <ttnp:WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">13434</ttnp:WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare>
    <ttnp:WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">9730</ttnp:WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7139</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">370804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-367279000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3532000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-8776000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-8776000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2775</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">8838000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">8841000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1505000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1505000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">381183000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-376055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5138000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-10206000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10206000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1151</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">5029000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">5030000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3564</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueOther>
    <ttnp:AmortizationOfRestrictedStockShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">387</ttnp:AmortizationOfRestrictedStockShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">450000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">450000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">947000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">947000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15016</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">387609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-386261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1363000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10206000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-8776000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">196000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">221000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2000</us-gaap:OtherNoncashExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">661000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <ttnp:ShareBasedPaymentArrangementMilestonePayment
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">50000</ttnp:ShareBasedPaymentArrangementMilestonePayment>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">947000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1505000</us-gaap:ShareBasedCompensation>
    <ttnp:AmortizationOfRestrictedStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">450000</ttnp:AmortizationOfRestrictedStock>
    <ttnp:AmortizationOfRestrictedStock
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">36000</ttnp:AmortizationOfRestrictedStock>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">7000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-76000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-772000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-187000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-35000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-164000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-163000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-751000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-1191000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">801000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-293000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-99000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">295000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-8183000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-7899000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">23000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-23000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ttnp:ProceedsFromEquityOfferings
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4980000</ttnp:ProceedsFromEquityOfferings>
    <ttnp:ProceedsFromEquityOfferings
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">8841000</ttnp:ProceedsFromEquityOfferings>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4984000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">8841000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-3199000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">919000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6332000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">5413000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6332000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ttnp:RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">149000</ttnp:RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization>
    <ttnp:RetirementOfPropertyAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1372000</ttnp:RetirementOfPropertyAndEquipment>
    <ttnp:AccumulatedDepreciationOnRetiredPropertyAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-1372000</ttnp:AccumulatedDepreciationOnRetiredPropertyAndEquipment>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2937000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">196000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">295000</us-gaap:RestrictedCash>
    <ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3133000</ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents>
    <ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6332000</ttnp:CashAndCashEquivalentsAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zZNWBbxitBej" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_zgg5wPALvye9"&gt;Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--CompanyPolicyPolicyTextBlock_zA3vYvJ9BHpf" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zyV5j9abquta"&gt;The Company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura&lt;sup&gt;&#xae;&lt;/sup&gt;, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician&#x2019;s assistants in a HCP&#x2019;s office or other clinical setting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our first product based on our ProNeura technology was Probuphine&lt;sup&gt;&#xae;&lt;/sup&gt; (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo&#x2122;) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our commercial operations has allowed us to focus our limited resources on important product development programs and transition back to a product development company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2021, we announced our intention to work with our financial
advisor to explore strategic alternatives to enhance stockholder value, potentially including an acquisition, merger, reverse merger,
other business combination, sales of assets, licensing or other transaction. In June 2022, we implemented a plan to reduce expenses and
conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses to enable us to maintain
sufficient resources as we pursued potential strategic alternatives. In July 2022, David Lazar and Activist Investing LLC, or, collectively,
Activist acquired an approximately 25% ownership interest in Titan, filed a proxy statement and nominated six additional directors, each
of whom was elected to our board of directors or the Board, at a special meeting of stockholders held on August 15, 2022, or Special Meeting.
The exploration and evaluation of possible strategic alternatives by the Board has continued following the Special Meeting. Following
the election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced as our Executive Chairman, and David Lazar assumed
the role of Chief Executive Officer. In connection with the termination of his employment as Executive Chairman, Dr. Rubin will receive
aggregate severance payments of approximately $&lt;span id="xdx_907_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220101__20221231__srt--CounterpartyNameAxis__custom--RubinMember_zcMNACqel82a" title="Aggregate severance payments"&gt;0.4&lt;/span&gt; million, of which, approximately $165,000 had been paid to Dr. Rubin as of December
31, 2022. In December 2022, we implemented additional cost reduction measures including a reduction in our workforce. As a result of the
salary reductions, replacement of Dr. Rubin and the workforce reduction we have accrued approximately $&lt;span id="xdx_90E_ecustom--AccruedSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zouBYEU4EPN2" title="Accrued severance"&gt;0.3&lt;/span&gt; million and approximately $&lt;span id="xdx_90E_ecustom--DeferredCompensationAndEmployeeSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zPEcATZqIfL" title="Deferred compensation and employee severance"&gt;0.6&lt;/span&gt;
million related to deferred compensation and employee severance, respectively, as of December 31, 2022&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying financial statements have been prepared assuming we will continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At December 31, 2022, we had cash and cash equivalents of approximately $&lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231_zcp1qz4aXPTk" title="Cash and cash equivalents"&gt;2.9&lt;/span&gt; million, which we believe is sufficient to fund our planned operations into the second quarter of 2023. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful. There is substantial doubt about our ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zZxEa46wNTd2" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zJy10FlShte5"&gt;Discontinued Operations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In October 2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind down our commercialization activities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization activities as discontinued operations (see Note 10). The accompanying financial statements are generally presented in conformity with our historical format. We believe this format provides comparability with the previously filed financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zdh4gOojcxKa" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zTDBcthOPDrf"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_84F_ecustom--SubstantialDoubtAboutGoingConcernPolicyTextBlock_z11IfNBdjWuh" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zDAugIUAEpm9"&gt;Going concern assessment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one&#160;year from the date the financial statements are issued or available to be issued, which is referred to as the &#x201c;look-forward period&#x201d; as defined by Accounting Standard Update ASU No.&#160;2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No.&#160;2014-15.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Annual Report on Form&#160;10-K for the&#160;year ended December 31, 2022, we did not have sufficient cash to fund our operations for the next 12&#160;months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12&#160;months after the date the financial statements were issued. Additionally, we have suffered recurring losses from operations and have an accumulated deficit that raises substantial doubt about our ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zg4dbgUlF9C7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zXYtwxiugYXa"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories are recorded at the lower of cost or net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantities on hand and write down to its net realizable value any inventory that we believe to be impaired. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. The components of inventories are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zFw8I2RCUKCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BD_zwQgDXxd7ph2" style="display: none"&gt;Schedule of components of inventories&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20221231_zopClSbFJpig" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20211231_zNRl7QSozVuk" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pn3n3_maINzzRz_zqTD0rCQOSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Raw materials and supplies&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;60&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;227&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINzzRz_zRvj2dGzynQ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;46&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzzRz_zisJ2WMp8qd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total inventories&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;106&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;293&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zf5WdfiqAL72" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The approximately $&lt;span id="xdx_903_eus-gaap--InventoryFinishedGoods_c20221231_pn3n3" title="Finished goods inventory"&gt;46,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_pn3n3_c20211231_zGijA3qiRnx9" title="Finished goods inventory"&gt;66,000&lt;/span&gt; of finished goods inventory at December 31, 2022 and 2021, respectively, included materials held for potential sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2Q40KMCUtfc" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zuJgaBuOSELi"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We recognize compensation expense using a fair-value based method, for all stock-based payments including stock options and restricted stock awards and stock issued under an employee stock purchase plan. These standards require companies to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. See Note&#160;8 &#x201c;Stock Plans,&#x201d; for a discussion of our stock-based compensation plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock_zA6tHAxrO7C7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zqvhPwBSTsbd"&gt;Warrants Issued in Connection with Equity Financing&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle the warrants in cash. For warrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrants as a liability at each reporting period and record changes in the estimated fair value as a non-cash gain or loss in the Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLPT0H3eQSmk" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zXe98InXtkq8"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our investment policy emphasizes liquidity and preservation of principal over other portfolio considerations. We select investments that maximize interest income to the extent possible given these two constraints. We satisfy liquidity requirements by investing excess cash in securities with different maturities to match projected cash needs and limit concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers and limit the amount of credit exposure to any one issuer. The estimated fair values have been determined using available market information. We do not use derivative financial instruments in our investment portfolio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All investments with original maturities of three&#160;months or less are considered to be cash equivalents. We had money market funds of approximately $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC6PDamtx5g7" title="Cash and cash equivalents"&gt;2.6&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zB7daW2mtYrb" title="Cash and cash equivalents"&gt;5.7&lt;/span&gt; million as of December 31, 2022 and 2021, respectively, included in our cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We maintain significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20221231_zaI6b590ufC5" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on our financial condition, results of operations, and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zGLIxeAchWRi" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zp5ppOHjV962"&gt;Restricted Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;In accordance with ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash, we explain the change during the period in the total of cash, cash equivalents and
restricted cash, and include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period
total amounts shown on the statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The following table provides
a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet dates that comprise the total of the
same such amounts shown in the statements of cash flows for the years presented herein (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zQzdvtfknjY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule of restricted cash&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_z67EUQUyzh1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,037&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RestrictedCash_iI_zSrOlLFABlA9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;295&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_z3E6GZdShyOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash as shown in the statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,133&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,332&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;


&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrnYI4RuKmW" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zBnqgHuuFLy8"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets
ranging from three &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zAImnZ9dZ4wk" style="display: none" title="property, plant and equipment, estimated useful lives"&gt;3&lt;/span&gt; to five &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKKN5BZgih38" style="display: none" title="property, plant and equipment, estimated useful lives"&gt;5&lt;/span&gt; years. Leasehold improvements are amortized over the shorter of the lease term or the estimated
useful life of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zv9A4l1Csre7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zL7NyY6UmKZ4"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department of Health and Human Services, or HHS, the Bill &amp;amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net Product Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Returns &#x2013; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rebates &#x2013; Our provision for rebates was estimated based on our customers&#x2019; contracted rebate programs and our historical experience of rebates paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discounts
&#x2013; The provision was estimated based upon invoice billings, utilizing historical customer payment experience.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Performance Obligations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transaction Price&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognize revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Allocation of Consideration&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Timing of Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract Assets and liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the activity related to our accounts receivable for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;&lt;span id="xdx_8B6_zlxRgL6XG39b" style="display: none"&gt;Schedule of activity related to our accounts receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;i&gt;(In thousands)&lt;/i&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Balance at January 1, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance"&gt;884&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions"&gt;1,526&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(2,298&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Balance at December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance"&gt;112&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions"&gt;557&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(633&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"&gt;Balance at December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;36&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zozZ1SMAQem5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvYi38FlWXy7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zupjTsqyUHTh"&gt;Research and Development Costs and Related Accrual&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (&#x201c;CRO&#x201d;) activities, sponsored research studies, product registration, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfDqOmscuOD4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zgESb6Qe4M6"&gt;Net Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic net loss per share excludes the effect of dilution and is computed by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method. Basic and diluted net loss per share was the same for each of the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of shares of common stock outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the&#160;years ended (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zSErRwgCzgI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B6_zjVqoyveczlk" style="display: none"&gt;Schedule of anti-dilutive effect&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from stock awards&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_zFPiHclvpiCc" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;964&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_z53MATNY3cG8" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;617&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Weighted-average anti-dilutive common shares resulting from warrants&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zIrI6wAmeRxi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;5,661&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zbWBbapW6Blb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,374&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdC0Xwmolla4" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,625&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zPx2K45tzhpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,991&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z1Yyx7WKv6C6" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zefpL2dPPYc9" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zkDFHNQZ39I1"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table presents the minimum lease payments of our operating lease as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zgROnTpnXa71" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8B6_zpn4eCwuDock" style="display: none"&gt;Schedule of minimum operating lease payments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20221231_zTvF1iEavTxd" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;2023&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;130&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Total minimum lease payments (base rent)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;196&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zfKHFgWnsUQ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;187&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zu2nSUyCQer5" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z4kb8wfQKuG4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zBFHIrbW1K9i"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have evaluated events that have occurred subsequent to December 31, 2022 and through the date that the financial statements are issued. See Note 12 Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbefMA3aXZTd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zWsUoEVgA2y2"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2013; quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#160;&#x2013; quoted prices for similar assets and liabilities in active markets or inputs that are observable;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#160;&#x2013; inputs that are unobservable (for example cash flow modelling inputs based on assumptions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. The approximately $&lt;span id="xdx_90B_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20221231_zZsgdzlXokR4" title="Money Market Funds, at Carrying Value"&gt;2.6&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20211231_zAZRblcItV26" title="Money Market Funds, at Carrying Value"&gt;5.7&lt;/span&gt; million fair values of money market funds as of December 31, 2022 and 2021, included in our cash and cash equivalents are classified as Level 1 and were derived from quoted market prices as active markets for these instruments exists. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zdP35IW7RjDd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zUz5PGUW6GWj"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In November 2021, the FASB issued FASB issued ASU 2021-10, &lt;i&gt;Disclosures by Business Entities about Government Assistance&lt;/i&gt;. The ASU codifies new requirements to disclose information about the nature of certain government assistance received, the accounting policy used to account for the transactions, the location in the financial statements where such transactions were recorded and significant terms and conditions associated with such transactions. The guidance is effective for annual periods beginning after December 15, 2021. The adoption of ASU No. 2021-10 did not have a material impact to our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounting Standards Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses&lt;/i&gt;, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January 1, 2023. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;i&gt;Reference Rate Reform&lt;/i&gt;, which provides companies with optional guidance, including expedients and exceptions for applying GAAP to contracts and other transactions affected by reference rate reform, such as the London Interbank Offered Rate, or LIBOR. This new standard was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are evaluating the effects that the adoption of this guidance will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the if converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective beginning after December 15, 2023 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. We are currently evaluating the impact this guidance will have on our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <ttnp:CompanyPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_ecustom--CompanyPolicyPolicyTextBlock_zA3vYvJ9BHpf" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zyV5j9abquta"&gt;The Company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura&lt;sup&gt;&#xae;&lt;/sup&gt;, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is designed to be administered subdermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician&#x2019;s assistants in a HCP&#x2019;s office or other clinical setting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our first product based on our ProNeura technology was Probuphine&lt;sup&gt;&#xae;&lt;/sup&gt; (buprenorphine implant), which is approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in Canada and in the EU (as Sixmo&#x2122;) by other companies that have either licensed or acquired the rights from Titan, we discontinued commercialization of the product in the U.S. during the fourth quarter of 2020. Discontinuation of our commercial operations has allowed us to focus our limited resources on important product development programs and transition back to a product development company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2021, we announced our intention to work with our financial
advisor to explore strategic alternatives to enhance stockholder value, potentially including an acquisition, merger, reverse merger,
other business combination, sales of assets, licensing or other transaction. In June 2022, we implemented a plan to reduce expenses and
conserve capital that included a company-wide reduction in salaries and a scale back of certain operating expenses to enable us to maintain
sufficient resources as we pursued potential strategic alternatives. In July 2022, David Lazar and Activist Investing LLC, or, collectively,
Activist acquired an approximately 25% ownership interest in Titan, filed a proxy statement and nominated six additional directors, each
of whom was elected to our board of directors or the Board, at a special meeting of stockholders held on August 15, 2022, or Special Meeting.
The exploration and evaluation of possible strategic alternatives by the Board has continued following the Special Meeting. Following
the election of the new directors at the Special Meeting, Dr. Marc Rubin was replaced as our Executive Chairman, and David Lazar assumed
the role of Chief Executive Officer. In connection with the termination of his employment as Executive Chairman, Dr. Rubin will receive
aggregate severance payments of approximately $&lt;span id="xdx_907_eus-gaap--SeveranceCosts1_pn3n3_dm_c20220101__20221231__srt--CounterpartyNameAxis__custom--RubinMember_zcMNACqel82a" title="Aggregate severance payments"&gt;0.4&lt;/span&gt; million, of which, approximately $165,000 had been paid to Dr. Rubin as of December
31, 2022. In December 2022, we implemented additional cost reduction measures including a reduction in our workforce. As a result of the
salary reductions, replacement of Dr. Rubin and the workforce reduction we have accrued approximately $&lt;span id="xdx_90E_ecustom--AccruedSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zouBYEU4EPN2" title="Accrued severance"&gt;0.3&lt;/span&gt; million and approximately $&lt;span id="xdx_90E_ecustom--DeferredCompensationAndEmployeeSeverance_iI_pn3n3_dm_c20221231__srt--CounterpartyNameAxis__custom--RubinMember_zPEcATZqIfL" title="Deferred compensation and employee severance"&gt;0.6&lt;/span&gt;
million related to deferred compensation and employee severance, respectively, as of December 31, 2022&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying financial statements have been prepared assuming we will continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At December 31, 2022, we had cash and cash equivalents of approximately $&lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231_zcp1qz4aXPTk" title="Cash and cash equivalents"&gt;2.9&lt;/span&gt; million, which we believe is sufficient to fund our planned operations into the second quarter of 2023. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful. There is substantial doubt about our ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ttnp:CompanyPolicyPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="From2022-01-012022-12-31_custom_RubinMember"
      decimals="-3"
      unitRef="USD">400000</us-gaap:SeveranceCosts1>
    <ttnp:AccruedSeverance
      contextRef="AsOf2022-12-31_custom_RubinMember"
      decimals="-3"
      unitRef="USD">300000</ttnp:AccruedSeverance>
    <ttnp:DeferredCompensationAndEmployeeSeverance
      contextRef="AsOf2022-12-31_custom_RubinMember"
      decimals="-3"
      unitRef="USD">600000</ttnp:DeferredCompensationAndEmployeeSeverance>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zZxEa46wNTd2" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zJy10FlShte5"&gt;Discontinued Operations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In October 2020, we announced our decision to discontinue selling Probuphine in the U.S. and wind down our commercialization activities, and to pursue a plan that will enable us to focus on our current, early-stage ProNeura-based product development programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to our U.S. commercialization activities as discontinued operations (see Note 10). The accompanying financial statements are generally presented in conformity with our historical format. We believe this format provides comparability with the previously filed financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zdh4gOojcxKa" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zTDBcthOPDrf"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





</us-gaap:UseOfEstimates>
    <ttnp:SubstantialDoubtAboutGoingConcernPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_ecustom--SubstantialDoubtAboutGoingConcernPolicyTextBlock_z11IfNBdjWuh" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zDAugIUAEpm9"&gt;Going concern assessment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We assess going concern uncertainty in our financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one&#160;year from the date the financial statements are issued or available to be issued, which is referred to as the &#x201c;look-forward period&#x201d; as defined by Accounting Standard Update ASU No.&#160;2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No.&#160;2014-15.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Annual Report on Form&#160;10-K for the&#160;year ended December 31, 2022, we did not have sufficient cash to fund our operations for the next 12&#160;months without additional funds and, therefore, there was substantial doubt about our ability to continue as a going concern within 12&#160;months after the date the financial statements were issued. Additionally, we have suffered recurring losses from operations and have an accumulated deficit that raises substantial doubt about our ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ttnp:SubstantialDoubtAboutGoingConcernPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zg4dbgUlF9C7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zXYtwxiugYXa"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories are recorded at the lower of cost or net realizable value. Cost is based on the first in, first out method. We regularly review inventory quantities on hand and write down to its net realizable value any inventory that we believe to be impaired. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. The components of inventories are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zFw8I2RCUKCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BD_zwQgDXxd7ph2" style="display: none"&gt;Schedule of components of inventories&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20221231_zopClSbFJpig" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20211231_zNRl7QSozVuk" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pn3n3_maINzzRz_zqTD0rCQOSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Raw materials and supplies&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;60&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;227&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINzzRz_zRvj2dGzynQ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;46&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzzRz_zisJ2WMp8qd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total inventories&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;106&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;293&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zf5WdfiqAL72" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The approximately $&lt;span id="xdx_903_eus-gaap--InventoryFinishedGoods_c20221231_pn3n3" title="Finished goods inventory"&gt;46,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_pn3n3_c20211231_zGijA3qiRnx9" title="Finished goods inventory"&gt;66,000&lt;/span&gt; of finished goods inventory at December 31, 2022 and 2021, respectively, included materials held for potential sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zFw8I2RCUKCb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BD_zwQgDXxd7ph2" style="display: none"&gt;Schedule of components of inventories&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20221231_zopClSbFJpig" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20211231_zNRl7QSozVuk" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pn3n3_maINzzRz_zqTD0rCQOSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Raw materials and supplies&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;60&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;227&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINzzRz_zRvj2dGzynQ" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;46&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzzRz_zisJ2WMp8qd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;Total inventories&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;106&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;293&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">60000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">227000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">46000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">66000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">106000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">293000</us-gaap:InventoryNet>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">46000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">66000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2Q40KMCUtfc" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zuJgaBuOSELi"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We recognize compensation expense using a fair-value based method, for all stock-based payments including stock options and restricted stock awards and stock issued under an employee stock purchase plan. These standards require companies to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. See Note&#160;8 &#x201c;Stock Plans,&#x201d; for a discussion of our stock-based compensation plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <ttnp:WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_ecustom--WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock_zA6tHAxrO7C7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zqvhPwBSTsbd"&gt;Warrants Issued in Connection with Equity Financing&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle the warrants in cash. For warrants issued with deemed possibility of cash settlement, we record the fair value of the issued warrants as a liability at each reporting period and record changes in the estimated fair value as a non-cash gain or loss in the Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





</ttnp:WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLPT0H3eQSmk" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zXe98InXtkq8"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our investment policy emphasizes liquidity and preservation of principal over other portfolio considerations. We select investments that maximize interest income to the extent possible given these two constraints. We satisfy liquidity requirements by investing excess cash in securities with different maturities to match projected cash needs and limit concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers and limit the amount of credit exposure to any one issuer. The estimated fair values have been determined using available market information. We do not use derivative financial instruments in our investment portfolio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All investments with original maturities of three&#160;months or less are considered to be cash equivalents. We had money market funds of approximately $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20221231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC6PDamtx5g7" title="Cash and cash equivalents"&gt;2.6&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_dm_c20211231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zB7daW2mtYrb" title="Cash and cash equivalents"&gt;5.7&lt;/span&gt; million as of December 31, 2022 and 2021, respectively, included in our cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We maintain significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20221231_zaI6b590ufC5" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on our financial condition, results of operations, and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">2600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      unitRef="USD">5700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">250000000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zGLIxeAchWRi" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zp5ppOHjV962"&gt;Restricted Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;In accordance with ASU 2016-18,
Statement of Cash Flows (Topic 230): Restricted Cash, we explain the change during the period in the total of cash, cash equivalents and
restricted cash, and include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period
total amounts shown on the statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The following table provides
a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet dates that comprise the total of the
same such amounts shown in the statements of cash flows for the years presented herein (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zQzdvtfknjY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule of restricted cash&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_z67EUQUyzh1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,037&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RestrictedCash_iI_zSrOlLFABlA9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;295&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_z3E6GZdShyOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash as shown in the statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,133&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,332&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;


&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrnYI4RuKmW" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zBnqgHuuFLy8"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets
ranging from three &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zAImnZ9dZ4wk" style="display: none" title="property, plant and equipment, estimated useful lives"&gt;3&lt;/span&gt; to five &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKKN5BZgih38" style="display: none" title="property, plant and equipment, estimated useful lives"&gt;5&lt;/span&gt; years. Leasehold improvements are amortized over the shorter of the lease term or the estimated
useful life of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zv9A4l1Csre7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zL7NyY6UmKZ4"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department of Health and Human Services, or HHS, the Bill &amp;amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net Product Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Returns &#x2013; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rebates &#x2013; Our provision for rebates was estimated based on our customers&#x2019; contracted rebate programs and our historical experience of rebates paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discounts
&#x2013; The provision was estimated based upon invoice billings, utilizing historical customer payment experience.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Performance Obligations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transaction Price&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognize revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Allocation of Consideration&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Timing of Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract Assets and liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the activity related to our accounts receivable for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;&lt;span id="xdx_8B6_zlxRgL6XG39b" style="display: none"&gt;Schedule of activity related to our accounts receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;i&gt;(In thousands)&lt;/i&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Balance at January 1, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance"&gt;884&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions"&gt;1,526&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(2,298&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Balance at December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance"&gt;112&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions"&gt;557&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(633&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"&gt;Balance at December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;36&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zozZ1SMAQem5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zQzdvtfknjY7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="display: none; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Schedule of restricted cash&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_z67EUQUyzh1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,037&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RestrictedCash_iI_zSrOlLFABlA9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;196&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;295&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_z3E6GZdShyOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash as shown in the statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,133&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,332&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;


</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrnYI4RuKmW" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zBnqgHuuFLy8"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets
ranging from three &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zAImnZ9dZ4wk" style="display: none" title="property, plant and equipment, estimated useful lives"&gt;3&lt;/span&gt; to five &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zKKN5BZgih38" style="display: none" title="property, plant and equipment, estimated useful lives"&gt;5&lt;/span&gt; years. Leasehold improvements are amortized over the shorter of the lease term or the estimated
useful life of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zv9A4l1Csre7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zL7NyY6UmKZ4"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We generate revenue principally from collaborative research and development arrangements, sales or licenses of technology, government grants, sales of Probuphine materials to Molteni and Knight, and prior to the discontinued operations, the sale of Probuphine in the U.S. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have contracts with National Institute on Drug Abuse or NIDA, within the U.S. Department of Health and Human Services, or HHS, the Bill &amp;amp; Melinda Gates Foundation, and other government-sponsored organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net Product Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior to the discontinuation of our commercialization activities relating to Probuphine in the U.S., we recognized revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue was subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration was estimated using the most-likely amount method, which is the single most-likely outcome under a contract and was typically at stated contractual rates. The actual outcome of this variable consideration could materially differ from our estimates. From time to time, we would adjust our estimates of this variable consideration when trends or significant events indicated that a change in estimate is appropriate to reflect the actual experience. Additionally, we continued to assess the estimates of our variable consideration as we continued to accumulate additional historical data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Returns &#x2013; Consistent with the provisions of ASC 606, we estimated returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which could impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rebates &#x2013; Our provision for rebates was estimated based on our customers&#x2019; contracted rebate programs and our historical experience of rebates paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discounts
&#x2013; The provision was estimated based upon invoice billings, utilizing historical customer payment experience.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Performance Obligations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transaction Price&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognize revenue at the later of (a)&#160;when the related sales occur, or (b)&#160;when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Allocation of Consideration&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Timing of Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Contract Assets and liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the activity related to our accounts receivable for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;&lt;span id="xdx_8B6_zlxRgL6XG39b" style="display: none"&gt;Schedule of activity related to our accounts receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;i&gt;(In thousands)&lt;/i&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Balance at January 1, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance"&gt;884&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions"&gt;1,526&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(2,298&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Balance at December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance"&gt;112&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions"&gt;557&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(633&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"&gt;Balance at December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;36&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_pn3n3_zZVn5HeU3dE7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;&lt;span id="xdx_8B6_zlxRgL6XG39b" style="display: none"&gt;Schedule of activity related to our accounts receivable&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;i&gt;(In thousands)&lt;/i&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"&gt;Balance at January 1, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20210101__20211231_zr6HWpxdYU64" style="width: 9%; text-align: right" title="Beginning Balance"&gt;884&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ContractWithCustomerAssetAdditions_pn3n3_c20210101__20211231_z5KC3Vk5wzKa" style="text-align: right" title="Additions"&gt;1,526&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ContractWithCustomerAssetDeductions_pn3n3_c20210101__20211231_z1jx31QY0mO5" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(2,298&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"&gt;Balance at December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractWithCustomerAssetGross_iS_pn3n3_c20220101__20221231_zOXNv9iGELd8" style="text-align: right" title="Beginning Balance"&gt;112&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"&gt;Additions&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ContractWithCustomerAssetAdditions_c20220101__20221231_pn3n3" style="text-align: right" title="Additions"&gt;557&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; vertical-align: top"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ContractWithCustomerAssetDeductions_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Deductions"&gt;(633&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"&gt;Balance at December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractWithCustomerAssetGross_iE_pn3n3_c20220101__20221231_zJoOr3rUx8w9" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;36&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">884000</us-gaap:ContractWithCustomerAssetGross>
    <ttnp:ContractWithCustomerAssetAdditions
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1526000</ttnp:ContractWithCustomerAssetAdditions>
    <ttnp:ContractWithCustomerAssetDeductions
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-2298000</ttnp:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">112000</us-gaap:ContractWithCustomerAssetGross>
    <ttnp:ContractWithCustomerAssetAdditions
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">557000</ttnp:ContractWithCustomerAssetAdditions>
    <ttnp:ContractWithCustomerAssetDeductions
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-633000</ttnp:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">36000</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvYi38FlWXy7" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zupjTsqyUHTh"&gt;Research and Development Costs and Related Accrual&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (&#x201c;CRO&#x201d;) activities, sponsored research studies, product registration, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research&#160;and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfDqOmscuOD4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zgESb6Qe4M6"&gt;Net Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic net loss per share excludes the effect of dilution and is computed by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method. Basic and diluted net loss per share was the same for each of the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of shares of common stock outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the&#160;years ended (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zSErRwgCzgI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B6_zjVqoyveczlk" style="display: none"&gt;Schedule of anti-dilutive effect&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from stock awards&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_zFPiHclvpiCc" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;964&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_z53MATNY3cG8" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;617&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Weighted-average anti-dilutive common shares resulting from warrants&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zIrI6wAmeRxi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;5,661&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zbWBbapW6Blb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,374&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdC0Xwmolla4" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,625&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zPx2K45tzhpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,991&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z1Yyx7WKv6C6" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zSErRwgCzgI" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B6_zjVqoyveczlk" style="display: none"&gt;Schedule of anti-dilutive effect&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Weighted-average anti-dilutive common shares resulting from stock awards&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_zFPiHclvpiCc" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;964&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockAwardsMember_z53MATNY3cG8" style="width: 9%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;617&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Weighted-average anti-dilutive common shares resulting from warrants&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zIrI6wAmeRxi" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;5,661&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--WarrantMember_zbWBbapW6Blb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,374&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdC0Xwmolla4" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,625&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zPx2K45tzhpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,991&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_EmployeeStockAwardsMember"
      decimals="INF"
      unitRef="Shares">964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_custom_EmployeeStockAwardsMember"
      decimals="INF"
      unitRef="Shares">617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">5661</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2374</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">6625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">2991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zefpL2dPPYc9" style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zkDFHNQZ39I1"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table presents the minimum lease payments of our operating lease as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zgROnTpnXa71" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8B6_zpn4eCwuDock" style="display: none"&gt;Schedule of minimum operating lease payments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20221231_zTvF1iEavTxd" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;2023&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;130&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Total minimum lease payments (base rent)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;196&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zfKHFgWnsUQ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;187&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zu2nSUyCQer5" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zgROnTpnXa71" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8B6_zpn4eCwuDock" style="display: none"&gt;Schedule of minimum operating lease payments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20221231_zTvF1iEavTxd" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;2023&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;130&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Total minimum lease payments (base rent)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;196&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zfKHFgWnsUQ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;187&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">130000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">66000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">196000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">9000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">187000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z4kb8wfQKuG4" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zBFHIrbW1K9i"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have evaluated events that have occurred subsequent to December 31, 2022 and through the date that the financial statements are issued. See Note 12 Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zbefMA3aXZTd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zWsUoEVgA2y2"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We measure the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three levels for measuring fair value, and requires disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#160;&#x2013; quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#160;&#x2013; quoted prices for similar assets and liabilities in active markets or inputs that are observable;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#160;&#x2013; inputs that are unobservable (for example cash flow modelling inputs based on assumptions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, which we believe approximates fair value due to the short-term nature of these instruments. The approximately $&lt;span id="xdx_90B_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20221231_zZsgdzlXokR4" title="Money Market Funds, at Carrying Value"&gt;2.6&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_pn3n3_dm_c20211231_zAZRblcItV26" title="Money Market Funds, at Carrying Value"&gt;5.7&lt;/span&gt; million fair values of money market funds as of December 31, 2022 and 2021, included in our cash and cash equivalents are classified as Level 1 and were derived from quoted market prices as active markets for these instruments exists. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2600000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">5700000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zdP35IW7RjDd" style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zUz5PGUW6GWj"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In November 2021, the FASB issued FASB issued ASU 2021-10, &lt;i&gt;Disclosures by Business Entities about Government Assistance&lt;/i&gt;. The ASU codifies new requirements to disclose information about the nature of certain government assistance received, the accounting policy used to account for the transactions, the location in the financial statements where such transactions were recorded and significant terms and conditions associated with such transactions. The guidance is effective for annual periods beginning after December 15, 2021. The adoption of ASU No. 2021-10 did not have a material impact to our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accounting Standards Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses&lt;/i&gt;, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective beginning on January 1, 2023. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;i&gt;Reference Rate Reform&lt;/i&gt;, which provides companies with optional guidance, including expedients and exceptions for applying GAAP to contracts and other transactions affected by reference rate reform, such as the London Interbank Offered Rate, or LIBOR. This new standard was effective upon issuance and generally can be applied to applicable contract modifications through December 31, 2022. We are evaluating the effects that the adoption of this guidance will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the if converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective beginning after December 15, 2023 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. We are currently evaluating the impact this guidance will have on our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zuEQIH6vXgJk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_822_z48fzNOdWvU1"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_ztT9QvDQYfej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BA_z2LPCDycrEk6" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross"&gt;132&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross"&gt;132&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Laboratory equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,108&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,108&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Computer equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross"&gt;577&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross"&gt;577&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,817&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,817&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Less accumulated depreciation and amortization&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zJPDPRrj4IVd" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization"&gt;(1,593&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zqykeNhDEr91" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization"&gt;(1,397&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20221231_znkThjA8sIt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;224&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zmJ1vNClmGbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;420&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_ztT9QvDQYfej" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BA_z2LPCDycrEk6" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross"&gt;132&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pn3n3" style="width: 9%; text-align: right" title="Property, Plant and Equipment, Gross"&gt;132&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Laboratory equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,108&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,108&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Computer equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross"&gt;577&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Property, Plant and Equipment, Gross"&gt;577&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,817&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pn3n3" style="text-align: right" title="Property, Plant and Equipment, Gross"&gt;1,817&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Less accumulated depreciation and amortization&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20211231_zJPDPRrj4IVd" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization"&gt;(1,593&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_zqykeNhDEr91" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation and amortization"&gt;(1,397&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20221231_znkThjA8sIt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;224&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20211231_zmJ1vNClmGbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net"&gt;420&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      unitRef="USD">132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      unitRef="USD">132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_PropertyPlantAndEquipmentMember"
      decimals="-3"
      unitRef="USD">1108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_PropertyPlantAndEquipmentMember"
      decimals="-3"
      unitRef="USD">1108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      unitRef="USD">577000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      unitRef="USD">577000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1593000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1397000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">420000</us-gaap:PropertyPlantAndEquipmentNet>
    <ttnp:JTPharmaceuticalsAssetPurchaseAgreementTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_ecustom--JTPharmaceuticalsAssetPurchaseAgreementTextBlock_zDPARa0EmA2k" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_825_zlDHRtmIFfHj"&gt;JT Pharmaceuticals Asset Purchase Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In October 2020, we entered into an Asset Purchase Agreement, or JT Agreement, with JT Pharmaceuticals, Inc., or JT Pharma, to acquire JT Pharma&#x2019;s kappa opioid agonist peptide, TP-2021 (formerly JT-09) for use in combination with our ProNeura long-term, continuous drug delivery technology, for the treatment of chronic pruritus and other medical conditions. Under the terms of the JT Agreement, JT Pharma received a $&lt;span id="xdx_90C_ecustom--FutureMilestonePayments_c20201001__20201031__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pn3n3" title="Closing payment"&gt;15,000&lt;/span&gt; closing payment and is entitled to receive future milestone payments, payable in cash or in stock, based on the achievement of certain developmental and regulatory milestones, and single-digit percentage earn-out payments on net sales of the product if successfully developed and approved for commercialization. In January 2022, we entered into an agreement with JT Pharma to clarify certain provisions of the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved and made a payment of $&lt;span id="xdx_905_ecustom--MilestonePayments_pn3n3_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zDja14sdsAfh" title="Milestone Payments"&gt;100,000&lt;/span&gt; and issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_zW2vbvcwMIT8" title="Issuance of common stock, net (in shares)"&gt;51,021&lt;/span&gt; shares of our common stock to JT Pharma. The related expense was included in research and development expenses in our statements of operations.&lt;/span&gt;&lt;/p&gt;

</ttnp:JTPharmaceuticalsAssetPurchaseAgreementTextBlock>
    <ttnp:FutureMilestonePayments
      contextRef="From2020-10-012020-10-31_custom_JtPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">15000000</ttnp:FutureMilestonePayments>
    <ttnp:MilestonePayments
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">100000000</ttnp:MilestonePayments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="INF"
      unitRef="Shares">51021</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ttnp:AssetPurchaseAgreementTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_ecustom--AssetPurchaseAgreementTextBlock_zXrYPCrHjQFh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_825_zu0Ogfm3Fsnh"&gt;Ocular Therapeutix License Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2022, we entered into a license agreement, or Ocular Agreement, with Ocular Therapeutix, Inc., or Ocular to license the exclusive rights to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the United States, or Licensed Patents. The grant of the Ocular license by us to Ocular is for an exclusive (even as to us), perpetual, fully paid-up license to use the Licensed Patents. The license comes with the right to sublicense. The Ocular paid a one-time fee of $&lt;span id="xdx_90E_ecustom--ReimbursementFees_pn3n3_c20220101__20221231_zi536lXPCWc8" title="Reimbursement fees"&gt;50,000&lt;/span&gt; and will reimburse our attorneys&#x2019; fees incurred by it in connection with the preparation and negotiation of the Ocular Agreement. Ocular shall make additional payments upon the achievement of certain milestone events as set forth in the License Agreement.&lt;/span&gt;&lt;/p&gt;

</ttnp:AssetPurchaseAgreementTextBlock>
    <ttnp:ReimbursementFees
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">50000000</ttnp:ReimbursementFees>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zNDhKU9LeMV1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_z5gjm9uNSEN7"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Lease Commitments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We lease our office facility under operating lease that expires in June&#160;2024. Rent expense associated with this lease was approximately $&lt;span id="xdx_90A_ecustom--OperatingLeasesRentExpenses_pn3n3_dm_c20221001__20221231_zOOLAqWsA099" title="Rent expense"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_907_ecustom--OperatingLeasesRentExpenses_pn3n3_dm_c20220101__20221231_zRSgsurwZ8Rl" title="Rent expense"&gt;0.2&lt;/span&gt; million for&#160;years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Guarantees and Indemnifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As permitted under Delaware law and in accordance with our Bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving at our request in such capacity. The term of the indemnification period is for the officer&#x2019;s or director&#x2019;s lifetime. The maximum amount of potential future indemnification is unlimited; however, we have a director and officer insurance policy that limits our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements is minimal. Accordingly, we have not recorded any liabilities for these agreements as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In the normal course of business, we have commitments to make certain milestone payments to various clinical research organizations in connection with our clinical trial activities. Payments are contingent upon the achievement of specific milestones or events as defined in the agreements, and we have made appropriate accruals in our financial statements for those milestones that were achieved as of December 31, 2022. We also provide indemnifications of varying scope to our CROs and investigators against claims made by third parties arising from the use of our products and processes in clinical trials. Historically, costs related to these indemnification provisions were immaterial. We also maintain various liability insurance policies that limit our exposure. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A legal proceeding has been initiated by a former employee alleging wrongful termination, retaliation, infliction of emotional distress, negligent supervision, hiring and retention and slander. An independent investigation into this individual&#x2019;s allegations of whistleblower retaliation, while still an employee, was conducted utilizing an outside investigator and concluded that such allegations were not substantiated. We intend to vigorously defend the lawsuit (which we have compelled into arbitration); however, in light of our cash position, there can be no assurance that the defense and/or settlement of this matter will not have a material adverse impact on our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ttnp:OperatingLeasesRentExpenses
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">100000</ttnp:OperatingLeasesRentExpenses>
    <ttnp:OperatingLeasesRentExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">200000</ttnp:OperatingLeasesRentExpenses>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zcmt9geVxk8b" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82E_zocpVBJgfIpc"&gt;Debt Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Paycheck Protection Program Loan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 20, 2020, we received an approximately $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_pn3n3_c20200401__20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zIAv1QhZHGh2" title="Loan proceeds"&gt;654,000&lt;/span&gt; loan, or PPP Loan, pursuant to the Paycheck Protection Program of the CARES Act that bore interest at the annual rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20200401__20200420__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_z3RxkSHNxWp4" title="Loan annual interest rate"&gt;1.0&lt;/span&gt;% and matured in April 2022. The proceeds of the PPP Loan were to be used to retain workers and maintain payroll and make mortgage interest, lease and utility payments and were subject to forgiveness in accordance with requirements of the Small Business Administration. The PPP Loan originally had a six-month deferral of payments period which was extended to sixteen months during the third quarter of 2020. In May 2021, the entire balance of the PPP loan along with accrued interest was forgiven and the approximately $&lt;span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_dm_c20210501__20210531__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zolHoTTrAaDd" title="Non-cash gain (loss) on debt extinguishment"&gt;0.7&lt;/span&gt; million gain on extinguishment of the debt was included in other income (expense) in our statements of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2020-04-012020-04-20_custom_PaycheckProtectionProgramLoanMember"
      decimals="-3"
      unitRef="USD">654000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-04-012020-04-20_custom_PaycheckProtectionProgramLoanMember"
      decimals="INF"
      unitRef="Pure">0.010</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-05-012021-05-31_custom_PaycheckProtectionProgramLoanMember"
      decimals="-3"
      unitRef="USD">700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrvV2W0rGyjk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82C_zNlcEU1qPsc6"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our common stock outstanding as of December 31, 2022 and December 31, 2021 was &lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_z5wD4L0KYZyc" title="Common stock shares, outstanding"&gt;15,016,295&lt;/span&gt; shares and &lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zJhoBYyybtm1" title="Common stock shares, outstanding"&gt;9,914,158&lt;/span&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amendment to Bylaws&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In July 2022, the Board amended our Bylaws to effect certain enhancements to the ability of stockholders to call for a special meeting of stockholders and make changes to the composition of the Board. This included (i) reducing the holdings required for stockholders to call a special meeting of stockholders from a majority to twenty-five percent (25%); (ii) enabling increases in the size of the Board to be effectuated by stockholders or directors at any annual or special meeting or by stockholder action by written consent in lieu of a meeting; (iii) provide that Board vacancies and newly created directorships resulting from action taken by the stockholders at a meeting or by written consent in lieu thereof shall be filled initially by the stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Activist Investing, LLC&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In July 2022, we received a letter from Activist requesting that our Board call the Special Meeting in accordance with Article II, Section 5 of our Bylaws, as amended.in order for stockholders to consider and vote upon the following two proposals:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An increase in the size of the Board by six (6) members from five (5) members to eleven (11) members in total; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The election of Activist&#x2019;s six nominees to serve as directors to fill the vacancies left by the foregoing increase.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In accordance with Activist&#x2019;s request, the Board set the record date for the Special Meeting as July 22, 2022, and the Special Meeting was held on August 15, 2022, resulting in the approval of the increase in the size of the Board and the election of the six nominees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;February 2022 Offerings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In February 2022, we completed a registered direct offering with an accredited investor pursuant to which we issued an aggregate of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zmpiwYWf79N" title="Issuance of common stock, net, shares"&gt;1,100,000&lt;/span&gt; shares of our common stock and &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zYqZSqlEJHb" title="Number of warrants issued"&gt;2,274,242&lt;/span&gt; pre-funded warrants to purchase shares of our common stock, with an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z5Qcc39g51ak" title="Exercise price of warrants (in dollars per share)"&gt;0.001&lt;/span&gt; per share. In a concurrent private placement, we sold unregistered pre-funded warrants to purchase an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z5qx8xJaXZ6e" title="Number of warrants issued"&gt;1,289,796&lt;/span&gt; shares of common stock with an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredPrefundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zzrYpPfpoZNh" title="Exercise price of warrants (in dollars per share)"&gt;0.001&lt;/span&gt; per share and issued unregistered five year and six month warrants to purchase an aggregate of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_z7UqE9qDdLI5" title="Number of warrants issued"&gt;4,664,038&lt;/span&gt; shares of common stock with an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220228__us-gaap--ClassOfWarrantOrRightAxis__custom--UnregisteredFiveYearAndSixMonthWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zwQrpnmMpqH8" title="Exercise price of warrants (in dollars per share)"&gt;1.14&lt;/span&gt;. The unregistered warrants were registered in April 2022. The warrants were classified as equity.  The net cash proceeds from these offerings were approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_dm_c20220201__20220228__us-gaap--SubsidiarySaleOfStockAxis__custom--February2022OfferingsMember_zmolLXFHG3e" title="Proceeds from sale of common stock"&gt;5.0&lt;/span&gt; million after deduction of underwriting fees and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant Exercises&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2022, we received approximately $&lt;span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20220301__20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises"&gt;1,000&lt;/span&gt; from the exercise of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zvAy6XpwVD49" title="Number of warrants issued"&gt;974,242&lt;/span&gt; pre-funded warrants issued in the February 2022 registered direct offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In April 2022, we received approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20220401__20220430__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises"&gt;1,300&lt;/span&gt; from the exercise of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220430__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zzQow3noLc94" title="Number of warrants issued"&gt;1,300,000&lt;/span&gt; pre-funded warrants issued in the February 2022 registered direct offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In May 2022, we received approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_c20220501__20220531__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_pn3n3" title="Proceeds from Warrant Exercises"&gt;1,290&lt;/span&gt; from the exercise of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zhb1LkiMrlEc" title="Number of warrants issued"&gt;1,289,796&lt;/span&gt; pre-funded warrants issued in the February 2022 private placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;JT Pharma Milestone&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2022, we entered into an agreement with JT Pharma to clarify certain provisions of the JT Agreement pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved and made a payment of $&lt;span id="xdx_902_ecustom--MilestonePayment_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pn3n3" title="Milestone payment"&gt;100,000&lt;/span&gt; and issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220131__us-gaap--AssetAcquisitionAxis__custom--JtPharmaceuticalsMember_pdd" title="Issuance of common stock, net, shares"&gt;51,021&lt;/span&gt; shares of our common stock to JT Pharma.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;Restricted Shares&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In November 2022, we agreed to issue &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockToMaximGroupLlcMember_zpY5xeZY4yrd" title="Number of shares agreed to issue"&gt;337,078&lt;/span&gt; shares of our common stock to Maxim Group, LLC in connection with the entry into an amendment to our existing advisory agreement. The shares vested immediately. We recorded approximately $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockToMaximGroupLlcMember_zJSI2mmuoiK3" title="Stock-based compensation"&gt;0.3&lt;/span&gt; million of stock-based compensation expense during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August 2022, we agreed to issue &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementWithMaximMdmWorldwideSolutionsMember_znnJP41tTw2d" title="Number of shares agreed to issue"&gt;50,000&lt;/span&gt; shares of our common stock pursuant to an advisory services agreement with Maxim MDM Worldwide Solutions, Inc. The shares vested immediately. We recorded approximately $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementWithMaximMdmWorldwideSolutionsMember_pn3n3" title="Stock-based compensation"&gt;79,000&lt;/span&gt; of stock-based compensation expense during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August 2021, we agreed to issue &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_zZqqZkC0NlBa" title="Number of shares agreed to issue"&gt;50,000&lt;/span&gt; shares of our common stock pursuant to a restricted stock agreement with Maxim Partners, LLC in connection with the entry into an amendment to our existing advisory agreement. The shares vested monthly over &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_z7xWei8ts4Ah" title="Vesting period"&gt;12&lt;/span&gt; months. We recorded approximately $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RestrictedStockAgreementWithMaximGroupLlcMember_pn3n3" title="Stock-based compensation"&gt;71,000&lt;/span&gt; of stock-based compensation expense during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table summarizes restricted stock activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_pn3n3_z9moU5jNuzZf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B4_zjh42pIkomY2" style="display: none"&gt;Summary of restricted stock activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"/&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"/&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; vertical-align: top"&gt;Outstanding at December 31, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231_zFW1l7qB0tPk" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;50,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Issued&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231_zuZnIkngtQaf" style="text-align: right" title="Issued"&gt;387,078&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Forfeited or expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220101__20221231_z9KSdmYjmAh3" style="text-align: right" title="Forfeited or expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"&gt;Released&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_pid_c20220101__20221231_z4QGZMT50lpg" style="border-bottom: Black 1pt solid; text-align: right" title="Released"&gt;(437,078&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Outstanding at December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220101__20221231_zinqwJKWrsD" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zBnBm0qYfqk9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Annual Meeting of Stockholders&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2021, our stockholders approved an amendment to the 2015 Omnibus Equity Incentive plan to increase the number of authorized shares to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwoThousandFifteenPlanMember_zoMDksnCUs9h" title="Number of additional shares authorized"&gt;1,000,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;January 2021 Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2021, we completed an offering with several accredited institutional investors pursuant to which we issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zy3bQkVjas3k" title="Issuance of common stock, net, shares"&gt;2,725,000&lt;/span&gt; shares of our common stock in a registered direct offering and warrants to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z1dMW6oDY7ed" title="Number of warrants issued"&gt;2,725,000&lt;/span&gt; shares of our common stock with an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210131__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_ziUjcjmse6s6" title="Exercise price of warrants, shares"&gt;3.55&lt;/span&gt; per share in a concurrent private placement. The warrants were classified as equity, were exercisable immediately and will expire in July 2026. The net cash proceeds from this offering were approximately $8.8 million after deduction of underwriting fees and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2022, the following warrants to purchase shares of our common stock were outstanding (in thousands, except per share price):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_pn3n3_zVVf7z7xIT6i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_8BA_zbRxWQFJpH85" style="display: none"&gt;Schedule of warrants to purchase&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Date Issued&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Expiration&#160;Date&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise&#160;Price&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Date Issued"&gt;07/27/2017&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Expiration Date"&gt;07/27/2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_z6sUk06JPpOf" title="Exercise Price (in dollars per share)"&gt;45.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_zF2WqR6vmWZf" title="Outstanding"&gt;12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Date Issued"&gt;03/21/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Expiration Date"&gt;03/21/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zMx4xgeR7sIa" title="Exercise Price (in dollars per share)"&gt;216.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zphKQvGQXgye" title="Outstanding"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Date Issued"&gt;03/21/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Expiration Date"&gt;03/21/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zojOlollJpSl" title="Exercise Price (in dollars per share)"&gt;216.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zjEhHIdgPgn7" title="Outstanding"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Date Issued"&gt;09/25/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Expiration Date"&gt;09/25/2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zGW8AgAcCbW4" title="Exercise Price (in dollars per share)"&gt;18.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zy7G5aAqAGKa" title="Outstanding"&gt;154&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Date Issued"&gt;09/25/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Expiration Date"&gt;09/25/2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_z4lGSm1yvi9k" title="Exercise Price (in dollars per share)"&gt;50.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_zxutXXMAyUy3" title="Outstanding"&gt;8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Date Issued"&gt;08/09/2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Expiration Date"&gt;02/09/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_zuxtVyhmz747" title="Exercise Price (in dollars per share)"&gt;32.10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_ztdRyIub9sXj" title="Outstanding"&gt;95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Date Issued"&gt;10/18/2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Expiration Date"&gt;10/18/2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_z2J8SrtCHIUl" title="Exercise Price (in dollars per share)"&gt;1.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_zmfl9eJ2sL27" title="Outstanding"&gt;230&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Date Issued"&gt;01/09/2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Expiration Date"&gt;07/09/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_z20QogSQuYji" title="Exercise Price (in dollars per share)"&gt;7.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_zWfaS2xKM2P7" title="Outstanding"&gt;290&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Date Issued"&gt;10/30/2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Expiration Date"&gt;12/01/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zo2cTgTkbN7l" title="Exercise Price (in dollars per share)"&gt;3.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zwSWDbIeN906" title="Outstanding"&gt;1,644&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Date Issued"&gt;01/20/2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Expiration Date"&gt;07/26/2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zngUN6Ov2Emb" title="Exercise Price (in dollars per share)"&gt;3.55&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zphRdumVeLqg" title="Outstanding"&gt;2,725&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_z3J7cL5Aswqd" title="Date Issued"&gt;02/04/2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zeCb7jssfk4i" title="Expiration Date"&gt;08/04/2027&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zbVprxbLBT6k" title="Exercise Price (in dollars per share)"&gt;1.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zrriKhX0HiUi" title="Outstanding"&gt;4,664&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zWyiDrxSuvj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding"&gt;9,826&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z97tWCJR8f2d" style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Shares Reserved for Future Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2022, shares of common stock reserved by us for future issuance consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_zPsdhuFo4Fz" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8B5_zxwXu46gpOdg" style="display: none"&gt;Schedule of shares of common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Stock options outstanding&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSnOPPSWHEcg" style="width: 9%; text-align: right" title="Common stock, capital shares reserved for future issuance"&gt;927&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Shares issuable upon the exercise of warrants&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zxipqE8V8488" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock, capital shares reserved for future issuance"&gt;9,826&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220930_zy3yxUBNEiVg" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock, capital shares reserved for future issuance"&gt;10,753&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">15016295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9914158</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">2274242</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-28_custom_PreFundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">1289796</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-28_custom_UnregisteredPrefundedWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="Shares">4664038</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-28_custom_UnregisteredFiveYearAndSixMonthWarrantsMember_custom_February2022OfferingsMember"
      decimals="INF"
      unitRef="USDPShares">1.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-02-012022-02-28_custom_February2022OfferingsMember"
      decimals="-3"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-03-012022-03-31_custom_PreFundedWarrantsMember"
      decimals="-3"
      unitRef="USD">1000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-03-31_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">974242</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-04-012022-04-30_custom_PreFundedWarrantsMember"
      decimals="-3"
      unitRef="USD">1300000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-30_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-05-012022-05-31_custom_PreFundedWarrantsMember"
      decimals="-3"
      unitRef="USD">1290000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-05-31_custom_PreFundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">1289796</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ttnp:MilestonePayment
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">100000000</ttnp:MilestonePayment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-01-31_custom_JtPharmaceuticalsMember"
      decimals="INF"
      unitRef="Shares">51021</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-11-30_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember"
      decimals="INF"
      unitRef="Shares">337078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_CommonStockToMaximGroupLlcMember"
      decimals="-3"
      unitRef="USD">300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-08-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ServicesAgreementWithMaximMdmWorldwideSolutionsMember"
      decimals="-3"
      unitRef="USD">79000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2021-08-012021-08-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_RestrictedStockAgreementWithMaximGroupLlcMember"
      decimals="-3"
      unitRef="USD">71000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_pn3n3_z9moU5jNuzZf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B4_zjh42pIkomY2" style="display: none"&gt;Summary of restricted stock activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"/&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"/&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left; vertical-align: top"&gt;Outstanding at December 31, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231_zFW1l7qB0tPk" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;50,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Issued&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231_zuZnIkngtQaf" style="text-align: right" title="Issued"&gt;387,078&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Forfeited or expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220101__20221231_z9KSdmYjmAh3" style="text-align: right" title="Forfeited or expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"&gt;Released&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_pid_c20220101__20221231_z4QGZMT50lpg" style="border-bottom: Black 1pt solid; text-align: right" title="Released"&gt;(437,078&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Outstanding at December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220101__20221231_zinqwJKWrsD" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">387078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ttnp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">-437078</ttnp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-01-012021-01-31_custom_TwoThousandFifteenPlanMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-01-31_custom_January2021OfferingMember"
      decimals="INF"
      unitRef="Shares">2725000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-01-31_custom_January2021OfferingMember"
      decimals="INF"
      unitRef="Shares">2725000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-01-31_custom_January2021OfferingMember"
      decimals="INF"
      unitRef="USDPShares">3.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_pn3n3_zVVf7z7xIT6i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_8BA_zbRxWQFJpH85" style="display: none"&gt;Schedule of warrants to purchase&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Date Issued&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Expiration&#160;Date&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise&#160;Price&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Date Issued"&gt;07/27/2017&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember" title="Expiration Date"&gt;07/27/2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_z6sUk06JPpOf" title="Exercise Price (in dollars per share)"&gt;45.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateOneMember_zF2WqR6vmWZf" title="Outstanding"&gt;12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Date Issued"&gt;03/21/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember" title="Expiration Date"&gt;03/21/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zMx4xgeR7sIa" title="Exercise Price (in dollars per share)"&gt;216.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTwoMember_zphKQvGQXgye" title="Outstanding"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Date Issued"&gt;03/21/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember" title="Expiration Date"&gt;03/21/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zojOlollJpSl" title="Exercise Price (in dollars per share)"&gt;216.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateThreeMember_zjEhHIdgPgn7" title="Outstanding"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Date Issued"&gt;09/25/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember" title="Expiration Date"&gt;09/25/2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zGW8AgAcCbW4" title="Exercise Price (in dollars per share)"&gt;18.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFourMember_zy7G5aAqAGKa" title="Outstanding"&gt;154&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Date Issued"&gt;09/25/2018&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember" title="Expiration Date"&gt;09/25/2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_z4lGSm1yvi9k" title="Exercise Price (in dollars per share)"&gt;50.40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateFiveMember_zxutXXMAyUy3" title="Outstanding"&gt;8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Date Issued"&gt;08/09/2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember" title="Expiration Date"&gt;02/09/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_zuxtVyhmz747" title="Exercise Price (in dollars per share)"&gt;32.10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSixMember_ztdRyIub9sXj" title="Outstanding"&gt;95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Date Issued"&gt;10/18/2019&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember" title="Expiration Date"&gt;10/18/2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_z2J8SrtCHIUl" title="Exercise Price (in dollars per share)"&gt;1.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateSevenMember_zmfl9eJ2sL27" title="Outstanding"&gt;230&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Date Issued"&gt;01/09/2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember" title="Expiration Date"&gt;07/09/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_z20QogSQuYji" title="Exercise Price (in dollars per share)"&gt;7.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateEightMember_zWfaS2xKM2P7" title="Outstanding"&gt;290&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Date Issued"&gt;10/30/2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember" title="Expiration Date"&gt;12/01/2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zo2cTgTkbN7l" title="Exercise Price (in dollars per share)"&gt;3.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateNineMember_zwSWDbIeN906" title="Outstanding"&gt;1,644&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Date Issued"&gt;01/20/2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember" title="Expiration Date"&gt;07/26/2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zngUN6Ov2Emb" title="Exercise Price (in dollars per share)"&gt;3.55&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateTenMember_zphRdumVeLqg" title="Outstanding"&gt;2,725&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantsOrRightsIssueDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_z3J7cL5Aswqd" title="Date Issued"&gt;02/04/2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantsOrRightsExpirationDate_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zeCb7jssfk4i" title="Expiration Date"&gt;08/04/2027&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zbVprxbLBT6k" title="Exercise Price (in dollars per share)"&gt;1.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ClassOfWarrantOrRightIssuedDateElevenMember_zrriKhX0HiUi" title="Outstanding"&gt;4,664&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zWyiDrxSuvj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding"&gt;9,826&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember">2017-07-27</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember">2024-07-27</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember"
      decimals="INF"
      unitRef="USDPShares">45.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateOneMember"
      decimals="INF"
      unitRef="Shares">12</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember">2018-03-21</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember">2025-03-21</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember"
      decimals="INF"
      unitRef="USDPShares">216.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTwoMember"
      decimals="INF"
      unitRef="Shares">1</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember">2018-03-21</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember">2025-03-21</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember"
      decimals="INF"
      unitRef="USDPShares">216.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateThreeMember"
      decimals="INF"
      unitRef="Shares">3</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember">2018-09-25</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember">2023-09-25</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember"
      decimals="INF"
      unitRef="USDPShares">18.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFourMember"
      decimals="INF"
      unitRef="Shares">154</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember">2018-09-25</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember">2023-09-25</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember"
      decimals="INF"
      unitRef="USDPShares">50.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateFiveMember"
      decimals="INF"
      unitRef="Shares">8</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember">2019-08-09</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember">2025-02-09</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember"
      decimals="INF"
      unitRef="USDPShares">32.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSixMember"
      decimals="INF"
      unitRef="Shares">95</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember">2019-10-18</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember">2024-10-18</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember"
      decimals="INF"
      unitRef="USDPShares">1.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateSevenMember"
      decimals="INF"
      unitRef="Shares">230</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember">2020-01-09</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember">2025-07-09</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember"
      decimals="INF"
      unitRef="USDPShares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateEightMember"
      decimals="INF"
      unitRef="Shares">290</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember">2020-10-30</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember">2025-12-01</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateNineMember"
      decimals="INF"
      unitRef="Shares">1644</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember">2021-01-20</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember">2026-07-26</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember"
      decimals="INF"
      unitRef="USDPShares">3.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateTenMember"
      decimals="INF"
      unitRef="Shares">2725</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ClassOfWarrantsOrRightsIssueDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember">2022-02-04</ttnp:ClassOfWarrantsOrRightsIssueDate>
    <ttnp:ClassOfWarrantsOrRightsExpirationDate contextRef="From2022-01-012022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember">2027-08-04</ttnp:ClassOfWarrantsOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember"
      decimals="INF"
      unitRef="USDPShares">1.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_ClassOfWarrantOrRightIssuedDateElevenMember"
      decimals="INF"
      unitRef="Shares">4664</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">9826</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ttnp:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_zPsdhuFo4Fz" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8B5_zxwXu46gpOdg" style="display: none"&gt;Schedule of shares of common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Stock options outstanding&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zSnOPPSWHEcg" style="width: 9%; text-align: right" title="Common stock, capital shares reserved for future issuance"&gt;927&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Shares issuable upon the exercise of warrants&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zxipqE8V8488" style="border-bottom: Black 1pt solid; text-align: right" title="Common stock, capital shares reserved for future issuance"&gt;9,826&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220930_zy3yxUBNEiVg" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock, capital shares reserved for future issuance"&gt;10,753&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ttnp:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">927</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">9826</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">10753</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z9XRyZui6vek" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_826_zT5KZC21LHe6"&gt;Stock Plans&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August&#160;2015, our stockholders approved the 2015 Omnibus Equity Incentive Plan (the &#x201c;2015 Plan&#x201d;). The 2015 Plan, as subsequently amended, authorized a total of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_zbKufc88w3F8" title="Number of shares agreed to issue"&gt;1,000,000&lt;/span&gt; shares of our common stock for issuance to employees, directors, officers, consultants and advisors. As of December 31, 2022, options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_zQ0abPWqQY9e" title="Shares available for grant"&gt;74,262&lt;/span&gt; shares of our common stock were available for grant and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20150831__us-gaap--PlanNameAxis__custom--Plan2015Member_z5yMe3m8x1Bj" title="Common stock outstanding"&gt;925,738&lt;/span&gt; shares of our common stock outstanding under the 2015 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In February&#160;2014, our Board adopted the 2014 Incentive Plan (the &#x201c;2014 Plan&#x201d;), pursuant to which &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20140228__us-gaap--PlanNameAxis__custom--Plan2015Member_zI2gSYfXDqZb" title="Number of shares agreed to issue"&gt;2,526&lt;/span&gt; shares of our common stock were authorized for issuance to employees, directors, officers, consultants and advisors. The 2014 Plan was terminated upon the approval of the 2015 Plan. As of December 31, 2022, options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20140228__us-gaap--PlanNameAxis__custom--Plan2015Member_zCWnHRcRk8R3" title="Common stock outstanding"&gt;1,189&lt;/span&gt; shares of our common stock were outstanding under the 2014 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In July&#160;2002, we adopted the 2002 Stock Incentive Plan (the &#x201c;2002 Plan&#x201d;). The 2002 Plan, as amended in 2005, authorized a total of approximately &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20020731__us-gaap--PlanNameAxis__custom--Plan2015Member_zBzhUZnmJzG2" title="Number of shares agreed to issue"&gt;7,234&lt;/span&gt; shares of our common stock for issuance to employees, officers, directors, consultants, and advisers. The exercise prices of options granted under the 2002 Plan were 100% of the fair market value of our common stock on the date of grant. The 2002 Plan expired by its terms in July&#160;2012. As of December 31, 2022, no options to purchase shares of our common stock were outstanding under the 2002 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table summarizes option activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z4NqZTrKZXc5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BA_zRTCYfMaY5pf" style="display: none"&gt;Schedule of our option activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;br/&gt; (in thousands)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;br/&gt;
per Share&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Remaining
    Contractual&lt;br/&gt; Term (years)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic Value&lt;br/&gt; (in
    thousands)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zeoMgsXWZ6Wh" style="width: 9%; text-align: right" title="Outstanding at Beginning"&gt;682&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zvp5FJQKfEAe" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at Beginning"&gt;12.53&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zhImmUb5p52h" title="Weighted Average Remaining Contractual Term, Outstanding (Years)"&gt;8.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20221231_zmc3srTqtBCj" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zMwkGictmsCh" style="text-align: right" title="Shares, Granted"&gt;310&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zK4zzYJcwOR1" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.18&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_z29ZI741Es42" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Cancelled/expired"&gt;(65&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zcoYLHtlQG5d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/expired"&gt;23.40&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zwEwtYAOrEw1" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at Ending"&gt;927&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zF0pmW48IIy4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;7.97&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zw7hKCJ6DXng" title="Weighted Average Remaining Contractual Term, Outstanding (Years)"&gt;8.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20221231_zvcUa3QjkpS1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zE7h3trfQ5Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Exercisable"&gt;927&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zHJIgUzBq6M9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable"&gt;7.97&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zDH1q3Jdd1Ub" title="Weighted Average Remaining Contractual Term, Exercisable"&gt;8.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zs4kvnoEU1fb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the stock-based compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zqsYXrZbwc42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BE_zPgA46M4ggo1" style="display: none"&gt;Schedule of assumptions to estimate the fair value of options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt; Years Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Weighted-average risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zimxS1yvFL7d" title="Weighted-average risk-free interest rate"&gt;1.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231_zIwhvJPbZuab" title="Weighted-average risk-free interest rate"&gt;0.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Expected dividend payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220101__20221231_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Expected holding period (years)(1)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_fKDEp_zXc30gJDtOE" title="Expected holding period (years)"&gt;5.26&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_fKDEp_zSWaTKOeVK1h" title="Expected holding period (years)"&gt;5.45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Weighted-average volatility factor(2)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_fKDIp_zL35OYstqh33" title="Weighted-average volatility factor"&gt;1.16&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20210101__20211231_fKDIp_zxaLCerXnlF6" title="Weighted-average volatility factor"&gt;1.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Estimated forfeiture rates for options granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20221231_zY92hkuGfTb4" title="Estimated forfeiture rates for options granted"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20210101__20211231_zNytV6xmn0Eb" title="Estimated forfeiture rates for options granted"&gt;30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F0C_zUnIg0WPiaN8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zwaiP8AJBf74" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F02_zudaHfL6q9m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zibsMcMXUBKb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average volatility is based on the historical volatility of our common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F05_zyhzoOTkCcwj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zhVrqttXD5j1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated forfeiture rates are based on historical data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zConnyx0AKug" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based upon the above methodology, the weighted-average fair value of options and awards granted during the&#160;years ended December 31, 2022 and 2021 was $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_ziRFRxoXK9kg" title="Weighted-average fair value of options and awards granted"&gt;0.95 &lt;/span&gt;and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231_z9RfQCsbqQwd" title="Weighted-average fair value of options and awards granted"&gt;3.29&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table summarizes the stock-based compensation expense (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_znRWAMNGLuE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BD_zus3gRP7DoR7" style="display: none"&gt;Schedule of the stock-based compensation expense&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Years Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Research and development&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;553&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;749&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;General and administrative&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;394&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;756&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total stock-based compensation expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;947&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;1,505&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zXzkhGsPpWO2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2022, there was approximately $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_dm_c20221231_zjHxAVykCw1l" title="Total unrecognized compensation expense related to non-vested stock option"&gt;0.8&lt;/span&gt; million of total unrecognized compensation expense related to non-vested stock options subject to shareholder approval. This expense is expected to be recognized over a weighted-average period of approximately &lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_zmzJqiVOZNFg" title="Weighted-average period for recognizing non-vested stock option"&gt;0.7&lt;/span&gt;&#160;year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 2, 2022, our Board of Directors, or Board, modified the outstanding options to purchase common stock under our 2015 Omnibus Equity Incentive Plan, or 2015 Plan, to allow for the acceleration of vesting of all unvested 2015 Plan options in the event of a change in control through the election of a majority of new members to our Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 15, 2022, the Special Meeting was held at the request of Activist, to increase the size of our Board from five members to eleven members and elect Activist&#x2019;s slate of six nominees to serve as directors in addition to the existing five Board members. As a result of the change of control, all unvested options granted under the 2015 Plan prior to August 15, 2022, immediately became vested. We recognized approximately $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_dm_c20220801__20220815__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYMEqZXNiOee" title="Stock-based compensation"&gt;0.5&lt;/span&gt; million of stock-based compensation related to the acceleration of vesting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 15, 2022, our Board granted &lt;span id="xdx_908_ecustom--PurchaseCommonStock_pid_c20220801__20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_zQ3UQiD8n7ee" title="Purchase common stock"&gt;125,000&lt;/span&gt; options to purchase common stock at $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_z6kVfYFRoyj4" title="Purchase price, per value"&gt;1.52&lt;/span&gt; per share which are subject to shareholder approval of an amendment to increase the number of shares reserved for issuance under our 2015 Plan. The options vest monthly over a 12-month period from the grant dates. As the shares underlying these options have not been approved by our stockholders, they have been excluded from the table above as of December 31, 2022. We have recognized approximately $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20220801__20220815__us-gaap--PlanNameAxis__custom--Plan2015Member_pn3n3" title="Stock-based compensation"&gt;60,000&lt;/span&gt; of stock-based compensation related to these grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On September 15, 2022, our Board granted &lt;span id="xdx_90D_ecustom--PurchaseCommonStock_pid_c20220901__20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_z2QbgzO6dpyi" title="Purchase common stock"&gt;900,000&lt;/span&gt; options to purchase common stock at $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_zOO879p58Nv5" title="Purchase price, per value"&gt;1.31 &lt;/span&gt;per share which are subject to shareholder approval of an amendment to increase the number of shares reserved for issuance under our 2015 Plan. The options vest monthly over a 12-month period from the grant dates. As the shares underlying these options have not been approved by our stockholders, they have been excluded from the table above as of December 31, 2022. We have recognized approximately $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pn3n3_c20220901__20220915__us-gaap--PlanNameAxis__custom--Plan2015Member_zVel9wJ41u1e" title="Stock-based compensation"&gt;250,000&lt;/span&gt; of stock-based compensation related to these grants.&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2015-08-31_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2015-08-31_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">74262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2015-08-31_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">925738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2014-02-28_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">2526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2014-02-28_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">1189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2002-07-31_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">7234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z4NqZTrKZXc5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BA_zRTCYfMaY5pf" style="display: none"&gt;Schedule of our option activity&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;br/&gt; (in thousands)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;br/&gt;
per Share&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted Average&lt;br/&gt; Remaining
    Contractual&lt;br/&gt; Term (years)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic Value&lt;br/&gt; (in
    thousands)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at January 1, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zeoMgsXWZ6Wh" style="width: 9%; text-align: right" title="Outstanding at Beginning"&gt;682&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zvp5FJQKfEAe" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at Beginning"&gt;12.53&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zhImmUb5p52h" title="Weighted Average Remaining Contractual Term, Outstanding (Years)"&gt;8.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20221231_zmc3srTqtBCj" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zMwkGictmsCh" style="text-align: right" title="Shares, Granted"&gt;310&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zK4zzYJcwOR1" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.18&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cancelled/expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_z29ZI741Es42" style="border-bottom: Black 1pt solid; text-align: right" title="Shares, Cancelled/expired"&gt;(65&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zcoYLHtlQG5d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/expired"&gt;23.40&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zwEwtYAOrEw1" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at Ending"&gt;927&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zF0pmW48IIy4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;7.97&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zw7hKCJ6DXng" title="Weighted Average Remaining Contractual Term, Outstanding (Years)"&gt;8.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20221231_zvcUa3QjkpS1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zE7h3trfQ5Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Exercisable"&gt;927&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231_zHJIgUzBq6M9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable"&gt;7.97&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zDH1q3Jdd1Ub" title="Weighted Average Remaining Contractual Term, Exercisable"&gt;8.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">12.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31">P8Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">23.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-12-31">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_pn3n3_zqsYXrZbwc42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BE_zPgA46M4ggo1" style="display: none"&gt;Schedule of assumptions to estimate the fair value of options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the &lt;br/&gt; Years Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Weighted-average risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_zimxS1yvFL7d" title="Weighted-average risk-free interest rate"&gt;1.9&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231_zIwhvJPbZuab" title="Weighted-average risk-free interest rate"&gt;0.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Expected dividend payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20220101__20221231_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231_pn3n3" style="text-align: right" title="Expected dividend payments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Expected holding period (years)(1)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_fKDEp_zXc30gJDtOE" title="Expected holding period (years)"&gt;5.26&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_fKDEp_zSWaTKOeVK1h" title="Expected holding period (years)"&gt;5.45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Weighted-average volatility factor(2)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_fKDIp_zL35OYstqh33" title="Weighted-average volatility factor"&gt;1.16&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20210101__20211231_fKDIp_zxaLCerXnlF6" title="Weighted-average volatility factor"&gt;1.14&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Estimated forfeiture rates for options granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20220101__20221231_zY92hkuGfTb4" title="Estimated forfeiture rates for options granted"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--EstimatedForfeitureRatesForOptionsGrantedToManagement_pid_dp_c20210101__20211231_zNytV6xmn0Eb" title="Estimated forfeiture rates for options granted"&gt;30&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;div style="width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F0C_zUnIg0WPiaN8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zwaiP8AJBf74" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F02_zudaHfL6q9m5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zibsMcMXUBKb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average volatility is based on the historical volatility of our common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0"/&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F05_zyhzoOTkCcwj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zhVrqttXD5j1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated forfeiture rates are based on historical data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-01to2022-12-31" id="Fact000841">P5Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31" id="Fact000843">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="Fact000845"
      unitRef="Pure">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      id="Fact000847"
      unitRef="Pure">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.06</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
    <ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.30</ttnp:EstimatedForfeitureRatesForOptionsGrantedToManagement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_znRWAMNGLuE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Plans (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BD_zus3gRP7DoR7" style="display: none"&gt;Schedule of the stock-based compensation expense&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Years Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Research and development&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;553&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="width: 9%; text-align: right" title="Total stock-based compensation"&gt;749&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;General and administrative&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;394&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;756&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total stock-based compensation expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;947&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;1,505&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">749000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">756000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">947000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">1505000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-01to2022-12-31">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-08-012022-08-15_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ShareBasedCompensation>
    <ttnp:PurchaseCommonStock
      contextRef="From2022-08-012022-08-15_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">125000</ttnp:PurchaseCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-08-15_custom_Plan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.52</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-08-012022-08-15_custom_Plan2015Member"
      decimals="-3"
      unitRef="USD">60000000</us-gaap:ShareBasedCompensation>
    <ttnp:PurchaseCommonStock
      contextRef="From2022-09-012022-09-15_custom_Plan2015Member"
      decimals="INF"
      unitRef="Shares">900000</ttnp:PurchaseCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-15_custom_Plan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.31</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-09-012022-09-15_custom_Plan2015Member"
      decimals="-3"
      unitRef="USD">250000000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zWOgoeSkwngh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_822_zD5nHuahUuZ"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2022, we had federal net operating loss carryforwards of approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zFOqvOabhB66" title="Operating Loss Carryforwards"&gt;183.0&lt;/span&gt; million that expire at various dates through &lt;span id="xdx_900_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember" title="Operating Loss Carry Forwards Expiration Year"&gt;2037&lt;/span&gt; and approximately $&lt;span id="xdx_90A_ecustom--OperatingLossCarryForwardsNotSubjectToExpiration_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znEVJNcVYQkj" title="Operating Loss Carry forwards Not Subject To Expiration"&gt;54.3&lt;/span&gt; million which do not expire but are subject to &lt;span id="xdx_90C_ecustom--OperatingLossCarryforwardsLimitationsOnUsePercentage_pid_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zucri4uBBe2l" title="Operating Loss Carryforwards, Limitations on Use Percentage"&gt;80&lt;/span&gt;% taxable income limitations. As of December 31, 2022, we had federal research and development tax credits of approximately $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zepekVoVY6J9" title="Operating Loss Carryforwards"&gt;6.8&lt;/span&gt; million that expire at various dates through &lt;span id="xdx_902_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember" title="Operating Loss Carry Forwards Expiration Year"&gt;2042&lt;/span&gt;. We also had net operating loss carryforwards for California income tax purposes of approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zs3nAlM2TuM6" title="Operating Loss Carryforwards"&gt;115.2&lt;/span&gt; million that expire at various dates through &lt;span id="xdx_902_ecustom--OperatingLossCarryForwardsExpirationYear_c20220101__20221231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember" title="Operating Loss Carry Forwards Expiration Year"&gt;2042&lt;/span&gt; and state research and development tax credits of approximately $&lt;span id="xdx_902_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zG3ZzKBM3QJj" title="Tax Credit Carryforward, Amount"&gt;9.2&lt;/span&gt; million which do not expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current federal and California tax laws include substantial restrictions on the utilization of net operating losses and tax credits in the event of an ownership change of a corporation under Internal Revenue Code Section&#160;382 and 383.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and operating loss and credit carryforwards. Significant components of our deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zsJNgv0oAJja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BD_zRakmePcaTng" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20221231_zzbQ8yFBDFh" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20211231_zyqaklV3x5wg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Deferred tax assets:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGzHnT_zFloHNuGRon6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Net operating loss carryforwards&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;57,895&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;62,097&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3n3_maDTAGzHnT_zw5i3kmAgoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Research credit carryforwards&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;10,521&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,738&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGzHnT_z6KwMd6nSwWd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Other, net&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,968&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,113&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzHnT_maDTALNzIFN_z7td1LOyCXhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;70,384&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;77,948&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Deferred tax liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDITLzija_z1MxwDEHj1t6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Other, net&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(46&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(65&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pn3n3_di_mtDITLzija_msDTALNzIFN_z5QaVimw2M1i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total deferred tax liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(46&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(65&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTALNzIFN_zfGjl7uejAH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(70,338&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(77,883&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNzIFN_zVgZrRQCX1M6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Net deferred tax assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zL0uaKTGQoC" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, our management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by approximately $&lt;span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_dm_c20220101__20221231_z00Xw7qIg175" title="Changes in valuation allowance"&gt;7.5&lt;/span&gt; million during 2022 and decreased by approximately $&lt;span id="xdx_90A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_dm_c20210101__20211231_zr7U6BQmwUD5" title="Changes in valuation allowance"&gt;2.4&lt;/span&gt; million during 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The provision for income taxes consists of state minimum taxes due. The effective tax rate of our provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zHv9ijIk1wUf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8B5_zyw4XYXvdES4" style="display: none"&gt;Schedule of effective tax rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20220101__20221231_zQLiD52LDRD6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49B_20210101__20211231_z1RgChIYsCH5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Years&#160;Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zViet8yeubch" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Computed at 21%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(2,144&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,842&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zPhvjNAlsNZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;State taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(488&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(67&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zLjEnK9bPSwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Change in valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,545&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,939&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zegCp17Q5T6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ziC4fAHAm2g8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Stock based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;627&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_zIeDUTepL5Bf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Research and development credits&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,489&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--TaxAttributesExpirations_iN_pn3n3_di_zGXoRsMlqR5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Tax attributes expirations&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6,216&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,767&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxReconciliationImpactOfInternalRevenueCode_zCTKlJufGY7b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Impact of IRC 162m&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(159&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;87&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zfhlnh9RtI05" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zh2Hk9fzpFm5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We had &lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20221231_zq4AlMX0YeHc" title="Changes in valuation allowance"&gt;&lt;span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20211231_zpm2bmCy8Nl7" title="Unrecognized Tax Benefits"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized tax benefits or any amounts accrued for interest and penalties for the three&#160;years ended December 31, 2022. Our policy is to recognize interest and penalties related to income taxes as a component of income tax expense. We do not expect the amount of unrecognized tax benefits will materially change in the next twelve&#160;months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We file tax returns in the U.S. federal jurisdiction and various state jurisdictions. We are subject to the U.S. federal and state income tax examination by tax authorities for such&#160;years 2003 through 2022, due to net operating losses that are being carried forward for tax purposes.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">183000000.0</us-gaap:OperatingLossCarryforwards>
    <ttnp:OperatingLossCarryForwardsExpirationYear contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember">2037</ttnp:OperatingLossCarryForwardsExpirationYear>
    <ttnp:OperatingLossCarryForwardsNotSubjectToExpiration
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">54300000</ttnp:OperatingLossCarryForwardsNotSubjectToExpiration>
    <ttnp:OperatingLossCarryforwardsLimitationsOnUsePercentage
      contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember"
      decimals="INF"
      unitRef="Pure">0.80</ttnp:OperatingLossCarryforwardsLimitationsOnUsePercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember"
      decimals="-3"
      unitRef="USD">6800000</us-gaap:OperatingLossCarryforwards>
    <ttnp:OperatingLossCarryForwardsExpirationYear contextRef="From2022-01-012022-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">2042</ttnp:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember"
      decimals="-3"
      unitRef="USD">115200000</us-gaap:OperatingLossCarryforwards>
    <ttnp:OperatingLossCarryForwardsExpirationYear contextRef="From2022-01-012022-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">2042</ttnp:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember"
      decimals="-3"
      unitRef="USD">9200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zsJNgv0oAJja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8BD_zRakmePcaTng" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20221231_zzbQ8yFBDFh" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20211231_zyqaklV3x5wg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Deferred tax assets:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTAGzHnT_zFloHNuGRon6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Net operating loss carryforwards&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;57,895&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;62,097&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3n3_maDTAGzHnT_zw5i3kmAgoT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Research credit carryforwards&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;10,521&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,738&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_i01I_pn3n3_maDTAGzHnT_z6KwMd6nSwWd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Other, net&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,968&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,113&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzHnT_maDTALNzIFN_z7td1LOyCXhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;70,384&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;77,948&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Deferred tax liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDITLzija_z1MxwDEHj1t6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in; vertical-align: top"&gt;Other, net&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(46&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(65&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pn3n3_di_mtDITLzija_msDTALNzIFN_z5QaVimw2M1i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total deferred tax liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(46&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(65&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTALNzIFN_zfGjl7uejAH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(70,338&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(77,883&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNzIFN_zVgZrRQCX1M6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Net deferred tax assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0942"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">57895000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">62097000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">10521000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">14738000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1968000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1113000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">70384000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">77948000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">46000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">65000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">46000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">65000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">70338000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">77883000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">7500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">2400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zHv9ijIk1wUf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;&lt;span id="xdx_8B5_zyw4XYXvdES4" style="display: none"&gt;Schedule of effective tax rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20220101__20221231_zQLiD52LDRD6" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49B_20210101__20211231_z1RgChIYsCH5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Years&#160;Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zViet8yeubch" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Computed at 21%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(2,144&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,842&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zPhvjNAlsNZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;State taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(488&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(67&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zLjEnK9bPSwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Change in valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(7,545&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,939&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zegCp17Q5T6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ziC4fAHAm2g8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Stock based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;627&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_zIeDUTepL5Bf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Research and development credits&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,489&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--TaxAttributesExpirations_iN_pn3n3_di_zGXoRsMlqR5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Tax attributes expirations&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6,216&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,767&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxReconciliationImpactOfInternalRevenueCode_zCTKlJufGY7b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Impact of IRC 162m&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(159&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;87&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zfhlnh9RtI05" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2144000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-1842000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-488000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-67000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-7545000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-1939000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">3000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">627000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-3489000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">9000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <ttnp:TaxAttributesExpirations
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-6216000</ttnp:TaxAttributesExpirations>
    <ttnp:TaxAttributesExpirations
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-3767000</ttnp:TaxAttributesExpirations>
    <ttnp:IncomeTaxReconciliationImpactOfInternalRevenueCode
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-159000</ttnp:IncomeTaxReconciliationImpactOfInternalRevenueCode>
    <ttnp:IncomeTaxReconciliationImpactOfInternalRevenueCode
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">87000</ttnp:IncomeTaxReconciliationImpactOfInternalRevenueCode>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zli9EvY5et31" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_822_zJuNTmfcGRL7"&gt;Discontinued Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table presents information related to assets and liabilities reported as discontinued operations in our balance sheet:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zNJs6Da8N5Ua" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B4_zQhLzqUB8xze" style="display: none"&gt;Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zfUoIBsVycG3" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20211231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zodZD3RsaaG8" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(In thousands)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzCWn_zUKunQHZMdfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt; vertical-align: top"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;14&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;12&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzCWn_z8nbOICulzsh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Discontinued operations &#x2013; current assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIz3aE_zVaRSiYLgd76" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Accounts payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;129&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;782&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_iI_pn3n3_maLODGIz3aE_zGoMJz5pUsQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"&gt;Other accrued liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;362&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIz3aE_zK8QBODzFzok" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Discontinued operations &#x2013; current liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,144&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2020, we recognized non-cash stock-based compensation expenses of approximately $&lt;span id="xdx_905_ecustom--NoncashStockbasedCompensationExpenses_pn3n3_dm_c20220101__20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember_zENLmcOZxrcc" title="Non-cash stock-based compensation expenses"&gt;0.1&lt;/span&gt; million which is included in discontinued operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_pn3n3_zNJs6Da8N5Ua" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Discontinued Operations (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&lt;span id="xdx_8B4_zQhLzqUB8xze" style="display: none"&gt;Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zfUoIBsVycG3" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20211231__us-gaap--DisposalGroupClassificationAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--U.s.CommercializationActivitiesMember_zodZD3RsaaG8" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(In thousands)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_pn3n3_maAODGIzCWn_zUKunQHZMdfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt; vertical-align: top"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;14&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 9%; text-align: right"&gt;12&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtAODGIzCWn_z8nbOICulzsh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Discontinued operations &#x2013; current assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_pn3n3_maLODGIz3aE_zVaRSiYLgd76" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Accounts payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;129&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;782&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent_iI_pn3n3_maLODGIz3aE_zGoMJz5pUsQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"&gt;Other accrued liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;362&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_pn3n3_mtLODGIz3aE_zK8QBODzFzok" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Discontinued operations &#x2013; current liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;129&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,144&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">14000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">12000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">14000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">12000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">129000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">782000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <ttnp:DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">362000</ttnp:DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">129000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember"
      decimals="-3"
      unitRef="USD">1144000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <ttnp:NoncashStockbasedCompensationExpenses
      contextRef="From2022-01-012022-12-31_us-gaap_SegmentDiscontinuedOperationsMember"
      decimals="-3"
      unitRef="USD">100000</ttnp:NoncashStockbasedCompensationExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHEsoDDzUQw2" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_z8mgodIatQ9g"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;In January 2022, we entered into an agreement
with JT Pharma, a company for which James R. McNab, Jr., a member of our Board, serves as chief executive officer, to clarify certain
provisions of the JT Agreement, pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement was achieved,
made a payment of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--TransactionTypeAxis__custom--JTPharmaAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JTPharmaMember_zDet9oliVWMl" title="Value of stock issued"&gt;100,000&lt;/span&gt; and issued &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--TransactionTypeAxis__custom--JTPharmaAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JTPharmaMember_z2YXVDq3L6M6" title="Stock issued"&gt;51,021&lt;/span&gt; shares of our common stock to JT Pharma.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;During the year ended December 31, 2022, we made
payments related to legal fees of approximately $&lt;span id="xdx_901_eus-gaap--LegalFees_pn3p0_c20220101__20221231_z2iiS2rgq4b5" title="Payment of legal fees"&gt;75,000&lt;/span&gt; to a law firm operated by one of our Board members.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_JTPharmaAgreementMember_custom_JTPharmaMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_JTPharmaAgreementMember_custom_JTPharmaMember"
      decimals="INF"
      unitRef="Shares">51021</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LegalFees
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">75000</us-gaap:LegalFees>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zUuLOH3YVMYk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"/&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82D_zX38P1zSQWzc"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 10, 2023, the Federal Deposit Insurance Corporation, or FDIC, announced that it had closed and taken control of Silicon Valley Bank, or SVB.  On March 13, 2023, pursuant to a joint statement released by the U.S. Department of the Treasury and the FDIC, the U.S. government reassured that all depositors will be fully protected. We held deposits with this bank. As a result of the above actions, our insured and uninsured deposits have been restored. &lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000841"
          xlink:label="Fact000841"
          xlink:type="locator"/>
        <link:footnote id="Footnote000852" xlink:label="Footnote000852" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000841"
          xlink:to="Footnote000852"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000843"
          xlink:label="Fact000843"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000843"
          xlink:to="Footnote000852"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000845"
          xlink:label="Fact000845"
          xlink:type="locator"/>
        <link:footnote id="Footnote000853" xlink:label="Footnote000853" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Weighted average volatility is based on the historical volatility of our common stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000845"
          xlink:to="Footnote000853"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000847"
          xlink:label="Fact000847"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000847"
          xlink:to="Footnote000853"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M8X\+,+8YN#,RD3 [$"Z(RU-HC- FN:_NS0>2QIT2H-: H$NM#+"("";NZ[<
M>[X/ZLG9[@WY ON1K[&:&B[I& ;Y^I)()LB8!S"6WH8K7SW\:0T/NM3*)(OX
M8.*N'R4Y77,E25QRD@;0CMM&6PE/:XC0I5:&5\0($W?^;^&YV19TX"E?QTIP
MN-R$IW)!)C0F YC-/?".*OPNKE(;X2FRA55D"PN/ V\1[@?!L>"K(/:47?F
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M_NXEXA%]BAWM]9B-<9.&5:T!";<&-T=#1\R@&5^(++-K V'WS)EW=T3<)F%
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M  "N7   &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U<67,;MY9^YZ]
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M.S.,FN-KTQ*8ZF^$5++:#E_WB1<K(KP432@3/(VGGL*I(.+JL(@O(AF\:,9
MLDM1$OJS#_(GWU#P.=^FM>R"A; 88K;V)!ZU:/@0BGRHV79HDM&!BV6?=ZU
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MAG'X /R^:,#XR =<(+ZB_.7_ 5!+ P04    " #2@W]6(/X+-+H"   P!@
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MC*A/'K/^_\OTJ+G[P9Y.U:-NU&\$^M_9\YF4E46?@_++I:E(+75EK$E;E<$
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MD?EQ'[.#OQTW+TY7_D:ZU@[W6_^820'6>0.^;[1VAQ<^H/L7Q<4_4$L#!!0
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M,^VH[89A0>\<&F] ^W.MW7KB"=J7<_P74$L#!!0    ( -*#?U;<>;8P"@,
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M11'N%;#!'OH%;+M;(CCKIJ!3>TG>0UH=G0: NM!BC0@L[@O\;M:R+4'@:D/
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MLQBT<\#[2BF[-5R";KKG_P%02P,$%     @ TH-_5O#VLONS P  4PD  !D
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M    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;,5676_:,!3]*U>9M ^I:SZ
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MB)PAD)"C8^#TV< -2.F(R,;/'6?02CK@_OB9_;V/G6)9< LW6GX32UQ/@HN
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MY+J!>K]D3#[?Z [* ^#)=U!+ P04    " #2@W]6".(<D#H#  "Q#@  &0
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MOY@Z?^_P@T&G3];(*=E*^>*,QR+%D4L(..3&,5#[V<,#<.Z(;!J_>DX\A'3
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M[FQL%>8F&$8VOE>WTMC.]\O*_FI .0=[7DIICH8+,/R\LC]02P,$%     @
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M7MUILOP.)1,E2".49!K6"^]B=+Z<6W_G\$/ SAR-F<UDI=2C-6ZRA1=805!
MBA:!TV<+EU 4%HAD/+687D=I X_'!_0O+G?*9<4-7*KBI\@P7WASCV6PYG6!
M]VKW%=I\)A8O585Q;[9K?"-B3&N#JFR#R2Z%;+Y\W^[#44!X*B!L T*GNR%R
M*J\X\B36:L>T]28T.W"INF@2)Z0]E ?4M"HH#I,'5.ECKHH,M'G'KI]J@<_L
M_14@%X7Y$/M('-;33UN\98,7GL ;A>Q62<P-NY899/\"^"2N4Q@>%"[#0<0K
M2,]8-/K(PB ,F<FY!C, &W6)1PXV.@';IOKK8F50T]WXW9=K S'NA[#U<FXJ
MGL+"HX(PH+?@)6_?C*;!YP&!XT[@> @]^5:C02XS(3>,(UO!1DA)1I_.!FGJ
MD&P9;I-)0$_L;WL$3#H!DT$!-\;4_Y]@0S=Y01?-9\%LWL\W[?BF@WQ496L0
M"!E3FL&^$KJ??1"E_U#8P'G,.GFS07GWU$FH_'LES5YLR*=Q='I'YAWE_#57
M -RHCW\0YA5;XA\UDA+TQK5+PU)52VQZ2C?;=>2+IA']=6_:^2W7=&$-*V!-
MH<'9C"Z-;EID8Z"J7%M:*:0FYX8Y_55 6P=:7RN%!\,2=/^IY ]02P,$%
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MM^87L3.@<KH'F,T \_X ZX$!HV; Z- !5C/ .G3 N!DP/G3 23/@Y- !DV;
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M\/\)[(R&04?#X!;Z_)NM*4Q[;(N2>@1(KEY[F40$7FFD S5(IM%%0HM,[<)
MF]ZTG0?](!Q/_>UI>&ZU8-BIG3D^[!P?WG3\TUM-78<N+^5;GF*50MW>HG*Y
M>A/+33&XKNJ_XYP%.^J"';TOV%P4*:\V4*/D(H6[/3*I7.7]=!OP)72F]6VC
M(=CC((:R;0TQI&SOXGOY/J#A$8BZS=^1SIBZ[YBZ_W?YO!4%T[S@>@\95;.0
M+K)N8[Y$3K+NW>D?CB[R_YK>P%T #UVD#[=S0FE.3R8E!0T.&7+=2+2EJHP
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M^2!. O#HF0"[#+"; <XS <,R8-@,F#P3,"H#1B]MDE,&."\-&)<!XY<&3,J
MR4L#W#+ U6^W>!WZ77I$DOF,LP/B>6E%RP^T$#I:O<(HS=V]EUS]&JDX.;^7
M;/4-W<4D%>BU1R6)8H$^$,Y)[M0;=($^WWOH]:LWZ!4:(+$EG H4I>AS&DGQ
M5EU4QY^V+!,D78O90*HFY>#!JJS^MJC>?J9ZC-ZS5&X%6J1KNFZ)]_XCWC8
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M^=I,;T'\<#W5:3X5V3(5)NA*<!TK])E'$%4!?)-WD3QY2?Z4.!'/(#Q$'7R
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MO-WBNFGF]4]XL_5F3*\Y-53@BE*CRS?$K)M-TAA657YZE\K2+O#'@I8O:A=
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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MO+0Q(=WXR+IYRXI3IBG/[8#D0\+QD84#ULNM5,@'Y[V0W0-6S&U,R$(^LH7
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M_CVISN=[X_7QE^7/27Q?U!>< _S]77P#4$L#!!0    ( -*#?U: A/B=P $
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M              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ TH-_5M]W(Z"3!P  ]C$  !@              ("!# @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -*#?U9R@07)S 4  *D8   8
M              " @=4/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #2@W]6<X;2?^X"  #H"0  &               @('7%0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ TH-_5O4K^^?&!
MJ!,  !@              ("!^Q@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( -*#?U:V4U3EC04  'LD   8              " @?<=
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #2@W]6+YOP
M$^ &  "N'P  &               @(&Z(P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ TH-_5G5L$-])(   KEP  !@
M ("!T"H  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -*#
M?U8@_@LTN@(  # &   8              " @4]+  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #2@W]6EW'Y,N\"  "]!@  &
M        @($_3@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ TH-_5H>:9B+F @  YP8  !D              ("!9%$  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #2@W]6IF-7WG4&  "M#@
M&0              @(&!5   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( -*#?U:*;3S2/P(  /P$   9              " @2U;  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ TH-_5ME(OD9C
M"   KA0  !D              ("!HUT  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #2@W]6F=[YO D'  "N$   &0
M@($]9@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -*#
M?U9FF'VQS 8  *T/   9              " @7UM  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ TH-_5B-+CS$6 P  10<  !D
M         ("!@'0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #2@W]6W'FV, H#  "L!@  &0              @('-=P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -*#?U9W#3L)]P(  ((&
M   9              " @0Y[  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ TH-_5@S87, \(@  W(<  !D              ("!/'X
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #2@W]6 S^C
M!#($  "["P  &0              @(&OH   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( -*#?U8,*[3VH0(  .D%   9
M  " @1BE  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MTH-_5O#VLONS P  4PD  !D              ("!\*<  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #2@W]6#]7P$5,$  #$"@  &0
M            @(':JP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( -*#?U97W<RID@,  #X(   9              " @62P  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ TH-_5B,AK<^T @
MF08  !D              ("!+;0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #2@W]6A8M$BWL"  !X!@  &0              @($8
MMP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -*#?U;7
M\D>$M@(  "0(   9              " @<JY  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ TH-_5GNTAR*^ @  C@<  !D
M     ("!M[P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -*#?U;R9]#UT (  *\'   9              "
M@0'.  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ TH-_
M5IKB+4$N @  R 0  !D              ("!"-$  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #2@W]6SRPT2E$"  #>!0  &0
M        @(%MTP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( -*#?U8-L!146P,  )X/   9              " @?75  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ TH-_5DB"OO!\ @  LP8
M !D              ("!A]D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #2@W]6$,F2[&,&  !M+0  &0              @($ZW
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -*#?U:K!A)$
MT@(  #L+   9              " @=3B  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ TH-_5BP"S?]5#0  RL8  !D
M ("!W>4  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #2
M@W]67T/DDPP$  !V$@  &0              @(%I\P  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -*#?U:V[)$ZV ,  %T+   9
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M970T-BYX;6Q02P$"% ,4    " #2@W]6,)-<!6H$  #_%@  &0
M    @(%,# $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M -*#?U9'#M#[3 ,  $\,   9              " @>T0 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ TH-_5KW8)B^) @  V@4  !D
M             ("!<!0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #2@W]6Y^%E,.X"   A"@  &0              @($P%P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -*#?U:E>IS?*@,
M $H2   -              "  54: 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Z #H S0\  .,F 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>257</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement</Role>
      <ShortName>JT Pharmaceuticals Asset Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Ocular Therapeutix License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OcularTherapeutixLicenseAgreement</Role>
      <ShortName>Ocular Therapeutix License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Debt Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DebtAgreements</Role>
      <ShortName>Debt Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stock Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlans</Role>
      <ShortName>Stock Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/PropertyAndEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Stock Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansTables</Role>
      <ShortName>Stock Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlans</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://titanpharm.com/role/DiscontinuedOperations</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative</Role>
      <ShortName>JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Ocular Therapeutix License Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative</Role>
      <ShortName>Ocular Therapeutix License Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/OcularTherapeutixLicenseAgreement</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Debt Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DebtAgreementsDetailsNarrative</Role>
      <ShortName>Debt Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/DebtAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Stock Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetails</Role>
      <ShortName>Stock Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Stock Plans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetails1</Role>
      <ShortName>Stock Plans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Stock Plans (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetails2</Role>
      <ShortName>Stock Plans (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Stock Plans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/StockPlansDetailsNarrative</Role>
      <ShortName>Stock Plans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/StockPlansTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/IncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Discontinued Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative</Role>
      <ShortName>Discontinued Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="titanpharma_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://titanpharm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="titanpharma_10k.htm">titanpharma_10k.htm</File>
    <File>titanpharma_ex23-1.htm</File>
    <File>titanpharma_ex31-1.htm</File>
    <File>titanpharma_ex32-1.htm</File>
    <File>ttnp-20221231.xsd</File>
    <File>ttnp-20221231_cal.xml</File>
    <File>ttnp-20221231_def.xml</File>
    <File>ttnp-20221231_lab.xml</File>
    <File>ttnp-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="442">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "titanpharma_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 442,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 122,
   "dts": {
    "calculationLink": {
     "local": [
      "ttnp-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ttnp-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "titanpharma_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ttnp-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ttnp-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ttnp-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 437,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 53,
    "http://titanpharm.com/20221231": 6,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 63
   },
   "keyCustom": 39,
   "keyStandard": 218,
   "memberCustom": 28,
   "memberStandard": 24,
   "nsprefix": "ttnp",
   "nsuri": "http://titanpharm.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://titanpharm.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttnp:AssetPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Ocular Therapeutix License Agreement",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://titanpharm.com/role/OcularTherapeutixLicenseAgreement",
     "shortName": "Ocular Therapeutix License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttnp:AssetPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://titanpharm.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Debt Agreements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://titanpharm.com/role/DebtAgreements",
     "shortName": "Debt Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://titanpharm.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Stock Plans",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://titanpharm.com/role/StockPlans",
     "shortName": "Stock Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://titanpharm.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Discontinued Operations",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://titanpharm.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://titanpharm.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://titanpharm.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttnp:CompanyPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttnp:CompanyPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://titanpharm.com/role/BalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://titanpharm.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://titanpharm.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Stock Plans (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://titanpharm.com/role/StockPlansTables",
     "shortName": "Stock Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://titanpharm.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Discontinued Operations (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://titanpharm.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetGross",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 3)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://titanpharm.com/role/BalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ttnp:CompanyPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ttnp:CompanyPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://titanpharm.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ttnp:JTPharmaceuticalsAssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2020-10-012020-10-31_custom_JtPharmaceuticalsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:FutureMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
     "shortName": "JT Pharmaceuticals Asset Purchase Agreement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ttnp:JTPharmaceuticalsAssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2020-10-012020-10-31_custom_JtPharmaceuticalsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:FutureMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ttnp:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:ReimbursementFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Ocular Therapeutix License Agreement (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative",
     "shortName": "Ocular Therapeutix License Agreement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ttnp:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:ReimbursementFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-10-012022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:OperatingLeasesRentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-10-012022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:OperatingLeasesRentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Debt Agreements (Details Narrative)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://titanpharm.com/role/DebtAgreementsDetailsNarrative",
     "shortName": "Debt Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2020-04-012020-04-20_custom_PaycheckProtectionProgramLoanMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://titanpharm.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Stockholders' Equity (Details 1)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://titanpharm.com/role/StockholdersEquityDetails1",
     "shortName": "Stockholders' Equity (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ttnp:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Stockholders' Equity (Details 2)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://titanpharm.com/role/StockholdersEquityDetails2",
     "shortName": "Stockholders' Equity (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ttnp:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://titanpharm.com/role/StatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://titanpharm.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2021-01-012021-01-31_custom_TwoThousandFifteenPlanMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Stock Plans (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://titanpharm.com/role/StockPlansDetails",
     "shortName": "Stock Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Stock Plans (Details 1)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://titanpharm.com/role/StockPlansDetails1",
     "shortName": "Stock Plans (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Stock Plans (Details 2)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://titanpharm.com/role/StockPlansDetails2",
     "shortName": "Stock Plans (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Stock Plans (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://titanpharm.com/role/StockPlansDetailsNarrative",
     "shortName": "Stock Plans (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://titanpharm.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Income Taxes (Details 1)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://titanpharm.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://titanpharm.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Discontinued Operations (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://titanpharm.com/role/DiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_SegmentDiscontinuedOperationsMember_custom_U.s.CommercializationActivitiesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_SegmentDiscontinuedOperationsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:NoncashStockbasedCompensationExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Discontinued Operations (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative",
     "shortName": "Discontinued Operations (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_SegmentDiscontinuedOperationsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttnp:NoncashStockbasedCompensationExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://titanpharm.com/role/StatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Related Party Transactions (Details Narrative)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LegalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://titanpharm.com/role/StatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://titanpharm.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttnp:JTPharmaceuticalsAssetPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - JT Pharmaceuticals Asset Purchase Agreement",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement",
     "shortName": "JT Pharmaceuticals Asset Purchase Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_10k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttnp:JTPharmaceuticalsAssetPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r490",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r490",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r490",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r490",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r490",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r238",
      "r264",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r292",
      "r420",
      "r438",
      "r448",
      "r449",
      "r467",
      "r471",
      "r478",
      "r521",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r292",
      "r420",
      "r438",
      "r448",
      "r449",
      "r467",
      "r471",
      "r478",
      "r521",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r197",
      "r422",
      "r468",
      "r477",
      "r516",
      "r517",
      "r525",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r197",
      "r422",
      "r468",
      "r477",
      "r516",
      "r517",
      "r525",
      "r575"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r290",
      "r292",
      "r319",
      "r320",
      "r321",
      "r396",
      "r420",
      "r438",
      "r448",
      "r449",
      "r467",
      "r471",
      "r478",
      "r515",
      "r521",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r290",
      "r292",
      "r319",
      "r320",
      "r321",
      "r396",
      "r420",
      "r438",
      "r448",
      "r449",
      "r467",
      "r471",
      "r478",
      "r515",
      "r521",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r238",
      "r264",
      "r454",
      "r455"
     ],
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_AccruedClinicalTrialsExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical trials expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialsExpensesCurrent",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_AccruedSeverance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance"
       }
      }
     },
     "localname": "AccruedSeverance",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_AccumulatedDepreciationOnRetiredPropertyAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation on retired property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationOnRetiredPropertyAndEquipment",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_AmortizationOfRestrictedStock": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AmortizationOfRestrictedStock",
        "verboseLabel": "Amortization of restricted stock"
       }
      }
     },
     "localname": "AmortizationOfRestrictedStock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_AmortizationOfRestrictedStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of restricted stock, shares"
       }
      }
     },
     "localname": "AmortizationOfRestrictedStockShares",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ttnp_AssetPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AssetPurchaseAgreementTextBlock",
        "verboseLabel": "Ocular Therapeutix License Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementTextBlock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OcularTherapeutixLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttnp_BasicAndDilutedNetLossPerCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per common share"
       }
      }
     },
     "localname": "BasicAndDilutedNetLossPerCommonShare",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "ttnp_CashAndCashEquivalentsAndRestrictedCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CashAndCashEquivalentsAndRestrictedCashEquivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash as shown in the statements of cash flows"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndRestrictedCashEquivalents",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrant or right issued date eight.",
        "label": "Class Of Warrant or Right Issued Date Eight [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateEightMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Issued Date Eleven [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateElevenMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant or Right Issued Date Five [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateFiveMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant or Right Issued Date Four [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateFourMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrant or right issued date nine.",
        "label": "Class Of Warrant Or Right Issued Date Nine [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateNineMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Issued Date One [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateOneMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrant or right issued date seven.",
        "label": "Class Of Warrant or Right Issued Date Seven [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateSevenMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant or Right Issued Date Six [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateSixMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrant or right issued date ten.",
        "label": "Class Of Warrant Or Right Issued Date Ten [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateTenMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Issued Date Three [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateThreeMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantOrRightIssuedDateTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Issued Date Two [Member]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDateTwoMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ClassOfWarrantsOrRightsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants or rights expiration date.",
        "label": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsExpirationDate",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "ttnp_ClassOfWarrantsOrRightsIssueDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants or rights issue date.",
        "label": "Date Issued"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsIssueDate",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "ttnp_CommonStockToMaximGroupLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock To Maxim Group Llc [Member]"
       }
      }
     },
     "localname": "CommonStockToMaximGroupLlcMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_CompanyPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company"
       }
      }
     },
     "localname": "CompanyPolicyPolicyTextBlock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttnp_ContractWithCustomerAssetAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in contract assets.",
        "label": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAdditions",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_ContractWithCustomerAssetDeductions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of decrease in contract assets.",
        "label": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeductions",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_DeferredCompensationAndEmployeeSeverance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation and employee severance"
       }
      }
     },
     "localname": "DeferredCompensationAndEmployeeSeverance",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_DeferredGrantRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant revenue"
       }
      }
     },
     "localname": "DeferredGrantRevenue",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jt Pharmaceuticals Asset Purchase Agreement"
       }
      }
     },
     "localname": "DisclosureJtPharmaceuticalsAssetPurchaseAgreementAbstract",
     "nsuri": "http://titanpharm.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ttnp_DisclosureOcularTherapeutixLicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ocular Therapeutix License Agreement"
       }
      }
     },
     "localname": "DisclosureOcularTherapeutixLicenseAgreementAbstract",
     "nsuri": "http://titanpharm.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ttnp_DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_EmployeeStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to employee stock awards.",
        "label": "Stock Awards"
       }
      }
     },
     "localname": "EmployeeStockAwardsMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_EstimatedForfeitureRatesForOptionsGrantedToManagement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated forfeiture rates for options granted to management.",
        "label": "Estimated forfeiture rates for options granted"
       }
      }
     },
     "localname": "EstimatedForfeitureRatesForOptionsGrantedToManagement",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "ttnp_February2022OfferingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to February 2022 Offerings.",
        "label": "February 2022 Offerings [Member]"
       }
      }
     },
     "localname": "February2022OfferingsMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_FutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This information is pertaining to the amount received a closing payment and is entitled to receive future milestone payments.",
        "label": "Closing payment"
       }
      }
     },
     "localname": "FutureMilestonePayments",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_IncomeTaxReconciliationImpactOfInternalRevenueCode": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents income tax reconciliation impact of internal revenue code.",
        "label": "Impact of IRC 162m"
       }
      }
     },
     "localname": "IncomeTaxReconciliationImpactOfInternalRevenueCode",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_JTPharmaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "J T Pharma Agreement [Member]"
       }
      }
     },
     "localname": "JTPharmaAgreementMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_JTPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "J T Pharma [Member]"
       }
      }
     },
     "localname": "JTPharmaMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_JTPharmaceuticalsAssetPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JT Pharmaceuticals Asset Purchase Agreement"
       }
      }
     },
     "localname": "JTPharmaceuticalsAssetPurchaseAgreementTextBlock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttnp_January2021OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to January 2021 offering.",
        "label": "January 2021 Offering [Member]"
       }
      }
     },
     "localname": "January2021OfferingMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_JtPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for JT Pharmaceuticals.",
        "label": "JT Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "JtPharmaceuticalsMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments.",
        "label": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This information is pertaining to the amount received a closing payment and is entitled to receive milestone payments.",
        "label": "Milestone Payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_NoncashStockbasedCompensationExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash stock-based compensation expenses"
       }
      }
     },
     "localname": "NoncashStockbasedCompensationExpenses",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_OperatingLeasesRentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenses",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_OperatingLossCarryForwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year.",
        "label": "Operating Loss Carry Forwards Expiration Year"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "gYearItemType"
    },
    "ttnp_OperatingLossCarryForwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration.",
        "label": "Operating Loss Carry forwards Not Subject To Expiration"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsNotSubjectToExpiration",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_OperatingLossCarryforwardsLimitationsOnUsePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to operating loss carry forward percentage of limitation on use.",
        "label": "Operating Loss Carryforwards, Limitations on Use Percentage"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUsePercentage",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ttnp_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to loans from Paycheck Protection Program of the CARES Act administered by the U.S. Small Business Administration.",
        "label": "PPP loans"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_Plan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2015 [Member]"
       }
      }
     },
     "localname": "Plan2015Member",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A.",
        "label": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ProceedsFromEquityOfferings": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from equity offerings"
       }
      }
     },
     "localname": "ProceedsFromEquityOfferings",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_PurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase common stock"
       }
      }
     },
     "localname": "PurchaseCommonStock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ttnp_ReimbursementFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement fees"
       }
      }
     },
     "localname": "ReimbursementFees",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OcularTherapeutixLicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_RestrictedStockAgreementWithMaximGroupLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to restricted stock agreement with Maxim Group, LLC.",
        "label": "Restricted stock agreement with Maxim Group, LLC [Member]"
       }
      }
     },
     "localname": "RestrictedStockAgreementWithMaximGroupLlcMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_RetirementOfPropertyAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement of property and equipment"
       }
      }
     },
     "localname": "RetirementOfPropertyAndEquipment",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset obtained in exchange for lease liability, net of amortization"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityNetOfAmortization",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_RubinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rubin [Member]"
       }
      }
     },
     "localname": "RubinMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttnp_ServicesAgreementWithMaximMdmWorldwideSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Services Agreement With Maxim Mdm Worldwide Solutions [Member]"
       }
      }
     },
     "localname": "ServicesAgreementWithMaximMdmWorldwideSolutionsMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ttnp_ShareBasedPaymentArrangementMilestonePayment": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based milestone payment"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementMilestonePayment",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_SubstantialDoubtAboutGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going concern assessment"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernPolicyTextBlock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttnp_TaxAttributesExpirations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax attributes expirations",
        "label": "Tax Attributes Expirations",
        "negatedLabel": "Tax attributes expirations"
       }
      }
     },
     "localname": "TaxAttributesExpirations",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttnp_TwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2015 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenPlanMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_U.s.CommercializationActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.s. Commercialization Activities [Member]"
       }
      }
     },
     "localname": "U.s.CommercializationActivitiesMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_UnregisteredFiveYearAndSixMonthWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to unregistered five year and six month warrants.",
        "label": "Unregistered five year and six month warrants [Member]"
       }
      }
     },
     "localname": "UnregisteredFiveYearAndSixMonthWarrantsMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_UnregisteredPrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to unregistered prefunded warrants.",
        "label": "Unregistered prefunded warrants [Member]"
       }
      }
     },
     "localname": "UnregisteredPrefundedWarrantsMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued in Connection with Equity Financing"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithEquityFinancingPolicyTextBlock",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttnp_WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares used in computing basic and diluted net loss per common share"
       }
      }
     },
     "localname": "WeightedAverageSharesUsedInComputingBasicAndDilutedNetLossPerCommonShare",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35",
      "r476"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r74",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r476"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r508",
      "r509",
      "r510",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "Amortization of restricted stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r99",
      "r100",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r117",
      "r125",
      "r141",
      "r154",
      "r188",
      "r191",
      "r195",
      "r205",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r353",
      "r357",
      "r369",
      "r476",
      "r519",
      "r520",
      "r564"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r134",
      "r144",
      "r154",
      "r205",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r353",
      "r357",
      "r369",
      "r476",
      "r519",
      "r520",
      "r564"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r12",
      "r72",
      "r76",
      "r132",
      "r133"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Discontinued operations - current assets",
        "totalLabel": "Discontinued operations \u2013 current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets",
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r59",
      "r137",
      "r450"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r60",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r59",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, cash equivalents and restricted cash as shown in the statements of cash flows",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r112"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise Price (in dollars per share)",
        "verboseLabel": "Exercise price of warrants, shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 5)",
        "verboseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r220",
      "r221",
      "r444",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock, capital shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r508",
      "r509",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r476"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 15,016,295 and 9,914,158 shares issued and outstanding at December 31, 2022 and 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "verboseLabel": "Schedule of activity related to our accounts receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "auth_ref": [
      "r202",
      "r209",
      "r522",
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r46",
      "r422"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r152",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r251",
      "r258",
      "r259",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Agreements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r118",
      "r120",
      "r124",
      "r159",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r376",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r40",
      "r113",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Loan annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41",
      "r159",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r376",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r23",
      "r24",
      "r119",
      "r123",
      "r338"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r107",
      "r557"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r107",
      "r557"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r105",
      "r107",
      "r557"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r107",
      "r557"
     ],
     "calculation": {
      "http://titanpharm.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r57",
      "r186"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r296",
      "r324",
      "r325",
      "r327",
      "r331",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "verboseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails",
      "http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails",
      "http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r12",
      "r72",
      "r76"
     ],
     "calculation": {
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r12",
      "r72",
      "r76"
     ],
     "calculation": {
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r18",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group."
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Total unrecognized compensation expense related to non-vested stock option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average period for recognizing non-vested stock option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r131",
      "r147",
      "r148",
      "r149",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r171",
      "r179",
      "r206",
      "r278",
      "r328",
      "r329",
      "r330",
      "r343",
      "r344",
      "r361",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r381",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r260",
      "r275",
      "r359",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r461",
      "r511",
      "r512",
      "r513",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r57",
      "r81",
      "r82"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Non-cash gain on debt extinguishment",
        "negatedLabel": "Non-cash gain on debt extinguishment",
        "verboseLabel": "Non-cash gain (loss) on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative",
      "http://titanpharm.com/role/StatementsOfCashFlows",
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails",
      "http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r13",
      "r14",
      "r15",
      "r16",
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails",
      "http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r335",
      "r337",
      "r342",
      "r345",
      "r347",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r156",
      "r170",
      "r171",
      "r187",
      "r333",
      "r346",
      "r348",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Computed at 21%"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods inventory"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r71",
      "r452"
     ],
     "calculation": {
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r143",
      "r451",
      "r476"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r142",
      "r178",
      "r215",
      "r216",
      "r217",
      "r421",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r71",
      "r501"
     ],
     "calculation": {
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Payment of legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total minimum lease payments (base rent)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r154",
      "r205",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r354",
      "r357",
      "r358",
      "r369",
      "r459",
      "r519",
      "r564",
      "r565"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r121",
      "r127",
      "r476",
      "r507",
      "r514",
      "r561"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r135",
      "r154",
      "r205",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r354",
      "r357",
      "r358",
      "r369",
      "r476",
      "r519",
      "r564",
      "r565"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r12",
      "r72",
      "r76",
      "r132",
      "r133"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://titanpharm.com/role/DiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Discontinued operations - current liabilities",
        "totalLabel": "Discontinued operations \u2013 current liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets",
      "http://titanpharm.com/role/DiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r44",
      "r58",
      "r122",
      "r129",
      "r133",
      "r145",
      "r146",
      "r149",
      "r154",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r174",
      "r188",
      "r190",
      "r194",
      "r196",
      "r205",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r362",
      "r369",
      "r460",
      "r519"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r172",
      "r173",
      "r175",
      "r176",
      "r188",
      "r190",
      "r194",
      "r196",
      "r460"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r188",
      "r190",
      "r194",
      "r196",
      "r460"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r84",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "auth_ref": [
      "r84",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different types of options indexed to an issuer's equity along with the different attributes of those options.",
        "label": "Option Indexed to Issuer's Equity, Equity [Table]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Option Indexed to Issuer's Equity [Line Items]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r62",
      "r63",
      "r69",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of furniture and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred shares, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred shares, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r25",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred shares, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred shares, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r25",
      "r476"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued or outstanding at December 31, 2022 and 2021."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Loan proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from the exercise of warrants",
        "verboseLabel": "Proceeds from Warrant Exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r133",
      "r145",
      "r146",
      "r150",
      "r154",
      "r163",
      "r170",
      "r171",
      "r188",
      "r190",
      "r194",
      "r196",
      "r205",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r352",
      "r355",
      "r356",
      "r362",
      "r369",
      "r435",
      "r460",
      "r474",
      "r475",
      "r503",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r73",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r75",
      "r128",
      "r436",
      "r476"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets",
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "property, plant and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r291",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r291",
      "r384",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r382",
      "r383",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r101",
      "r130",
      "r572"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Costs and Related Accrual"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r499",
      "r505",
      "r573",
      "r574"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash",
        "periodEndLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets",
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r86",
      "r126",
      "r442",
      "r443",
      "r476"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r131",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r171",
      "r206",
      "r328",
      "r329",
      "r330",
      "r343",
      "r344",
      "r361",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r184",
      "r185",
      "r189",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r287",
      "r288",
      "r422"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of anti-dilutive effect"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of activity related to our accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r13",
      "r14",
      "r15",
      "r16",
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Schedule of assets and liabilities reported as discontinued operations in our condensed balance sheets"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r96",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of the stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r19",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of components of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://titanpharm.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r293",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of our option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of assumptions to estimate the fair value of options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Summary of restricted stock activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of warrants to purchase"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DiscontinuedOperationsDetails",
      "http://titanpharm.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Aggregate severance payments"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://titanpharm.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows",
      "http://titanpharm.com/role/StockPlansDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Forfeited or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Expected dividend payments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Weighted-average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Weighted-average volatility factor"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Number of shares agreed to issue"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Shares, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Shares, Cancelled/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted Average Exercise Price, Cancelled/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted-average fair value of options and awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at ending",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Common stock outstanding",
        "periodEndLabel": "Outstanding at Ending",
        "periodStartLabel": "Outstanding at Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails",
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected holding period (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term, Outstanding (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Purchase price, per value"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares",
        "periodStartLabel": "Beginning Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/DebtAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r85",
      "r131",
      "r147",
      "r148",
      "r149",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r171",
      "r179",
      "r206",
      "r278",
      "r328",
      "r329",
      "r330",
      "r343",
      "r344",
      "r361",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r381",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations",
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r179",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfOperations",
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock, net, shares",
        "terseLabel": "Stock issued",
        "verboseLabel": "Issuance of common stock, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/JtPharmaceuticalsAssetPurchaseAgreementDetailsNarrative",
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://titanpharm.com/role/StatementsOfStockholdersEquity",
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon exercises of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock, net",
        "verboseLabel": "Value of stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockPlansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r29",
      "r30",
      "r70",
      "r476",
      "r507",
      "r514",
      "r561"
     ],
     "calculation": {
      "http://titanpharm.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets",
      "http://titanpharm.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r153",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r278",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r203",
      "r204",
      "r260",
      "r275",
      "r359",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r511",
      "r512",
      "r513",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r332",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r180",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Changes in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://titanpharm.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://titanpharm.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r489": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r494": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r496": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r498": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001829126-23-002504-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001829126-23-002504-xbrl.zip
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MCDPFMO3ZU<RWM!NGV7'W8QP'Z4X4G,GD0ODR/8O#X+J5EZ%R;)5;K9FO\J,
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M8+F^E$&*J_A=('1D^U<R\55Z6V/SQ"IGJ(\0$)^J7A\0"XX3XRVRXPZ3_4-
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M>C_,=E>F*/TSGF.&-[_UZO76NVL-%M^U]EDN%BF"Z  QR$:(EHE0*9*FH<J
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M\C5V$1#MFVE?8-["#2:2_7_O:*D'@Q^BVQE#@%A-M89HIN(8/AK:#\,F$.0
M*J)T2TRJ,GPL'P[1O)$,'#.)8QK)4R:,88R&,M#>0"+I W/S613Z?JL);;2\
M>1XUE*1_%[<1(B=/J'J<5M4PY)"X"2AW<"845M+$%Q*4Q (*6<M3$G#/.?B-
MH]EHJ<7 #6-2HXA%&$Y/[O4D;()U9;TO+#\(PP-[BA ^C,F)Q9/5'W_XO:A2
M1_=",2S62 @7(@5JA?2/F<7OBP3D<#B.E*R-:*)$TQ:7SV-CWL@3%ZC.DQ(:
MYAB@Q'"!\55D*N"#H8,,4;&$@TF1@;("@]I[$*<LS B\_ R9:TRR='$EH,H#
MZ]0'E%!E.CY=LD%^+PM<:IUT;G>(^&5IF[%+DR!:Y%BA 2,($A/N@L7(R,)$
M" W2%"BK"*)D+!_(K!_S*QR'ZQ+,*?9P$F@;'B=XDI; ]&@<]#610(41B^IK
M,Y(>1<((OHA*>K,Q:SNF+]027#,O%X;$MKL<8(<Z*=,>FB\?XBSM-6\ N^AS
MA%H)A7%!VC:N%PC#.5; 0E8-@!)&K(?8J%=;Y<G0'D)*#*=%6D/(61C0]#$A
M]FFYM5&LP347<2$:6]Q"DT)G*0)T@610+(,,60<8NTR:!=[-3HEVD6'Q8&^G
M438Z?L9:H6A@\': &/HCMC]^UB;\7R2H6GUKU-,E-HI3TERKJ./:1?.93,HG
M130-"(S2!?(T$%3 +)X6L5NX+%#'<LH][,-/<21U:'5'Q4U!.CA<\C #V$@U
MBQECXBC8ZTA&0+R^UQ\%L.=^W$%K  RD/\.2_&(VIR(M1NZD_?@RTC197HVM
MWRX;K@#M%HG"JT/@M]5 IW$ /0**"%J*0!..&$EKB#1?\U@7(AGA+X"(&%F2
M%/'VB(5\,,S+:'[[,M'V+L7> :L"FL&&F&&< *O@4H4&QP6S)&2JUL>5Q&B0
MF)G)<BXYP37!1YMUG-'V6AUGM' @O<BJ(NC)>PX?/-%NDV>A$2^55(IY 'F"
MC"?4(A3[UXS)M<HYYL1 E(0ALK!38D0A #GEY6$"F"H39#R_))_E)0>"L&F9
M4A3(B!EZ4XL NOZ!I69X"[J9]VK[_*2)?KWW+]4LVFS,PZ:6GPR<:;P;28%>
ME!X7[>_('HQOG.<1&G6,&A6*#CJ#4.LIA&HR6*#WC7\T7@_OU_.)_ X/4SM(
MB[$_-DC.35.C_8[I(EK>19I@7['IH-] Z1$FU@*6CPJ543QH%@V4C;$8,JO<
ML#;B.INH5GCA ,8EZ$%PE\=^%FMO1XO.JE0UI:C.8OR$69R! &>-D;KQ",YC
M!GUA_FC:5?VD%>]<IW.29C=,%+E[2/\2D4+!:Q##Z:0F$H0]Z(I<J^0\IT (
MCJ'1D]B#<ZJA$_W&H?$ZAWV"A]*YHL]IR [,2=V?S9,((Z@SL^976 .H7@S[
MD3T\""[(#)](R_X5C@NC^/B&</F@I0,D8MZ9NHBU8]0X^2M@@ZVCSO5,A/.9
M.+YA@LE[:&L4S&PXZBR0-!CK97 YK/7#UUW*\14 V1EH8.Q7Q<'3;S!+*-CK
MC-86DPB"3M]+*;_!;6 #]"30+2 $[*Z]B=$#"K 2=-'/B"<1>A4;WA&@@@0.
M&JXV*#)0Y],%WMHZ^6;;[7?>AO7<>3L#N"%?@&J);G;,]$.S]O@6<:FD4OLY
M<&!)=E)DI@3I6,H/MAC&/6KPLLLR0'%FMNN&A\R[#^@$E(6T>]@3X'",\7T
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M-(H"221?<Z*(B7MR%'@[;MK@I%&6F)N!ZBE* T59"F4"*9*H&>>94T@@\B(
M*5O.I%2BIWO_CF&K/_YP6 K_6FLP4)2J)A!,H*<3_:L42N5CN1)K9[>=P<=
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M1Z>PK&D6=!/*"[UDNCD#Z!3Z7&*KN$B H5 W)Z/.9BSZZ),@-<^>A:^;-<+
MYB;,8B=@6*^=EDI]EU!<"&6/XW#,A6*QDF\Z-\7OP\5)K B$0UT : :*^_<6
M)2O+O;Y-"V!'+RW.H985%GJ'ARY$(?$M2DN"<@+PV[--BI@R&&$8H:C (I_+
MGU158ZZB>B5JAN5KJ947JA"Z!+/)*=<I41P5YIBB@"@,%(6?&1(P$=+-@6IE
M25X+YPYI ^V$0'U"6]%E5CC@D3=MS937JRU!KN>J46.A:C6\[P V.*W-3W1K
M\[HFQ:+!)E:![,68*D,<EV,#&T5M::H^'%$U6,W<*,-:6XQ)EL^MO0-+E04J
MX)K^3D Q&M4Y^@Q_X&)JNOZU:S*Q'4:LFX$Z E-F&M;:QIFX7UPJ_42:SL)<
M*IL+BZ$E745=5(.<DFONV-I<@_S:BFDT#:7O5K4G,)7[375^$ZGBX=D-XU#Y
M(WUZ0A?")AG"/4[N1^R$VK$JTDEBV V5NW:0::B1R3UH6_+9G+@A^I,G;\_5
MM+*NN!OW0$I]HI&%5%U$48:R'$!$+?HH0(B6+A(JH*B[4>-@+ _==+J"3L()
MTYX$-6/Q$5U8+H;TF[0\,O-+]U'1@T-G/91:NF,^,>8'FEOQ5>+G V;CA<SV
M#%G0->%(K^MPI.V-.AQI.>!\F7;XNZ[#R,D@7C[4/"[]IJ@PPK<HO@QET),-
M72R&8!:)+/[2[,>71E>%V42OL$'8,B"<Z.[$\H.FBT[BL.'Z471)72[=PMU!
MJ&!%A.898>B_X9G,(N 1RJ/JRW!H"/9$>S&S3&/=-(2_8P00-"0QY^^2:UYG
MB[FELHP:KI.)L."C\M%L1+FK),V0]:,HQY4@V\8QR1JH&97FH/0;'K,C>Y3X
M#3<$04,4!3A0A0$;7*8[D=F]FAX7?!24Z2"Q NJE;;!LZGB0*YZ:%4A9/MN&
M/?+J4RYR=,F)?]WB\!IA>7W54;KFJDHQD$*7['9?'1<5'+E&-VQOV"TXHQ"#
M3[$: ($3ZY;&>!F -MQPP0T_H74)RP]9V<M>L1I@:IUV.U+W#MT+YAER[V7:
M8=&+I]UJ5 B))R(S=.K<-(C6S3_([O?E[.3\N&'B1H21'QF,0!$P.H>M7S1F
MG9RH810/R?5@/12 K-0[76DK/]K_BIJ_/!O3'C\4:I!2MA85C:;A<6B=D%H:
MEH58,5$@Q%:+ ,Q KP&*LHE*)WV8>"+<7A#+ %/)BHP4!3\&U60TX'2GS)3=
M3<=>+U6:QY56E8M&@[.N)F]VZKB\@%;NP-I"#"G:<,H>Z[X]^N9V8]W1".MB
MX6F,S%A.%)AQ<F"\&AGX*<BM.5&)10>[N5D'$Q=H:Z<L,]HL/V$PX@[!E+%N
M3D).ZG:O:W@[.6;!A$HTK!5U%^ =_N$JWPW0-&&<W^ _&'H9X(._BJ&(=(K-
ME?)CEBY,D1TNAL&EJP&Z0C4TA;(1( ?PM_XXUF;5-GA("Y$E!%V7$W;C!&,L
M8:TYU:]+;;2F2.W4'#GRB&< EQ'G0)5^ P4&ON/3@"]A5@$KUK(7/[/3Q>)H
MY:,BDL9-TP+KG>SD29K5N+C0.[1UX(OT=R-HLX>OC_[@&-T!"-:&/-N6M5S+
M'M.]\DB!,FTL7;;5)8KKIKN!;3]@0CLUDI 8FLE>XI2=MZ#'E=R+Y%;3B; 4
MQ;RJ>5):5'RH7GA16=<$J]V$8#/'K!IC%GJ'!ZQ ^AB, _#G*W;#87AV'PVE
M1+(U)0_%I3?0$1HV9D!PJ44R8FN@C9,JVM\HVFDVJ&@$JLRFFFP6-W3A12=\
MA$S!RYUNN<BNI_>=[5UMOZ:,[]JQ]B2H?P<S++<=&I/_='\6QY$"BT7&0<:-
MQ.V#\C<[T!,Q5 'RKHLXO*! E.)=MH9D)A+90(=V15W38YFGLM8N%8W7[Q$]
M=M./=]R)J<EV7YJ0!?Q865\$K6DH/W--:>U((DX>R(P">C!I0Y?^*!:/O:VC
M"Y7$9!RJR=&\[@C(T6>W!E1-D!9-%CF.>C$5^:DN](66K:(4)/4Y#BA/#S_"
MM7,E"9FB^5VE?7Z&1-5+]&"?&N^!K6-&=KFSR]/#]VD^Q/-]O8'G"W]3WMD9
M)D]&61PI$$[.Y95Q*>A2V.FTNF.9[C[M@T!-Y2V4=%1DDU&A:[!Y&#B@J!*7
MR8*XP+A#]%.3]H#K ^D^SH=:;R6?2:8X87)R=B.:>;KLK2Z/K<_'TG1T2BMA
MDN3(]TUU@$P?LGWV0="Y.TW&]O9W&J40S:+$)[?\+MJS.QT?QTT,E-I16CGW
M&,=,AT *4T]WDEGH\/$29R#?AOE@SI[91:V;+/0.2^1\+$(/"U0-$P4+4-A)
MQB4+>R?GWB?3D(("9VRB%OS4X()8)B_,C0L>0Z9R'BF.2NC?0XM]I(.D2XG
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MQ"#Y_>MHMS?'+%!C#VP5/T^LP\6>N-L%IFRP!U:@ ^019[A"131:]799/*C
M+EPSA8Z8E!:7K6#,:*)TH*VV0@"?"DU2*>SKQJ.P; FS0DU)2^ 8P-GZ:H@I
M"5'/%-8V26^Z1-THS@OY_;J)2H<]87=S"<XSY$O7A6VTZ["-[3=UV,9R /HB
M>W"G.;<_:'F::-UA%.18P&'F[NN%O>.E$? *(?M:TPLGA&4>>?] Y$8+!M5A
M*3Q.-UB1BHZZG.\V12C/:QE[^<CF>8P%2+#IH$[2%)&U:Z)XYYAZ0&8[_K)G
MG4GF"<?<=ZG]U$76<1P!.(9JH+AYR125T''+<F8O5]<I 7ZH",!3C#<>V*PM
MD[#&SB3T]=(V"I-1T:8D->8QLH>815O#:%^D[ -'NPF[34/,C.4XW\[(.SK$
MJAQL%J(0X'&3$#XP*6DZ.=Z..=-XU^YB#&77HZWR[!@/"WNQFQCZB$9C8]@U
M58NZ;$F[S8V/&QS=Q%T_3MFY.UZ"UC3GG"AP4M75G+4T4C4P1MLU(UN5A1(;
MG4[S[*357OC"+ E#<UZP]/L157=:]0Z[QN":1U8#FS3'31A(J4<8=8;75G*5
M!%ZEM=3U-TR82!LV.L-DW*52?G/OVQ!W=!-S^ <F_>L>A56T'DL#B0N8WAHK
MW;J&I0T7YE-"/MM=WA9!H(CY<5]R]28XNZ]#OG5=PSS A &-2Q5&^S&3K9D&
M5#]4( ?:?X-%SXL#O6",CG2!":(7;(@R:).G;(("V,(-]$WJ.UZ2N7<"W(H*
MD7%2."5LZ SMBR:ZI- PO!_<'&^$,BQ+K@TXHE12 0TJ"^6C$_^^BT -G<S-
M;+7&! ZB)<7]DH&:Z#Z[4(J%/HB2O @<?5'CQ([+@14%<@(3-M"&E$Y;ABI
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M^SD\5LJVMS2.:ZQR@W2=+$I54XOFMPYX^J%0 ^861:E3W1S6E)PH"JM/O@_
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M+5G(FEGB2+!D,E5&8WU.ZB31VN=>^]P?S>>N/2-(S[]).=0$WI6;Q@UBH*^
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M4D'/XYTPJ9>>$'-"(-)@YN)YJ<1+#&F(MY9.21X-T2[PKJ9-P6%VD[N93("
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MQED7>N@%A>;BZM6QC$80P)1"%S,P]#3&4+#=KX''DWRZVJH0@ '-7+X$!0C
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M59YZ86U)UUR]NU;B&>P@MX=4AX02%K,)Q)4G\ZS[QVW6A!\\OS'OW9UD(5\
M17GI%FN7JLKR0"N7\"A;4"97E'$M02L:7,?5P)$6^?')$@],]/C:F_G18''T
M]^_4_^WN[GUGI-6;4L^"P?.Z &N;[@U7K\$4?TVI20T6F9Q2'2IF]*$;96ER
MP:4@&:_6BN].WHYM$K#OLVWO!=KQLMO@9?MU7C:\"ZSL)$?= ]VG'>O: M;U
M@?144U*>85655 4E64A0'NA<K#F*'O6&A_M!\7M%1>H(QX$J*+T9(#<@??$T
MJ\II< JS?(6 'H@<T@N.$9$A P57V5@59F+,%Z)!XZ]!2=ZA\F)1<4%]3BB9
M'K1\=@#%J=3H[@[W0(DG;R=[T:D; Q<9^) A6/!%93OM\]INSKTN__*PR[]\
M-GC<Y5]N'%%WZLAMJ"./Z^K(H[N@CKS5$[@]H)2$6B,A=%K)-F@E1T#,>*YS
M>ZX4+AUI3 /&TE EH2A%3BE0'?1LGF0+3?%U/:&LX#Q+)^,J";Q"EQYYVQ+K
MNDK'21R:>(J>99)1$,5%F1-X?:HGL!/:9!-P8X9>,&5-A,M>C-9!U>2)0DT&
MLUP"W%C,H,.WV?L63Y2DDE)>1(R^./(I5BIQE3*X .?;.X?'RD2/$HG$>=.'
M/V'N48E>.BS@DRWH$>R$@_P%U2Z)_\OSI;@=NA+=A+)<ZG@I@F80GQB\UYN*
MH%^57AXN8JC5?9EG\23+&2,OTF-M,+'5.981!0^DEEQ<P534E22DEV'!>#Z*
M);KU\&DPA>6>8;83 510GW?Q6:,C=IX5SFV[#D&.O;ICQ*<S>5N%+F$_C5^7
M3F&F"&Z*W)VVNX]:KNMWF4(UC^M6ZX^=J+T-4?ND+FKW[H*H?8=UQ*=JK,M%
M\,*6FG8NS*V0N.^YZ:"48-XQEG:9#WZ!_3O<[>S?9X,GG?U[MRGX2QGGE9$;
MF=9N5*X=6+EV<O3Q$Z_WS9M+I)C<W*J_&5YEITE=H$D9(CFT1'*]K=-0D]J_
M$YJ4 ZKZ",8JEIZDI34 I<W52RJ(Z,$3"5F[IU[>XSLR6#BKZPTU1 I.!'*!
MC$9^U\.3Z92T;\#W6]6[ZP[6-)%SOKSUF9>V5"QF<-0&(NC3I_<G\M =4P1O
MEC8VBMJ!C1RYL%SPWM8<U^_^(I#LO^N4L7=A_=M_VX]*@WJ_9X'(N4<5_F>P
MW]L=/.90[.JD3C]-G^"*1HO@<,^O\LIUF&'K+<)@MT3$O[7/H4/1( 89D"ZJ
MZZ+'[*<IL1XQG=3$Y._;CO:<H(^9Z:D>Q]P)@A+8ETJFSCU<-(I$^SA+J9KQ
M4L]4CMTX'%Z9P/_T L'_Z8E[%N4K(?&$B5;LMH79A2P4.^9V)U<$S.V%R;7M
M&->F,:YZ18)-$\]65R=DZ1+KZC62O#'B$,9SZNK'A3<MXR"BA@\<LB;Y&\N0
M)>>Z@876FD9NVZA*3"$NPES;2AR8.W4PY#G+HR[Z4\UE@5)^K:BEC<D\9ZP$
M9J)>];IMPN-UQ^)-H=@,U_ 9M%AIL\B3B+2>87YZHL_4-9:4;L*]V2A. %Q.
ME+5C']_P!/L5O'%(C1T#W#0&^(EX#O:=(E@&Q1 1)95N8-.*R001^TM=P^-T
MC0:H=H0)HP9\R75;P-.D"E$1SUAJF/;#5E_X+_"B76;!XO,/X=34O( YF']=
MS6W&6]'B)&N-*0Q<3(%6?ZXQTLW7>=E-]C18]37B&)BM.<GR1;M3JV5\V3\[
MIX&_Z;4Q8"_P$/[^W?"[:UJ/<34[L[6&'O_C* _^]HQ*C]"[%;$$Q>KA,"ZT
M_)4$KS-O,H88[LE?SU5.*!!D!!  A/SA@7K8OD4M^]&RCA5;=+>W^3=Z0D<[
MBA'N92O,AMK:8[.S;EO-;UHWMVC9W=']V]TV(I;MX!8KI*U:V"Q@^?)7T3\M
MK@DYY,S9+ L ^0N) ;/=X?5MM_,(7\3?@%W"3DWR#":,+#/+?PCRR>C!<'>O
M-WQTT!ON[S]<'2AXO/?]99@;12#,,O 1E-0#+V)NY/>._/H[HTVU"$T&!>"<
M,>LQ$"OAP6#%'AK&__UZJK2/M44V+O'B8>-%ND_?/3L<[O>>/#JXF6]^U9K^
M\B7+>=(?'M[!M7SY^3P!6G\\_+I/?MV5^VT:E[KEGBW?K59N<*,7+N5\DM67
M;GAYQK7^E"YBXE<[\ZN,)H0PZ T.5I!VZ[Y?;4+?8#]6W.<OV(K]O4'_8'>3
M]^*::6/GNO;BQH7SQ4QCV-^_)K;Q*2M5<KF=H8]^P;'0>T&45:!Q7<LYKQ[0
MRNO'O</ADRLLZVO)_Z;VYBK\X,)M>=(_W(8]N7YZ6:<_?,G67)#047/>++MN
M_(2Z9MXD]FK=,<ET?A*@J#G#?=# 6A(HZ5OM1I7X>?RCPB0^^:^?Q%?[^$UZ
M@#PWSR5=70UV?/E/M;#0%H[\E=ZZB].RKND#U^X^)8-L38+65\W[9KHV,Q%C
M^^/>,GR]U8.Q#?-,IY'?!V>X.]@//LS2>%05)G?C#2&]84&VZ6Y<:RGFPO2J
M*J=93AV@)%X.SPYZN[N[^#_36\S?S'8NT5VI;;]2PXVY4I0F4@1D58$9F>[\
M7B%L0(PTSCDM[(N4] X+PD7$'JASA0DIA #,.&:F+ XS0PPPF:EXP\ K^3$Y
M%0YO+MS'/>\"HFN]'[S"(KD IA7F\=QO0D9/XS/8N58'[[-2,RLXL)T.;<C7
MM1F[Q(V\[S&;^Y7Y?!.Y]H/=>@W9XUO/?/[_/NI"YR (__][F8F\KA)IT%4B
M/1L<W,M*I"V@[(Z_7ZZR93"XP<J6)[?.WZFRQ:!WVW(6+!6NJ'DQ:5U'U&P]
MIM255U8W.C;I</3,1Y<1]\%FQ'4E++(BS J,PYM?V(VG2:'&$C_[<(:X&OK\
MQ[_%SRZ1ZO:M5M]EO%TQY9>LKV .5MA,A;HBGDN106X^1,V6I+5RKN;T0.%A
MDS D<3;/8UVJ?$'-='<P+S>(\FIB^EXOT"-28M)<#T%_WNLJ5S\6U1RW^,D>
M;C'\NV<[%)>@&Y2VPY-.,&LNG.99"A04Q86F>CE\F)%)BE*K:,&&FOLB=?:C
M24PES7:>$>8+K,\#9U:4EP>K#FV+J(+!$KCDH>S;&7-_8 /,'Q2@=B0]UND0
M8R11U*D( 9^QT$(%L_@/2A1!D)IR"J>5ZIVS.%TD >QT2?C:\+67_SCB_&"9
MK0"UA-S:4-*,N6]-AM PTN"9OCI38$;_89N'@*4+-,;V,R8]1[,X-644,"SH
MI#CE!3<>&<&1C='M5<Z!4^-F$VQ/A#.F!DR8BSPC!Q@]7\1 8XHZ/6##$LFH
MUM00O'%JU, GNE<9S!O-!CY0CGM>E);&&'A1TM\M_9<ZG*99DDT65%H$OQ]5
M\VF<:K[&P0/X,=>@D-,OS9UX:!IQQ9Y/55+\?TUC+I*%VU @TF2J(F5[O;VL
M$+44%@F/8<H]WI9?'9O '"VXT0P;Y+,,X%@9W YL^ 7L@HPQ:NR1P'4(Z084
MK/L*Y0-[4-25[B"846>0!!O5PGU4Q$:R'%A&;6E]3.* ]]T.6.3*0BX?%D5@
MFAZ<]W]YO=[B9/4O?PT>P#Z>QG_,,E"\]@Z&3Q\2+#\5"3 3MDT?J39#Q_0G
M$*6(C43%&=0N+]>1W[&+&- GD+DI0?ACV8-,+ZI-3/E.,<M?Y&CZI_T N($P
M?]AU[&07('YHR6[LX>YP%U>K,&4:^\%A4[\LK!C7,P%^@6>+$-I53JWH4OL-
MOXL?_&Z2J]G]JNO::'[Q)G7IZQP\.4>9D6:5[0990W4]S_+/U&&P44VCHC.\
MGMQB:)YDV'[:]G-4"9 9%O><\9W2Z91NNM](B-H5])Q@)]GFNB?ZK21[ 5#]
M!*')L.L/PH*9G_FVV?[4<#]&%G?.MM%6!58"].3F20,A?M/K2T3-*0S*[9"V
M!9D@65882+*!(>DIB2TP4E1FC&,;_6RVA(C%NL%W4T8KVSE'O85&,!V.89HJ
M-YWT0%2'V& 0\TFH2A,L:6Q5X9!Y[6=I6XD3\NTECHK/%A7J1*05N/NKJ'W@
MO,HIM]MI4^UG)GN!+:IH+[B?%36S8HN2VLZ"S'G#F';8<./M<?  ,_AUR.W[
M>J:VW3QLB^ MUU--G./A_O<MS2!QEX0ACN.$SP)>6CCW/DTJS:B@#/4ET*N\
M;H4V!M$+M,(Z+H3X R:+<I 45-:ZVANJ! ^0@<I2J-C+K:/$\YIKN@\SK4TK
MSUHDDBIIX:2/J@FP :PAICVM#7LJ8[SC,<P'6(GDVZ6LI:[QXECF/\_ SJ=B
ME_;+!Q+)5:E-&:10A(E7+@-/-.9PKQCZ1EFV8,(?8\([VGI'80A\F^CN!(R*
MT+ 1T@&X&^Q+F"7>KJZH=^-$]2=NO3M77@.ZF@QVX4WI?8=6.F8SD+Q6CCC
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MGDZ54!G,'ZFWF,YA8XXQ#,/F(7)J^,Y/613\I.#Q'&\%'W\CBF!6V&)P<LC
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MK1#Q(Z4<1Y:US4KTT^>OWM&R&J(81T^K,H\E!8W4$UU/QUM>QK ?'(E-*WF
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M$$XWOVY^W?QN8'YWP,S] O7P%U42?(T.GFL]TL$+_0^%74EM*X;M5!D?[1Z
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M$G-3(@ID,&#5;:Y:EIKB//7B&<Q%M?*V$G#EF",/8>]$,D"XS$L0V1)0I7"
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M.4IEN\P*3W7J3;*%LEYN#SZ<(.J(V'T7$9?8^P9^@AUDT* .?4C;E<@CBDV
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M]GS1RUG=X K&=PA>,HVRZ%J"$98>=C?-09<LAW?K@COUO>FRZG065WLC-=^
M']S8(&]QE[%1S0H0=1Y1E@0!G 9M=>G8J#07C)\Q.F'<Q/*( 9G@P4XT<F)'
M:L\(0EXH+57?2/4(69K_FF)J[E1T3WU-4 <+1"&3,MHE%?P\OLZ(&I7J&_@?
ML&MS@ZH_O\Q9ZY3,R9FS5:EN@#FE&C)GJV3."/)TZC'6QLMC3JE5WVNNF3EK
M;RHM9,YVR9Q1;IC8:G5*]N2>6W5O31"JGE7UAI[JG9(WHVST1F49@+)MY\[Z
M7F4]0'*>;G@C58 [:U+)G1'481 $)7/RDWU/BFF1D-6Y+KVI-) [JUEQYUHA
MRK/%H)3JZ]4<.6;4J.ALQM3(/&R[5DY-YVBIK@=2K@ ,66_N-=:K.N-BGR5#
ME@RY$8;,/'Y4/'[LU&,N)EX>/VX@:%1[DVW(J'C\6/KB6^Z+%X\E&Z4#7AP'
M/!([.,.$+P]MSIW-Z@4CJ[Y[+9 LLH[( KP8;R'H("V[H_!4I!]9NL=Q-?%Q
M)EZ!(KY@ 9_H@L*J]T2;L.)%=SSZ$ACTGEBV8(#\"]4ZARUD^'P-#^60U0,%
MYH+/T,(AADQEJ8^[]$F8D0ZO,BU<+'\V 'M+A\7/3(+HD#A"3]9HS:,WXCVO
M+_2_0AM-$Z+/8"IN(:^X8K"]*[SPP')]*%19N!X3"BU\1H@+R78=+-RE*)!$
MZV/9(N..7P[EVX'01>Y6X>=3G3.1*'SZ=$AK=]V_B<CHJJZ8!*6'L>R3AT''
M #X&IC$2!EC=-J+5;%3BB$;ND?/X)RAP[%/%]@;W$((M1+FE57;JHZ ;(U4G
MQ K!5OI ="C\<#[3K%0.L$P>528#=!)L4OS%%,Q41F%V- _0%%2!?D>8R.NV
M:6@BQ?5U*!D"PNHJDHC:7<3EPQ)G8W9/U-&(]%6&Y=0CBCQB,DKZI?P5NEP4
MY.^:C&V.W.IMMP\W[;++[+DD"I;3^Q& &*>XSV/; U#D^+NLRE[68N!E9JKA
M0R7GLDU18]UD^S%-MH<O_2'MU21$*60/B@SCFOV981%3F= ,BU:QNH_-E+3+
M'#N;0K #_7\2FR.QHWR2@:K'B H_ZV:)%SCAPB<L/5D1O/&!:"#1!-$?V2&F
M40ANPP[#@#.4==.RYQ^C>Z#IF,*X1RQ=1%Z;U07"J_G+>8V8:9.IVOXIQ?&@
M@CJ1'6!-F?H&,&NZ)"0AJ 1C1(1 28M+H+ZK!'%_9N<5 7./3S%4-K[67& +
ME+KFV2L$80 ;DQJ: 00]OSJJ-Z'R&5-='H,,OXTEY?/PI!HEGM0^.*\EGE31
MF+K(L"%_]?8OB6ZA=>["CY?(*$4[?KZ",6* [().',/!@Q#=8/+X&-SP01B4
MV[67>FS+&<;W=I\\1>9@K,4V='_[CLB F(CT>QA <"_%MKABZ[600;F-%E7J
M5J@]AS6Z,O%SQ@,A%'\FR-0Y"_(&_C)2;9N .\D 6E6+/FA2\Q0L*8Q^@%."
M(9YJY1UZ2XCV[X5QZ.?2NZ#KB)A)O,>!%8#J%Z1F]=7H=1"H7X3U37@L"1UD
MWDH +6+/ O;!]SU$..8S/8<:/;>AANI.)HHD\##K<45!I, M[QNTT8Z!1,*6
M03#/'O-PL>.+90.!8>L\52O8\J.P8(KUBO3JYVN&.05#LCWPPN-B5&P<*8+=
M80Z&\!Z-T!8_*K:62"DT51@9+Y36\OJYT/8_7;<1T,LPJHK,BJD%>]]BV]'D
M(5W$\P0US-$)JQ6I$^PN]?MOB]M+@>Y@#[.K-J9>:7C=X$V[9%W'B)S7NPNC
MC+4JO4]C9T74X!;58#+KR?+[;P'D/8Q@O66$*NIN1RN>C #O JAV"1<ZE361
M_%7)VZP]8Z]"W4EWYO1>2_$=*>Y\I]GJ^%N?^MS3G.R!H3M>BT(_;@CFE.A>
M$*+M!G::I9C$[8&*'_?H%0?\XM_$<8C?D(6D^'9ACU"P7;#,3&[=(3XFTQP]
MG >.YHS1@N,7YD.5HF[J@<Z ,*^Q/*%B!(I#D:TAOI:C;++H/)I3A"&TAKMA
M+6I:5VJ;4MN4VB9#;7,#!_L[X8;W^\7&N%3O1-JSPE#&FWZA6N<),6@5L Y$
M/%\F8-4PM%Q) &>(NH(]$NPJS#H[#WC4"C,7L!V=37^S8<:SUX"V/\5 7VAP
M6D'C.-ARS\2/[9#.Q/'O#*/OO@#=;E11AJYSQY4:4Q$WC!3['(:WW,L[[ KK
M>GFT[:O;.9521IQZ,2A)5'*VQCI[OE)?,Z+X#8('7#/#$$ 0"K@G5=F7>)H2
M_X*;0\1U/,Y&A '=$66T_013MN$'PW1/ R1C4(W3)]Q'IM\S$ XO#JZZ7L]B
MUG#JE7K/OX^O]1(F\'X3O'J3[J*7U\3>Z-VQ!OOPL8MPORDWORB;VF!&S] F
MJVR'@=BU"IM(7YY8?E('ZT4;6HIOKT9NZ=P]DOV<%32;IT:>(5)Y<)4'5WEP
M;?#@NN(Z!D7YT  E@NTBYAU>KF=KZ&1W0K Q,[;_#FH<W="IH6RSS#7461B)
MQ#MG1;5YL!4];8MJL%(#E!J@U ";TP"'FOR -21)A!Y,BP<C1NP5/@X>\M[M
M@2?G@CJ3CX;F#=@_(_X!&(5@H6&"+TMA!:=W;+CQ?FK8>*/2;"':8_BE:8]M
MNL,#R_4<3AR_EVJU(K6#$5QAB0#NU U0.)(KS\9R)RR2VUP0R74YG_5(F0WD
M;O%54GE0E0=5K@ZJG$=T6?9T&=$MM4VI;;9 VRP1T<U-8!8;1.8G+CL5( T8
M3T,26BY6@VQ%,+;4V:7.+G5V88*9OG/G%Z>7T<S4BI*:95'2?JU6%B45CJFW
M+,AV0GJFBRPB!9!%/$R":(01[\_1&8XT!LO;F@=3TYG-&Y$TV?'Q2/ZHM>DO
M8>@1T:N[I@D1V#1X=JI^^$_&*E';>[]?<UVKL)P):F-?@+N/'\:N/33@P#%9
M(GU@X-G.Q1'#!&B$XP0\ =7#LF#/=C6-9^O[KV8V.$,SP?IY++>V55I,3:,:
M0.:RRKG0F!'YVST?8Z4:Q'<(!L1^_\V+B+F1- ;_H *W4\X%_L9['!N]05Y"
M([S"[_%BF"OO3UBISRMA7J-,F$0Q[G0U&*7C7BJ_*,*)&);*YA%Z>]B1M#@J
MS,A'A:%1-2L(#1.<TQ2,C#<I8P9TAEF.O%#'FT1X3>@+@Y(8$FT,/K'EH%(4
MK)%A8%X7^,)L!2)&]S2G[T%0P*ZKH"/=Y2/X"P6I8,7NBF.:J!?\>A[4C%[P
M,I11CG 3X171.B6-0=CHY$&;4&+KP#&V@SO&J$@>86S7C26(;@'J"BQA&]W@
M.U419 W4$AK!]X0N<20_JB-$Q,%Q*1H&)0G.5[8L8O.1]"$-  2Q/NB7]U(I
M#X"O+E4B\'S(L)3%KFO1:B1AFIE^_PVYB0=:H@]<?M^5 !8L<"R_4E\'PAML
M[_P(!_RJFA[H@L=5O__&D5M<K@E(*>6>=SR< H/#J65@* J1D2BT!T:1/+GF
M,O<>@U17-$CEEL-1,>!\SOPG@Y60R;XB8//PXD[>:4M#3\*#X6A]FHRHPQ%M
M66!K *_[G"X$WLI$>?;RD!,3SVQ9@QD$*$<OI^F4V#1<HP13MP,[9 T14(D+
M-!$<^%<35)OJA9 5$(5HXL$Y^1ZD!XOB339@,_S^6[31@$&I:+-!.)FO*K!,
M[I/\))LP$JAOA8/Z<!ZSJ'@?#E4RP";4//QWP2H/-R/1I=6Q%(Z39[U*=?>8
M7^J"W>>/A%?J]4ISPU?JN=V.[6>XHD2(D\5]IX*J\U!50U^=(4SBP.?&(Z^1
M]^V^#J!H7V!N$!A(Q:T%]4$!WK"@09^ZGN&73S9L!^$97@-[@O!L&'837C4J
M?[YV#]3 I3EUV]T<<G'>RUGR/Z@5''. D2X\7'MLV@(-UGI3DBW5"EW'HV%$
MK^3!DGD# W%CQK_DH3<[/BH:,\^(#"<S VF#I2=;D(L;P"R%'II(8T)%$.=(
M[6<%3MA[+Q,.SE::;0<R"/,Q=-R#$Q:9&!D(:S>;2W?HW? =&K/8;OS['BGG
MAG9>TQ."31;H%=@ F:<^>.OWB,_67_O3PRYP<33[ O,L @8D^$CWZCUJ?+"'
MQ@;ONLYR_NCI@I8DM8!F%K5,=#VD%F:50M@U*!55D155]%4]FT.D!3)$<Y]Q
M+TMFI;9]9B56;";N=?ZA>YV/:@+8'E;*OHOO"+@L8GR=5;2T+[C/9[/P'<K7
MBV_U!?]"GZL0U+)N'D$P@#&E\J+JLF14%*K19_.@A5I"N$;+AW/VR[/<&WQ\
M8-81Y-H=[_%!2%B4!+Y,<XC54<\Q+;;AS&)E[V>O9K-@[^>9!,+"O .$;9D^
M:?S, F'II (VB10R"[;*B"R3#<ID@V(G&\QW>Z5JF6N0=JY!J\PUV*_5RUR#
MPC'UJD!62Y_>;J^75/&ZCDZOC@]O+JZ$PXNSR^/SZ^[-Z<5YFGA=JQHI^=VX
M/+ B[-RU,QKQD.T1OU<L(3$+M:*T4@K"AOQSUG83CN=3@]VB? ;3MF@V@5]L
M0^_Z*+([6#CN17>@0(?@?6;?A7<'UXKM(+KKZ*?V*9;K5&8.M9@H7 HZ?/Q2
MW<)K++<YBS'X_3>OG<MV7F!EY"AQ4TJ!_97'%LS!_2GD0RT,8#&&B?![(DTU
MR3?5Z.H?:)\G)JAAFK-N:&@2Q;L-4X^[S>_<5TI!FD:-\<PINB?P=V#AZ!=$
MS"ABU/F3?-9"84^1F?[>J>ZDO.@3S&(Y9C)MF'_U3.'-/MBN*@U/'<K6D'_T
MZH_7+XXVM(N5T*5U@2^8#.P=]#WK"&=E8A!?\%2:F<VTG/'^*PDV%7]P"1LR
ML5[<?I_#P7_,:E]/O=I7FE,7,D1?KD L!JZG&A6F^9+5!B9'7="$ZI)M*$%N
M#%O6,EC_\YH2FW>]5]5*7:S6VF*UT7@=UY]XMNUP3)-B;G56,7 _:PE^-"PR
M'@K=/:'[DV8 5V,(X1JO?R:Z-VW_&4US]#X6C!\URP1O3#BQZ/'_F/M,:^H9
MWGZX614;<<V8Y[Z-'7*UJ4,NJ[4E>#!F@3&MGXNW4VVQW>CD<#';M37E:O*[
MFI7$IB6)M>?*3<X.PV247[HQ/,;2UM*)?C&W+'E0Y6%^,0*3AZFUJV*M5L_O
M_'),NG)JJTQ-JM?%]DH<]SQ-^W6HVB0#]=J]-^6A/,+.C[LW3_?J\Q5MC/^0
MA\VKUL5:JY'?^>68[\NIE5/+O9CF4\6^  LVQ\Q43JV<6CFUE::6^]C )79M
M%3[M82&)12;;;;M6Q&8U\:&X.(2=/W8KIU9.;<NFMIS0%DGUED9M.;5R:N74
M"C>U?,8(CDU5$=Z;A.@]8MYMMR&[U&U7:<B64RNGMO&I+2>TN5>WI?5:3JV<
M6CFUPDTM]W&!LSWA2+Y7^\*9K)S(IB;K1'A5?[TB78MAT38EH&9IT3Y_:G/R
M@/,PO1Q3KIS:*E-K542IL@K#Y5X-OP #M\R:75W/EEFSY=36.366-;N*"9?/
M^,&9;-M#\B <[@EGRIEC]HVM-G"EMM@J#=QR:N74"C2UY80V]RKW!5BT.6:F
M<FKEU,JI;6?(]J.,\$!7:,J>RSU1^&CN":\:6QZR+9,0RI!M.;7B36T>YD&Q
MU? +,'#+D&T9LBVG5HRI;5O(EF4EG,NVK&^U95NMB?5:N[1LRZF54RO,U)83
MVMSKVA=@RN:8F<JIE5,KI_;,6.WS>[&&.WU=.1K9==L_!=M6N?"_C3]W]B-:
M?M%W12,H<\CV(#(SMIWB_PVVG0J]/,OF&B$"X=DP3:( X'&B-ALP4DQ?I)F-
M=;OYQ;<+G.H9&V4-IP6ASR#RX[O_12XIO==W1W#,VY9@#8T'[$D\-HF%O?M8
M*U,9?NIC:\^!K)JTL3&P@C$:.S;KLBHK"C ?;0U*&[6>=*\/A.[UH="2VJPQ
MH&Q9SHBW"' LK[LL_3:\:DP4F_55)N&^R:P-*)M"L#VH3-L,T&ZO%J%M3F$@
MF,FY8?-^.6UWO(&JP\Q468-'80VT!6RH@Z"0Q"8J+%]5-\I7=._O[DQRA^RC
M.[1KD;^O?!N'H'6PM?!L7Z,'V1)J#;%::;V@+:MM?LNX.@!% )+E-U+'_L/5
MRKMP3YM0-QOZ#>D=HOP[(QW;H6M.'[[M][<:X,.\R15VJZ+[3)MB#>5[(O0(
MT;&#,^OY #(,?Z\A<^#[W5'\/NX::Q#]@KBCOGGN2$&@JY47M&6-K=BR>!V\
MM9UW-]]:,&4VZ!F@8IDMWS?@<=VP71WMMEQGQA;3O0I(H R:W=?>P#!=YPZ6
M($B-0._!:S*V&=NX'XO8?1!TMN4/C-::8NA]VN09CPYVJ,AC;.T,]AG8A-BB
MD%IX0T/KL[Z%,#Y.T20R#,7/(=FQAP8V5^P'^-GM(7\OJQI=(9XN*AB>U#!U
M8$M,^G"U(C5HNZ6];=[N%\'0P% /^!_=\)B,/!)34;F+X7>_%+SFEVYG3632
M'') ?$1@IO=WN^S]O5]KE+V_BR:XT:IIA0A3XK;%@0A2PM6F;XK^N= 2;65N
MB?[5XX.I_;]WY-M*5?+:*9_"^2U(J!$#S1DW8*UBBVZB@(JV)\+%@P[:>ZB.
M48$?<EOD@.ADH-* #OL[-4#.9!W$!8,[]-<KHLEHPUS[MH2 -5CP]9D5)C-D
M"]4B^T4<_K,MMXEM\5"@3,_\,]E4AD*U3BW2FDBMOQE[D=L&BC$:&3H/+_8\
M'M/ )GW0F37Q2GTM$!E&' ,;P7<?A@;8E\)/'6.F+* )-G./T/?X0] !Z!M'
M<-I@J$,7!MCR$X;!\S%J!N_@9>[;7..;,K;WBVZ,5)T0^D7WFS 072*<D7TT
MA!2'MA8U!C 1%!1N/5_3UN23<$/-&R3A._J.5^K]:P&6'C#[\>.( 8',LH!7
MQ.,]H1M)\@<B#.4^>@45J2E6.XT V4,D1T,=9HTO,AS;LN$'V-F]H+@;GCH
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MN;A)%!()C\.A.K9"($DW<,!9LL(=&?S+D8LR<ZKWR9A@GI!"IE?] HZR(F-
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M-@_BCDVRRWKKX'?HW]F1H>^RWS!X@I3DJ7I\8KXQ&WJSZPSC&Z-)/Z*-&.$
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M:C6@<VT*#/FYFFH+,+87L4()D[Z=6UA$ /4W-L+'PL^___;7V!UR8*"FD"I
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M0:>1XU*ZLTCP4RL-]$?=M,@/!%+6I;0J<@-9#I46H.%-)C1'V]>%<4]!*)_
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M#4=^*@/CF/$[?X!:WL&AN>@M3 "8+ 6?6"@&0=Z$$\<T+%6N4WDCB(+ I10
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M!H0^L/L(MR!>Y74P22JEBLX8HD48TM$2@BV(4AS3YJ$$ZB1UAP5+5)A+[?2
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M'T0]\:/J#NQ4/#1?Q%(!,9+\>5J,&D&0-DT71-V69=XC+H6P3R6:K]ABC\L
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M$R9.^@"Y)V..&/5M^557$_7*O/>M ^:;EYRT2/K0T/Q=MA4ZCK =*^HJO)*
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M3B(_!./GHL9TX]@23U0]X8<BN:^]=VS0/$QY)H_L0U@5 G1&A?+B8Z ]8 4
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M2RO;23[[^)9&%$^Z>9=6+8T%G')J-BH>!DY77E3>Z@+S68E34^L-_ %-*OA
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MW#3 /H=;02_:C C+*7E*\D$0ZA*,C_ U<=OP;2]HB$?X\V)VU$]1!ZN%;?E
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M.T)TNR\GR>?OD2^+P+-E VN"/(WZ5BNMJ>.K"KV7'BZP:Y)3<)NZ[[EH#2,
MO%PB-N)2.HKU8WVUHVZ[RI I78(W31;6>H4GW!TF<GJ;#G?^M;2&:,P744Q3
ML:>Q:Q*ZYT9=;J&7#AYYU.%R ^TW+2!%3'P*0ZWQ!D4)+D2*Z\K7?&H31QVA
MB3ZWPTP%CB\O#7L_U36(:A#>$R4A!AE+Y!\T6 N6:TCO8$3V.=&WFN\!3^U
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MA]&U<&=IQ^W=UQ</#;LCEMRCN$\6;_Z\##GCOO,0(87]=UF(^;A.0I^0#/>
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MMN<V0BTW/VW#V0V 71F#]*(H/A"T03\;QH(VX ^R-JJ"YTG:'(?:<8@R(*(
M=  1!TU.E<'<UN7NTNJ$$/-B+#[P\ ?#;,#AX6?6+(@XZ.CP_;HN6?BR[ 2+
MASE09[GFCY"@CT1:4443RO(ZX/LR!$]O3B1%>;-D$1XO_TP4%$D'LFC?!L10
MJ2"12,)G="!)(A&!S%(7B9K"BP!R49KV_R+B(I'04(< 4U2(VG/Y.6*+9NI^
MHFHAKH.6:NDIF$=@G&;] 0OC- 0[BUTKB).&;/F,NHRN8A;W11#10?N^_5A-
M<5E$=.-+&XYW&4P+D>D%>)Q\?;6RGU<NO3WQ;(N++<I*18*ZX?'<=U=<FRM7
M8%?&&[T0D<-9EPS)A@(6 BDJO.2'NS+C/NO/H3\7 7F]7,X+'3G].F.%L=WW
M&37 &RINY;1#&M_EW89WN7$.B(Z5E2MT+6J6NR(K[]54]N)%/D!C*! (!ZV$
M<CK ,GMXVL?R$Y>:W9*4]Q.DB[#D!8Z<A:7-)*GCL)1# 27K#KU/PNF*N91W
M%;$362$Z3-$!)#.#. \%B;81EFP[N905;ENR8L$WE:R[\I11UW?+X#SF<T\Y
M3+.A[5.V^8=[&Y@4NY#!G!DG0ORI&9UWP&/VA9OK]!4)5<G #6$FG/27#;C5
MK99]4MPFX YT=\-]W+96?$+5ZG-*E+._;.+1_D;#0M,%_6-9M]Q_;X7+SRE;
M[O^VLN7N5"$_!*^3VK-HWU@!^TMD_(5*82/N[<X%WM%5L*^ARK4;6@"*&-@A
M'VPM(+\50G.L25SB#8E3'>$OL\7-GF5S<[B"UK(26V"M8-;]5(! R/02HC^"
M($-3>R&XRYIYW"SD1_F7GILC\1GG)J) ))Z)/&=RJH4[YCX#5;VB;8<+QC,4
M,K=9G^#W^RF6%2#Z%@GY,47 =6RCAB;*0$,YK[)@\-8=1D+OB[QF0^=N.!;-
M_ BXK+,;>E7I&&KJ=H.IEJCWC6%M"/_O(:HJ4SAZ.898B !& '?P6LOSP@&G
M1(3GX<GJJ"164E2'=\5)F)_1>F(=&@RU703;D1=?5D69%T?0K$HL>V#C_&,<
MK"3"STM61^RUAF=5 VK\%/,G]]<3Y8?_78SFN-E*S/@^)T-S(\)C-$)FY;]]
M[L+0/Q%"] 4@1(5PB[O8,\012UKM201EA-0BYV.VPP':'H$ER#BUPT%I]E2:
MH59]-KYHDJ2/P=?. SJ+A7VE?4@]9XJU@\#[C#'XA4;?2[2:1^T;=1P*&5=X
M _MCW3FT?9SBXD82]5R+I4\]GI//Q/5SJ',S15:&<TBX.K23$9W5^#X8<FX?
MS'G4Y/89Q2+YNS@CN-_(.X'Y8EZ4!QT40'(_I!1/)._BF.*@*\KB14_I.N@J
M'XG>Q8'EN0Z0[I&BRM7$71Q0>5F$]\YIZO#=_[4=5PQUJ<;W85"STX&*.D=#
M&R#.Z1PT J"E^&<7W=SIMM\\(TLH/0L?,K(34!=N#GXB$**\Z,<*1\:AVCL.
M]$ S]^,;]Q[3Y7S?#F_?FB)S^&EQM^:\XK-U:)I%.O3V]2B>1'2S :ES?YVW
M;NA.S_ZO\TYO[>57>"%W_ MV6[T[Z._\(;?,<0ET]>72R&?&Y7[V1^0M';^8
MBY.QW!616Q"9[+H*.*M5?1^2+&[MWD/1[Q8)0\,<VO.(:HF1HN+P ,LZ%S4"
M6!3\_!$[OGY<N ^$FX*#?<"B;'%O)'.76%"&(F;G7549KAT[XN$JD$1LWALC
M^)N,#H9$@*3^[/R%2JG@KB"@M[!?:D^YNT#*(?'[R2-U#'VKN^,>*O]<5PNN
MEWQ6K2.MLAPJZ (5AP79-+.S)NWB(XLV4/P9YL'P'SB@L?;$$']BE:JH/!,,
MPSS1-$71@;_N@H9<1 G]DU%"D4078D1 'RSS**V&S*0'E'6@,'<-E(@,3U^"
MWR MS8&/IQPNS8)^-0><2EA1K\MP%,8JQ<)X8%D'B_^NP1(S5-4*"EA#2PB!
M9<%.'!W>0U:'=P\CZQAA?SQ&(B-5E*RN#538@\<Z/ (_'AZXP:Q59(0*>O!8
MAT?PQ\/#+@9GM;$*>?A8QT?HKO%1@::*#E3('[8UULI28QW!=RJ"K;-F#1D0
M#.FA91=:PG>-E@/<Q JO=RBKK >0G<XT\F<C9-D^A?6TU9WXN&]OZX?XL&LG
MASQT[$3'?7M9/T3'LN>JAX_=^+AOY^K1TL4NJ.G!8P,>]^U./>![MX4+]I-1
M'N_8"8[[]J-^" Z[]2WIL8Z=Z+AO-^KG_" >7+;@\F/=JANEO0,>/G;BX[[=
MJA\&%5&^R)XB\!Y2-I!RWR[5,P3/RLGJ29\]L6@_T<EJ!:VN1- BMLCZG/*0
MLA,I/]S=N@Q6#%M-'SQ\;.#C)SI<-SF)K:)8'UM1:!Y2MI#R$UVOAV4.[3&5
MW5"Y;S?L<5!9M%"P/F>L:GP>4C:0<M\^V>.0@L,760\@.P%RWV[9XP!BQPQX
M$-D-D9_HBMV$B",PC?)@LA,F]^V1=<//YF%F$S/W[9L]S>8A*-I#R<Z$3\\;
MZT3)837E"FOM;'4H"7C-2-::D="WW8SD&]#U%>^VSMW58KT=>S!1^,\?W!M)
M!_]8%+^M95+%2+U13=3^\756%7&_<+D7X(>[F\^<L9B=U6Z/7Z&(2Z>C8E&T
MR\6BRHZZQXB]JY!V115?UN/R2G8M9/L*C2$4Q+__%/ZR/CBN!/>C/?*RFS$J
MZ2,@GP;/&1H4#;B8CVI)#SB/#B TN%-6;IZHH_(_?4[J(H&$!C+@9JC6 WAD
M%1@R_!4>D#/TOJ+"]0G/WWAJEX>@5VYMYR&YK;G%H>;R]R(NTC*;]S3?A'N#
M/O[/'_09VW[))=0S]4B1**<CU4(DEFC4,[%(OO9(9(JQZ];2]Q;,8]TM#KY!
M7^ZIY^N3OL$Y^R\]Z<]@SF5L[0/PS9S9#J/6S=E'YW\?G/I.<V>CONCUGHU/
M\VTVM_)@>HLPQ8;IETW>_=WW0'@'(*R+NO0-*+1>@E_T25/'>L\7VSFQO@BZ
MCFX^=O^>-</GIA?XC_C[SWUMBU:?;S4P^NL?G^ATI[CK+3W?POV\/^MF?2)'
MNCQ6/HUE"6/;K=$!DC)=N#.ZT*I6IJCYW0BH&JYJ+2\\'O;+'*X3A!91QI_R
M'#+]\130IXKU*7*V:_ 1 77,\MP@U^@&V2&/W=.?CVGCMK@06!AZ+O=8[ORN
MP==PNJ&"-5_PYR3AA]=V&ZNBOMKDOK,SQ&J,=WY?='Y4R.WS0[[+S>.["BMB
ML7+/CKBJV7O;_T6S_T[\N^OFQSO^1;Y ]R^S#WO]KO1&ZJ(T]07V/#958GU.
M5.$@-[","W,!-Z>*KRGM9)(==Y5?0?K7LA4>65]JHLB+-5IZJ\"2O!4'>:^^
M[RZ]6<HN;];U+O.&R/Y[A/SUKOZG(<J;J$>CMZ^(YS@4R8=ZM$8!Z  B#IJ<
M*H/Y(U'N/\>??S(<W9XHZFB,>VX^$I:27AH!5*A)[JTIZ7%1!;RN_&CMR5/2
M+[@5'LE[$[UA2O;T[I^-*&^B'HW>OMZ=530PZA.19R(R *KVD^'G>O*(IT![
M"O0EM\*C76^B-T2YGL+\LQ'E3=2CT=M7F",3E>MS0R(*Y*>Z.1$?B8@P\9Q5
MGMY\Y93MZ<W+K?!(V)OH[1&PIS[_;$1Y$_5H]/;5YS* @Q+Y9Q0#K*&[WH0V
M]D2OISU?.6%[VO,J?,BC8&^BMT:_GO+\LQ'E3=2CT=M7GA.JR!,I%0"Y ]3>
M3T:?IS7? D5[6O-R*SS2]29Z.X3KJ<L_&U'>1#T:O7UUN?!LU_<H<'R24R5.
M!EYND:<ZWP1U>ZKS:BL\,O8F>I-$[*G1/QM1WD0]&KT#-9K3]3[\1>R9*/ %
M0Q44[\[74Z)O@;8])=JQ%1X1>Q.]/1+V5.B?C2AOHAZ-WKX*G>70;ZI(]A:Y
MSB.153W!ZVG/5T[6GO:\JK3AT:\WT=NB7D]Q_MF(\B;JT>CM*\[6Q6^1TW]V
MLQ!/8;X%<O84YA7 /+KU)GH;5.LIRC\;4=Y$/1J]?44YJHIPM,0S$5.5J03F
M/QE_;D^T*?* <'1-2>*N9N &9GY#).XIS\NM\&CY<A-=[U_(\;QBR+CUD=>@
M\#N$MT_G.A* ?__[7_^,3I_XD%-[HOP$R?EO CZ^_& ALO%GSM6]&YHN=N>K
M28VL=__7TQ-DZT 2_B;*7 _\@B\8&P R^;^)0/ 7T>0D _[IIXBGI\5&"^+D
MH*) KQ0%YS0#.Z89P,C<6+^LJ$,(T?/.[ZBM@>]TK'NQXE]$?3Z"BXVH7$?D
M?T$C?@BL72DJ:/E^QODKW^)GZ"NTG?_XX,8L]LCY(!K!VCZXW[Z.(LQ_HS_Z
M^E#Z3:P?00WHB_?.A-DO(A/'?[R1H>@;7"J0-5&1-6LP_#N0-9,M(SS/O ]*
M77^6C5*-!WXZ[9>H9B?DIRN#PHA/B+V>%)YP1N]AV)I1(9*F3/U=RSZ0'482
MNZ^^2B@VB@R#0K-8+\RBG;*/GF43^MS4_(%74PADDP4R5/#E U6F4&@:TE1,
M%@J-5#PWR'.%CAE^8$#/%^CZ\SG2K+S+/KU6X;EQ-JI,Y%:Y&VZ2F7SW0<SH
M,_VA+_C2E#(!5'>:"K\$?4S7G\[ZA,'+2S\\EOA>6WHMB%$N*0ZC8KC0SPF%
MDA$I1(5)RY"T8%,.1_QTLR73Z1#MG^3+H9<'E3'+[Z:2]*7&9B.4%YAN7)N'
M!-]#-T^WF>I#6WUEBYU1/,?6S8SX$N?JU,L\G&/+0BA-UJKS>@*,I'RVEJN:
M%3;_&@CRS9RBT\.H-N^/RP+KH\RV;@9?:[Y2LCHIM=-F7! SIE(8S^("69\;
M0)HR[]/>H VW>SJ*%T=IS4CI[5Y9KH]5N48GI6(R/I,:,Y.>C"/! =LID<EX
MR<SIY0AC!B:M5RK8#1O##E<J#]-\JE[GZ]ED2:J\)D"\$ !]V5^<IF9&:#"L
MQX 8;W1 *IH)M(1)@-'G<6$\T))]<5(N/[2KI4J<K&6T*ODJ-QE?EA6,<B.8
M&>9J_DZC\/!:*942P?SK-#DB_?Y&O:&FPZK^(&9YC2*-=JDF3(.Y:GN>?>G-
M_?'^**64(Z#_,*_40)%B4KQ6!"+?T@*)V:N?:K[6.P_]Y)3)Z<GH-&?,JR5?
M-&R"66+4"&?+@7Z9;TU*2MKL@=)+ +!5DPQ56T8\T9X_9!HY4>.Z5#>=[B;R
M#X/V(#-_X4?*>.J3&I(1B,<5,>N';RN70CPEC(:UTMPHI:(SDQ$BO5)VG&XE
M6"8W+K\SN?+H=:)&2P^%*C7JEI*I^8P,#OUDJ29+>D0L/O3JP\%#/,)W.RWZ
M?9J8)#/M4&T0JG7X@E*/U6IC,4.GIS'9%U$Z#5 B&]E<M50LEMK]]WEK3C.I
MAX=J-/9JCAIQN1UM#$!JJE1"E62CUQL69W1EKI3+=);,E=)1^-9ZI66,U/=X
M22''FJ\?F+4G\U KJO&ZT0J,#+V@SI+A080%_;:LEUOM?#';&D5-RC=KIJ:M
MC'_.)XQ61D\/@I5I+AU[:( '<3I-R9%(+Z1%_/FI&)N+K]-8=#KULU55SL=;
M?IF4>7KPPL6+#".\EL+C,96<*HP9346JB7&'"[6KS8JO2A5&Z>F[P5;I1"HU
M2\TRDRA=DS*Q5I&:)S*QUU:#C,;-E\;KM#4;]CF!RT_',Z#PTTDD(G"=3*K1
MFX5-.I8=!HVP+Z9"\DG[='_9YRL^-(U4L#UG^E5)U\1BN"I-^L7W\:POUGV9
MC!IE?!.Z-JQ*XDLQ.QGV8J)A\--X/-MCPZH\$[O3RJ@=JB;%=-.?YZGWI@S!
M1,6Y2DTQ QTSEG[)< ID/O%Z.RWUA72?GBKIK)&.M7*!EWGN1572E1$W?DA4
MND5]%HU.7O)331^82C>7F(X&E1(='PG# E?OQ1]&B;X1J1GO)6[$*MU99E:=
MS_LU+5B)1Q):K-5KMT?,J-UO5TFCT-7S$DMFAJ.!KUP=5IG66*QK@V0N4JK7
MFJ5L9%ZICO-2;-IND^U74VR_:.'>-#O0S1X$@%%_;^7,<&!89"BE^9K5,XV\
M7)Y7.K5681B$S\_,INR?#RLUPV RA?Q@5BJ^@&XQ-\RI3:I/-\>^1#_13HBC
M@CS7Z?R,S-%M.=K@6/&]H*G\2-#B5"C] L'=G1I0J,S"L?*HFA)\9247GA7*
MPTJ]I=79"#7@M48L)?GSG6R'"G5C+5W.E7,Y.=37LI5.G:MW? +)UAA?-T+6
M3&FF^HULG.859IY]KW9E\B'SWAM6'\+YQIPT SR;,/2TT4PV!M149OP#:CB1
MAZ%:H%3/IWKCO-&B7GR9;(FGS(CV,)X&*97R%[I5IIQY?R^0>3,;>Z "X0>S
M'R1%KO@2D'WR4!IG\X,"/7JIA?5.F4F-Y]UT*4Q1@70!J*D!I\_F6AKT%,8(
MO>3#$[4[*(C#QE0%N6"V'JS,?/7<:X\57KKODB"\BT8*BHN71K*A"7*PJ;0?
M #2#@@VCUI33O)S(<*.L,9('>:BHQ$I*)U16^G[?0V\^5P94MS"?L\R@'FD
M-D29_"00"92,+CO(9P/C:(?,-.KL?%@:A./#0<BH*E1$)&NO#5Z?QQK9AR@?
M3&9"G=XP$V@& 3MO/+0$K1L/ 3!25$.;JN_EHIK7PFQQ*LRE:EVAWSG0&ROQ
MC))J<WFU*#<>BG(ET2G'>XU AD_FC$HV7WVMOT=?C!(HZN_]E_@TYJ/CF;02
MI^1 Y"$X$-(3<52E&.7](?G YN;3@<P!?Z6>C;Z/F.BTT2[/HY'(##*YAX!"
M!M]-MLNS/MD47L@<"&1\_?JDG&V$<S7N@>+C[+@2CJ?*0S4*@<=,:H&0KU+5
MU8FL0C9>3(?F-!5ZS?/^#!UGLDQ[,C*E9#)9]55+DB]AO#3%5B.<+[P\2(..
M\I /-JN#[F@,"7 R"PU21;VLC4=IMMY7.YI1UBJYX*@ET?GBJ^XK@A0MF'G1
M-QIJOHKP,*P_#-41%TZF0;.;-^/#V. AV\@6FR&)!:3&YWH#/AZMM-O12<J,
M]*F>/R[W0JGD,-G,,KU@H!7AVLUN+9%BBG4RQ68U+E1IIEZ%(0@%,TEZ_B#$
M)PUN]FJR#2Y)!UY#*A1QM*[TTSS@BN6,.:ET]=>)+#+A^JO)-,.Y%-\I^(8!
M)9QNOL<R4B;3:^<J4B;=[/6ZM5HW23]$FJ779#D3J>;)W/ EQR6[4(8I]*A5
M]4U"/:E6-?LQOU&O16J3=] ;)&NAZBA5B+<S@1)H2.U^)S,KM"#84_WZM%6+
M-Q0A4V+[/48OO[]68B_E=&1>++]JW3%9RS>#T920GS'F2"U1];X8["1[.;.I
MY87X*].:)%(/HTDG6)>JHY?**)]O\GJG7ZA,\_&^5M?+7(E.,MV)U,F'&:5=
M"#(O[7GDA6^#4'C\FH5ZH-:8Y#M).6,P/:Z<XMED/5Q\Z>@!\,[&6R*M<Y7I
MC,L7*Z]:;VB:AJ]9JM6J]?=\+?<:58"<"IC)KBR7\D.I%Q=RH\)+)]",IYG^
M9)QIQ..IJ>I[54)TBH[TRLV1?]+K^_5"(5X9U#*=/-^+!N/:D,U&$IG&1&IF
MVKE<+5H9S72Y&@CJFL[VPK.HJ%;]]>HL45?93-:7RH0GHQS<:CHS:1;#+9)M
MCUO=4+^4SD9DT:^*5$BE)J'63"@/(0-L^9K5UW'VH3BNB-WJ^TLQ4HC$,KU&
M(MI(%)M1*3R0\N.:V$VPXK2:KQ>B&2,:3/;E1I0D)^FX/]#/T#U=4R>#6=^H
M17(/K_%J08FJ=9$GR0Y9-31E5F$S,:FDRWHJ"%K#5[BJ6JH".$I)Y\I19AI5
M\K&*'IDV*L(X0Y/=::3 ]M1X_D%IT24NJ\0U7S =,L$[,]8F,].8O<K#&",E
M@LV4,C=;5 *DF2*E^DPMGRHF.DFJ46X7FF*G$TX7P\%0*_^@%TF->IGFN8DI
MM$+C().LZ9GW3MI4PO,N79MHOD"9FVK3__S',BG^'U!+ P04    " #2@W]6
MVPA["8T#  #Y#P  %@   '1I=&%N<&AA<FUA7V5X,C,M,2YH=&WM5UN/VD84
M?D?B/YPB)>JJ>/&%RX9UD!8P"2H+%G8:Y7$P Y[6GG'&0W?IK^_Q+<MNK#25
MMC2M I+'9^9<YOO.\5SLM_[M8M1LV&^=FRFVD/UL?^XOG)'=*5H<[93#]G@U
M_0">_V'AO&[M!%=#,/1$@<]BFL*2WL%:Q(2WBXXV>%2R70L-T=2M[&(B]XQK
M2B1#T*^A%#="*1'G/5_K^!H4O5<:B=B>#^'70ZK8[M@:V;/5TC^=I+8C,8N.
MP[_RENNF[ ]:!&^-7O)-FES;G<PATN'F0![^#Y"^?L:/P"?J<_A9WRDLR?:A
M>DY0]GCDW(=LPU2S85J7AMT9CYY / NP<^7K+& "RA65SYRFR6KI.4N_V5C-
M8+Z<.JZ##W2_=M[,/=]9.U-PWXT7\PG<3":K=TM_OGP#L_GZ]GM*OTTP[VFS
M$5))-T<(!$^Q9D )4"$%Q@,A$R&)8H(#CDNZ0T4>9$.YQIKN6:I*!4\116.T
M3P&EF9 Q>)H!/\Y81&$ITDNP+$L#T^Q?=8UV+IB6-3#-=K.1"]U7O9Y>#O0,
MXVI0O9O=*Q,(WQ9BW^P;W8MV%<%Z&L&T]$'W1-\T#+-_D<NER=53$V. X8QF
MXY.-/GC5TR] [) ]13BX(9$Q">A!L8!$R.:<!Y?9L#A(I 5)4K!%^%NX)3((
MBP*Q$*6IFU8;'F5K0X+?]E(<^%8+1"3D$.Y"IFAKA$T0-AM(>W388@XQ+KU/
M(L*)$O(("9%D+TD28L (*>?[*E$3$2>$'U_*].-!7*/AAD5,';-A3"EJ'B@0
M[(:]R*RP+Z"2MQ^5<>6SV2B=[A@G/& D@O0DL5\DI TY!"!)0HE,BRIA:4&[
MH6L_7]9L6__5[Z9^$?!OQ@L')LYBX=Y,I[CVO6[IK5SVW)M))5>5(.26RJP*
M(I*DZ+EZ^SO'C3NV56&FJK_(#C6VOZ[<_TYEGIV*!*3K,2L1W:E6><"R_6EE
M5WKLZ2_JU)^/P4[:*6*_9RH\Q%Z,S4]C*>[0U)U\8M:?GFF*G^44(^-C_3RL
M_J/3/&^T;Y"4FO+R<)F:R6P-2P/1A@F&V0G)&?E.W)>)J]G"_GW*.OG*^O_<
M-7) /V@:S!B-MD-PR1ZW (]^/&2'+30%3:MHG\Y_J;NS]FOPY'WE'E/UC2,\
M?8")9*4B8EN$5G\%KK]+U%'V@,E%0#B]<J;E?$]@=3)<!902<R>[NA=W^>S*
M_R=02P,$%     @ TH-_5A$LMW7C!P  G#\  !8   !T:71A;G!H87)M85]E
M>#,Q+3$N:'1M[5MM3^.X%OZ.Q'_P1=H52"T%9KD?H(,$M+-;71804UUI/[K)
M2>N+8W=LIZ7[Z^\Y=M(&Z,PT.YD1[10D2A._G&,_?OR<XZ3]1__/FXO=G?8?
MW<L.?C+Z:?=[_9ON1;L5/O%N*[_=OKKK_,4^]O^ZZ;[?2[1R9^SX:.Q87Z1@
MV2U,V8-.N6J$"PWV$8Q(]K B5KVO6N^<I=P,A6HZ/3YC6'Q^8:"=TVE^S<&3
M:W(IANJ,&3$<N;V+7]7 CL_;K?L?WG/[P]UMO]Q=,^&ID+.SKW7HRUKQ-P3[
ML*6KB^[32 R$"]Z\.SX\;K>N<%:HBXL?ZMS_,NM$,JO3O6**?KPS$2@'IN:I
MNNX^]'L?>M>7_=[=[7::7K>\Q,Z5/*S3F5YC=Z?#)R)FW4-VP__FIH%H,&0+
M<R/NSC;$SWHG3:@8J,+1X<FI4&_#P^/#W9T>&_$), ,3 5.(<0:%99=*95RR
M!QAKXYA6[(,V:1B/XZ/F?YA.L&G'%;L?<9/R"#(G(BYM(Y3IJ>APHP=N\Z%Q
M@M"XXA8!@;.?SMBCTE,)\1 : 2$F0"/6V*K2CD78 !>*<35CF7(F V8==Y"B
M9P07CO;B?B$050F/\))A.A6..1W*O2J@( )KN9GM[F"9E#\"=EQJU.*U&*W!
M/B6)!NJ$"D3"1%F*Q1361U-B,&PZ$M&(V8S^+.I/P4#>"'F0"BN!QT(-V52X
M$7IHQQ!Y"['=W9TQ&J=C='2"]6(VF)4'8J.QL/EH?_<EM -+A$(X$307\&D@
MU+$XWC:E^T(ER)3<"6Q'J$AF,;:)$"U!I8'X%D;.V!@11JN#5HV4<_CO[N3(
MLR_ZQB46"VJY0=C,)!9 S&O$I>_/>H,B;D<LD7IJBP5A8"BL,QQ[XG0Q&(YF
M!M\"K&UAS<)<LF,+[;7W\#>_Q_/4\QFB1 PDT.PS0"P/I+ C8CR"1(K\31Q.
MWV-A(ZEMA@Q)S&ZT#/ :&QU!C)<MVT<TQ8#P#)#I/D4CKH; +I$S'S()-M<+
M[WCS^'0?#L)7;&1WY_@T#M<.?*."(@D5$$Y=,:+8$O ##LFL:GTFBSY9WF5Q
M"0< ]Y47JP.+D1;:;/W:O[RZZ;+K[LW-_66GT[O]_?W>T9[__O'^\KKX7MGA
MJ8C=B(H>_;*JH_V'ZMU,*,Y I5F,+79!>9%VOU/3'.5^A!6\1\F;SL7W:[VV
MN=[G!_.)KM'B.DWL@,6F(<ZS8RO^>-'V=39JD*",>$9;^(I5JMF!*G  R#W!
MAUQ7HE*P&6Z@$V']MHR%0/D^*0Y>"-JR*C @N>>R0E=6L6+!5HU<7E!+ I6
MS096Q((;08,A@CKV.D913RF08/5JQ7IYZS=Y;0$-=B@JL%(U2\:<%F(F.2D9
M'$_OT5Q.$#D'T5T.%O"_ 5!!U!I8'^+S9YAM]1_H#_'3EG>WO+L>O#O89-Y=
M69B]HM^OU*S*>H7^6Y6%D>4G(B9UQZU6G"0OMTC,E!0@$N6&B+/B#N#5HA1\
M(*1P,PJOEDE4VF0\$7J."YS_K&@I ^%E^%,8J8KTFYDQLK?UP6,4:1-[UWSB
M8@@*0T*)O(QW8$PA'17)E O<BQN'&*-6WK+OEGW7G'VC-\^^W0F7&2[XBO1+
M# )) I$3$US.=DDVYU=C/V7ZW*X2JX>O>8*GFB7/DU=,9X9Z0>EI0\YIH#/W
M>7-74.[5S.'SIH'2;TE9="Y/S;)!D=CS.Q.$"4'CS\F2+0=N.7"].3!^\QS8
M"23PC<Q#)TMYNL_?6<J%*RO6JG2,X;R.HLP0OY3"W24FI-HZO$[/1V#'%B'+
M/F48+:,=^\NK5+,E00I&E?>BZ7Q((N0Z?]Q&)W'^##=X?!!<&'$[STJ0/O24
M#;&7[Z*B'7-M/6-2/ )^^'.Z%XTW_N%,_<,(X6?C]$TZJ3A=/(T0%XS16.S>
M&.:5E]9B'R>\5XA40]YM&21Y%@NG#:Z#(HCS5[#--!7. 7Q!A TTQI1T/Q9H
M(+7"]G%1H3*Q))/PDU* !6W ITR@_9XB,A7YX[N#[;G#5GVLG?IX^^<.E[+B
M9D+))9'@;./JI,/&2 "22!Y%S7/Z4^"/%.F$'(R/=7Q:RC_94IS)+Z.F:L9\
M]B@TI->Y@>4;,8^QHH7Y/OP9WJH8?.6I+VP?24X;I&<?R%D<?INEN-IPW/TP
MY9IMZ8,1/]L>O66^C62^MY_YOU2SBJ&%0<'30&H!_U@3,IE_,"ZGO$:((82:
M:#D!"B04'^8/^)G\22A(QU+/ .].1SIH.5XFU(JR7LM:@KW#GXAMUM29#H+L
M;'?G3VZB4?&F1H.=')V\VQ 'O[8WE/>"EWO%M^T- ]RHP30C+24?6S2H^&_/
MOZE4YZY BY:8\/J._+E]OW<R-SZWHAC=*\FC1W:,/5DM11P&K/IL2DAJG:66
M;04OGK_@4.:/A9??A,.Z+7^!KX+HOM<,?[/O<Y">_E+G,-SRM/0 7[W3-3?Y
MMWIM]E@+=GYGP"T&_:A6#]8-?'7ZWA=.?C?(U6GH]4A DL/L":*,SNK878+"
M#+8$][8QM@;3T^Y=[-^'9TN*[/TKE/G4P+P0^S!7ZOE]C*AZZ^#KEZ X#RQ^
M[+NJS]_5]MKR7\TF#C'(^(S=8Z!VCIU\RD!%Y 9K-HO![?3^6QA:[O[?2[KW
MUY8*N9-"R.$PS_U^_;KPBJI[X4R[A>;EEN;VEMQJD5_!E<5ONT5OUX?7[>FM
M_/\#4$L#!!0    ( -*#?U:B36GLR00   $@   6    =&ET86YP:&%R;6%?
M97@S,BTQ+FAT;>U9:V_:2!3]CL1_F$5JE4B89U.UQ$$RV&S04HS 66T^#O88
MS]8>.^-Q$OKK]XX?A"1L&W9-=I,&(@CSNN?<>^?XCJV>6U\F_6I%/3<T';Z1
M?*G6V)H8?;69?4-O,^]6!Z9^B1;6Y<0XJ[DA$SW4;D4"630@,9J2&S0/ \SJ
M64,=+0BG;@TF9F]UMN_<4Q1@OJ),$6'40S!\T[ ,A0B#O$V06Z%@GZY8#_V9
MQ(*ZZUK_/5O&T:G:G/6?S3:G*T_4^NK(G%K;YA07!]1?]WYD,!T;TV\DPP<K
M#?K&K4>75&1LNIU&6VT.(#;21/]9R6T<6QZ](D3/3\8F3!!><JB&QMP:C\9#
MS1J;TVIE=C%?7&BPO&7^5S$[",WVIVKEHK%H#!MH80PEURR.[>Y)J_ZJF&J+
M:D73S9EEZ&@KFO=I?VY]?%6DS5&U8IT;:*'-!]K46"CF'Q/C$FE#"YDCU&FU
M.F\*]'CE%"=E#I$36HT3RG9B?Q+K,@F.6;5BAXP16]"0H1LJ/"0\&B.-L03[
M:$ZBD L$7:.0!_E&;BF_H="%I05F:.9A'F";)(+:V(_KV9@QLQOH2'@$O?>=
MJR0\'89!A-GZ/4]_'0,2CF3WFF"."#C&J59T8I-@23CJMNN029U.'>$8N=0G
M3H&, !,[X510H(F9@XQ;V\-L11 8"&@<2Q;P)T<Z6!#D$4X ZS:4C%.!I)Z.
M30 !CR$4$D?HNM0&&#!/]N70TZ66:]A5'$)%I5>CA,<)9@*)$+4_H4+U,F=N
MJ9ZD@9TP$D!D>\Z]D2 4A<4%YDO,2*R8MSY9@\C80G;)S27AXG2R'+@D<=HC
M(_:5A3?@J17I_6V^[LRX4G?DX3>?I0TF!AH:D\E,T_7Q]->S6JN6_E[,M&'Q
M.[=_0QWAR?5:[\HG:LWWUX%KF3RP3XHH@ E9 *N67E*,<L:IQ-1DD:[W#[!X
M)UN]M% ?M8\W<2X1<9D0+8_D!Z GOG+I=!/?!]$ #?&E9FUTC).KA'(2P!4A
MEELXUP+4[A[A8P3JV#XY<HXWBG"G>H7B[8<FEY#VY^Z'4RF<]]S=M.;R0^ZL
M-\5X4XP7H1B=UZ<8E$%5%.!4!J H$YA".0*MJ0(4<H(I!SV).(FE<M1E-_9]
MR#<H]2E4;- 1@93$65WC4H:9#>W[(0'K#DUQR!H+EDS\3*7"B/ 48/R@.FK\
M1(+R0LGHD"*]:N4+YK:7WR_*ZNSN*R'X(_G?EON'EX.]=?G>A6(9<C@_*';H
M^SB* 5#Q7RV]:UJF\,OM*=5N:$H^T[-:9P,^1U%X=^!C^RMJ@Z4X]*FS3^"V
MX^X3M]0H->-FQD+'UQ0.< TTP=\PW]:/.Y;_[*!](.0/\JL0ND-%^%]SWR3I
MR;LRW3#%P=89L]QP;2!_*!=SFFL9S@,GW)W36Z4R>&G)5VHE185_L)0K$^C0
MH\3-T^P6CFR"7A-D9K>37@#\GSG''G/_GP)5Q_VC&:=0U4=%6?\HU]*R?3,(
MC8I30-$/9Z=Q_P5P_5Y"[CQ>W*LX']>;#Q_[II-_413P$/&='IKA%3D%-%<)
M8;9$@12E\(T^_GV7E8\[ZMJT;6<UUBFJ,?#2SBH[>V;SQ-+YCHS:!'@YTASO
M%JVFY)51^?Y;;<I'^-DS??GH_R]02P,$%     @ TH-_5MG0:O%E#@  R9D
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M2!>\QP!H X(17HKW=F3)VX)OAWVK",3LU?P;KR3*-GP!UM*9/*>%7XQ!97B
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MN/%X(2]Q";S_><-[A1P^_A=02P,$%     @ TH-_5HSL_=HI#P  3<@  !4
M  !T=&YP+3(P,C(Q,C,Q7V-A;"YX;6S=7>MSVS82_WXS]S_PU)E.^T&1)3EM
MXB37460Y=<^Q?);2WGWJP!1D<4*1"DGY<7_] 10ID\1K*1$$[C*91):QR]\^
ML%@L'GS_R]/:=QYP%'MA\*'3?W72<7#@A@LON/_0^3+KCF;CR\N.$R<H6" _
M#/"'3A!V?OG[7__BD#_O_];M.A<>]A=GSGGH=B^#9?C.N49K?.9\P@&.4!)&
M[YS?D;^EWX07GH\C9QRN-SY.,/G%[L%GSNM7_3?(Z78!?'_'P2*,OMQ>[OFN
MDF03G_5ZCX^/KX+P 3V&T=?XE1NN80QG"4JV\9[;R=-)]F='_M[W@J]G])\[
M%&.'Z"N(SYYB[T.'/C=[[./P51C=]P8G)_W>OSY?S=P57J.N%U"]N;B34U$N
M/+K^V[=O>^EO\Z9,RZ>[R,^?,>SE</:<R6\]2?L"DM@[BU-X5Z&+DM3LRL<X
MPA;TIV[>K$N_ZO8'W6'_U5.\Z.3*3S48A3Z^Q4N'_D^LMW]JXA%DFQ6*UM1D
M/?KKWC@D+DFPIH2K""\_=)(DV!#^@T%_L./^7:E1\KPAKAE[U+,Z3N_@)W]$
M/M73;(5Q$JL0<!MK07*#(APD*YQX+O)KP>)2-H61=AV\)OSCZ7*ZH=V=^)-2
M;7(J'=AF2>A^787^@L2;R;>MESS7P2BFUH%UC.+5A1\^UE(C0]04LFETCP+O
M/ZF)1L%BMEVO4?1,=.+=!]Z2^%20C%PWW 8)&3%N0M]S/:Q$?A33IB2[B4+B
M>\DS 4"-NJ&:5 &7T32%Z[?DAGZ!7+Q-^VP\BF.<W&PC=T5"[.@^PA@"M2:;
MQOS%W?HHFJ](K][0)S]=>2X.:N &,V@*,<E&UEZ2]B-BUG&8.AW)@0!^#"!M
M"N4YODOV*E "X[=N+EK5CZ;Z(RAYP@T9]P!AL]JR*0R7)'%>XSEZ4GL.IVEC
MGN+%;NJ)6[R C\ERJJ:PW6*?C%D+DI,DS_.(F "Y('0JNL:\:'L7XV];TFDF
M#Y!^)FIO=/35.@KK&HT/ C-'=[XF.<NL=>8<,"'4E/JB.PRABJ[Y2%\#%Z>]
MAJ@/ R0DT#L"P,!!:(WV^7.<(,_7T^DKO&V0LZ]3T+Y-D@YT2CJP2=*A3DF'
M-DEZJE/24YLDO481C94/6*?$S$-TYB7 0 L@;;DR4M<B1[)MK7)2V],.9=A"
M9:6N+ >PTE-YJ0L<1JTO=P?V8B6A=H3*1$=-J1VC,D514VK'"/9,.(?F9VYU
MO))'H T1S NY%-HPP;R.2Z$-4STODU)JF(<#W4M,H0^3TL$D)/I0@<T)(-5;
MQ0":%D3<"E)XIE"+B^Z*?%WT=?G(\),<G*:NE/Z*_%RBP$\)#A9XD?.A0L"W
MDI &M'FVOZ?O=.EFH"U-S<C'K*5&+/S](B5, P)DO[!//G\<78VNQQ-G]NMD
M,I_E.VIR='[HEA#Y=$M/6-DYDV^/2C?N+%%\E^[>V<;=>X0V/6K%'O:3./\F
MM6MJT^R+/]/Y4#S>1E%A^=5'=]A/G_AGUJ[2K&<$*]T(06<(Y#^:U#P@/YTS
M)&/B@,]DSI!N\A++ "2ORE;PDE'D.F%$DJH/G7W@1I%;\@UV&U76HA?3<@!E
MT_6("^3TRRA<RU2=J34\1)2B20B*CO.(O?M5DJ(W8\);'">1YY)H0K&+;55M
M!S/*P*A1^++9I/VL^!3?8A<3I[GS\35.U'U?2@6SS-"H92!RVV2GRX"N.(?1
M,X$IMDNY%<P.IT;MP)/+)KW?1'B#O,7D:9/6TH+%-%GA"#A$@HAA5GIMU$HU
MM&"3\78 ITN2:V_"&/F?HG!+/,[UMW3#.S<#!Z8]A_&$F?HGLX'Q:)W9YP$J
M:]J2X4E-8K&6\T4A6OA)BBM#TL%*3F5'>B>,AVJ!;3)0(5Q?AX&KBG&"YG;D
M=0*32$6TRA:[L!G<7V$4XUN*9KK\0D95BEUB$SF9';F>R#80D6VRT96'[CS?
M2SRL3O)X;<W.Y6[0,YW0@&=QU?:F!T.Q]@63.+[ #3H46P"EWU"%1R01&I.6
M="?!//*0'V=)LL1Q*"V,U/0@J+8$7!;[>OENR-B!K]/C572FQTEP_X$IP"J3
ME4:2'/.SVF0*.M/#)]QD( 7H#WWG>(G)(Q>?(I(!W^('''#K[+0MOZGIL@<L
MM,G$M*E?%*1IMMQQ-&/3-0]PSVI(A99Z!<C"5J5^:C-9K'E!F 9-OM6D%J6%
M]88INV?FXF.KK)5X;8VM4.S&J!228L&;V]ATIY<<%V:6(42BVN1'=/=R&$#,
MP;8TW;7!MA ):9,A1HN%1T5&_@WR%I?!&&V\Y.5:%$Y%1$1@>DH'-HM"9)NL
M<TOWB@5X,4%10$:*F$Q$M^MMNJ^,I-V>ZTD&20BMZ3D=V&9P1=ADOD(20 \V
MU1@[U92F1R2H;.+<M)[%#"9P=>13W>LA$O-]KRKE%?FYI8V7_!NQ2KLPA])=
MF,X/)18_:MTSJK@LJP3[M )[-A_-)Y\GUP3R],*9WDQN1_/+Z;6A;:3[*4!>
M"09,>5Z:FLK<XF2Z_!2&B[1?X.C!<W$\(QXOR^'$-*;CF- &3#*GDMNFD><6
MQY@@H=M=S_$#]L-TZ3T3498S2,E,QV2HK4#2VV2NW<V@/L$[6JR]P(N3W=D
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M.))^WXC]#UI/Q,3,@\LEN^[NW@GYJG:O;7DM5=?VDP(F(8O3%*$!2%N>7[\
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M>(2W_%[M!T,!.FT.!)Q;4R6=131^,)><L,\APZ9R5;:W3=&.B32V0OO9ZAZ
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MHN6>Z79WS\IKA4/!)E%5/+'($DCV=.VO-P"^%$F\DL4"LN8<OKM15V;R ?
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M2XI8P>^21JL AD8V*(?$JD317A:*UW)/S6!",%UZ9N%OACE')NIVZE&#[<]
MHAP8^FC B?-1+8JX+)R!B?)XDZ5FRDCD7/)%";-+%D$(#%-4R(8TJ>2@<601
M13';3PV2^R".;M*+8!L70:+EBT'')7>LX'=YI%4 PRD;E$-^[7404SJ/4U2K
MP6'; RZ".,7154#2.%WE6IJIA%WR2P^X2RRY)!A&:>$-J=0(HT;ZR PR[.U=
M9&5:8+(-2+%CIU^*O3VYF*N]/1W(9F]/)N.=(09@XC2V%^5GD3/YR$615@/&
MF[?50=P?V%]^?2B?XU0Z3(@_NVAJ%2C6Q,/?O#>M I#0W9D$G$GB(LC7BS1B
M_X<MR%Z"Q+"8UBDX=62-P'L>K5+:.V^L(0J# Y7DV[7\'QT=* OI#W1=O_L0
MD-]P<5VFD=X!40F[Y)0><)=/<DDP7-+"&_*("Z-*&G%Q.,/3=1 3'G7S;O<!
M!WE)^"[3-<&_ES@-=YIQRDK3);E&%*7+- LU,+2SQRIP<"^.6GDHXUA;K [*
M_ &')2'47]>.:G:J7FAH41@I#S5Z\(AH!CMD(E.M OW.4*OA=TGV0/&IUF&=
MWUPMO@0XS8JK_<$[#V1HA@W-SBSBO(C#($'=X>>8@XZAH3_$:;PI-](11?*[
MJP:7PFH:O?<CB(:7(1+FFTK&;[_^$+SJF[O_N[/FEL%JF[O[(XSFEB 2FKN2
M@>/7WFW9[O%-&N%7%BMZD^<E)GEU)%K];XUK:ZOLTJT85Z"N8V&GZ9UJD^ .
M>5@IHUH;%1FJ]/\Q1_5Q^%'W]ZXVVR3;8<R/Q1:? Z)8DYN$G>W]&0&W.X%*
M2>_$L8(G.B?LX+(2]#Y8_1P08]#50,;ET".%UQUA>@+>^:!#-:1!+0-GWKHG
MV1:38G=/81:+-&*CUI:YS>]V3_2SFDG+2M-QT*9M40:AG"8U,!2SQRI$ V?I
MZOPV?J&3U!/]>_R<8+3(<WS<Y=&8/9F2I'%!UVRT6-?Q*_N7?G]9I^!T_\4(
MO+?KHI0&0S(C1&&'I5'@AQ>-R@F,<:;P<[T6B+%-&Z*N4P%#-SN<DC!VKG6&
MN!YG7JL)AWHL&+8L,+&CG%+:<4"A#O(@K% F"H9:>GR2$$,N#9%'?*I>A!18
MSL/4-'Z97-1I6*$&;"^:4"('ACL:<$+L(/>C.K+'7?3_5-RO [()0ESRS6[-
MDE\IZFS!;P#;+O<5<M[I8 %N2(>?GM! ',XX<HF?BYLT+TC)QC?-*"(3=#F&
MJ(%V1Q!1RCMAC-"&=&&":"]YW+'C/MB%:QS^1MVG H=LK*+_6I%@<YL%FD!!
M*S5G8\J(0K3CBX6.=^J,!"JXQ/?W**%"_O<7'\OG/([B@.P>@P3?+:M-4LU]
M/K6\T[M\)MB]>WPJ8>\TLD4H;%%3*90MFSLVQQR&KO$S*2DP]LO=<HF)\CJ#
M6=S9L&,!NAUN-++>^6$)4-CEJ3404T&M#AS?YB()\OQN66^QWY&'>+76N3@:
M>:?K;1/LWHI;)>R=5;8(A54WDV?#3G,TDA'$=8[L"!',(F-Q5']6,_HH1=TY
M/'JP>R='+N>=&Q;@)->"SROQAACSC30*2GQ*"5[%>8$)CMBM9$MZ6*DYH\J(
M0K2TL="!02%[H$,Z=371ME%%GSU0ZSI^P7_# 6%I?.+7#UE:K,>1S,* %[I9
M%TQ*/*,V/ K:0M:2<4F-H!VUPH\P\O@5;9BA^:EYL'_%3ICOE@L&:X4-VT<*
M69=^E19NUZ>2"GIGFPTZ\00CH=H9"0I&JHX.YU;WO^^*-2:H6 <IZBL=U>GJ
M)'MXRG@(YWN2E=O;)%2/?&8=9X.=+?QV?#,I>"?9&)3:C!Q/&>*:B*LBJGOL
M*;5.:9<O5@1S3O\<%VN.X4.T^3DC2?0YCO!CEI1L#TTSM4XTY(QU!Q6TI>(D
M*S#X>0AT88^KMH5:8XA9J\E+[:'6(&HM'IO*#S@O2!P6=;HDL9SF47*T"7>W
M_:<5;I\18)P^#,I. RTF$FFLH)R/LD%+VL][TG)39^CV]@*.J\AB<A2Y1N0B
M3F.I).!Z@5.=W[W320-*V#*A_^4@I\C3Y^QIG95YP*(#EP7&*?NP>FC2RSL;
MAVQ@MX..3M@[)6P1#OGQ]KLW?^+1<L>>SWX*TOIHX4US3* )45$+NPM2,0'>
MAZFH)&&PP@1/"%6IY-F1SIOV2.?8])">$/!K4]%E4."[5)Y5?*2NNU7AR.+L
M5X>6BC"H-1*M_3%/90,Q(XA:\<P^.JY.9E]'%PK[A.+8LJ]5/ GV#=%.8Q^U
MXIM]5'GZZ-?3!L- L4C6'-RKG@8+!;P3><CL>&;B-:VUR43L*D/AH5@@6QKN
M-4^"A0)<.0GO#"1D9GQS,'Z9/AAVE<%P4"B0-0=;S=/@X!#N1 [R$RFO'&0'
MNU,IV-&%PD"A.+8$;!5/@G]#M-/H1ZWX9A]^P9JMM3':8!@H%LF:@WO5TV"A
M@'<B#YD=STR\8O\YF8D];2A,E!3)EHD=U9-@HHAW&A.OJL!<KTS\&!^P0=A5
MAL)#L4"V--QKG@0+!;A&$M[)2,C,^-ZG.6!6?H(W)PO%L=ZA.:GY>(AV&OV>
M_,_%R4%N85\="@=EA;*>CI,3\PPE@*>1L3($)_"CEQ:O2HXHY:F%O,N0$"/L
M;GR(4M@[]6P1"E%QZX#@\W=!3FEU'^QXA%$G6O@,U6DNP=#L.DZ#-(R#Q"J7
M@5+::9HP/>1>CC"Y*!AZZ?$)]T8;:7=)#NCW6;"+YDK?0,+=33XIM/T%OM[/
MWAM<C4D:>\8#C,",$3S7JB&'Y4#&:9(D&;Q>=J2N@'<JZ% )^9"8#&)"4))+
MVKHCGMT0*_<#KMMAZV[4F;&A.14W:9AM</OR]2W[B#[5FE;#)7$LH'<II!$'
M0R8SQB&M*@W4JJ!&!\HH](!S3&N3/0IW29=M2<:3#%Z];G&:R[<T1VFZ?=G5
MNBC]9UZ-:F (:(]5<F^#:_);EQU=5"O#&?+>XQ23(*%%7$2;.(VI?\ZO@=IP
MTE+7)2M'%:?+2RM%,,P<@W;(S5JWNA#<TX;'SFI ?PI>%V6QSHC^#165L/MI
M6 58G(&'DF 8IH6GF'>I-&K%H4RYEQ09>Q*,O[M,=MH!32'K-.NE#FXO\:5,
M$ Q]=.B$])>U[) _4 8A"NN"X"@N+@)"=LN,L,6M+O.%6MYI]@L3[%X&#)4P
M&$:9$ Y9Q<A4*:"N!I1AJ?$0K9Q^G_Z]V94'-O1(82D=="5-H(P^XD1LN%:M
M4_#K"NFN7*NEP1#+"-'&+3J;\W[VX0DS@R2FC$_CX)H$:;B.<U:^=QGM =J!
MR4+/:0)-VV+T$FF:E, 0SQ:I$$#0ZJ%6D;.1J\(9XOA^'5W+LMVZY*>2Q'D4
MAQ8[]08MM_OV5D7H[^)K5<"PSPZG["GFZC4HKH>ZBG"8=QGGVRP/$IY!A<?;
MQ,O8N.EOU'*Z8+0K0F_IJ%<!PSP[G,)RLM:J$Y'U]:!,O(]XQ?:#*5;:Q$6<
MECBZVV(2J#.5C=)T.O39%Z4W_)G5P!#1'JN$C*T*VNO &0$'AVSO @H_Q(]K
MC N^NQSQYXR"A!4DR7+VK-^[7:]CYM1$4D9QNI+7C_WIZ=$^[O$@]L@5JCG3
M/=*7P71*I\4U3#+'S[GUZ9O\&Y9O$Q,62!?_O9H%J3OU0HNI>"=UC**[?-%C
M"K+/$VVCY9V:HZ$*>:&I+A*4T5X;SL3Q1%>4><#]>4.(G532Z4ZX&FIO#UP4
M\\XH,S9AWWLO.6< GBK1VU/UT%V;WU(]$"E%W25YTX/=IWB3RWDG@P4X(;T;
M:IXB[.2[!3.&/."$SM[1?4"*78>W=)[N_J(96L88<'MX,K9@_8,56VWOE)P,
M63R0X6*(R[D9L\Q#E;<1RC P01R/;(>AHPP^.0Z_664OWT8XKL8=^H_]<$/_
MX]>+[ 63Q3,+=0J+03DDO[MH<24LUM["C]Y;6X5(?!6 RM >7$NY;NC++.07
MC)CO(RE!_V=7S2P#U;1R]S<0C2P!)(;L5"+<PW3<P OZX8A]_#H)5A+X@]]=
M-;$45M/&O1]!-+(,D7"+IY%!3,A7,U_B/"0QORFB*T=/S'FC2T *;=^1@44!
M$9B:"1U93P/[ W\YJ]JB:W?_-,.80M[UT*^%/9P+I,(@2&.#4#E;=)7VMW0\
M\6B1IF60/.!M1G3TZ8NY9HT,Y) L71E0')$ 4U*CDD65L"=&_.^2+CXQ279&
M4@B2KGFA@#JDQD ,%#ODV)0$:<7]<H1O;O"3)2-)1%'GRPT%6&'I,9 #Q1,%
M./62I)7WRY3'-4Z2BVRS#5+S@"(3=LT6-> A7T1)4(Q1PE-RAFN@6@4.;:Y>
MF'=.W23+PG;D?9)'@*WC3RL,ED)#A)8LXFH\1Y<G)MUC$F<1=;.)B4."I&OV
M** .>3,0 \48.38E5RIQQ.7]D^0JC:PHTLKY(<@ IIP>M1! <O21F:AQE48^
MB7$=YV&05%BNZ=^&1[ &6=<$4<(=DD00!$44%3HE62J%AC-<Q2MA_H8#8D>7
MCJ0?L@A0Y51IQ0 298C-1!,F[X4D%R4A/=3J&4<MZNQ0U@"V/9]5R($@B@&<
M<&I;B?>(XFD&NDJ+N-A=QPG^6$HB-.0BKKBA M=P8O@[""XH0 E9V;@88G*H
M$O32\LTI05JPL&IE<89B;AD@!]EG05\&$!.DP!1LV,OR*'<OC+B@(Q-AR68C
M_/J_\$Y9+D'.+2<4,/ND& @!8H4<F8(6M3#BTHB*>R'&/8DW =D]QJ%AJA %
MW5)#!;3/C:$4('(HH"G844NCQYL+GS/)4_!Z$U&BMM<_#2Q1RKLEBP%VGS,*
M84#4T2-4,(BE*>AK^202NVM&MEDGW*%.;'6116H/Q:#EEE161>A32ZL"B& V
M.!4TZZF>53$I[.&KV@!B%KPP;A%%M*+R^O_<QBE^HRR_5-8MNS1P^YR2" )B
MDAJ=@C^UY%GS#\1TV"/V0$CS=D11W_HGS5M;TKP%39JW4TCS]#D#0IKO1Q3U
M>_^D^=Z6--^#)LWWDTC#'HKW29L+^L\[\I1]E@5G*R6]4$:$*B7,7@P>701L
M)K(P!>;/,!6?-.&.U1VY)]E+G(9JEUDE[H4P"M!2U@QDX5%'#M#$G]8A;O2\
MCC654V[L)(V8GU&F#U(^Q%0R\$C2!V8<7"IIGY2XS_(B2/YOO-4NQ.7"7N@A
M!2PE24\2'E5D\$R$J7005?*QL*[IR@XTI%?)!K^[NP(L@;6_ MSY$00)9(C$
M*\#5[DDEY+J9&4<)#A0C0O]G9XTL =6V<><W&$TL A):F/=K*N.C(_.,HO?K
M+%4'"(@BKEI:!:YI[>'O(%I< 6K8ZE4J5R[G:3?^M<!I+A^^.[\YF]F'<-J)
MO/D!1.L.T0C3=/.[X];\F<0%_3++=U:F]2F/+&Y0(>>JE;4PFQ:7"H%H?1VR
M(1-J6=07=DR+QRR)P[B(T]4'NO@D<2 KE4S(%2'4 !LVB!(@J*"$)63O;@51
M(^F8!/<$\SR(M"'X)4"<1IC<+9?2V5XG[(H49L -.=22($ABA">\_$SP>=C1
M0)4*XCI^:7.3YR4FH\@C4?%$(25X!9$$>8AT4H$TDJI2],FM1QR6[ F7-V^?
MG^(BD2TN11%G<Y("7#LC#7X'P0T%*"&E*?L-94OTYNW7SW]$C9;CYO^8/9&
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ME;CK2Y4ZT,/;E#)90!32 E3>GVQU6*J8H.&4MY0QY(*Z6JM,$R4^D'*?.$:
M*.:.:44 T4.&2Y-!AJ!&U@L7'C=!DKPK\SC%N7HB&DBYY8(48I\+/1% 7)#A
M4G"!BZ)&U@L7KC:8K.CT]IYDGXMUG9]563:%M%MN:"'W.2(5!<05'3X%9QH5
M5.DT*77]D.=UGU"\RK*H+JE$U#%ME& 'G!'D(!%&!4Y@2X)#MM_R,2O04X8^
MY1@5:XQX.&M$_][)!%_9\?722!BR"Q&55YY& 9%12"?L_-41)6#A[1%!$@21
MC/#4[Y"T&JA1<<R:.\IATEW'<1 W!=XH;SN855PQR!9\PR.3/ @V68(<<HJK
M]1?77!$Q39_9C+K)[=4N7D_(L6<L 3APC#L2(#BBA*5RB[MO!?C)G5<^)W%X
MG62!>I>E)^,X8YX(;Y L;R\ B $B*E6*/"Z(N*27]G\7I+^1<EN$NWN2A1BS
M**N\':U,^V^6VFXY,ZI(?399J0+BV1B\"@;N3:".C;/.C.5S,X\%C;-L;EGX
MV^,ZH!5X5Q8YFT$I,/4NN%;)\?&"10$&APP:#4#4LX"I.G#@FHBKGJ%*&76T
M/:W/\GT60!RQ%^N7F+![!T_XM7A'/_2;9H5AH>MZ]69=G.%BSJ@(@H1CT:J6
M>CGJ&D#/+$:L-H%^8480M^+Z_?*;<$EX($E&%D6!:=?@04SRVP8Z85>T,P-N
M>*:6!$$L([PADVXNKA]0K8$Z*EZ>RZY@7,=D<R/;7AK\[C0\; BK%PO6_ B"
M C)$TB@OVN!,"-U<^FEGQ46$WJ^.VUAV[:#S$Z3VU5PR:%K7P]6"^M,LR8;J
ML?NAA.,F'D(;-'/S,Z2F'F!2-7<C-FN3+X/\F:,M\_-5$&RK=L=)D3=_V1.@
M_L.O;:CHW;*-'[W/JE.,Q3-[B",<+LK'J;J@S)3","Z-T?-.L@E@A=L)C2J[
MU[(/%VZTT2^-_KQ.Z!1>+O(<%[F!@4,AEUR3 ^RRJB\!AC]26,(XQ86 L*#>
M%K(B@R#KGA,*N"(U!H+ &")'IWK'+> Z/WIGS$60KQ=IQ/[/U>]E_!(D;.F]
M*"X"0G9QNOIKD)1#3W:DKDM&C2I.EV%6BF 8-P:MP$"JA((T0B'[!]ZK>^?B
M UV@DYB%C#",BJ(/A5RR2PZP2Z.^!!B^2&$-B;$7XM3P3H<ZU"-_P"&F''U.
M\$=<R,^][%2<3FT6X'LSG$8>#(TL0(JD:D3]CR\WZ0L%FI$=1:TH85_$)6%D
MX+H$Z?X.AA 24,(F;"/BO?GO"=X&<73UNL5ICNGTR0. >LZ;HIA6FB[),J(H
M70Y9J(&AECU626HRIHEPI9IS9R?CP5YAS_OVSLBJ-'?+RSC?9GF0O"=9N;U)
MPZ1DIZWTKY0*19R6.+K;XNH--,/\=X!!]PN_0PHNK@ZG6 /#]H.+()RB=E10
MUNCDZ!QF'["AM4>F&LGG@T]%5@3)K>V^A"IM#S,"C1/WA#&VV-U3J 4=^MD:
M=\OV8=6.FU[%[=QL!M^?E-7R8,8G"Y#B-%RI\.D7-_)G*,7S!JQ-(5C'E_A(
M6U0[^"AD75)*"[?+):D@&!+IT,F#\X&,1_6<FZYN<9#CAWBU+NZ6GZA7RN"I
M"JO7<4H?&_@]&ND4X-#) J5 JT8')4P)$:9UGBW/2_H?G&W>R59U$.V4[L,%
M4OL^$)T>K;<#9%2YC8/G.(F+&%N>V.D47!+"#+Q+$K4TF)'$"%%UBI?L%?T?
MY36[L_?!CNVWVNV4#X5][)'+ <MVQ_N28/BCA2>$"M3":%M)'\J;HD@K,KQY
M^_T;3@CV%X:)T+7_!96,PR!Y8F^$Y/5NFF*Y/4+/!4U&%X,QQEK).WG&(I7P
MB*FBL-9%!5=NMSV]CT>5NU^A%$=8[1I!K>1^V64J@+C^4FEXI]PHF(H56<VZ
MSLSGGVB]A4!3H)V!: 8E?PLT50'4*[2A!ARBV< TK=$:JNW.FGW*(TV9E^Q^
M$<'1>Q*P3'TO.!5"GS1RSJ9$'<QV"I0)>:>%"9EPB%&+HA631:02]C[>=(;,
M&<_N#K;J:0DXURG>@2:]DWO><HP_SX,T(UN[>[Y=/#NWSK,K9]SSLO;A^J=]
MD!BC\!3,IS-F/0">G.'4QJ0$9FRS13K"I4NS]'PFMV[.8<O<T[P-5(81"NS0
MI!V3((U%+ U&7/ <!"S(GD^[*YR&%!N;AI,L+PDV[-6/M.'TCL24XO7N2HPQ
M &;LFH):V/??VZBN4'2MH*\_9@5&?_JC=P+S!"[K+(DPR5FD1K$S7DU5*[B]
MD&H"WK^&JI(&0SHC1/'*Z5[A'_[PY[=O_N4O/'BFV/D_8+HG]7J<@]3=#)-*
M.@Z05D$=!$0/Q<!01XU-$O!<[Y/D5>:F__[=-]]]]P9M X)>F!ZB[A?*63JG
MOZ _G7WWW7?L?ZH_T'&L+-89B?^.(^Z,812S]VOH(I.@;)_Z"04%NL0A9DDQ
MT?=OSA!C!Q\#Z3_>?..=FYVD5]HKBX*8ZYE7!G(XN79EP/!1 4PV169IPT3*
MFF#3''?&T7F<ZMGY]JV&G^@-_?'-/Y^]_>%/G'D_G/WPYI_.WOSISXUHS5P>
M[V]+W3-$-;>8/Y&1[/P3>1%%/+E D-S3"KM)+X)M3!UDU<FS2MKI.;X><N\@
M7RX*AN1Z?,(1;"O=L!N%E8)W&CW@(HA3'%T%)&5I(Q=A6&[*A*52N\3+.(Q5
MKJ"-HML[M[8%Z=_#-6F!H9PU5$D 0".(HDK2.^U$?]?:,?:]TK!;8<#:75'B
MDV^RY,K%A7?B=/:)Z.K<FD9F-4^;=-I"*';NI#JP"&>)UKC'Q]TOP'3L+[[N
M W)'>#*HB+N^]YCPY+A6*S>ULK\%L:E ZC6R2A/,=#H*KF8ES5<49_M5"C!*
M5LF9%^W:R*HV1"5_%%050$V]H090RBE@FJDFK'=!4HZ_;CR&;HV";ZKU@9MH
M5DF#IE@/HC6]JCT2D-12OR!@K>6;9(HW!"Q50-/-_(J DG/9D9X0.'"C>*1;
M9Z7I:3MYC$-GH0:&B/98]?O0S(W+",JY^G#;&1(G+?TZK88G#MIX=!IQB)RS
M].7Z7(/GQPDETCIQ2FFOO%*[;PI1N'S2.FY=+K7S*!"G;<2;3W8J7AEE\-5
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M$\,EA9=DO"==O;)U)=9Z"U::;LEI791!)GR3&B :VF*5S.1<LPJ8W>LBOO7
M_]K$PBS"D)1!XIV:5P%ACP&RISOYE1R[X=.HY?3>MET1>A>Y]2I@J&B'4_9\
MZFV6YXBJ(:[GG6:W.,\QY@]?62[EM1HNZ64!O4LMC3@86IDQ#BE5R7JGT3"T
MQR:69J2NS\ K8XS-*$5HRY$QH(\>HW4P%:^#F/#WBC[0KE%6CZ2-H>,(?9>4
M'%VL+BVME<&,A&,1#WG)]!$W@#H6_+/S(_[<>1>!9"G]9UAA&T/2\69<<G5J
M(;N4'6L##',G A>7+"$>/'71L^6=R8_A&D=E@N^6;2S!14D(2R :/"?F)$'6
MZDXG_I&%ZLW]EKI@F#H2L##UU^K\H:YLL\U27#_;%0.*%MD74GX",)*L=D;\
M4'9, >7$M;$ D+XC8.M(S.X^O; S=U+O!149HHCIW_D8G-._AYA:IV:]TUJV
M#\O3.=-Z:%^PMN+V)$MN@Z,F%[4?*#7:#+2%VO0B?"FTW_?Y!76*HC@I*7;\
MB,.2Q 6=;JY>V0UR'%5'%9MM63U0=K<<;MC9C_CS?<C/K#!W1<EGCKF^ G!V
MF;EHVJY(/W7>? OAY1*'_L]UJTW)^F9+NN([CNUH\R$H6(783363++G?4IY4
M5'&K>909,+R?CEU'[$V<QIMR@[+&+DJ88;2M<\QY)[DR)&-R5 VT>)IID33P
M"&H-5<?';3>$!H,)H=E/.OLDI?V ^28BC0?"]Y[FYG_YE,9%OJ@=NI%+VV-\
MTH_+<[S*DSL_\W\/3&]S4$CQ2*E]]+?S6GS.LXPV:Q5(/56:9[L)\+\C#_%J
M;9%Q8KH]3WUL6K$5'6B<,8B]8U()=%/4Y^:*"%V.;^LWNHYUB;C?R5G4-"8O
M=&V3D>N2>GR8W5()*#FT,\IAIMQ=*3ZLL/N;Q=/L>.?N#.!UM,VYO?I,8).E
M]<!-Z@^@94;0DG\"Q?4W( WF;?;K[B3'._?=MDH$=X!S-<FP1Q?J@(K0.$H3
MK'KO-+,71=>%V.9KQFV ]'>&">(7=*:*KC;;)-MAS"N@>5*2+=%8# :OF@7M
M[9NJ9B;WG=F^Z+M3S5QUIMXVT^= =\-YRZC=I=WK,N<,URE>4+'&:,GBCEYX
MW!'KR5L8N8#V]=76#)V-XQ#+1[%%PF'P[>SZNL;?:05C$F?597W[OCO[]_ST
MW"-5F[S?SOPQ@+WV."74]5G6-[DG>LZW,'C 2O,AA*LK)("ZZ25>8D)P]!2\
M\@/>O'/"&^.Q$^A(:WZZV*0BRSO0*%, N\<4_#KR1[4]5 2O/ T4@ .7SF#
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MBN+Q)_;X[:K*^+]3//+&\QGM69W?%6M,GM9!6C_ 2&OAA5(51Q_+S3,F2G_
MV??=^FN.J[7O CKZ.,3LMZX++Z0 *XN\"*JTB4&!GIN\NE]P3W_/7\J^2;4.
MB+O/?QG]7%ZI;KIY_]M@W"C'!9;MI./H"^['UQE9XI@.<-ZZL@3!E]&;E57K
MID,+G_]/T*=5919NH#1R*"-L)SPFAW=RQ0')\0K[@'F2#E7/=?YU9\<W[JNT
M/0UR]VGOO=5/><6SJDK,5^C!?XXU'<#D]>X+;UC58?XO[Z[@11+D^=WRYX#5
M1'%''N+56GM:JE-P>EO1"+QW95$I[7U@M(8H!LY1!79$6JLPYX,K@3DCE1;I
MUG!6:E+R3C*A $:BW8([0[6".8)PMT</X^TCSFO(.5]17P:%-"V)6<?=PSV6
M\/>O]A@4O%-I#$HA[0A+7S3/9L@XNERQQ5EUZ68<9X:*OHDC+XB)/7TMT!22
M0A7>%FJ%T"6$]^"EP^K5*R9AG.-[$K.@@6%!55G4)MKR/CW:%M<X:YH,>:?O
M'.A%1E=JB.OQX.HH2Y* Y(BN<ZI :_^IIJ4E[BQPQE143\T[>R6%,!*UHP.;
MDR)0S2+5/\GX50-^=^$BV,9%D%07%NIWJ:/KC%0WC9J +%55C+?C]CW9B<7L
MOR8XT@@<HDY$+BQ.>A=3PLI4?3&%O9;,C:$E7;(LN3D4U_:\\_RQ?,[C* [(
M[HY4NTT?<+'.HIMJ7PD_!CQXFA7LW4X4;L2T(>ZS?L+I>=H1*J>W*3JC?3!]
MZ@B%$N*J6RVV"U"_3%=]!37Z9XA]B ?QLT^AYQV2JC7R8/:M]B@[-67:MS(I
M^>DUN@+(^X%, R"S-3#57!TR$M1M *G+5ATJT(*V#]E=!$F"HW>[X8IBC",X
MQJIWEWQ\%1@]=GN38)@_3SF$.&-N@'6(S[4"]XN\'9!ZWE$ =W/[L&(H-Q>V
M?'.AT^IGM:?L?1"47[3I+!(4%66AY_]"E*08YOM0'24P@Y$M4DFZ-ZY7O<&:
MUW-Q-Z> IW&G6Z"Z/S6=19633RD/;Q2Q0JMOJ^;(K]5SE*=%=F(@RGC+TB(<
MO P%O'=9'2IUBI:9DO'XBU1N/2,^K2U*NC E\=_Q[/'(ZN^<1-2QJ9IFB1]3
M?<1[WSAVR=3>=KTO&:P('6)1D55>]^EV-_Z__LJR53=7496/0\WZB9/H9)K*
MF:5_2>R??M=2%VK8JVHA5,6!GFX?:@:3113QY(C-2<CQ)R_=%T^BA]E7W:P3
MFOISI]__K,NHGN2"5K6=[UKET^VF==AWYZ3\.+?3U=\YB2YIJJ99.J+J(U_4
MK7)#(0WW#-Z=_NUQL0)^QFRG$T<+]C3="O<V1(]?_?JOGVCOM*G2(_59W:>_
M\)YL4?1A_VY44*V#^B&#9PCV /!LKK?GT?7V@#=!S,IXD:4%"<*B#!*6F.NM
MK@5=(W$^,/BI:F&0< L#EN?MI>S&$:,U@#H6$#/1'SV^_AL.R.%IG2%Y#C>T
MO'&:QZ'NH;(C?N]$O0-YM1W)'^A_[ OW *2%5;_YWHI7[[$)L_T7D"Q*FE!'
M][S;4;YT2AU54U5S=E')9V#-MD<IFYA1F&UEL;?IJ,8I;&3EHXI^C*7UG A
M]<OYJW94?YWO\Z?3CV<O\^CU]<ET?$--U5FK2K:IGT;[J[1'2\-H_UU0G7RN
M:IQS*C9^%-K3EZX*K)JM+UB((@N-_G:F_&SPNZ^'3?(#,7U1W=[UAOI!@$YG
M_G=0"Z,]@E&#"V!.>SJL_9+2Q1D+:3BNO3+>O3\-_D ]3ORRN695]$,/%+\4
MBOK<T_ZR::@H[/1=;2#),@^MHKICL4ON1XT9DWSGE%QK937-V3>%CWPQ+K"J
M9*JE<4?^2^IA'I:_UE\_T=[HVJFS_/27V'/G7Z8BNOY%_/, N_P!<3+J2E/%
MR6BO)KE&<DI180=4]9Q181-@P!HBO)3]H*BP+W3 Z"]4'(P+P@=/M/LK*NY(
MO7SPM2^Q,\N+.&+%#*Z'3O&#KH.8\/(L\KS<U"^[Q/EOUP3C[INW<_M?]M\]
M"<]];#7.XK/;?A16[W504M7$>Q[4$R^ANN=+JFS_.//I=>.KURT.::DOXY<X
MPFDC/WM,Y[AOGVQW-E7GT;JTZL-?9K<VE%;R'@$71U$MWR32\9]8;;*OHJN6
MHZRF+3YX$EZS=<7-XC4;OP:K@QZSB,I>N<Z2:)\I!'V]._'K3;(*&>P*_#5+
MJ+4D+G:N_&8#@).=<:TJ]FC3KO;KL+JVRR(;?>N75@LM@Y#VW2/E+;S*BWC#
M@F#W 6@,)HM'ZP:FTX$J^Q"D054;@UH\Q)"S#(@'%;1-DSC)BG>:'PQ=F)D:
M6^QABMH87_OE_*6*K+*'5E!N'(1K')4L[_K59IMD.XP?,7F)0ZSH]PF'0?]U
MMWS 8;9*6>:?*@SS(LN+7/MDQ7&^Y73Z.69U]6::8WS(>V]S43II3,0YMXGJ
M^0EUIB^VS<H^1'\-Z.*N?K"&V3]#BTU6IG#>7IVGKFX-CU[,_A67_?-(5=3M
MF3-_ DR?/$ZYCM ;;P$]\%'7!X[DU5471E'CMLHN.]"X G7[A9TF&+J/@CMD
M\5/&7R)CV>W/^9X&2WC?ZGIGY7YZ-:[>E'=O[1RY@^W[<=YFJA:YPW:@<3 ]
M9.X2"5-!;9^_W=29%KK?Z,X-.7]M3#9_L"^!\=(F;YB8'+,Y#)_$5IW6_3K<
M*IP.-E=1=$Z6JC<9.A,D)VMR/0UR^;\$<<+&B.N,\/V<N9O%^+F3Z'V6E7:,
M9R2&WSK]GFI70/DU#A0TXGSGD.\8GOX5/9>WD+\_?0(9RZ9[-!EE@-[^/K0*
MM%F ^(^7=#G7GCH=J2%&HSB),?^P*CY>0CHCA"^F@T\KM_&L=$D5T O38*NL
MYO");:T%[.-PSJ&L=A\_9M6STM5+,CG?A>G^SG8@/V;%WW"QWYL\9+=SVO?
M[7<?4FVC=[ZG? Q,+SYV">7[B&5*6L'>1B+"U2XD(CCA1\I%AM(L/:\^W\SQ
M6Q![CD>KNFI$I!YS_2<FIPI0= WBB^CJV@IVTO^E"+[\04%7;./,7@<\LI5A
M,WJP.,@C#0^*$*E[6L]K6A47RL><U6+.PILT(-O@)8F,=_X9@ F/^]:2UF\O
MNUOUY3?\ 7I^9YV2GO]-YT?+Y9VOI'2PA36/3-@[A6P1*KFTK=)%T<&F6D5X
MY],E7F)"</04O"[R'!<YS^N]>,[Y[69%\4U*+IEE5X NO?0:8#AF!7-(M$8)
M%<$K"KC:C_ X=D?Y'[ '26]IB2X"0G9TVN7SO&U=Z"QX99^Y:%HJJM7A\M*(
M67C^$A?4C:J54$*U4-A5@T=8^H\+^M]QT2O> \XQ;82U;469K'@EKET1M>35
MFX!+8"O<0Q(W/Z.0JT)G\%VQ5N;24PG['4B[@/5C)I.$RZXN/"&S+?OM#*58
M>Q#IT1$<Y9M </SL'3ZGC"G8_L7M:&]/N\T9B;X>)!;=QL$SNU46XQ'+":F2
M)U9I"J!@ET0#XKBDAJE=3B1[-5!KBDYQ+&<Y4<,_Q6SFNZ$XM!=,S%!/8 *\
M2<-L@_M%,)17KN*#4SKP,E+)Y'VPZLEV?M0 MI@E.T,8&+ZU,SX+1&@O!7UF
M[V78^@HR3:^NF+HH6K],5 ,\PAD@#]G8"J*@D81'P4ZG^HBM=W^'6EZI)R^"
MEG9]%>#K BE8V0X;Q.5!.WJS$]HTI.7@7:+]<WU+[!U.\3(N%L4UCC )DL<B
M*$J*9K?75V=JF?D;+LE\E.KI4G_6#X!9VARC5)(PX&W)H@"" KU]\S^@]B16
M)KQ(HUOZT:2543JPHZT Z VF(EKP764".J,-N(5K#TR<#?\ O%U%B2[6+)[W
M)IWN#,]A& "K)U2$!=%'6(7._?%%$89P;@'%*0^]@.:+*XK--T@6T7^4>:'+
M!6NM#8#JJB)9\'FH"IVT"KS273#O#+Q:+G%8Q"^XYP\-9B!%<H<0Y^P8M7&Q
M>&81157-_QFG4<-'JJ1>7/#,WP#32XY4,-'O88&Z /.(*$:)-O[ %%$R0A_
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ML3; <'8B<'F$3PXUQ.=3)R_=_BA;M<962KMDI0%REWP*43 <T^,;4JDKC=@
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M%N\2Z>F*7AY*.]K"E$9HJ_4\34;2>Q[Y?9;$X4[:5*,4 ;39-+S:]TOWZG0
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MJONG6_HO^N?F3_1_/0<YIG_Y_U!+ P04    " #2@W]6PS)Z$=(Y  "IW ,
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MID;[]H<&$7N:#]_=D0PFWPB;S2B7P.F*]Q/]^>&S.%G0P'D4)_'^X9SM]47
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M:3;:U&)V-(-C;+:I<2C-0Y$BA [5TG5KDN*6T EQU6I8D-@@[&B!TBFJ+F)
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M#WT^JTG\1P+D$"B.O7'0A$4C9-!Y+$8$XHD'C$)I.9%0>>03GIZFG]47AXS
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M6,*9\TS4+\]]6XVPR@5'F23VTW,[(_8:ZJ.FE$(X+>NBZ)&94N,X)DF<O98
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M:71A;G!H87)M85]E>#,R+3$N:'1M4$L! A0#%     @ TH-_5MG0:O%E#@
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M,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ TH-_5L,R>A'2.0  J=P# !4
M             ( !PID" '1T;G M,C R,C$R,S%?<')E+GAM;%!+!08
.."0 ) %@"  #'TP(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
